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By
Heather O'Neill

Medical Writing Internship

This thesis project was designed so that I could gain a better understanding of a career in
medical writing. For six months I worked with a freelance medical writer, Sarah Staples, MA,
ELS. I was given a variety of projects to work on, so that I could better understand the

versatility required of a medical writer. My projects included writing abstracts, proofreading,
editing, formatting and documenting sources.
This portfolio contains the projects that I worked on, many written for a professional
audience (physicians, pharmacists, veterinarians). I have also included helpful resources, such as

proofreading marks and a guideline for writing abstracts. Presentations from an American
Medical Writers Association conference that I attended conclude this binder.

I chose this internship because I enjoy writing and the life sciences, so I wanted to find a

career in which I could use both. Sarah Staples introduced me to the field of medical writing.
Although the type of writing I did is not typical for someone working in a large company, I was

able to gain a general understanding of freelance medical writing and most of these projects were
done for large companies.

The projects in this binder are separated by tabs and introduced by a summary page that
describes the assignment and audience, required skills, client, format, and style manual used.

The topmost documents are my final copies. When the project consisted ofwriting an abstract,
the original document from which I worked appears at the end ofthe section.

I gained practical knowledge of medical writing during this internship. My writing skills
improved tremendously, and I have become a better editor and proofreader. I also decided that
medical writing is a career I wish to pursue.
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relationships with people who influence buying decisions.

Audience: Primary care physicians, employers (payers), and managed care
organizations.

Message: The key to successful management of mental health costs is to identify
illnesses early, refer for appropriate care, and treat on a timely basis.
Skills: Comprehending and summarizing primary material. Understanding regulatory
constraints on products currently awaiting regulatory approval. Writing detail copy.
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<Front>

<Headline>

The identification and early treatment of depression can help
reduce both direct and indirect health care costs.

<Subhead>

Depression is Unknowingly Costly to Employers

<Copy>

According to a study performed by the Washington Business Group on
Health (WBGH) and the National Institute ofMental Health (NIMH),
depression has been found to be one of the top reasons that people miss
work. If it is not identified and treated properly, it becomes expensive
for the employer indirectly.

<Graphic: pie chart
using statistics from
page 9>

Annual health Care Expenses for Health care in the U.S.
17% Premature mortality costs
28% Direct health care costs

55% Indirect health care costs (i.e. excessive absences and reduced
productivity)
<Copy>

<Subhead>

Many physical illnesses are caused by or related to depression. Almost
one-tenth ofthe U.S. population suffers from clinical depression each
year, costing the nation billions of dollars each year. Fatigue, memory
lapses, and poor concentration often accompany depression, lead to
errors and injuries. This can cause to a reduction in workplace
productivity by 20%.

Depression can be Treated Effectively and Efficiently

<Copy>

Investing in employees' mental health has cost employers an increase of
less than 1% in annual health care costs. Attendance and production of

employees increased when mental health care was provided.
<Back>

When considering treating mental illness and how to incorporate it into
total health care, there are some important things to consider.
• Depression is a medical illness, not a weakness of character

• Providing treatment for mental illnesses will not increase costs, it will
decrease them.

• Combininghealth and human resource programs will help achieve what is
best for a company as a whole.
• Incorporating mental health care with primary health care can aid in
identifying mental illnesses early.

• Depression can be the basis of a physical illness.

• Spending a few thousand dollars on wellness programs can reduce future
costs of millions.

• ufao

Preface

any human resource and benefits executives are
faced with critical "people" issues in today's
.competitive business environment. We are in
the midst of dramatic change in the way large businesses
and the people within them are organized, managed, and
led. Increasingly, employers are being asked to demon
strate the value o{ their benefit programs and health and
human resource management strategies to workforce
productivity and company performance.

In leading corporations, workforce diversity is valued,
as are customer service, teaming, and risk-taking.

Work/life programs, health and mental health benefits,
and other human resource supports are provided to
enhance employee health, performance, and satisfaction.
And compensation incentives are used to motivate a
shift in employee behavior and performance to that of a
stakeholder.

As part of this change in corporate behavior, many
leading employers no longer look at health costs in isola
tion. Instead, they are working with health and other
corporate systems to manage both the direct and indirect
consequences of physical, mental, and behavioral disor
ders. They are encouraging early recognition, appropri
ate and cost-effective care management, accommodations
and other performance supports, and timely return to
productive work.
Since 1989, the WBGH/NIMH National Worksite

Program, a cooperative initiative of the Washington
Business Group on Health (WBGH) and the National
Institute of Mental Health (NIMH), has played a central
role in modifying employer perceptions and behavior,
particularly with regard to mental health problems. This
has been accomplished by educating and assisting
employers with workplace strategies and health system
practices that have contributed to reducing the
frequently unrecognized impact oi mental disorders on
both employers and employees.

The Worksite Program's initial focus was on the prob'
lem of depression in the workplace. With input from
senior executives of major companies regarding their
own innovative program approaches to dealing with
depression, the Worksite Program conceptualized an
integrated multifaceted human resources approach to
improving the management of this common and costly
disorder. Major elements include management and
employee education, expanded Employee Assistance
Program functions and services, redesign of benefits,
improved data collection and management, integration
of health-related programs, and health plan performance
monitoring.

This approach has been widely disseminated through
WBGH and NIMH Worksite activities, with the result

that a number of major employers have introduced some
or all of the elements into their worksite policies and
practices. Through its ongoing consultative and educa
tional activities, the National Worksite Program has also
encouraged employers to apply those management prac
tices to other mental health and behavioral health prob
lems as well.

With increasing recognition of the significant impact
of the indirect costs of mental and behavioral health

problems on overall corporate performance, the National
Worksite Program added a new strategic direction to its
program-promoting purchasing for productivity. It has
now expanded its focus beyond the health area itself to
include other areas of management concern that are
affected by health problems, such as disability, workers'
compensation, absenteeism, and employee productivity.
In support of that new direction, an invitational exec
utive briefing on Investing in Workplace Productivity:
Managing Indirect Mental Health Costs was convened
in Spring 1997 to hearTrom leading employers and
analysts about the state-of-the-art assessment of the effect
of employee health on both workforce productivity and
on human resource and health care purchasing strategies
aimed at reducing behavioral health risks, managing total
costs, and optimizing employee health and performance.

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs
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At the meeting, several employers who have been
leaders in improving health care delivery systems,

reported on their experiences in developing organized
systems ofcare that are patient/employee-centered and
accountable to purchasers and consumers for both cost
and quality. Significantly, the systems also include
elements that, though not always viewed as part of
health programs, demonstrate a positive impact on
productivity in terms of decreased disability, improved
return-to-work, reduced health costs, and more respon

sive health/mental health services. These include modi
fying and expanding the use of human resource programs
including Employee Assistance Programs; improved

design and management of health and disability benefits;
and modifying data systems to ensure improved capabil
ity to monitor health plan performance and track key
indicators such as health costs, productivity, absensism, and short- and long-term disability.

Discussions and case presentations in this publication
reflect the outcome of the meeting. In addition, building
on the experience of these and other leading employers,
we have taken the discussions of organized systems of

MaryJane England, M.D.

care to a new conceptual level and are proposing a differ
ent framework for viewing the value to the employer of
employee health and productivity. This conceptual
framework will be discussed in this publication together
with innovative case examples of systems approaches and
recommendations for positive change.
WBGH is the nation's premier business group dedi
cated exclusively to the analysis of health policy and
related worksite issues from the perspective of large
employers. WBGH members-Fortune 500 and large
public sector employers-include the nation's most innov
ative health care purchasers who provide coverage for
more than 39 million U.S. workers, retirees, and their
families.

NIMH is the lead federal mental health research

agency, with responsibility for national research and
education programs aimed at increasing scientific knowl
edge and advancing effective strategies to deal with prob
lems and issues in the promotion of mental health and
the recognition, treatment, and prevention of mental
illness.

Steven E. Hyman, M.D.

President

Director

Washington Business Group on Health

National Institute of Mental Health
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Investing in Workplace Productivity:
Innovations in Managing Indirect Mental Health Costs
Introduction
In today's dynamic and competitive business envi
ronment, increased productivity continues to be the

engine for growth in many companies. Recognizing
this, employers are grappling with the dual challenge of
enhancing and effectively evaluating workforce produc
tivity. Employee health has long been seen as a key
component ofproductivity, although it has traditionally
been evaluated only in terms of the direct cost of

providing health benefits. Increasingly, corporations
are realizing that there are significant indirect costs-in"
the form oflost work time and impaired performancecreated by poorly managed or unrecognized employee

Building on the ideas and data presented at the meet
ing, WBGH members and staff together with NIMH staff

subsequently developed new perspectives on productivity
and related health and disability issues which have now
been incorporated into this new WBGH/NIMH National

Worksite Program report Investing in Workplace
Productivity: Innovations in Managing Indirect Mental
Health Costs.

The publication is organized into three parts:
•

ilth problems.

To deal with this cutting edge issue and help large
employers meet the productivity challenge, the National
Worksite Program, a cooperative initiative of the
Washington Business Group on Health (WBGH) and

the National Institute ofMental Health (NIMH), in the
Spring 1997 sponsored an executive briefing on
Investing in Workplace Productivity: Managing
Indirect Mental Health Costs. With leadership by
WBGH President Dr. Mary Jane England and NIMH

a presentation of health and productivity from the
perspective that employee benefits function not as a

cost center but as a catalyzing force for promoting
human and intellectual capital;

•

case studies offour innovative corporations that are
successfully managing both the direct and indirect
costs of mental illnesses;

• a review ofthe issues to be considered when focusing
on a health and productivity approach, and recom

mendations for more effective management ofcorpo
rate mental health costs and programs.

Director Dr. Steven Hyman, this special meeting
''primed the pump" on communicating innovative
productivity management programs through discussion of
the experiences of major corporations that understand
ptohts aivi sWcWukt value.

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs
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A New Perspective on Mental Health Costs
In recent years, several factors related to the mental health of employ
ees and families have led to an increase in awareness, attention, and
targeted action on the part of major employers. As a result of the

educational activities ofthe WBGH/NIMH National Worksite Program
and the efforts ofother business and professional organizations, many

JL#

employers have increased their awareness of the prevalence in the work
place of valued employees who also experience mental disorders, of the
treatability of many of these disorders when properly identified, and of
the impact of these disorders on the workplace and the employee. This

has, in turn, led to the introduction ofinnovative approaches to manag

A New Model for
Managing Benefits:

>

ing mental health problems, initially with particular emphasis on
improving the management of depression, a disorder that from all

reports is the most common mental disorder seen in the workplace.

Expanding Cost

Currently, as many as ten percent of all adults experience clinical
depression each year-with an estimated annual cost to the nation of $44

Elements for

billion. But only 28 percent of that cost results from direct health care
related expenditures; 55 percent is indirect cost associated with excess

Maximum Return

absenteeism and reduced productivity; 17 percent is associated with
premature mortality costs.1 Related to indirect costs, the average
episode ofdepression is estimated to last four to six weeks, resulting in
significant levels ofabsenteeism and an approximately 20 percent reduc
tion in productivity,2 since depressed individuals often suffer from poor
concentration, memory lapses, indecisiveness, fatigue, apathy, and a lack
ofself-confidence. Not surprisingly, individuals who suffer with depres
sion are also prone to errors, waste, and injuries.
Clinical depression tends to be concentrated in individuals of work

ing age between ages 25 and 44. While they may have short-term or

long-term periods ofdisability, clinically depressed employees typically
stay in the labor force, often struggling with their symptoms for months "9
or years. The good news about clinical depression is that effective treat
ments are available, and there is currently a better-than-80 percent
treatment success rate utilizing medication, psychotherapy or a combi
nation of both.3 These treatments lead to positive long-term
results-results much better than for many serious physical maladies,
from back pain to cancer.

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs
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At the Spring 1997 meeting that led to the development of this
publication, Patricia Owens, President ofIntegrated Disability at
UNUM Life Insurance Company, NorthAmerica's largest disability
insurer, validated the importance of indirect costs to the health/human

resources system. An UNUM study found that indirect costs accounted

for approximately 37.5 percent of the total costs ofall disabilities, physi
cal and psychiatric. Psychiatric short-term disability claims have
increased by 33 percent since 1993, while psychiatric long-term disabil
ity claims have skyrocketed 316 percent since 1989 (compared to a 154
percent increase for all long-term disability claims). Mental/nervous
claims now account for eight percent of all new claims.

In addition, Owens emphasized the relationship between physical
and mental illness. People with physical illness tend to have a higher
prevalence of mental illness, most notably depression. She also noted
that mental, psychiatric, and personality disorders now represent the
single largest cause of disability claims under Title II of the Social

Security program, with roughly 22 percent of all awards being for these
types of claims.4

UNUM surveys also suggest that psychiatric disabilities tend to be
more prevalent in females and younger (i.e., working-age) individuals,

and that they tend disproportionately to affect individuals at higher
income levels. A higher incidence of psychiatric disabilities is also

reported for employees working for companies that go through layoffs
and/or mergers. Interestingly, front-line managers who have responsibil
ity for disability management tend to suffer less frequently from psychi
atric disabilities.

The key to successful management of direct and indirect mental

\

health costs is to ensure that individuals with mental illnesses are identi

fied as early as possible and referred for appropriate care management /
and treatment on a timely basis. Addressing these issues requires the
development oforganized systems ofcare that have in place all the
resources necessary to achieve the goals of early identification, appropri
ate treatment, disability management, return-to-work programs and
performance supports.

Ideally, these systems should include training for occupational and
primary care physicians as well as mental health professionals-such as

social workers, psychologists and psychiatrists-to ensure that timely
identification and treatment become an accepted part of the direct care
system. There also should be systems in place to deal with the comorbid
ity that is often present with multiple mental illnesses (such as substance

abuse disorders coupled with depression) as well as the comorbidity of
physical ailments and mental illness (such as depression occurring
following a heart attack or stroke). Employees should also be encour

aged to take advantage ofother resources-for example, community
programs, consumer education, and support groups-to help them
manage their mental health problems.

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs

Methods for Measuring the Indirect Costs of Mental Illness
' n an Analysis Group/MIT mental health econom
ics study, researcher Paul Greenberg reviewed two
.different approaches for measuring the indirect

I:

costs of mental illness in the workplace. The first is

the "asking approach" where employees are asked to
rate, on a scale from zero to 100, how well they have
performed over a relevant period oftime, such as a
week or month. By gathering this type of subjective
data on a regular basis and comparing it to a

commonly used measure ofdepression status (such as
the Hamilton Depression Rating Scale), one typically
sees a relationship between the level of depression
and work performance. In otherwords, work perfor
mance deteriorates as individuals become more

depressed, and vice versa.

In the searchfora better system, Greenberg has
embarked on a joint study with Aetna Health Plans,
a U.S. health insurance company, to construct a

different approach to measuring indirect costs. This
study5 has identified a particular work group that is
idealfor evaluation: claimsprocessors. These

<

employees work independently and are compensated
in partfor the number ofclaims that they handle on
a daily basis. Error rates are also evaluated and moni
tored frequently. In addition, researchers are able to
distinguish between productivity (i.e., the number of
claims processed perhour worked) and absenteeism
(i.e., the numberof hours worked).

The Aetna study evaluated two separate groups of
"claims processors-one group of 1500 for whom
medical claims data were available and another

group of 1200 for whom pharmacy claims informa
tion existed. From this information, the study found
the following:

•• With respect to anxiety disorders, there was a
large drop off in performance, and then a subse
quent improvement after treatment, both in
terms of increased productivity (i.e., more
claims processed perhour) and reduced absen
teeism (i.e., more hours worked).

• With respect to depression, there was a
smaller drop-off in performance than for
anxiety. A strong increase in performance
occurred after the treatment period, both in
terms of increased productivity and reduced
absenteeism.

However, Greenbergpointed to some problems
with these data. In particular, because the study is
not precise in defining when an episode of illness

begins, the data are likely missing some ofthe effects
from symptoms of illness that manifest themselves

prior to treatment. In fact, only about one-third of
the total time periods in the study are in the pretreatment and treatment phases; two-thirds of the
study period consists ofthe post-treatment phase.
What is ultimately needed, in Greenberg's view, is
a "marrying" of these two different types of
approaches to measuring the indirect costs of
illnesses. In other words, he would like to bring

together the good clinical measures ofhealth status
from the patient surveying approach with the good
productivity estimates ofthe Aetna study.
Recognizing that many work environments do not
lend themselves to the precise measures of productiv

ity that exist for claims processors, he would also like
to find away to better validate the subjective instru
ment used in the surveying approach.

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs
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Benefits as a Means to Foster Human and

Intellectual Capital
We are proposing a conceptual framework for improving workforce
productivity and value that rests on the premise that it is advantageous
for employers (1) to expand their understanding of the multiple, inter
related direct and indirect factors that influence productivity, and (2)
to modify their perception of the role of benefits from employee entitle
ments to employee investments. This change in perception could lead
employers to accept the idea that the value of health and related bene- \

fits and on-site program supports can be demonstrated through

J

improved employee functioning and performance and higher corporate^
financial value.

Innovative employers around the nation are already in the midst of a
dramatic change in how they manage their human resources and bene

fits programs. Selected case examples are presented later in this publica
tion. Rather than fostering a culture where employees operate in a
static environment, many corporations are trying to move away from the

"entitlement mentality" that surrounds employment'. These companies
are trying to create a culture of dynamism and entrepreneurism.

Whereas the primary concern has traditionally been on minimizing

the cost of providing benefits to employees, the new focus is on the overj)
all impact that human resource programs and services together with /
employee benefits can have in bolstering the company's bottom line and

shareholder value. From a benefits perspective, this means a change from
a defined benefits system to a defined contribution system. From a
compensation standpoint, it attempts to make companies feel that bene

fits are contributing to productivity and are making employees feel like
stakeholders who have a role to play in the overall mission ofthe corpo
ration. It has meant a focus on people and the intellectual capital that
resides within the work force.

Expanding on this theme, Ray Werntz, Vice President of Human

Resources Benefits and Compensation at the Whitman Corporation,
producers and distributors of Pepsi-Cola brand products and other non
alcoholic beverages, has described the traditional, "mainstream" view of
human resources and benefits as a set of programs that serves to attract
and develop competent employees, increase employee satisfaction, and
control "people" costs at the corporation. From this perspective,
compensation and benefits programs are seen as "carrots" to be dangled

infront ofemployees to give them a reason to want to work. They
function primarily as guidelines that serve to influence behavior and

define limits to overall people costs. If they are not well constructed or
are not generous enough, they often cause problems in terms of
employee turnover and morale.

12

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs

But Werntz and his colleagues believe that this common view of
compensation and benefits largely misses the boat. At Whitman

Corporation, senior managers have embarked upon a completely different
strategy in which human resources and benefit plans are viewed as impor
tant components of efforts to grow the business and enhance shareholder

value. In otherwords, all of the benefits and compensation programs
offered-including health care coverage, disability coverage, compensa
tion, training, and pension plans-are thought of as catalysts to boosting
employee creativity and productivity. By addressing employees' four basic
needs-health, financial, work/family, and work/competency-these
programs, in aggregate, serve to foster growth and boost overall returns
and share prices.

Investors Look at Human Capital As Well
Part of the push to develop human capital has come from the
investor community. Whereas conventional wisdom would suggest that
the investment community primarily concerns itselfwith bottom line
profits, one important non-financial issue relates to human capital-in
particular, the ability to attract and retain talented employees.

According to Werntz, Whitman Corporation's senior managers are
among the first to recognize the importance of human capital to
investors. They realized many years ago that the traditional approach of
focusing solely on cost management had backfired—especially when
initiatives that emphasized "costs at any cost" beganhaving a negative
ripple effect elsewhere in the company, raising questions about quality.
To address this issue, the CEO of Whitman shifted the company's
focus to regard the human resources function as a strategic partner that
would help the company to reach its business objectives. In fact, in
Whitman's 1997 annual report to shareholders, the CEO identifies the
company's long-term performance compensation plan as one of three
critical processes resulting in long-term growth in shareholder value. In
other words, the compensation plan is being offered to current and

potential shareholders as evidence that the company is a good invest
ment opportunity. In essence, the human resources function at

Whitman has been intricately linked to other business processes that
are deemed important to the company's ability to attract and retain
outside investors.

Investing in Workplace Productivity. Innovations in Managing Indirect Mental Health Costs
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Applying the Purchasing for Productivity Perspective to
Health Care and Disability Benefits

Nowhere is this shift in perspective and attitude more dramatic than
in the management of health care and disability benefits. Rather than

focus on the direct cost of providing coverage, innovative employers are

looking at the impact that having ahealthy (or unhealthy) workforce
has on overall costs, productivity, creativity, and profits. Senior
managers are just now beginning to realize the importance of having a
healthy workforce. While health issues often were viewed as unrelated
to activities and performance in the workplace, corporate leaders are
increasingly realizing that health and productivity are closely connected
In other words, human capital (i.e., people) issues are rising to the fore
front and are seen as away to ensure that US corporations remain
among the most productive and profitable in the world.

/ Evidence would suggest that employer actions may help to reduce
/the incidence and length of disability as amajor productivity and cost
issue The data presented in Case 1, BANK ONE Corporation (pages
18-21) support that. UNUM's Pat Owens notes that studies6 have

found that the existence of formal grievance procedures at acompany is

positively correlated with the presence or absence of disability.
Correlations are also found between disability and the presence of

nployee assistance services and retirement plans. Companies offering

rehabilitation programs tend to have alower incidence of psychiatric
disability. Still further, the length of disability tends to be reduced in

companies where staffs maintain contact with the person after the

onset of disability leave.

UNUM staff is currently investigating the relationship between the
types of medical and psychiatric plans available to employees and the
incidence and duration of disability, as well as the effectiveness of

providing early intervention and treatment to individuals suffering from

depression that is comorbid with physical impairment.

14
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A Key to Success: The End of "Silo" Health Care Budgeting
This movement to look beyond direct health care costs has had
dramatic implications for the management of health care benefits and
costs and has raised questions about the utility of the "silo" approach
that assigns the costs and management of specific health and other
benefits to separate categories. Rather than merely trying to control a
budgetary line item, managers are beginning to assess total costs related
to employee health. They are looking not only at direct health care
costs, but also costs that are indirectly related to employee health,
including absenteeism, prolonged disability, turnover rates, and produc

tivity levels. In many instances, th^s^Jndirect costs substantially exceed J
the djxectcosts-of health care.

/

Ted Rooney, Manager of Employee Health Management.for
L.L.Bean, a company which sells outdoor products through catalogs,
retail and factory outlet stores, has noted that self-insurance is a huge
benefit for companies that wish to end the "silo" mentality. When all
costs associated with programs, services, benefits, and the like, are attrib
uted directly to the company's own costs, senior management has a
much greater ability to make decisions that make sense for the organiza
tion as a whole. To the CEO or CFO of a self-insured company, a
"dollar is a dollar is a dollar," and it does not matter if it is a health care

dollar or a workers' compensation dollar. It does not matter if the
employee is suffering from a mental problem, a physical problem, or a
social problem, or if the problem is or is not related to the job.
Questions about whose cost it is-the employer's or the insurer's or the
carve-out company's-become moot. Rooney comments that such
discussions often end up being silly, if not counterproductive, since the
name of the game is to reduce overall costs and make decisions that are
best for the company as a whole, as well as for the individual employee.

A silo mentality creates inefficiencies, as each manager becomes
concerned with his or her own budget without taking into account the
impact a given choice may have on other budgets. As a result, they can
easily make sub-optimal decisions. As Rooney notes, the power of
financial incentives and performance-driven budgetary objectives is
quite strong. If not properly constructed, these incentives can drive
perverse managerial behavior, i.e., behavior that is completely counter
productive to the company's overall objectives.

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs

our employers who have introduced innovative approaches to
managing mental health challenges are profiled below. These
employers appreciate the treatability of mental disorders when

properly identified and the importance of providing appropriate
treatment and support in order to minimize both the economic

impact of these disorders on the workplace and the personal impact

II

on the employee. Innovations presented have led to reductions in
health costs and length of disability; utilization of creative

approaches in employee assistance programs in managing disability,
productivity, and return to work; and the use of a holistic approach
to managing mental illness.

Employer

Innovations
in Mental Health
Management
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Presenter: Wayne Burton, M.D.,
First Vice President &Corporate Medical Director

Company Profile:

The High Costs of Depression

According to Dr. Wayne Burton, First Vice President and Medical

Director and Dr. Dan Conti, Vice President and EAP Director, depres
sion was clearly taking its toll on the company in the late 1980s and

early 1990s. Evidence of this high toll included the following:

• The incidence of depressive disorders continued to increase at First
Chicago NBD.

• Medical claims for depression were quite high in 1991, totaling
$930,000, almost as much as the $1,200,000 for heart disease.
• Depression represented 52 percent ofall mental health claims

between 1988 and 1991; spouses and dependents accounted for 44
percent ofmedical plan costs related to depression.

• Between 1989 and 1992, depression accounted for 52 percent of all

BANK ONE Corporation

BANK ONE formed as aresult of the
October 2, 1998 merger of First Chicago
NBD and BANC One Corporation. Tfe
resulting company is the parent corporation
of the fifth largest US bank, the largest
credit card issuer, and avariety offinancial
subsidiaries. As of October 1998, the com

short-term disabilities (and 62 percent of all short-term disability

pany employed 98,000 individuals who are

days) related to mental health.

served by ablended employee assistance

• Between 1989 and 1992, the average length of disability for n

• Between 1989 and 1992, depression exhibited the highest rate of
12-month recidivism among agroup of common chronic disorders,

program (EAP). Employees are offered
both aselfinsured medical plan and ammber of health maintenance organizations
(HMOs). Most of the data presented in
this section, however, were derived from

• Between. 1989 and 1995, women accounted for roughly four in five

pre-merger studies, when First Chicago
Corporation had 18,000 employees who

depression was 40 days, which was longer than the average (

duration for many other chronic ailments, including low back?

pain, heart disease, high blood pressure, diabetes, and other ^

mental health conditions.

with roughly one in four individuals with depression having multiple
bouts of short-term disability within ayear of the initial disability.

episodes ofshort-term disability for depressive disorders.

were served by an internal EAP.
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The Response:
Full Commitment to NIMH/WBGH National Worksite Program

To help reduce the negative impact that depression was having on
the company, Drs. Burton and Conti spearheaded a comprehensive
effort to improve the company's ability to identify and get appropriate
treatment for employees with depression in a timely manner. To that
end, the company embarked on a variety of NIMH/WBGH National
Worksite Program initiatives, including the following:
•

Managerial training (initiated in 1992)
This training helps to reduce the stigma associated with mental illness and
assists managers in understanding and recognizing the early signs of
depression as well as the early, subtle signs ofsubstance abuse. The goal
is not to have managers making a diagnosis, but simply to allow them to
identify individuals who could benefit from a referral to the Employee
Assistance Program (EAP).

•

Increased awareness of EAP services (initiated in 1991)

There are now seven clinical psychologists on staff, along with
social workers.

•

Medical plan enhancements (initiated in 1994)
The maximum benefit is now at $2 million. In addition, the benefits
design (particularly outpatient benefits) has been enhanced.

•

Increased awareness for employees of depression as a treatable illness
(initiated in 1992)

This program helps employees to understand the early signs ofdepression
and other mental illnesses.

•

Short-term disability management of all employees that are off-work
for mental health reasons (initiated in 1992)

Psychobgists and staff of the EAP unit serve as case managers.

•

Expanded health risk assessment screening (initiated in 1992)
The assessment now includes questions specifically on depression.

One area that managers at First Chicago NBD paid close attention to
was the management of complex short-term disability cases. A

complex case was defined as one where there was not only a mental
health issue, but a medical/surgical diagnosis as well. In these situations,
EAP involvement became extremely important, since the indirect costs
could be substantial. At First Chicago NBD, the typical complex shortterm disability case resulted in 55 days of missed work, compared to 40
days for the typical mental health case and 28 days for the typical

medical/surgical case. Women represented 89 percent of all complex
cases. Depression, moreover, was the comorbid diagnosis in 61 percent
of all complex cases.
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The Results

Substantial Reductions in Direct Treatment Costs

Between 1991 and 1995, the direct treatment costs for depressive
As apercentage of total mental health claims, the costs of depressive '
disorders dropped from just under $1,000,000 to alittle over $400 000

disorders fell from: 62 percent in 1992 to 45 percent in 1995. (See Figure
1.) First Chicago NBD has proven that acompany can provide avery

Figure 1

Direct Costs for Depressive Disorders,
1989-1995

(Percentage of Mental Health Claims Cost)

rich benefit without "breaking the bank." The key is in successful

62%

management to ensure appropriate and medically necessary treatment.

62%

The primary source of the savings has been reductions in inpatient

care costs, which have only been partially offset by increases on the
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Indirect Costs Generally Holding Steady
Perhaps even more impressive is the fact that indirect costs have not
risen as direct costs have declined. As Figure 3indicates, the average

duration of short-term disability cases for depressive disorders has
remained relatively constant over the past several years.

Opportunities for improvement still exist in reducing the average
ength ofdisability for depressive disorders which remains relatively high
at 42.1 days, near the level for psychosis and much worse than for anx"
ety disorders and chemical dependence, conditions for which managed
care has made great inroads over the last decade in reducing the length

of inpatient stays.

Figure 2

Total Direct Costs for Depressive Disorders
per Covered Member, 1993-1995
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Future Plans: Influence Practice Patterns to Reduce

Indirect Costs, Continue Measuring Results
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Short-Term Disability: Average Duration
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Drs. Burton and Conti firmly believe that BANK ONE can bring
down the indirect costs of depressive disorders as well. By working with
,

,

11

primary care physicians to alter existing practice patterns, they hope to:
•

improve the ability of the physicians to identify depression so
that patients can be referred for appropriate treatment in a
timely fashion;

•

work with managed care organizations to provide individualized,
intensive, tailored treatment for disabled employees with appropri
ate duration of time away from work;

•

enable individuals with depression to return to work earlier on a
measured, part-time basis.

By helping employees reintegrate into the workplace, the company
expects to see an increase in productivity levels, a reduction in absen
teeism, and consequently a significant drop in the overall indirect costs
of depression. Part of this effort will also involve participation in the
NIMH/WBGH National Worksite Program.
Drs. Burton and Conti and their staff also intend to continue

measuring the impact of the different programs in place at BANK ONE.
They are integrating some of the most sophisticated productivity
measures (such as those presented by Greenberg) into their measure
ment system, so as to be sure that improvements continue to occur not
only for the corporation as a whole, but also for employees with depres
sive disorders and other mental illnesses.
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Case 2. Abbott Laboratories: Employee Assistance Programs As
Key Players In Health, Productivity and Return to Work ~

Presenter: Chelle Dainas, Ph.D.

Director, Corporate EAP & Lake County Employee Health Services

Corporate Vision for EAP: Optimize Quality of Life

Company Profile:

Abbott Laboratories maintains an active Employee Assistance

Abbott Laboratories is aglobal, diversified

Program (EAP) whose goal is to improve the quality of life for employ

health care company devoted to the discov
ery, development, manufacture and market
ing of pharmaceutical, diagnostic, nutrition

appropriate behavioral health services are not provided, it is expected

al and hospital products. Abbott is among

and disability costs, and decreased productivity.

the world's largest corporations, with more
than 54,000 employees, apresence in

Key Vehicle: EAP Services

ees and families. Dr. Chelle Dainas, Director ofCorporate EAP and
Lake County Employee Health at Abbott, believes that the failure to
provide effective EAP services results in "sub-optimization." When

that there will be an increase in medical utilization and costs, lost days

According to Dr. Dainas, a 1995 study conducted by Abbott indi
cated that EAP services were cost-effective for mental health/substance
abuse (MHSA) disorders.7 The study compared the inpatient costs of

approximately 130 countries and worldwide

sales approaching $12 billion.

MHSA services with the total inpatient costs for all health services

Employees can choose from four basic
health plans: Point of Service (POS),
Preferred Provider Network (PPO),
HMO, and Indemnity. Mental Health and

between two populations—those receiving EAP services and those not

receiving EAP services. The results showed that among those receiving
EAP services, MHSA inpatient costs were higher; however, overall

inpatient health care costs were significantly lower. For example,
MHSA inpatient costs were $4,000 higher for those with mood disorders
receiving EAP services, while total inpatient costs (including both
medical and MHSA) were $8,500 lower. The study demonstrated a

substance abuse coverage is carved out of

similar phenomenon for combined outpatient and inpatient costs, with

all health plans excluding HMOs.

overall costs about $3,500 less for those in the EAP.

Disability plans include: short-term medical ^

leave of absence, extended disability leave,
workers' compensation benefits.
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The findings of this study also support the medical offset theory,

Swhich postulates that offering appropriate behavioral health services
Sseems to diminish utilization of additional medical services, resulting in

(, lower total health care costs. Thus, paying more for MHSA services
appears to result in lower overall health care costs.
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Dr. Dainas suggests that the benefits of the EAP go well beyond

Figure 4

overall health care costs. Therefore, in future studies, Abbott will eval

1995 EAP Cost-Benefit Study:
Average Inpatient Benefit Costs

uate the impact of the EAP program in reducing absenteeism and

improving productivity. The study mentioned above did not include the
HMO population, which now represents roughly a third of all employ
ees. Abbott plans to work with its HMOs in order to include their data

$20,000 r

SI 5,000

in future studies.
si o.ooo

Action: Proactive Disability Management Program
S5.000

In 1994, an Abbott task force was formed to study opportunities in

the area of disability management for all medical leaves. The following
problems were identified:

•

so
Mental Health/
Substance Abuse

The approach to managing medical leaves was more reactive

than proactive. Case management began only after employees
entered into extended disability leave or when return-to-work
problems arose.

•

Management efforts in different administrative areas/functions were
not always communicated resulting in a fragmented approach. For
example, staff of Human Resources was aware of job performance
issues, while Employee Health staff had medical information relating
to the employee's ability to do the job.

•

There were missed opportunities to keep employees working.

•

Providers were unfamiliar with jobs and the workplace.

•

Employees were becoming psychologically "disemployed" when away
from the workplace for an extended period of time.
As one might expect, these problems resulted in significant costs

related to health care:

•
•

Workers' compensation costs had doubled in the previous five years.
Extended disability costs were increasing at a 10 percent
annual rate.

•

Short-term disability costs were higher than average.

•

There were productivity losses related to delays in employees return
ing to work. '
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Based on the findings, the task force recommended implementation
of a proactive disability management process. The explicit goal of the
program is to optimize employee health and productivity, rather than
focusing solely on returning employees to work. This emphasis was
chosen so employees would fully appreciate the company's philosophy:
When employees are healthy, they are more productive, and when
employees receive appropriate treatment in a timely fashion, they are
more likely to return to work earlier.
Key components of the program:

•

Early identification of employees on short-term medical leave

allows a proactive approach. As soon as employees know that they
will begin their medical leave, Dr. Dainas' Employee Health
Services program is notified.

•

Case management is provided throughout the medical leave. Case
managers work directly with the employees, their providers and
managers. All relevant issues are taken into consideration and judg
ment is exercised to balance the needs of all parties involved. Good
case management facilitates intervention, enhances the recovery
process, and coordinates the return-to-work plan. Such a proactive
approach also can prevent extended disability leave.

•

Liaison is established between the company and health care
providers. Employees are referred to appropriate treatment and

providers. Case managers consult with providers regarding the
medical leave process and the workplace. This liaison function is
especially important with providers, who need more education

about the specific requirements of the workplace when making
recommendations regarding medical leave, work restriction, and job
accommodation.

•

Follow-up services continue with employees after their return to

work. As needed, case managers maintain contact with employees
to monitor work restrictions as well as assure that their medical

condition remains stable. Case managers also educate managers
regarding return to work accommodations or misconceptions
regarding illness. For example, some managers may feel that
employees should not come back to work unless they are operating
at "a hundred percent." Or managers may think they should not
address job performance problems with employees who have psychi
atric disabilities.

24
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Quality assurance evaluation tools have been established to analyze
the program impact on lost time utilization patterns and related
costs, as well as employee satisfaction. In addition, quality improve
ment (QI) monitors have been implemented to ensure that the
process works the way it is supposed to. The QI monitors include
very detailed standards that define procedures and level of perfor
mance. Each quarter, random samples of client files are audited to
ensure that standards are met. Case managers receive additional
training in any areas that are identified as problems.

The project began with a pilot site, which offered many valuable
lessons. A steering committee, headed by Dr. Dainas, is now responsible
for applying these lessons in rolling the project out across the country.
As of November 1998, the program has been fully implemented at three
locations. By the end of 2000, plans are to roll the program out across
the remaining twelve Abbott locations and field sales population.

A Human Perspective: Disability Case Managemen
T h e following psychiatric disability case illus
trates the benefits of an effective disability
management program. An office assistant in
her early thirties was a divorced single mother with
two children. Her manager, having observed her
recent problems with concentration and productivity,
referred the employee to Abbott's EAP.
Due to the severity of the employee's condition,
the EAP recommended that she be placed on medical
leave. The employee, who had a history of childhood
abuse and symptoms of depression, had been under
the care of a psychiatristand therapist. These
providers were not responsive to the EAP's request
for additional evaluation and more intensive outpa
tient treatment. Therefore, with the employee's
agreement, she was referred to in-networkproviders,
a psychiatrist and psychologist team, who quickly
determined that she needed more timely intensive
care. Her medications were modified and she began

partial hospitalization treatment. The EAPcase
manager also arranged for the employee to receive
financial assistance through a company program,
which helped to reduce her level of stress.
After seven weeks, the woman had stabilized
and was returned to work. However, shortly

thereafter, she had a relationship break-up, and
quickly slipped back into a crisis mode, including
suicidal ideation. The employee was again placed
on medical leave and her providers admitted her
into an inpatient program. After a few days in
the hospital, the employee stabilized again,
returned to partial hospitalization, and began °
attending a depression support group.

Within six weeks time, the employee returned to
work for the second time. .This time, she was eased
back into the work routine, beginning on a part-time

basis, and slowly increasing her work hours. Within
a month, she returned to full-time work. The EAP
case manager maintained contact with her after the
return to work, and also worked with the employee's

manager to ensure a successful transition back to
work. This employee has since demonstrated posi
tive progress with a good prognosis.
Over a ten-month period, the EAP had made a
total of 163 contacts with the employee,

providers, and company personnel. This invest
ment in support has enabled an employee who
had been a probable candidate for long-term
disability to remain productive.
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Case 3. Owens Corning:

Expanding the Employee Assistance Program Role in Managing Disabil

Presenter: Amy Ahrens
Leader, Integrated Health Services

Senior management of Owens Corning believes in the quick devel

opment and implementation of innovative programs and strategies that
support the company's core values of customer satisfaction, individual
dignity and shareholder value. According to Amy Ahrens, Leader of

Company Profile:
Owens Corning

Integrated Health Services at Owens Corning, the company's philoso
phy is that employees must be given individual autonomy and responsi
bility. Employees are provided with employment, hut they must work

Owens Coming is a global organization in

with management to reach the shared corporate goals.

With more than 18,000 employees world

Toward that end, the company is currently embarked on a major

campaign to re-engineer core processes within the organization. Senior
management has also introduced a variety of programs that are designed
to motivate employees to contribute to the company's overall success.
These programs encourage employees to provide their perspective on

the business of manufacturing fiberglass.

wide, the company strives to enhance cus
tomer satisfaction, individual dignity and
shareholder value. These guiding pnnciples

how to reduce waste, cut overhead costs, boost productivity, and the

extend to the company's disability manage

like. By introducing programs that include wage and/or stock incen
tives, the company hopes to create an atmosphere of greater employee

ment program, which is integrated within

autonomy, innovation, and creativity.

()wens Comings Rewards and Resources

Problems with Disability Management

Department—more commonly thought of as
a compensation and benefits program.

A few years ago, short- and long-term disabilities related to both
physical and mental health represented a major problem area for Owens
Coming. The disability management program was not integrated-in
other words, workers' compensation-related disability claims were not
coordinated with non-occupational claims. Consequently, individuals
on workers' compensation received a tremendous level ot service; every
thing possible was done to accommodate the employee and hasten the
return to work. At every large location, there was a full-service occupa
tional health clinic on-site, staffed by at least tine occupational health
nurse and a plant physician. (That said, these sites did not engage in
much medical management.)

But individuals suffering from non-occupational disabilities were

largely ignored. The prevailing attitude was "out of sight, out of mind."
Some employees who had been out ot work for 10 years had never been
contacted by a company representative. At any point in time, Owens ^
Corning had 880 out of 12,000 employees on long-term disability, at a (
tremendous cost to the company. Each year, about 100 additional
people joined the rolls. Many were not returning to work.
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The Solution: Integrated Health Services-

A Comprehensive Disability Management Program
In 1990, Owens Corning began to implement a change. A compre
hensive disability management program was created, thanks largely to
the head of the department who pulled together a team of middle
managers from risk management, finance, compensation and benefits,
health care, retirement, and payroll to put together a new and
improved program.

Owens Coming's short-term disability program is self-insured and
self-administered. The company uses a consistent definition and
provides the same management of disabilities for all employees. A
disability is defined as a condition that renders the employee unable to

perform his or her own job or, after 18 months, unable to perform any
job offered. The company integrates benefits, including workers'
compensation and Social Security. While the administration of workers'
compensation is outsourced to a vendor, that vendor has a dedicated

unit on-site at the company's headquarters in Toledo. These individuals
work full-time on the Owens Corning contract. The interface between

short- and long-term disability is handled through UNUM Life
Insurance Company.

The team concept is at the core of the program. At both the corpo
rate and local sites, the "Total Health team" consists of the treating
physician and the employee, as well as representatives from occupational
health, disability management, human resources, EAP, wellness, safety,
labor unions, and industrial relations. As of 1997, the company had 25
dedicated on-site disability case managers that were either certified
occupational health nurses or vocational rehabilitation counselors.

The expectation from the first day that an employee leaves work is
that he or she will return to his/her original job. In the first conversa
tion with the individual out on leave, the case manager raises the issue
of when it is reasonable to expect the employee to return and begins to
work with the employee to put in place a plan to provide any and all
necessary services (such as transitional work or the use of assistive equip
ment) to achieve that goal. That plan focuses on preventive services
that can reduce the likelihood of further functional decline, as well as
interventions and treatments that serve to minimize costs and encourage

rehabilitation and an early return to work. When necessary, employees
are sent to an out-of-network provider to receive needed services. The

underlying philosophy is that "whatever it takes, Owens Coming's
program will provide it." But the quid pro quo is that employees must
cooperate and comply with the plan. In other words, employees are not
"entitled" to workers' compensation and/or short-term disability. As
Owens Corning employees, individuals must cooperate with the disabil
ity management program.
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I Owens Coming's program emphasizes comprehensive services from
the first day of disability. The diagnosis must support the leave of
absence-even if the absence is only for one day. The disability case
manager will contact the individual and his or her doctor to ensure that
the diagnosis is consistent and that the individual does indeed meet the

definition of being disabled. To achieve this task, the case manager will
work with the doctor to ascertain precisely what it is that the employee
can and cannot do. Then, after evaluating the requirements within the
workplace, Owens Coming staff will make the determination of whether
or not the employee is in fact disabled.

Assuming that an immediate return to work is not possible, the
team will then jump into action to try to come up with a plan to get
the employee the assistance needed to return to work as quickly as
possible. Through one-on-one attention and coordination of benefits,
services, and resources, the team strives to provide the employee with
the right treatment at the right time for the right price. In some
instances, this step involves finding a meaningful, new position to
which the employee can return. In these cases, Owens Corning staff
focus on the abilities of the employee, and try to match those abilities
to the job requirements and essential functions of different available

positions. To assist with this task, the staff of Owens Corning is work
ing to develop consistent definitions of essential functions; presently,

different departments have different rules. They are undertaking a
similar task to develop consistent rules regarding issues such as job
accommodations and communications.

28

Investing in Workplace Productivity: Innovations in Managing Indirect Mental Health Costs

How It Works for Individuals with Mental Health Disabilities
Mental health problems are within the top three diagnoses for short-

term disability. The company sees an average of40 lost-time claims per
year with mental health as the primary diagnosis. (Other individuals for
whom mental health is a secondary diagnosis are not included in this

figure.) On average, Owens Corning is seeing about 1,300 claims per
year from its United States employee base of 13,000 individuals.

All mental health disabilities are coordinated between headquarters
and the site where the employee works. For individuals with mental

illness as a primary diagnosis, the EAP counselor—working out of a
centralized, dedicated unit at corporate headquarters in Toledo—serves
as the primary disability manager. These individuals work (mainly by
telephone) with the site case manager in an effort to get the person back
to work as quickly as possible.

The EAP counselors also serve as coordinators with managed care
providers. EAP staffhas responsibility for approving providers and
developing the in-network list and is responsible for coordinating
disability leave.

Ahrens believes that the disability management program has gener
ally been a success story for the company. A consistent definition of
disability is being used across the company, while integration of the
management of physical and mental health disabilities has occurred at

all the company's locations. Occupational-related and non-occupa
tional-related disabilities are now all treated the same. At most loca

tions, there are comprehensive disability case managers on-site.
Figure 5

Comparison of Disability-Related Costs:
1992 and 1996

As a result of all of these efforts, the company has been able to
reduce its disability-related costs dramatically, from $25,000,000 in 1992

to $13,400,000 in 1996. This reduction has occurred in most major
categories of costs:

s io.ooo. ooo r

•
S8,ooo.ooo -

Health care expenses fell dramatically, from $8,900,000 to
$3,400,000.

S6.000.000 -

Long-term disability costs fell sharply as well, from $4,500,000 to

S4.000.000 -

$2,400,000.

$2,000,000 -

Workers' compensation costs fell from $9,600,000 to $5,000,000.

/
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Only the costs of short-term disability have risen, from $2,000,000 to
1992

1996

Health Care

1992 1996

Long-term
Disability

1992

1996

Workers'
Compensation

1992 1996

Short-term
Disability

$2,600,000, most likely because many individuals who previously
required a long-term leave of absence are now returning to work aftet
taking a much shorter amount of time off the job.
/
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But Further Improvement Is Still Needed in Mental Health
Despite the successes outlined above, Ahrens would like to see
further improvement, particularly in the area of mental health. The
average length of disability excluding mental health cases is 20 days.
Including the 40 mental health cases seen each year, the average dura
tion jumps to over 45 days. These statistics suggest that the mental
health piece may not be treated as consistently and effectively as it
could be.

One Problem: More Case Managers Needed

A big problem facing Owens Corning is that the EAP personnel are
overburdened. The staff has not grown in conjunction with the increase
in the population being served, resulting in EAP counselors falling
behind in their efforts to work with the providers and coordinate bene
fits. They are also having difficulty keeping track of which providers are
in and out of the network, particularly in locations where there are few
employees, and therefore few claims each year.
Second Problem: Still Too Departmentalized

While Owens Corning has made great strides in knocking down
walls and reducing the "silo mentality," more work needs to be done in
this area.

Owens Corning is putting in place an integrated information
system that will encompass not only medical, human resources, and
payroll data, but also other information, such as safety and industrial
hygiene data. The system protects employee confidentiality by giving
different levels of clearance to different types of personnel. For exam
ple, a disability benefits specialist can pull up medical records to see
what the employee has been treated for and whether there are any
EAP issues. An EAP coordinator, however, will be able to look at
more detailed information.

Finally, at the corporate level, Owens Corning staff are setting over
all health goals for the company and charging the local health teams at
individual locations to initiate programs that will meet those goals.
Ahrens notes that locally adopted solutions tend to work better. For
example, corporate personnel would have little success pushing a smok
ing cessation program in facilities that are situated right outside
tobacco country.
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Case 4. Digital Equipment Corporation: A "Life Cycle" Approach
Presenter: Bruce Davidson

Manager, Work/Life Programs
•'4*J|f

Company Profile: Digital

Equipment Corporation
As ofJune 1998, Compaq Computer

Corporation acquired Digital Equipment
Corporation. This case represents work of
DIGITAL up to the date ofacquisition. As
of the date ofthis publication, benefit

designs and strategies across the former
DIGITAL and Compaq are being integral
id, with 1999 being a transition year.

The data presented in this section were
derived from pre-merger studies, when
DIGITAL had 24,000 U.S. employees,
who were served by a variety ofHMOs.

Why Get Involved? Let Me Count the Reasons
Bruce Davidson, Manager of Work/Life Programs at Digital, states
that the company had many reasons for getting more involved in the
management of health illness. As a company in the field of high tech
nology, Digital needed a high-performing work force; lapses in concen
tration and indecisiveness simply were not acceptable. Given the rapid
pace of technological innovation, Digital had to stay ahead of the
market, so its engineers and other employees had to be at the "top of
their game" at all times. Employees had to continually be trained and
educated on new technologies on both the manufacturing and the
design side. Product defects could set the company back significantly.

At the same time, however, Digital's highly trained and accom
plished workforce demanded more and more balance between work and
"play" in their lives. Thus, Digital had to put in place the kinds of
benefits programs that provided for this balance, including those that
limited the impact of common workplace-related issues, such as stress
and depression. Such programs served to both attract and retain topnotch talent.

Furthermore, the cost of mental health problems was quite high.
\
According to Davidson, interventions in this area provided an attractive )
return on investment, generating perhaps $3 to $4 in savings for each /
dollar invested. Finally, many employees may have had nowhere else to
turn when looking for help with their problems. Fewer and fewer

community resources exist to assist individuals suffering from mental
illness. Those that do exist are highly fragmented. In many cases,
therefore, the employer has become a primary source of help.
Digital Equipment Corporation (Digital) devised a unique strategy
for tackling the problem of mental illness-related disabilities. By hold
ing its health plans strictly accountable for a variety of performance
measures, Digital put in a place a system that ensured a high-quality,
holistic approach to managing mental illness.
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A Conceptual Model for Managing the
Costs of Mental Illness

The driving force behind Digital's programs and initiatives was a
model that attempted to redefine exactly what goes on from an
employee's point of view. Benefit structures and communication of
these structures were also redefined across this "life cycle."

Traditionally, the systems that delivered care within this model were
fragmented, with hospitals and other provider systems at the lower level
and EAPs and wellness programs up toward the top. Worse yet, these
systems were very reactive in nature, waiting for patients to come in.
What Digital was trying to do was to mesh these programs together; to
challenge these disparate, fragmented systems to begin to integrate and
deliver services in a more aggressive and coordinated fashion across the
entire life cycle; and to proactively work to manage the risk of the entire
employee population.

Figure 6

Digital's Life Cycle Model
Information and Prevention

Early Detection

Brief Counseling
Health Care System

A Practical Strategy for Applying this Model: Performance
Standards to Ensure Achievement of Objectives
Digital developed a unique approach for applying this life-cycle
model. The company relied upon the roughly 80 or so HMOs with
which it contracts to provide top-notch service and care. To ensure that
this occurred. Digital developed a detailed set of performance standards
upon which all HMOs were judged.

In the late 1980s, Digital faced the same problem that most major
corporations did: rapidly rising health care costs. In looking for a way
to manage care in a cost-effective and high-quality manner, Digital's
senior management decided to turn to managed care, and to develop a
set of objectives for each contracted managed care company to pursue.
These objectives centered around four critical areas: quality of care,
access to care, choice of plans and providers, and cost effectiveness.
To achieve these objectives, Digital first set about the task of identi

fying and contracting with a set of HMO partners that offered highquality care. To ensure adequate choice, the company designed
point-of-service options (at a time when few HMOs offered such
options). Digital was committed to ensuring that the quality of care and
service delivered by the HMOs was high and developed a detailed set of
performance standards around five key aspects of quality:
•

Access to care/member satisfaction

•

Quality of care

•

Mental health and substance abuse

•

Information management and reporting

•

Financial controls
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These standards have gone through three different iterations. The
most recent set of revisions was quite extensive, emphasizing in particu
lar the concept of moving toward a more organized system of care deliv
ery. In particular, some of the key changes in the latest set of revisions
focused on the following:
National Committee for Quality Assurance (NCQA) accreditation
by HMOs and behavioral health care companies

•

NCQA-approved member satisfaction survey

•

Women's health

•

Health education and preventive services

•

Information management

Specific Performance Standards for Behavioral Health
Davidson notes that Digital also included specific standards for
behavioral health care that included performance measurement in the
following areas:
•

Flexible Benefit Design

Digital looked for a design based on medical appropriateness and the
management of care. Consequently, Digital management did not
believe in benefit limits, which were seen as an artificial means to limit

care. Measures that had to be reported in this category included the

number of behavioral health cases that were "flexed," divided by the
total number of cases seen by the plan.
•

Quality Management

Digital had developed a number of measures to gauge the quality
management and improvement capabilities of its participating plans.
•

Access and Triage

Digital held its plans accountable for providing timely access to
preventive, primary, and specialty care services, including the use of
programs that triage individuals to the appropriate levels of care in a
timely fashion. A variety of specific measures were developed to evalu
ate plan performance in this area.
•

Case Management Based on Individual Need

Digital was looking for very aggressive case management to deal with
the complexities of behavioral health, particularly for individuals at risk
of high-cost hospitalizations. Case managers were assigned to inpatient
admissions and "at risk" cases to develop and implement a plan of care
and to coordinate with internal and external systems (e.g., the Primary
Care Physician, Employee Assistance Program, Occupational Health,
Disability Management) to ensure a timely return to work.
Unfortunately, at the time that Digital first proposed these standards,
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many HMOs did not understand case management. They lacked the
capabilities to follow patients through the system, and instead adopted
an episodic, reactive approach. In some instances, the HMO did not
even know when a patient had been discharged from the hospital so no
one was aware of the need to provide follow-up care.
•

Outcomes Measurement

HMOs were required to collect data to test the effectiveness of treat
ment, to document value, and to improve quality. The company did not
want to see plans that blindly follow protocols, formularies, or other
standards. Rather, the HMOs had to test the efficacy of any standards

by collecting information and evaluating service outcomes. To that end,
Digital required more than 60 measures to be tracked in the behavioral
health area.

•

Prevention, Education, and Early Intervention

Digital required its HMOs to be actively involved in improving
health and supporting healthy behaviors, and to provide comprehensive,
integrated health education and preventive care services relevant to the
specific health status needs of employees. To that end, Digital asked its
HMOs to begin educating primary care physicians and teams to recog
nize cases of depression, substance abuse, and domestic violence. The
company also urged HMOs to develop clear protocols around how and
when referrals to behavioral health specialists take place. Finally,
Digital required that HMOs come up with a system for integrating
information related to behavioral and physical health. Patients expect
their doctors to be able to assess both types of problems. Without
adequate education and information, this was not possible.
To assist HMOs in these tasks, Digital worked with the plans in
setting up the following kinds of worksite activities:
•

Consultations on the use of health risk assessments and related
educational interventions

On-site education and support programs based on risks and
claims data
•

On-site health promotion programs, including immunization
and screenings

The underlying rationale for these types of interventions was that the
worksite provided an excellent setting for the delivery of preventive,
screening, and educational services. Several years ago, Digital ran 40
health fairs at various sites around the country which offered services
such as flu immunizations, cholesterol screenings, sugar screenings, body
fat screenings, and education. HMO partners provided the entire deliv
ery system at the fairs; as a result, the whole series cost Digital only
$40,000.
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Another example of this type of program can be seen in a partner
ship between Digital and Harvard Pilgrim Health Plan to provide exten
sive educational information and advice to employees via an intranet
system. In addition to offering educational materials, the Web site
provided links to other important sites and offered a "physician forum,"
where employees could ask physicians medical questions directly.
Responses were available through an electronic bulletin board to anyone
who was interested. The HMO also offered all members a health self-

assessment book and a 24-hour nurse hotline, and was working with
Digital on an extensive health risk appraisal program that would give
employees the option of completing the appraisal on paper or on-line.
Results would be made available quickly to the employee, who would
have the option of having the health plan forward the information to
his/her primary care physician, along with recommendations and guide
lines to deal with identified problem areas.

Finally, over the last several years, Digital was involved in a tele
phonic screening program8 for depression, developed by the National
Depression Screening Project, and has found the program to be an enW
tive way of reaching many people in a short period of time, including
individuals who had never sought professional help before. In the first
year, 4 percent of employees used the device during the 30-day period it
was available, with 75 percent of users exhibiting some level of depres
sion. In year two, utilization was 4.5 percent during the 90-day period
of availability; 70 percent of callers in year two had never seen a treat
ment professional for depression. Finally, in the third year, utilization
jumped to 5.5 percent, primarily because the system was available during
the holiday season. One half of all callers had never sought professional
help before, even though 70 percent had some level of depression. Ten
percent of users exhibited signs of severe depression and were counseled
to seek professional help right away.
•

Integration with Primary Care

As noted earlier in this case, primary care physicians often
missed opportunities to detect cases of mental illness; RAND

Corporation studies suggest that they miss as many as 40 to 50

percent of depression cases.9 To correct this problem, Digital helcj
HMOs accountable for ensuring that integration takes place, even
if they use a carve-out company. Digital management believed that
behavioral health and physical health initiatives should be fully
integrated to promote a holistic approach to healthcare. The^goal
was to give primary care physicians access to a mental health

professional for consultation, and to provide for easy referrals when
necessary. Davidson noted that some interesting, innovative models
are evolving to achieve this type of integration.
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A Vision for the Future

All of the activity at Digital is headed in the direction of high-qual
ity, well-organized systems of care that are responsible for (and account
able to) an entire population. These systems:
•

integrate the financing and delivery aspects, since organizations
cannot survive without knowing true costs;

•

offer a wide range of comprehensive services, coordinated across the
entire continuum of care, either through ownership or contractual
partnerships; and

•

put in place programs to allow for continuous quality improvement.

Realizing this vision, however, was no easy task. As a company that
operated in 48 out of 50 states, Digital faced a difficult task in manag
ing a diverse set of delivery systems against a common set of standards.
And, as Davidson noted, the biggest challenge seemed to be in inte
grating "the body and the mind." For a variety of reasons, the systems
and paradigms in health care have historically "orphaned" behavioral
health care. Digital was trying to determine how to bring behavioral
health care back into the fold, into an integrated system where plans
and providers are responsible for the whole being. Toward that end,
Digital was continually seeking out innovative benefit designs and
practices that deliver preventive, screening, and treatment services
based on clinical need, using a broad continuum of resources where
outcomes could be measured.

Screening for Mental Health:
The Computer-Assisted Telephonic Interview
D r . David Whitehouse, Senior Vice President

and Corporate Medical Director of MCC
Behavioral Health, recommends another tool

a series of questions about themselves or a loved

one. The system provides an immediate feedback as
to their mental health status. Once the feedback is

that organizations can consider using as part of the
effort to boost prevention and screening servicesfor
mental health—a new technology known as CATI:

received, the caller has two options: the informa
tion can be immediately aborted, or at the press of a
button, it can be sent on to the patient's primary

computer-assisted telephonic interview. Under the
program, the patient or employee can call a number

next visit.

care practitioner so that it can be discussed at the

at any time, day or night, and answer telephonically
. 'iM
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Executing the change in perspective required to adopt the "purchas
ing for productivity" model is by no means an easy task. Getting
employers to look at benefits and human resource functions in a

new light, let alone to rethink the traditional role of physical and
mental health benefits, is a Herculean endeavor requiring consistent and
tireless communication, cooperation, monitoring, and management.
The following recommendations are presented to help managers begin
to develop change strategies that are effective in overcoming resistance

JLJ. JL*

and emphasizing the positive aspects of change.

v'^

Moving Forward:
Recommendations
for More Effective
Management of

Mental Health

Recommendation 1:

End the Stigma Attached to Mental Health Problems

Recommendation 2:

Invest to Maximize the Cost/Benefit of Treatment

Costs
Recommendation 3:

Integrate the Management of
Health/Human Resource Programs

Recommendation 4:

Coordinate Primary/Mental Health Care

Recommendation 5:

Recognize Co-Occurrence of Illnesses

Recommendation 6:
Measure Outcomes
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End the Stigma Attached to

Recommendation

Mental Health Problems
O n e ongoing challenge is to reduce the stigma associated with
mental health problems felt by managers as well as employees.
From her vantage point, WBGH's Dr. Mary Jane England
emphasizes the tremendous stigma attached to the very idea of mental
illness in the workplace, and even more so when additionally associated
with substance abuse. Despite some signs of improvement, society still
struggles to accept the idea that mental disorders are true medical
illnesses and not the result of a weakness of character.

NIMH's Dr. Steven Hyman recalls that it was only 15 years ago that
writings in the field espoused the idea that mental illness was somehow
rooted in subtle unconscious forces, moral failings,- and/or the inability
of people to take responsibility for themselves. Alcoholism, for exam
ple, was seen as a weakness of will, a bad habit of an undisciplined indi
vidual. While experts today recognize that these old theories have no
scientific grounding, such perceptions are slow to fade. As a result, indi
viduals with mental illness may not be identified or treated in a timely
manner, even though effective treatments do exist.
Mental illness is less well understood as a disease of the brain than

most physical illnesses, since research into the brain is still ongoing.
Also, since the brain is the most complex organ in the human body,
science's understanding of mental illness is well behind that of other
common illnesses, such as heart disease or cancer. This "research gap"
serves to further heighten the stigma associated with the disease.
The good news is that science is making progress towards closing that
gap. Research is beginning to demonstrate that different mental disor
ders are specifically caused by abnormalities in individual brain circuits.
The scientific understanding is only about 50 percent complete at this
point, but with sufficient research, the stereotypes and stigmas presently
associated with mental illness should die out.10
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Dr. Hyman notes that once we establish that different mental disor
ders are diseases of different circuits of the brain, there will be no basis

whatsoever for discriminating between physical and mental illness. Just
as coronary artery disease is rightfully seen as a disease of the heart, and

hepatitis a disease ofthe liver, mental illness will simply be viewed as a
disease ofa different organ-the brain. Under this view, continuing to
treat mental disorders as different from physical disorders is simply
discrimination against people who have relatively common and serious
diseases of a particular organ.

In the workplace, stigma may impact productivity by keeping
employees from seeking help. Stigma may also contribute to a supervi
sor's failure to understand the relation between mental and behavioral

health problems and employee behavior and performance and diminish
the supervisor's willingness to deal with the employee, make accommo
dations, and when appropriate, encourage and support the return-towork process. Stigma may also contribute to the reluctance of

decision-makers to accept the broader concept ofpurchasing for produc
tivity, including investing in human capital, by providing appropriate
health and other human resource supports.

Positive steps to reduce stigma involve educational and management
policy and practice initiatives such as those outlined in the

WBGH/NIMH (formerly D/ART) National Worksite Program publica
tion Managing the Impact ofDepression in the Workplace: An Integrated
Approach,11 i.e., educating managers and employees regarding depression
and other behavioral disorders, redesigning benefits to maximize early
recognition and appropriate treatment, broadening use of Employee
Assistance Programs (particularly regarding accommodations and back-

to-work strategies), encouraging coordination among corporate human
resource programs, improving data collection, and monitoring health
plans to ensure access to and proper treatment for mental and behav
ioral health problems.
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Invest to Maximize the

Recommendation

Cost/Benefit of Treatment
A

second issue to consider in realizing the vision of "purchasing

for productivity" is misconceptions about the cost/benefit of
mental health treatment. Many employers are still concerned
that the costs of mental health care are going to "break the bank,"

particularly since the passage offederal legislation that calls for parity
in insurance coverage between mental and physical disorders.
However, Dr. Steven Hyman notes that concerns about cost are exag

gerated, since they reflect data from the fee-for-service sector that are
generally irrelevant today as we head into the world of managed care.
The key is to use appropriate management principles, fundamentally
the doctrine of medical necessity, and for employers to recognize that it
is in their interests to recognize and intervene in common and
disabling mental disorders.

A May 1988 NIMH report to Congress on Parity in Financing Mental
Health Services: Managed Care Effects on Cost, Access & Quality,12 indi
cates, "In systems already using managed care, implementing parity
results in a minimal (less than 1 percent) increase in total health care
during a 1-year period. In systems not using managed care, introducing

parity with managed care results in a substantial (30 to 50 percent)
reduction in total mental health costs." As one example, a major West

Coast employer13 tracked the results ofchanging to a carve-out behav
ioral health plan and introducing managed care for approximately
179,000 covered lives between 1988 and 1996. In the first year, mental
health costs were reduced 40 percent, with costs continuing to decline

slowly in the next six years, despite an increase in the number of persons
receiving mental health care following the change.
Further, as shown in the cases presented earlier in this publication,

investing in employee mental health can produce other benefits, includ
ing a reduction in disability and absenteeism costs and a faster return-towork. As a further example, a study conducted by Johns Hopkins
University's School of Hygiene and Public Health for the UNUM
Corporation14 found that, when employers had low deductible provisions
in their health benefit plans, psychiatric claims were one-fifth of the
rate expected for employers with higher deductibles, the rate of returnto-work was about 50 percent higher, and the duration of disability
about one-third the length. When mental health "carve-outs" were
used, the duration of disability was reduced by 38 percent.
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Recommendation

Integrate the Management of
Health/Human Resource Programs
There was general agreement among presenters and participants at
the Spring 1997 Investing in Worksite Productivity meeting
that managing the utilization of behavioral health services has

been quite successful in accomplishing its stated objective: the costs of
providing mental health and substance abuse services have gone down
dramatically. In fact, costs have dropped so much that the mental
health and substance abuse components of insurance products are now
considered commodities from a price perspective; the costs of these
premiums seem unlikely to go any lower.

But MCC's Dr. David Whitehouse and otherexperts expressed the

belief that evaluating the success ofmajor employers in keeping direct
mental health costs down does not provide a full picture. Viewing these
mental health costs from a single "silo" perspective has, in fact, created

other problems—primarily because it keeps employers from focusing on
the indirect costs ofmental health and substance abuse problems. In
particular, it prevents them from realizing that a narrow emphasis on
direct costs could, in fact, yield negative consequences by driving up the
indirect costs, such as reduced productivity, increased absenteeism and
prolonged disability. Whitman Corporation's Ray Werntz reinforces this

point by discussing the interplay between medical costs, disability costs,
and workers' compensation costs. Pushing too hard on one of these cost
sets can have an adverse effect on another. For example, an exclusive
focus on controlling the health care costs associated with mental illness

might have a negative effect on disability, workers' compensation, or
other costs.

Perhaps nowhere is evidence of this misguided approach more
evident than in the arrangements that many companies have with
mental health "carve-out" companies. Companies that carve out mental
health benefits, and then reward their vendors based solely upon the
overall costs ofproviding mental health services, are inviting their
vendors to under-invest in the types ofstrategies that might boost
mental health care spending, but could have an overall positive impact
on the company in terms of higher productivity, reduced absenteeism,
and/or increased levels of creativity and innovation.
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Dr. Whitehouse points out that a carve-out mental health company
never goes "looking for business." These companies do not seek to
proactively identify individuals with mental illness. They benefit
economically if the case is not identified as needing referral, and they do
not bear the costs of absenteeism and lost productivity when the illness
is discovered later. Studiessuggest, in fact, that referrals to the mental

health carve-out company do not occur as frequently as they should; 60
to 70 percent of behavioral health services are still delivered in the
primary care arena.15

To rectify this situation, companies must end a "silo" approach to
managing mental health services. According to Dr. England, Dr.
Hyman, and other experts in the field, employers simply can no longer
afford to look at the direct costs of mental illness in isolation. It is in

their best interests to manage both the direct and indirect costs of
mental health. Leaders must recognize that managing these disorders
will not in fact "break the bank," but rather will result in greater overall^

profits through reduced absenteeism, higher productivity, and greater
creativity. As many corporate executives have come to realize, it is a
lot less expensive to pay for a few office visits or medications than it is
to pay a high-salaried employee while he or she is on short- or longterm disability.

In short, then, budgeting and responsibilities must be set up so j
that departments and senior managers begin to look at the "big
picture" when evaluating the merits of different strategies and
programs. Only then can decisions be made that are optimal for the
company as a whole.
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Recommendation

Coordinate Primary/
Mental Health Care
Primary care providers often lack the knowledge and skill necessary
to adequately detect and, where appropriate, treat mental illness or
refer patients to mental health specialists. This issue is further
complicated by limitations in time that can be devoted to each patient.
Primary care practitioners are frequently not aware of the extent to
which mental health (e.g., depression and anxiety) and substance abuse
disorders are present in their patients, since the presenting problems as
expressed by the patients may not appear to reflect mental healthrelated conditions. Many physicians are not knowledgeable about the
symptoms of mental and behavioral disorders, and additionally, may not
be sensitive to the presence of depression as a separate disorder in
patients with medical illness.
Moreover, even when physicians recognize mental health-related
problems, they may not feel comfortable discussing these issues with
their patients, may be ill at ease in using screening instruments, and
most important, may not have mental health consultation readily
available. As a result, in the primary care sector, many cases of poten
tially impairing mental disorders are neither detected nor given appro-/
priate treatment. As noted earlier, a study of the recognition of
depression conducted by the Rand Corporation showed that depres
sion in patients seen in the primary care sector was not recognized in
40-50 percent of cases.16
Significantly, many patients with mental disorders become "high
utilizers" of medical care. Studies of costs in prepaid health mainte
nance organizations (HMOs) have found that a relatively small percent
age of patients accounts for a disproportionate amount of medical
utilization.17 Since studies have also identified depression as a factor
common in "high utilizers," the question then arose as to whether the
cost of providing mental health treatment for these patients would be
offset by a reduction in overall medical costs as well as a decrease in
disability and other work-related indirect costs.
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In one Seattle, Washington HMO, for example, researchers found
that 15 percent of patients accounted for 64 percent of total health
care costs.18 Studies of "high utilizers" in two of a Madison, Wisconsin
HMO's primary care clinics showed that treatment for depression
resulted in a significant reduction in the depression itself and marked
improvement in quality of life.19 These improvements were further
accompanied by a reduction in absenteeism, and an increase in patients
reporting not being impaired at work by their depression. Medical
service use also decreased with treatment.

However, the researchers recommend further studies to determine if
treatment is associated with a statistically significant decrease in medical
(including mental health) expenditures. But given the current recom
mendations regarding purchasing for productivity and elimination of the
"silo" approach to corporate budgeting, it would be important to deter
mine changes in an employer's indirect costs as well.

Important steps in improving the coordination of primary and
mental health care include:

•

training for primary care physicians in diagnosis and treatment;

•

access to mental health and substance abuse consultation and referral;

•

the establishment of systems that facilitate patient movement across /
the continuum of health and mental health services; and

•

schedule adjustments to allow providers to make accurate and timely
diagnoses and referrals as necessary.

The good news is that some primary care providers, particularly those
who have completed medical school and residency programs more
recently, have had more extensive psychiatric training and have
improved their ability to diagnose mental illness.

A large-scale study is anticipated that aims to evaluate the ability
of physicians to diagnosis mental illness in a "high utilizer" popula
tion of patients.
According to Dr. Whitehouse, MCC Behavioral Health is conduct
ing research'in six different sites that will evaluate the ability of physi
cians to diagnose mental illness in-patients who are "high utilizers" of
health care. These experiments will evaluate the relative merits and
return on investment from three models of primary care intervention:
•

"Major league" education for primary care providers.
Enhance knowledge of diagnosis, treatment, and management of
depressive disorders.

•

Placement of social workers and psychologists in the primary
care office.
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Other pilot studies have found that the use of mental health case
managers in primary care offices has been successful in identifying

mental health problems early, and in ensuring timely referral to appro
priate specialist services.

•

Placement of a clinical nurse specialist or psychiatrist in the primary
care office.

Chambersburg Hospital in Pennsylvania has reported success in
getting employees back to work by having psychiatrists meet with the
primary care physician and the employer to design a customized plan for
proactively managing an employee's condition.
A special issue related to the coordination of primary and mental
health care relates to the role of "carve-outs" for mental health services,
relative costs, and treatment outcomes, when services are provided by
independent companies under contract with the primary care organiza
tion. Under these conditions, it is common practice, mainly for cost
considerations, to split the treatment of mental disorders between
psychotherapy provided by a non-physician mental health professional
and pharmacotherapy provided by a psychiatrist. However, one
exploratory study of depressed patients in both integrated and split treat
ment models,20 contrary to the prevailing assumption regarding compara
tive costs, showed significantly lower treatment costs on average for
patients in integrated treatment.20
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Recognize Co-Occurrence

Recommendation

of Illnesses
There is much evidence that there is a substantial degree of co
occurrence (i.e., comorbidity) among medical, psychiatric, and
substance abuse disorders and that the health care system does
not yet deal well with this potentially significant issue.
In many cases, medical care providers do not fully appreciate the
extent to which patients with medical illnesses also suffer from mental

illnesses. Depressive feelings can be a common reaction to many medical
illnesses, but when the symptoms are severe enough to warrant a psychi
atric diagnosis, treatment for the depression should be considered even
in the presence of another disorder. For example, depression occurs in
up to two-thirds of patients who have had a heart attack, up to
25 percent of cancer and post-stroke patients, and frequently in patients
with neurological disorders including Alzheimer's Disease and AIDS.21

Failure on the part of care providers to recognize and treat co-occur
ring illnesses may lead to serious and unnecessary consequences for
patients and families and ultimately can contribute to increased health
care costs, diminished and unsatisfactory rehabilitation, excess absen
teeism, and unnecessary disability. Consideration should, therefore, be

given to ensuring that health care systems are sufficiently integrated to
treat both the physical and mental illnesses simultaneously and that
other human resource systems are also integrated into the treatment and
rehabilitation processes.
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Recommendation

Measure Outcomes
B e t t e r outcome measures are needed in mental health. Further

improvements to existing measures of functional status are

also required. Some of the work being done by Greenberg at
The Analysis Group (see box on page 11) should help with this
task. At a minimum, Dr. Whitehouse believes that companies and
health plans must begin to profile providers on their ability to get
employees back to work in a timely manner. In addition, L. L.
Bean's Ted Rooney affirms that managers must be sold on the valid

ity of those measures that do exist. They are, in his opinion, a lot
better than they get credit for. Furthermore, it is ironic how freely
companies will spend millions of dollars on coronary artery bypass \

surgeries, yet are reluctant to spend even afew thousand dollars on)
wellness programs that promise great strides in reducing the inci- /
dence of mental and physical illnesses.
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• Conclusion
Employee health is well recognized as a key compo
nent of employee productivity as well as a compo
nent that requires careful tracking and assessment
of cost and outcome. With the expansion of managed
health care systems over the past several years, employ
ers have found that substantial reductions in direct

health care costs could be achieved through a restruc
tured health care system. But new information now .
coming to the forefront has also highlighted the need to
look beyond direct health costs to fully evaluate
employee productivity and associated costs.

Increasingly, leading employers are realizing that

These innovative employers have developed practices
in conjunction with their health and human resource

systems for managing both the direct and indirect cost
consequences of mental illness. As evidenced in the

case studies, employers are encouraging early recogni
tion, appropriate and cost-effective care management,
accommodations and other performance supports, and
timely return to productive work. They are also proac
tive in dealing with stigma, demonstrating the
cost/benefit of treatment, integrating benefits, coordinat
ing primary/mental health care, recognizing co-occur
rence, and measuring outcomes.

More knowledge is needed to assist major employ
ers to understand more completely the importance of
the health-productivity connection and identify ways
to apply the concept. To this end and in an effort to
shape future mental health services research, the

there are significant health-related indirect costs-in the
form of lost work time and impaired performancecreated by poorly managed or unrecognized employee
health problems, including mental illness. As described
earlier in this publication, to gain a complete picture of
employee functioning, including health status, some
employers have developed special approaches to track
these indirect costs as well. They have come to under
stand the relationship between health and productivity,

National Worksite Program Research Advisory
Group. Comprised of private-sector purchasers,
health plans/providers, and service system

and are improving their management strategies by work

researchers, its goal is to stimulate collaborative

ing toward "purchasing for productivity."

research among key players in the service system and
a research priority-setting process that integrates
employer perspectives and experiences.
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National Institute of Mental Health has formed a
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Senior Thesis Project

Assignment: Revise Enteric Diseases ofSwine, a technical training manual.

Purpose: To educate veterinarians and pork producers regarding etiology, diagnosis,
and treatment of common enteric diseases of swine, and to describe management
strategies for controlling enteric diseases.
Audience: Veterinarians and pork producers.

Skills Required : Ability to incorporate changes from several sources. Basic
understanding of specialized vocabulary. Familiarity with WORD software and use of
templates for layouts. Proofreading. Fact checking. Scrupulous attention to detail.
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INTRODUCTION

Section

1
Introduction
Underlined words are defined Despite modern agricultural management techniques and

in the Glossary.

advances in veterinary medicine, infectious diseases remaina
major challenge for swine producers. Minimizing losses from
enteric disease is an important strategy for large and small
operations, which can both realize healthier profits from healthier
pigs.

This self-paced learning program reviews basic principles of
swine management, discusses disease dynamics and immunity,
describes common enteric diseases of swine, and presents
strategies for controlling enteric diseases.
We hope the knowledge you gain from this program will increase
your productivity.

OBJECTIVES

Learning Objectives
As a result of completing this self-paced learning program, you
will be able to:

•
•

Explain the basic principles of swine management.
Discuss swine management practices that affect enteric

•

Describe disease dynamics, including the pathogen-host
relationship and immunity.
Describe the etiology, diagnosis and treatment of common

disease.

•

enteric diseases of swine.

•

Understand management strategies for controlling enteric
diseases.

MANAGEMENT

ection

3
Swine Management
Overview

In the past decade, swineproduction has shifted from numerous
small producerswith relatively inefficient operations to fewer but
largerfarms that are systematic and efficient. Whydid this change
occur?New technologies have made largerswine productionfarms
more efficient with standardized and uniform output. Many pigs are
now marketed with some form ofrisk management.

Productionplanning often starts with the finishing phase—feed
efficiency, feed cost, carcassvalue and marketing strategy. Efficiency
then depends on stable productionofhealthy pigs from a breeding
herd that optimizesthe number ofanimals going to market. New
technologies and careful management also allowsmaller farms to
remaincompetitive in periods ofdecreasedprofit margins.

MANAGEMENT

Swine Operations

Swine production methods vary considerably. In all operations, the
breeding and farrowing stages must provide a predictable number of
healthy pigs to the grower andfinishing stages. These pigs must be
of uniform size andage, be healthy, andhave the desired genetic
potential They must also be raised cost effectively.

The production concepts used to achieve profitable operations apply
to operations ofallsizes. However, specific techniques vary
considerably, depending on geographical location, herd size, and
available resources, such as labor, capital, feed and facilities.

Whether theoperation is large or small, sows andtheir piglets still
need to be cared for individually.
Small Farms

Traditional one-site production is suited to small farms with<500
sows. Small farms relyheavily on laborfromthe owner. Somemay
employ multi-site technologies andage-segregated rearing.
LargeFarms

Large farms rely more heavily on capital investment andsystematic
production techniques, such as multi-site production andagesegregated rearing.
Segregated Early Weaning
(SEW)

Segregated rearing moves pigs, grouped according to age, through
successive production stages together. Early weaning attempts to
protect piglets from infection with pathogens carried bytheir dams
or byolder pigs. Segregated early weaning (SEW) combines these
and acts to capture efficiencies of scale andto control disease. While
efficiency isrelatively easy to achieve, no systems cantotally prevent
disease. A major misconception about segregated rearing following
earlyweaning is that it eliminates alldisease.
In the efforts to minimize disease, greatest success hasbeen achieved
with the more severe swinepathogens: swinedysentery

(Serpulina/Brachyspira hyodysenteriae), Actinobacillus

pleuropneumoniae, Mycoplasma hyopneumoniae, pseudorabies,
hogcholera, transmissible gastroenteritis (TGE), swine influenza
virus (SIV) andatrophic rhinitis. Less virulent organisms or ones that
commonry colonize young piglets (early colonizers) still cause
disease. These include: Escherichia coli, Salmonella spp.,

Streptococcus suis, Haemophilusparasuis, Actinobacillus suis,
porcine reproductive and respiratory syndrome (PRRS) virus, and
rotaviruses.

MANAGEMENT

Successful disease control with SEW requires that:
• Sows are immune and not shedding organisms;
• Eachpiglet receives mateirM irnmunity through adequate
colostrum intake:

•

Cross-fostering is limited andcontolled (usually the first 3 days

•

No pig isolder thanthetarget age(usually 17to 21 days) when

ofage);
weaned;

•
•

No commingling or shared airspace witholder pigs;
Rules ofall-in / all-out production are followed absolutely

•

These rules are never broken.

Production of healthy 5 kg piglets at 17days of ageis a realistic
goal Ofcourse, weaned piglets canquickly lose condition and
becomeilliftheir needs are not adequately met after weaning.
Mostmajor diseases canbe controlled bymanaging pigmovement
through thesystem, maintaining biosecuritv. and using strategic
vaccinations and/or therapies. Health and disease are intertwined
with genetics, nutrition, facilities, sanitation, andmanagement. The
most aggressive health program canfail ifnutrition or housing is
faulty, for example. Likewise, disease cannegate any advantages of
improved genetics, nutrition and facilities. Therefore, the following
critical factors in a SEWsystem mustallbe in place for long-term
financial success: genetics, nutrition, facilities, sanitation, biosecurity, farrowinghouse management, cross-fostering, pigletprocessing and record keeping.

Genetics

The genetic potential ofthebreeding herd isirnportant to theoverall
productivity of a swine farm. Carcass quality isgenerally given first
priority. However, modern genetic programs canhave marked
effects on farrowing house productivity, directly affecting litter size
and piglet rjerformance, and indirectly sow longevity (for example
feet and leg soundness). Genetic improvement iscontinual, with
intense efforts to identify specific genes for valuable traits. Improved
genetics canbeimplemented quickry, due to therapid replacement
rate ofsows in breeding herds. Genetically inferior herdscan no

longer compete economically because of carcass discounts and
reproductive inferiority ofimproved genetic lines.

MANAGEMENT

A sound nutrition program isimportant for overall health and vigor.
Nutritlon

We still have not defined the optimal nutritional requirements of

sows and growing pigs, inpart because ofgenetic variability and in
part because ofthedifferences that exist in facilities and
management. The goal ofgood nutrition isto provide optimal
nutrients to maintain bodycondition for breeding, and to maximize
milk production cost-effectively. Producers should monitor feed
quality and ration formulation, observe animals carefully, feed sows
as individuals to maintain condition, and keep good records. Many

producers still do notevaluate production records or study the
scientificdata to determine the costs and benefits ofvarious nutrition
programs.

A major problem onmany farms isthat sows are not fed enough.
Maintaining optimum sowcondition increases milk production so
that piglets are heavier at weaning. Good weight gain inpiglets is
critical for early weaning. Maintaining sowcondition through
lactation notonly increases milk production but also shortens the
weaning-to-estrus interval in sows.

Piglet starvation isvery common but can beprevented byearly
intervention Starvation results from sow inadequacies (nipple

number and integrity, illness, oragalactia) or from piglet
inadequacies (low birth weight, illness). Feed consumption of sows
should bemonitored, bothto prevent agalactia and to spot depressed
appetite due to illness. When the sow produces inadequate milk,
piglets canbe moved to othersows

orfed milk supplements. Piglet illness (diarrhea, arthritis, septicemia,
and pneumonia) canalso cause starvatioa

MANAGEMENT

Facilities

Housing should provide protection from the environment, from
other animals, and frompotential sources ofdisease. Feeders and
waterersare designed for easy sow accessand minimal waste.
Individual crating ofsowsis favored, because it allows individual
care and feeding, evenin verylarge production units. Sowsneed
more feed when effective ambient temperaturesdecrease.
Sanitation, warmth, and minimal drafts are extremely importantfor

piglet vitality. Farrowing crates aredesigned to prevent crowding
andprovide piglets a warm andsafe area(thecreep) forsleeping.
Flooring inthe farrowing house should prevent manure build-up,
allow easy cleaning, provide goodfooting withlittle abrasion, and
not conductheat awayfromthe piglet zone. Concrete and wood
flooring are least desirable for disease control.

A room temperature of approximately 18° to 24°C isoptimal for
sows, butneonatal piglets require 33° to 35°C temperatures to be
comfortable. Supplemental heatlamps inthe piglet areaare usually
required. During the suckling period, thetemperature ofthepiglet

area can be gradually lowered to 26° to 27° C. Mats are often used
inthepiglet area to prevent heat toss. Keen observation isthebest
method forassessing piglet comfort. Individual piglets lying flat
while sleeping arecomfortable. Piglets huddling inpiles need more
heat.

Sanitation

Scrupulous sanitation and disinfection between farrowings are
imperative inall facilities. Disease-causing organisms, such as
Isospora suis (coccidiosis), Clostridiumperfringens, E. coli,
Salmonella, Serpulina spp. androtavirus caneasily survive on
contaminated surfaces. All-in/all-out production should be usedin

farrowing rooms, nurseries, and grower-finishers, with thorough
washing and disinfection between groups ofpigs. The rooms should
bethoroughly dry before restocking. The facility must becompletely
free ofpigsbefore a new group of pigs isintroduced.

MANAGEMENT

Biosecurity

If a particular disease isnotpresent inaherd, every effort should be
made to prevent itsintroduction through biosecurity. It is far more
cost-effective to prevent infection than to treat it. Farms free from
porcine respiratory virus (PRV), Serpulina hyodysenteriae,
Actinobacillus pleuropneumoniae, porcine reproductive and
respiratory virus (PRRSV), transmissible gastroenteritis (TGE),
toxigenic Pasteurella multocida, Mycoplasma hyopneumoniae, or
parasites should prevent their introduction bybreeding stock, semen,
people,other animals or

fomites. This requires knowledge ofthe pathogens present inthe
herd aswell asinthebreeding animals to be introduced. Serology is
often employed to "match" thehealth status of breeding herd with
the stock being introduced.

Isolation and Acclimation

Isolation andacclimation ofincoming breeding stock hasbecomea

high priority onmost farms. The goals are to prevent introduction of
new diseases into the breeding herd, and immunize incoming stock

for disease already present inthe breeding herd. This isachieved by
providing 30 days of isolation after which the new stock istested for
diseases not present inthebreeding herd. This is foltowed bya60to
90day period ofacclimation when newstock isexposed to and/or
vaccinated for diseases already present inthe breeding herd.
Acclimation iscritical to preventing the circulation ofdisease agents
such as PRRSV, Swine Influenza Virus, andMycoplasma

hypopnumoniae inthe breeding herd. With isolated facilities for
incoming breeding stock, isolation and acclimation can be
concurrent.

Farrowing House Management

Proper management of the farrowing house iscritical for prevention
of piglet diseases and deaths. Larger farms provide detailed
procedure manuals for their employees(see example inSection 9).

Attended farrowing isdesirable because itmaximizes the number of
pigs born live. Induced parturition can facilitate attended farrowing.
Yet attended farrowing depends on certain resources, particularly
labor, and on oflsetting the costofthose resources by having more
piglets survive.

MANAGEMENT

Cross-Fostering

Cross-fostering, movinga piglet from one damto another, is
intended to:

•

Distribute piglets uniformly across litters.

•

Balance littersby birth weight.

• Assureeachpigaccess to a functional nipple.
• Wean healthypigs ofuniformweight.
Here are some pointers for successful cross-fostering.
• Assure suckling ofcolostrum from dam for at least 1 hour
soon after birth. In large litters, first-born or larger piglets
may need to be placed in a warmbox untilthe last-born or
smaller pigs have nursed.
• Transfer piglets based on the needs ofthe smallest piglets.

Larger piglets often compete better if they are moved when
they are <12 hours old. Smaller piglets canbe transferred to
recently farrowed sows with small litters. Transfer can also be
•

made to balance litters by piglet size.
Be sure sows receiving additional piglets have adequate

functional nipples. Milk letdown lasts for <1 minute, so
piglets cannot share a nipple.

•

Transfer piglets from sows that are sick or have a limited
number of functional nipples. Piglets canbe transferred to
suitable <4nurse" sows as some oftheir own piglets are
weaned.

• Transfer piglets within 2 to 3 days ofbirth. Later transfers
increase the probability of disease transmission and also
increase the agevariation withineach litter at weaning.
•

Euthanize small, weak or ill piglets rather than allowing them
to remain as a source of disease for the rest ofthe herd.

Never retain piglets in the farrowing area past the target age set
for a particular farm.

Piglet Processing

TheFarrowing House Production Manual inSection 9 (Reference
Materials, p. 50) describes some ofthe steps inpiglet processing.
Providing supplemental iron by injection is probably the most
common practice inpig processing. Virtually all other processing
steps—injections, vaccinations, or surgical procedures—are
optional. Processing practices reflect the needs of the piglets, and the
needs, customs, and preferences ofthe producer and consumer.

MANAGEMENT

Record Keeping

If production decisions are to bebased on facts, then good record
keeping isessential Collecting and anaryzing information allows
producers to compare production methods, identify opportunities for
improvement, and measure progress. Virtually all modern swine
productton facilities havecomputerized records. Managers usethe
compiled data to decide where to focus their efforts.
Farrowing house managers should be able to identify the specific
problems ina facility and thenapply solutions. There isno single
"best" management practice, since each swine production unit is
unique. Carefiil record keeping and scientific investigation cannot be
overemphasized.
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Section

Health and Disease
The Cost of Disease

For swine producers, disease is costly. The direct costs ofdisease
are

related to morbidity (illness), mortality (death), diagnosis,
preventative measures and treatment. Indirect costsinclude losses
from stunted growth, poorreproductive performance, and increased
susceptibility to other diseases.
The immediate cost ofdisease is obvious. Less obvious but ofequal

significance isthe cost ofinfection ofyoung pigs with pathogens that
mayhave long-term impact throughout the growing period. It iseasy
to understand why infectious disease in suckling piglets impairs
subsequent performance. Many disease agents infect suckling pigs
but are not apparent or transmitted untilthe nursery, grower or
finisher phases. Suchdisease agents (dysentery, ileitis, mycoplasmal
pneumonia, colibaciltosis, salmonellosis) have already stunted
growth by thetimetheyare recognized, and treatment onlywhen
clinical signs appear istoo late to prevent economic losses. Most
diseasesare best controlled before clinical signs appear.

Often, producers only the immediate consequences ofdisease and do
not understand the necessity to evaluatedisease occurrence on a

systematic basis. Disease ingrow-finish operations isoften theresult
ofinfection acquired inthe nursery. Likewise, disease inthe nursery
is often the result ofinfections acquired in the farrowing period.
Successful control strategies consider all stages ofproductton and

producers musthave athorough knowledge oftheepidemiology of
each agent and the disease process.

Ofcourse, maintaining health incurs somecostsas welL Yet in most
cases, preventing disease ischeaper than treating it.Understanding
the disease process canlay the foundation for cost-effective
strategies thatminimize the impact ofdisease.
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Profitable Health Management

Exposure, Infection and
Disease

Whereas Profitable pigs conform quite well to modern production
processes, pathogens rarely cooperate. To successfully control
disease, producersmust understand how certainagents are
transmitted, persist in pigsandthe environment, incubation periods,
andtheirclinical signs. This urKlerstanding reinforces the need for
scrupulous detail in a systematic production process that includes
age segregation andall-in / all-out (AI/AO) productioaTheir
partners in protecting herd healthareswine veterinarians who
supervise diagnosis, treatment, andotherinterventions. A strong
working relationship betweenproducer andveterinarian is the basis
for profitable health management.

Pigs encounter pathogens all the time, but most pigs are not sick
all the time. Contact between an animal and a microorganism is
called exposure. Animals that have never been exposed to a
particular pathogenare called narve. Infection follows exposure if
the microorganism succeeds in invading the body and
multiplying. If parasites are involved, the infection stage is called
infestation.

Colonization is an important first stepinestablishing someenteric
diseases ofpigs. Colonization occurs whenmicroorganisms attach
themselves to the epithelial cells lining the pig's intestinal tract. By
itself colonization is unlikelyto cause disease, but colonization
allowsother virulence factors of pathogens to exert themselves.
Various toxins (poisons) can also increase the virulence of some
pathogens. For example, undercertain circumstances Escherichia
coli, a naturalinhabitant ofthe gastrointestinal (GI) tract,
produces a potent toxin that causes fever, weakness, diarrhea and
irreversible shock. Clostidium perfringens type C produces a
potent toxin that causesnecrosis ofepithelium.

Some pathogenic bacteria evadethe host's immune system by
forming protective capsules. This strategyis called encapsulation.
Some vaccines are formulated to destroy capsular structures.

Encapsulation is the most important virulence factor for
streptococci, but is also seen with E. coli, salmonella, Klebsiella
spp. and a variety of other bacteria. Virulence factors are
intensively studied to better understand pathogenesis and to try
to find more effective vaccination products.
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The Pathogen-Host Relationship

Interaction between a pathogen and its host is influenced by many
factors, among them genetic susceptibility, the amount and
disease-causing ability (virulence) ofthe pathogen, nutrition,
housing, the presence ofother diseases, and stress. A healthy
animal can mount a vigorous response and may never show
clinical signs of infection. An animal already weakened by illness
or stress may be overwhelmed. The conceptual relationship
between these factors can be expressed as:
SEVERITY of DISEASE - DOSE
X VIRULENCE
RESISTANCE OF THE PIG

The veterinarian and producer want to decrease the dose and
increase the resistance ofthe pig to mitigate disease severity.
DECREASE DOSE

1. Use all in/all out productionwith thorough cleaning and
disinfection

2. Age-segregated weaning; no exposure to older pigs
3. Ensure good sanitation
4. Eliminate infections in suckling pigs (carriers)

a. Sow herd immune to pathogens and not shedding
b. Strict adherence to weaning age
c. Enforce the rules of cross-fostering
d. Euthanize chronically affected piglets

5. Provide cleanair / good ventilation practices
6.

Prevent concurrent diseases

7. Feed certain antimicrobials, additives
8.

Others

INCREASE RESISTANCE OF THE PIG

1. Assure passive immunity through colostrum transfer
2.

Provide comfortable environment

3. Provide adequate space (decrease pig density)
4. Ensure good access to feed and water (design/availablity)
5. Sound, proper nutrition
6. Eliminate other diseases and parasitisms
7. Enhance active immunity
a. Controlled exposure to low dose
b.

Vaccination

8. Use certain antimicrobials
9.

Others

Many infectious agents that cause disease in modern production
systems were previously recognized as sporadic causes ofdisease
nr as
or
as nntential
potential nathoeens.
pathogens
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The im mune System

The humoral (antibody) andcell-mediated immune systems act in
concertwith other mechanisms asthe body's defense. The humoral
system (sometimes called systemic) produces circulating antibodies
inthe bloodinresponse to foreign materials or antigens. Several
types ofantibodies canbe produced, but the most commonone is
immunoglobulin G (IgG). It canbe measured by serologic testing
andis present in pigsthat haveacquired it through colostrum
(passive immunity) or by exposure to aninfectious agent or antigen
(active immunity). Antibodies transferred in colostrum disappear in 3
to 12weeks. Antibody is important in resisting infectious agents in
bloodor tissues, but generally not as important in protecting against
organisms that live inside cells (intracellular) or thatare present on
mucosal surfaces. The antibody measured in serologic tests often
predicts resistance to infection butisnot necessariry protective by
itself. A positive serologic test indicates that ananimal has been

exposed to the disease and formed antibodies, a process called
seroconversion.

Cell-mediated immunity involves immune system cells (lymphocytes
and macrophages) that can recognize infected host cells and kill or
removethem. Cell-mediated immunity is important in resisting viral
infections and bacteria that survive within host cells.

The concentration ofantibodies in blood serum can be determined by

titratioa a methodofdiluting the sample until the antibodies canno

longer bedetected. Theresulting titer, indicates thestrength ofthe
humoral response to a given antigen. There isno comparable method
for measuring cell-mediated immune responses.
The site ofinfectionalso determines what type ofimmune response

will occur. Agents that infect mucosal surfaces (such as transmissible
gastroenteritis) generally stimulate local reaction atthe site of
infection (mucosal immunity). A local response isrequired to prevent
severe damage from this typeofinfection. Agents that enter blood or
tissues, causing septicemia ortoxemia generally stimulate a systemic
response. A higher level ofsystemic immunity isneeded to prevent
diseases associated with theseagents (erysipelas, for example).
Pathogenic organisms vary intheir ability to cause disease (virulence)
aswellas intheir ability to induce animmune response (antigenicity).
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Table 4.1 Humoral and Cell-Mediated Immunity

Mechanism of
Action

Humoral Immunity
Antibody is produced in response to

Cell-Mediated Immunity

antigens. Antibody attaches to
antigens and inactivates them or

Specific white cells (a variety
oftypes of lymphocytes) are
sensitized to recognize and

allows white blood cells to eliminate

eliminate infected host cells

them

Most Important
Against

Systemic diseases (erysipelas),
toxemias (tetanus)

Viral infections(psuedorabies),
cancers, intracellular bacterial
infections (salmonellosis,
brucellosis)

Best Vaccination

Approach

Injection of antigen, which can be
either live or killed vaccine products

Actual infection with either

virulent or avirulent organisms,
ie a modified live vaccine

Table 4.2 Mucosal and Systemic Immunity
Mucosal Immunity

Systemic Immunity

Site of Interaction

Mucosal surfaces: nose, airways,
gut, vagina, etc.

Blood, lymph, tissues
perfused by blood

Principal Immune
Response

IgA (secretory antibody), localized

IgG (circulating antibody),
circulating immunecells of

cellular immunity

cellular immunity
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Immunity

Natural resistance or immunity is the natural ability ofthe host to
remainunaffected by pathogens.Usually natural immunity is genetic,
so that a whole specieswillnot be affectedby particularpathogens.
Swine, for example, are naturally immune to bovine virusdiarrhea
(BVD). The genetically determined absenceofreceptors on gut
epithelium in somegenetic lines ofswine renders them resistant to
certain strains ofE. coli infectioa

Passive immunity is temporaryprotectionafforded by preformed
antibodies and/or cells that can be transferred in serum plasma, or
colostrum from one animalto another. Passive immunityprotects the
recipient immediately but onlylastsa few daysto a fewweeks.
Neonatal pigsacquire passive immunity from colostrum the first
milk produced by the dam.

Active acquired immunity occurs whenthe host is exposed to the
pathogen or a vaccine and creates itsown antibodies or cellular
response. It is slowerto develop but lastslonger than passive
immunity. In some cases, severaldoses ofvaccine are necessary to
stimulate sufficient antibody to protect the animal
Table 4.3 Active and Passive Immunity

Mechanism

Active Immunity
Stimulates both humoral (antibodies)
and cell-mediated responses

Passive (Acquired) Immunity
Transfers of previously formed
antibody or immune cells via
colostrum or immune serum

Strategy

Protects the animal being vaccinated

Protects the recipient of colostrum
(newborn) or serum

Duration of

Immunity

Methods

Requires 2-4 weeks for immunity to
develop, but duration of immunity is
long-term, perhaps for life

Effective immediately but duration is
short-term (days to several weeks)

Administer oral, intranasal, or injection
of immunizing agent or actual infection

Assure colostrum intake (newborns)
or inject immune serum
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Vaccines

Vaccinesare preparations ofkilledor modifiedpathogens. When
administered to an animal, vaccines stimulate productionof
antibodies and cellular immunityby multiple, very complicated
mechanisms. These antibodies, a formofacquired immunity, then
helpprotect the host from infection by that pathogen.
Maternal antibodies are produced by the dam and passed to the
young in the uterus(humans) or throughmilk (most domestic
animals). In young animals, passively acquired maternal antibodies
canbtock the active production ofantibodies for a time. So to be
effective,vaccinations must be properly timed to avoidthis maternal
interference. The time and extent ofmaternal interferencewill vary

with eachparticular agent andwiththe quantity ofantibody initially
acquiredin the colostrum.

The goal ofvaccinatton is to stimulate immunity anddecrease
disease severity, perhaps even preventinfectioa Antigens stimulate
animmune response to produce humoral and/or cell-mediated
products that may or may not protect the animal fromdisease. The
humoral antibody measured aftervaccination indicates that the
animal hasrecognized the vaccine andresponded to it. Stimulation
ofimmuneresponse is not the sameas stimulation ofimmunity,
although in most cases highantibody levels suggest increased
resistance to disease. Some vaccinatton productsarehighlyeffective
and others are not. Several factors influence how well vaccinatton
will work.

Agentandvirulencefactors- Some agents havecellular components
or virulence factors that stimulate specific immunity that is quite
good(clostridial toxins, E. coli pili, modified live pseudorabies).
Virulence factors and cellular components from other agentsare
poorly defined or less immunogenic and often produce variable
results (Streptococcus suis, killed salmonella, Serpulina
hyodysenteriae).

Dose ofagentor antigen - A larger antigenic masstendsto
stimulate greater immunity, particularly if the organism is killed.
Modified-live (MLV, avirulent) vaccines multiplywithinthe pigto
increase mass. MLV productsalso provide a greater diversity of
antigens that may be protective and stimulate bettercell-mediated
immunity.
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Antigen chemical structure - Complex molecules and proteins are
more likely to stimulatea response.

Persistence ofantigens - Chemicals inthe vaccine can prolong

exposure (oils) orstimulate inflammation (adjuvants), both ofwhich
lengthen the time theanimal isexposed and makes antibodies.
Multiple doses ofvaccine canalso lengthen exposure.

Pig's ability to respond - Veryyoung pigs may notrespond as well
as older pigs. Healthy pigs respond much better than sick or stressed
pigs.

Priming andbooster responses - The initial encounter between the
immune system and the antigen primes the system A second
encounter (booster) strengthens immunity. The booster dose is
usually given 2 to 4 weeksafter the priming dose to stimulate
maximum response. Immunity reaches its peak about 2 to 4 weeks
after the booster dose and then declines. This is another reason for

using multiple booster doses.
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Swineveterinarians play a primary role in observing pigs for

Diagnosis

symptoms of disease ordiscomfort. They also must be experts at
diagnosing specific diseases, identifying risk factors, and developing
intervention strategies. Diagnosis ofacuteoutbreaks ofclassic
entericdiseases—such as swine dysentery,transmissible

gastroenteritis orcolibacillosis—is fairly straightforward. The goal is
to obtain specimens that accurately represent the clinical problem,
conduct appropriate diagnostic tests, and formulate a treatment plan.
A differential diagnosis considers all ofthe possible diseases that
couldhavethe observed clinical signs. The diagnosis is reached
through careful evaluation ofthe clinical picture and the results from
diagnostic testing.

Tables 4.3 and4.4 (on the next several pages) listthe specimens that
are most helpful indiagnosing enteric diseases innursing or weaned
pigs. Properly obtaining fresh specimens improves the chance of
accuratediagnosis.

Necropsy—exarnining a carcass for evidence ofabnormalities or
disease—can be a valuable diagnostic tool Some tissue changes,
such as gas-filled intestines or pooled blood in lungs or intestine, are
frequently the result ofpostmortem changes (autolysis). Changes
caused by disease thatcanbe observed by gross examination are
called lesions. A competent veterinarian determines whichtissue
changes are dueto disease. Practical Necropsy and Diagnostic
Techniques describes the steps in a carefiil necropsy (Reference
Materials, p. 53).
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Table 4.3 Diagnostic Specimens from Nursing Pigs
Specimens to Submit

The best specimen is an acutelv-ill (<24 hours), live, untreated pig. Alternatively,
tissues should be removed from a euthanized pig.

Jejunum

6-8" fresh/chilled

Ileum

6-8" fresh/chilled

1" formalin-fixed

1" formalin-fixed
6-8" fresh/chilled
1" formalin-fixed

Lesions

Colon or cecum

Entire organ fresh/chilled
2-5 mL fluid contents, fresh/chilled

Samplesremoved at necropsy in the field are betterthan an entire dead pig
submittedto the laboratory and the autolysiswhich results.
Sampling Techniques

1. Samples must be taken as soon afterdeath as possible (within minutes).
2. Intestines do not need to be tied off at the ends.

3. Flush intestinal segments for histopathologic examination with formalin and drop in fixative.
Or, gently open ends of 1/2" segments with scissors or forcepsto expose mucosaas
immersed. Do not split open.

4. Pool allformalin-fixed tissues from each pig in one bag; individual pigscan be pooled or kept

separate as desired. Package fresh Intestines separately from othertissues and each pig
in a separate bag. Chill fresh tissues before mailing. Do not freeze.
5. Do not send whole, dead pigs.

6. Antemortemfecal samples as the only sample are not recommended.
Agents Detected bv Routine Examinations

Bacterial isolation:

E. coli, Salmonella, Clostridium, Serpulina spp., Enterococcus durans

Viruses:

Rotavirus, TGE virus

Parasites:

Coccidia (impression smears or histopathology)

Comments

1. In cases of necrotic enteritis, submit both necrotic and adjacent non-necrotic segments fresh and
fixed

2. In-house impression smears may be ofvalue in diagnosis of Clostridium perfringens, E. coli enteritis
or coccidiosis.
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Table 4.4 Diagnostic Specimens from Weaned Pigs

Specimens to Submit
The best specimen is an acutelv-ill (<24 hours), live, untreated pig. Alternatively,
tissues should be removed from a euthanized pig.
Jejunum
6-8" fresh/chilled
1" formalin-fixed

Ileum

6-8" fresh/chilled
1" formalin-fixed

Lesions

6-8" fresh/chilled
1" formalin-fixed

Colon or cecum

Entire organ fresh/chilled
2-5 mL fluid contents, fresh/chilled

Mesenteric Lymph

Fresh/chilled and formalin-fixed

node, liver

Samples removed at necropsy in the field are better than an entire dead pig
submitted to the lab.

Sampling Technioues

1.Samples must be taken as soon after death as possible (within minutes).
2. Intestines do not need to be tied off at the ends.

3. Flush intestinal segments for histopathologic examinationwith formalin and drop in fixative.
Or, gently open ends of 1/2" segments with scissors or forceps to expose mucosa as
immersed. Do not split open.

4. Pool all formalin-fixed tissues from each pig in one bag; individual pigs can be pooled or kept
separate as desired. Package fresh intestines separately from other tissues and each pig in a
separate bag. Chill fresh tissues before mailing. Do not freeze.
5. Do not send whole, dead pigs.
Agents Detected bv Routine Examination

Bacteria:

£ coli, Salmonella, Serpulina spp., Enterococcus durans.as wellas

Viruses:

Lawsonia intracellularis with histopathology
Rotavirus, TGE virus

Parasites:

Gl nematodes, coccidia, whipworms (gross lesions, histopathology)

Comments

1. In cases of necrotic enteritis submit both necrotic and adjacent non-necrotic segments, fresh and
fixed.

2. Fecal samples are of limited value and should be used only when tissues are not available. Results

(both positive and negative) may not be completely definitive and must be evaluatedwith
considerationof clinical signs. Samples (10-20 mL) should be taken on the first day of diarrhea.
Serpulina hyodysenteriae can occasionally be isolatedfrom feces (swabs are even less reliable).
Salmonella spp. are seldom recovered

3. Ill-defined conditions, such as dietary hypersensitivityor non-specific colitis, may be implied but
cannot be confirmed by routine diagnostic investigations.

4. Wet mounts of colonic mucosal scrapings or fecal flotations may be of value for quick in-house
detection of coccidia, whipworms, etc.
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Sensitivity: the ability to
identifypositive samples
correctly.
Specificity: the ability to
identify negative samples
correctly.

When investigating disease problems, the veterinarian must
remember:

•

Not identifying a pathogen in a single pigor single laboratory
submission does not meanthe pathogenis not present in the
group or herd.

•

Finding a specific pathogen does not meanthatit isthe most
importantor only pathogen present.

•
•

Tests for all pathogens vary in sensitivitv and specificitv.
The presence oflesions he^)s determine ifa rjarttoular r>athogen
isimportant. Many potential pathogens are carried by pigs but
simply isolating a pathogen (for example, E.coli from intestine,
Streptococcus suis from nasal cavity) does notconfirm anagent
is responsible for the disease observed.

A veterinarian candetermine a diagnosis withoutnecessarily

knowing all the fectors contributing to a given disease. For instance,
dose, pig immunity, management fectors, and various stressors could
all contribute to a diagnosis ofaubiquitous potential pathogen such
as"salmonellosis dueto Salmonella typhimurium?" The impulse isto
medicate or vaccinate only. The attending veterinarian must
combine diagnostic information withon-site observations and

analysis ofrecords to control risk fectors before complete and
effective control strategies canbe implemented.

22

ENTERIC DISEASE

Enteric Disease Overview
A Pig's Digestive System

Swine producers make a profit by converting inputs (feed) to output
(edible pork). Feed conversion is a dynamic process involving the the
digestive systemand immune systemofthe pig, the feedstufls, and
the broad range ofmicrobes inthe pig's digestive system More than
400 species ofmicrobes live inthe pig's gut. Feed composition,
formulation, andprocessing caninfluence the population dynamics
(numbers andmetabolism) as wellasthe relative populations of
differentbacterial species.

Scientists still cannot explain all ofthe interactions inthe gut, and the
interactions are constantly changing. Age, feed ingredients, feed
formulations, rapid feed changes, waterquality, microbial
populations, stressors inthe environment, phis the pig'sresponse to
these, all determine how wellthe pigwill grow. Fortunately, the
intestines are adaptable and canusually compensate for small
changes in feed quality, microbial populations, and challenges to the
immune system Diarrhea, a clinical sign ofintestinal distress, only
occurs whenthe gut damage is sufficient to overcome the functional
capacity ofthe colon.
Numerous eventswith no obviousclinical signs (so called subclinical
events) also robpigs ofnutrients and ability to add (accrete) lean
tissue. Unfortunately, veterinary diagnosticians canonlyidentify
processes that are:

•
•

Relatively severe asevidenced by clinical disease.
Have defined etiologies, usually but not always infectious.

•

Can be tested for specifically.

•

Produce characteristic lesions.
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Etiology and Pathogenesis

Etiolosy is the cause or
origin ofa disease.
Pathogenesis is the way in
which a disease develops.

Most enteric diseases in suckling pigletsare caused by organisms
already present in the herd or environment. This statement is true for
Escherichia coli, Clostridia, rotaviruses and streptococci. Infected
sows shed these organisms and/ororganisms are present in the
piglets environment and colonize very young piglets. Diseaseresults
when the pathogen dose is high, when pigletsreceive insufficient
passiveimmunity through colostrum or when pigletsare stressedby
cold or starvation. Management ofenvironmental and common
pathogens stresses good sanitation, immune dams, and passive
immunity through colostrum.
More severe infections stimulate a stronger immune response in
dams, which generally will prevent shedding afterthe acute illness,
and will also providebetter passive protectionto piglets. Early
weaning with segregated rearing canbe quite successful in
controllingthese more severe diseasesthat may be constantly present
in the sow herd (examples includeActinobacillus
pleuropneumoniae, swine dysentery, and porcine rotovirus).

Experiences in large production unitswith segregated rearing
suggest thatmanydiseases in the nursery, grower or finisher stages
are actually acquired by a few piglets fromdamsduring lactatioa
After weaning, infected piglets cantransmit pathogens afterweaning
to other pigsinthe group, causing disease outbreaks. Examples of
such diseases include pseudorabies virus, swine influenza virus,
PRRS virus, Actinobacillus pleuropneumoniae, transmissible
gastroenteritis, atrophic rhinitis, Mycoplasma hyopneumoniae,
Lawsonia intracellularis, and Serpulina hyodysenteriae. These
infectionscan also come from commingling(mixing groups ofpigs)
or breaches in biosecuriry.

Patterns of Disease

On tradittonal swine farms with continuous pig flow, certain diseases
ofswine were associated with pigs ofa particular age. Modem

production techniques havechanged the age distribution ofdiseases
in swine. In all-in/all-out (AIAO) production units, disease
prevalence andclinical presentation have changed too. These units
limit exposure to disease, alter maternal immunity, andprovide a
steady source of susceptible pigs. Manydisease agents do not fit the
textbook examplesor classic presentations in modem herds.
"New" pathogens are rare in swine productioa More often,
changing production methods allowdifferent diseases to emerge or
re-emerge. Porcine proliferative enteritis (PPE) emerged inthe
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1970's and re-emerged in the 1990's, aided by elucidation ofthe
ettologic agent, Lawsonia intracellularis. E. coli and rotaviruses
were prominentin the 1970's, but increased sanitation, vaccinatton
and environmentalmanagement have markedly reduced their
significance. Coccidtosisand Salmonella choleraesuis septicemia
prevalence peaked in the 1980's, while swine dysenterywas
eradicated on most modem ferms. PRRS virus, porcinecircovirus,
and spirochetal colitishave been recognized in the 1990's, the
former as a new infection in swine.

Althoughclassical outbreaks ofsingle pathogens still occur, today
disease is more likely due to the interactionofmultiple pathogens
and specificherd managementtechniques.

Enteric Pathogens

Table 5.1 positions pathogens according to the approximate age at
whichthey typically colonizepiglets. It also indicates appropriate
strategies for controlling enteric pathogens
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Table 5.1 Pathogens of Swine
Early Colonizers <-•

--> Late Colonizers

Streptococcus suis
Hemophilus parasuis
Actinobacillus suis

Pasteurella muttocida (toxigenic)
Bordetella bronchiseptica
PRRSV

Mycoplasma hyopneumoniae
Actinobacillus pleuropneumoniae
SIV
PRV
Escherichia coli

Clostridium perfringens
Coccidia
Lawsonia intracellularis
Rotavirus

Serpulina hyodysenteriae
Salmonella

TGE

Age (Days)
0

3

7

14

42

21

63

Control Options
-Management-

<-

-Environment and Sanitation

4-Sow Vaccination-* «-Vaccination Efficacy Difficult to Predict-* <
«-

-Pig Vaccination
>
Segregated Rearing-

-»

-Medicated Early Weaning......

Table 5.2 (on the next page) summarizes clinical signs, lesions,
diagnostic and controlmeasures for neonatal infectious diseases in
swine.
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Histopathology

Culture
EUSA feces

Histopathology. FAT / IHC

None

Fibrinous enteritis

Villus blunting

Villus blunting

Diarrhea

Diarrhea, septicemia
Diarrhea
Diarrhea

Clostridium perfringens type C

Clostridium perfringens type A

Salmonella spp.

Transmissible gastroenteritis

Comment/Control

Pneumonia

Septicemia
Polyarthritis
CNS symptoms

•

•
•
•

Polyarthritis

Polyarthritis
Pneumonia

Polyarthritis

•
•

•
•
Pneumonia
Pneumonia

Coughing
Rhinitis

Actinomyces pyogenes

Pasteurella multocida

Bordetella bronchiseptica

Porcine cytomegalovirus

(PCV)

Streptococcus equisimilis

•

Haemophilus parasuis
Septicemia

CNS symptoms

•

Pneumonia

Pneumonia

•

•

CNS symptoms

•

•

Ill-thrift

•

Polyserositis
Meningitis
Pneumonia

Polyserositis
Meningitis

•

•
•

Necrotic rhinitis
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Purulent exudate in joints,
lung
Purulent exudate in joints,
lung
Rhinitis (with toxigenic
forms)
Necrotic pneumonia

Pneumonia

•
•

Hepatitis/splenitis

•
•

Brain / tonsil

•

Histopathology

Culture and isolation of the
causitive agent

causitive agent

Culture and isolation of the

causitive agent

Culture and isolation of the

causitive agent

Culture and isolation of the

causitive agent

Culture and isolation of the

causitive agent

Culture and isolation of the

causitive agent

•
IHC/PCR
Culture and isolation of the

causitive agent
Histopathology

Herd immunity

Air quality / management

Vaccinate, segregated rearing

Prevent skin trauma

Prevent skin trauma

Management / medication

Management / medication

Eradicate / vaccination

Lymphadenopathy

•

Diarrhea

•

Aujeskey's disease
(pseudorabies, PRV)
Streptococcus suis

Establish sow immunity

Mesocolic edema

•

Pneumonia

•

PRRS virus

•

Rare in midwest US

•

Interstitial pneumonia

•

Culture and isolation of the

Rare in suckling pigs

Histopathology

Gastritis

Sanitation / seal surfaces

Diarrhea
Diarrhea

Fibrinous enteritis
Mild colitis

Histopathology / smears
Culture / histopathology

Herd immunity / biosecurity

Sanitation / vaccination
Sanitation / feedback

medication

Management / vaccination /

medication

Management / vaccination /

Management / vaccination

(TGE)
Coccidiosis (Isospora)
Serpulina spp.
Strongyloides spp.
Diarrhea

Gross lesions

Necrotic enteritis

Rotavirus

causitive agent

Polyserositis

Septicemia
Sudden death, diarrhea

Diagnosis
Culture and isolation of the

None

Lesions

Table 5.2 Neonatal Infectious Diseases

Watery diarrhea

Clinical Signs

E.cotf

Aaent/Disease
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Specific Enteric Diseases
Thissectiondescribes transmissible, parasitic, and nontransmissible
enteric diseases ofswine. A similar review ofenteric diseases is

available fromPharmacia & Upjohn as a slide presentation. For each
disease it reviews agent, age,morbidity, mortality, clinical signs, fecal
appearance, incubation, source, organism resistance, prevalence,
mechanism, cost ofoutbreaks, gross lesions, microscopic lesions,
diagnosis, treatment, control, and therapeutics.

Transmissible Enteric Diseases

Rotaviruses

Rotaviruses are a common and diverse group of viruses that
cause diarrhea. Many serotypes and serovars exist. The viruses

can infect pigs 3 days to 8 weeks ofage, but outbreaks are most
oftendiagnosed between 2 and 5 weeks of age. Disease severity
is directly related to dose. Disease recurrence can be due to

superinfection or sequential infection with different serogroups of
rotaviruses. Clinically significant diarrhea is usually the result of
ingesting large doses of rotavirus or from superinfection of
rotavirus-damaged intestine. Untreated infection predisposes

piglets to other diseases, including colibacillosis, salmonellosis, or
respiratory diseases, withEscherichia coli (often hemolytic)
infection the most common problem
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Gross lesions include fluid intestinal contents, poor absorptionof
undigested food, and mild villous blunting. Microscopic examination
confirms mild-to-moderatediffuse villous atrophy, loss or metaplasia
ofapical epithelium, and mild diffuse nonsuppurative infiltrates into
the lamina propria. In later or chronic stages, the terminal portionof
intestine may 'thicken" due to hyperplasia ofPeyer's patches and
nonsuppurative infiltrates. This lesionis not specific for rotavirus and
should not be confusedwith the hyperplasia ofporcine proliferative
enteritis(PPE).

Diagnostic confirmation can be done by: ELISA testing of feces,
electron microscopy of feces, isolation from feces, fluorescent
antibody testing (FAT) on fresh intestinal sections, or
innumohistochemistry (IHC) testing on formalin-fixed intestinal
sections. Specimens(feces, ileum,jejunum) shouldbe collected
within 24 hours ofdiarrhea onset and preserved fresh by
refrigeration or fixed in 10% formalin. Histopathotogical
examination ofthe ileumandjejunum can demonstrate attenuatton of
villiand ruleout other diseases, including cocckhosis,colibacillosis
or transmissible gastroenteritis (TGE). Simultaneous bacterial
infectionsare common and can be identifiedby bactertotogic
examinatioa

There is no specific treatment for viral infection. Pigscanbe treated
with oral electrolytes, weaned ifthey are still nursing, andgivenoral
antimicrobials to helpcontrol secondary bacterial infections. Control
in the nurseryis accomplished by:
• Decreasing the viral dose with scrupulous sanitation.
• Providing a warm, draft-free, dry environment.
• Providing properration ad libitum.
• Delaying exposure by AI/AO productioa

A vaccine is available for piglets andsows. It does not prevent
infectionbut may decrease the severity ofsymptoms.
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Transm issibie Gastroenteritis
'
'

TGE is a severe epizootic diarrhea caused by coronaviruses that vary
in virulence. Enzootic TGE occurs in unitsthat segregate pigs, use
continuous farrowing, or provide a continuingsource ofsusceptible
animals. Clinical signsusuallyappear in the late ferrowing or nursery
stages, but can also occur in the grower and finishing stages.
Enzootic TGE produces less severe diarrhea and moves more slowly
through groupsofpigsthan acute outbreaks, because animals have
partial immunity.

Diagnosis is by gross observation ofvillousatrophy, microscopic
observation ofseverevillousattenuatton and epithelial loss, and by
demonstration ofvirus with FAT, IHC, or rx)lymerase chainreaction
(PRC) testing, or by isolation ofthe organism Specimens (ileum,
jejunum) must be collected from acutely ill pigs (within 12 to 24
hours ofsymptom onset) and preservedto demonstratethe presence
ofvirus. FAT testing requires that the epithelium be intact. Falsenegative results occur if samplesarecollectedtoo late in the course
ofthe disease (>24 hours after onset) or improperlypreserved.
Examination may reveallesions, but isolating the TGE virus is
difficult. Only acutelyaffected pigs shouldbe selected for necropsy,
andrepeated examinations may be necessary. Monitoring antibody
titers in sentinel pigs is an alternative strategy. Seroconversion of
these pigsdemonstrates the presence ofthe virus. Finding rising
antibody titersbetween 3 and 12 weeks ofage is not definitive,
because the TGE virus and porcine respiratory coronavirus (PRCV)
arecross-reactive. Electron microscopicexamination of feces may
reveal coronavirus, but this test is not specific either, since other
coronaviruses (PRCV, HEV) can also be detected. Several serology
kits can differentiate TGE from PRCV antibody.

Controlis by creating complete herd immunity,usually by
intentionally exposing the breeding herd, except for sows due to
farrow within 2 weeks. Vaccines are available but have limited

efficacy. Treatment ofpiglets <2weeks ofage is generally futile.
Pigs that are old enoughto eat anddrink canbe weaned immediately
and givenwater andelectrolytes. Producers with TGE-free herds
should enforce strict biosecurity.
Eradicating the TGE virus is a realistic goalthat beginswith
establishing iinmunity in the population to suppress virus shedding
andcontinuing exposure. Vaccination ofdamsto prevent neonatal
losses in acute outbreaks has not been completely successful, though
the severity ofdisease is sometimes decreased. The decision to
vaccinate is often basedon frequency of ferrowing (infrequent, large
batches), type ofhousing (loose, outdoor), andseason (late fell and
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winter). Complete herdexposure during an acute outbreak may
preventenzootic TGE.
Prevention depends on biosecurity, preventing introduction ofthe
virusby birds, fomites. feed, personnel, or carrier swine. Producers
who have a herd without TGE should carefullyconsider introducing
carrier animals.

Porcine Epizootic Diarrhea

Another coronavirus, porcine epizootic diarrhea virushas not been
reported in the US.

Other Viral Agents

Otherviral agentsthat cause diarrhea in swine areneither common
nor severe. Porcine reproductive and respiratory syndromevirus
(PRRSV) and porcine cytomegalovirus (PCV) cancontribute to
diarrhea. A common feature ofPRRSV outbreaks is diarrhea in

suckling or nursery pigs. Diarrhea associated with PRRSV could be
a primary or secondary effect ofinfecttoa

Escherichia coli

Escherichiacoli infection can cause diarrhea, septicemia,

endotoxemia. or enterotoxemia in pigs from birth to 16weeks of
age. Sequential infections and reinfections are likely, withthe clinical
effectsdepending on dose andimmunity. E. coli is a common
bacteria and easily isolated. Its significance to swine producers is
related to virulence. Pfflj (K88, K99,987P, F41), enterotoxins (LT,
StA, StB, shigatoxin Stx2), endotoxin and capsules make E. coli
more virulent.

Large populations ofE. coliinthe small intestine can be present with
colibacillosis. Neonatalcolibacillosis is recognizedby watery colon
contents, normalvilliin the small intestine, and chyle in lacteals. Pigs

mayalso die suddenly from septicemia, enterotoxemia, or
endotoxemia. Severe congestion ofthe intestines and stomach wall is
common, but should not be confusedwith the enterotoxemia
associated with Clostridium perfringenstype C.
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Bacterial isolation from untreated pigsdemonstrates large

populations ofE. coli intheileum and jejunum Histopathologic
examination confirms the presence ofnumerous organisms adhering
to the brushborder ofthe intestine. Attaching andeffacing E. coli
(AEEC) mayalso be seea Enterotoxin (Stx2) made by hemolytic E.
coli cancause angiopathy, known asedema disease, leading to
central nervous system(CNS) disturbances or sudden deaths. At
necropsy, edema ofeyelids, stomach wall, intestine ormesentery is
sometimes present. The diagnosis isconfirmed by large numbers of
E. coli(usually hemolytic) from the ileum and jejunum, along with
characteristic microscopic lesions inthe brain, colonic mesentery,
and intestine.

Prefarrowing vaccination ofdams is quite effective in preventing
neonatalcolibacillosis. Vaccine failures are usually relatedto

management and environmental inadequacies. Prevention inolder
piglets requires good sanitation, AI/AO production, environmental
comfort, gradual changes inappropriately formulated rations,
antimicrobial therapy and, in some cases, immunization. Preventive
antimicrobials eventually fail

Clostridium perfringens type c xhis pathogen is a well-recognized cause ofneonatal diarrhea and
death in pigs 1to 21 days old. After3 weeksofage it rarefy causes
enteritis. Diagnosis isconfirmed by observation oftypical gross and
microscopic lesions inacutely affected pigs. Pigs will have
hemorrhage and necrosis ofsegments ofthe small intestine, perhaps
with emphysema. Sacrifice ofacutely affected pigs isoften required
for definitive diagnosis, asexamination ofchronic, necrotic lesions is
not helpful. Gross observation ofcongested or hemorrhagic
intestines is not definitive for clostridialenterotoxemia, since necrosis

isthe key lesion. Similarly, necrotic enteritis in pigs aged 5 to 30
days isnotnecessarily associated withClostridia infection, butcould
bethe secondary effect ofsaprophytes associated withother primary
disease, often coccidiosis.

Preventive measures include AI/AO production, sanitation of
facilities, vaccination ofdams, washing sows before ferrowing, and

perhaps incorporating antimicrobials into the ferrowing ration.
Preventive (prophylactic) treatment ofpiglets withantiserum atbirth
is also a common practice.
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Clostridium perfringens type A

This organism, very common in the intestines ofanimals, hasbeen
associated with neonatal diarrhea in pigs. Disease results from rapid
multiplication ofsporulating organisms that produce alpha toxin and
enterotoxin. Diagnosis is by histologic observation ofspore-forming,
gram-positive rods associatedwith mild inflammationin the small
intestine ofacutery ill piglets. Duringdiagnosis, other causesof
diarrhea must be ruled out, because C. perfringenstype A frequently
colonizes pre-existing lesions. Control is generally achieved by
antimicrobial therapy, feedback to dams, and perhaps vaccination.

Clostridium difficile

Clostridiumdifficile may cause neonataldeath by producing
enterotoxin in the coloa The characteristic gross lesionis marked
edema ofthe colonicwall and mesentery. Diagnosis is by
histopathologic observationofedema and inflammation in the colon,
often with superficial mucosalnecrosis. Enterotoxin canbe detected
by ELISA testing. Control is by sanitation and assuring passive
transfer.

Coccidiosis (Isospora suis)

Caused by Isosporasuis, coccidiosis is a dose-related disease that
generally occurs in suckling pigs from 5 to 21 days ofage. The
source ofthe disease is large numbers ofoocysts (eggs) shed by
piglets during previous ferrowing. Necropsy ofaffected piglets
reveals fibrinous to fibrinonecrotic enteritis in the terminal third of

the smallintestine. Pigs euthanizedearfyin infectionmay have thinwalledintestines typicalofa viral infection. Impression smears and
histopathology demonstrate typicalorganisms. Chronic stages of
coccidiosis are similar to chronic clostridiosis. In feet, necrotizing
saprophytic enteritis often follows primary coccidiosis. Sacrifice of
acutery affected pigs is required to determine ifcoccidiosis is present.
The disease occurs year-round but is most common in late summer
and fell due to high temperatures and humidity.
There areno effective therapeutic agents for coccidiosiscaused by
Isospora suis. AI/AO producttonand sanitation can minimizethe
dose ofoocysts, which areresistant to most disinfectants. A 50%
chlorox solutionmay reducetheirviability. Controlis often achieved
by thorough cleaning and sealing ofall surfaces with paintor water
sealer. Sealing may breakthe cycleofinfection but must be repeated
as oocytes accumulate.
Occasionally, coccidiosis due to Eimeria spp. is found in swine after
weaning. Disease is the resultofnarve pigs' exposureto large doses
ofoocysts. This could occur when incoming giltsare isolated in
contaminated facilities. In severe cases, frank necrosis and

hemorrhage are seen in the terminal smallintestine and colon.
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Sanitation and AI/AOpig flow generally eliminate the threat of
clinical disease.

Porcine Proliferative Enteritis

(PPE, also known as Porcine
Intestinal Adenomatosis)

PPE is caused by Lawsonia intracellularis and perhaps other
organisms, which have only recently been grown inlaboratory cell
cultures. Similar organisms have been identified inintestinal lesions
ofother ariimals, including rats, hamsters, rabbits, dogs, ferrets, and
guinea pigs. Few strains oftheorganism are available for study
because it is hard to grow.

PPE is also known asileitis, porcine intestinal adenomatosis, necrotic
enteritis, or adenomatosis. It is a naturally occurring disease that
affects pigs from weaning to young adulthood. The disease can be
classified by stage andoutcome. The incubation period is
approximately 7 to 21 days, and disease severity isdose-dependent.
Maternal immunity prevents successful reproduction ofthe organism
inyoung pigs. Transmission from dam to offspring occurs early,

perhaps at<7 days of age, but clinical disease ismost common inthe
grower phase.

The rjredominant lesion is proliferation ofcrypt epithelium, and
changes inthis tissue define various forms ofthedisease. The initial
lesion maybe foltowed by acute hemorrhage, ormaybecome
chronic due to necrosis, iriflammatton, and superinfection with

saphrophytes. The form taken by PPE islikely related to thedose
and virulence ofthe organism and to acquired oractive immunity of
the pig.

Gross lesions ofPPE canbe present inthe small or large intestine

and vary from severe intestinal hemorrhage to marked hyperplasia of
mucosa, to obliteration ofmucosawith diphtheritic, caseous.
necrotic exudate. Differential diagnosis ofthe acute form includes

hemorrhagic bowel syndrome, intestinal volvulus orgastric ulcer.
Differential diagnosis ofthesubacute form includes salmonellosis,
swine dysentery, coccidiosis and whipworms. Concurrent infections
also occur.
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Diagnosis ofPPEis by observing typicalgross lesions with
confirmation by typicalhistopathological lesions, in which the
intracellular curved rods are visibleby silverstaining. For lesions to
be seenmicroscopically, samples must be carefully selected and
preserved. This is especially true when the entire mucosais
obliterated by necrotic exudate. Salmonella infection may coexist in
pigswith PPE-compromised mucosal surfaces. PCRtesting canbe
performed on feces to determine the presence of/,, intracellularis
DNA. An IFAT serotogytest can alsobe used, with seroconversion
occurring approximatery 2 weeks after infection.
Various treatments have been used to control the clinical signsof

PPE. Commonpractice is to inject visibly affected pigs with
antimicrobials andto orally medicatethe group. Antimicrobial
selection is somewhat random Recent antibtograms indicate that
most antimicrobials, except aminoglycosides and bacitracin, have to
vitro activity againstL. intracellularis.

Control programs often relyon AI/AO production andon
segregated early weaning (SEW), although the organism isnot
eliminated. On ferms with enzootic disease, pulsemedication during
the grower phase hasbeen somewhat successful. Pulse medication
programs assumethat immunitydoes develop andthat the
incubation period for clinical disease is 2 to 4 weeks. Consequently,
untreated pigsbecomeinfected, which primes the immune system
Subsequent pulses ofmedication at 2- to-3 week intervals prevent
clinical disease.

PPE occursin pigsworldwide andis economically important due to
deaths, increased medication costs, poor weight gain anddecreased
feed conversion. Recently developed tools should help researchers
studythe economic effectsofthe disease. Althoughswine producers
are workingto reduce the use ofmedication, controlling PPE
requires feed-grade medication.
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Swine Dysentery

Swine dysentery due to Serpulina (Treponema) hyodysenteriae
causes mucohemorrhagic diarrhea in grower and finishing pigs,
although younger pigs can beaffected too. Theincidence and
severity ofdisease varies withdose, virulence, herd immunity,

suppressing antibiotics, management, sanitation, and stresses on pigs.
The organism persists in asyrnptomatic swine carriers, the
environment, andcarrier ariimals, particularly mice. At least nine
serotypes ofS. hyodysenteriae are known and their vindence differs.

Typical gross lesions include diffuse accumulations ofmucus, fibrin
or blood limitedto the colon and cecum, which areoften hyperemic
andedematous. Chronic casesmay have velvety diffuse adherent

fibrin. Scrapings oflesions stained with crystal violet orvictoria blue
demonstrate typical serpentine organisms, though it iscommon to
find nonpathogenic spirochetes.

Histopathologic examination reveals nonsuppurative
mucohemorrhagic to fibrinous colitis, and silver staining
demonstrates typical spiral-shaped organisms within crypts and
debris. Definitive diagnosis isby isolatton oftypical beta-hemolytic S.
hyodysenteriae. Isolatton of& innocens orS. pilosicoli from
clinically affected pigs with lesions ofswine dysentery does notrule
out swine dysentery. Continued efforts should be made to
demonstrate the organisms, though autolysis and chronic disease
hindertheir recovery and culture.

Whipworms, salmonellosis, and porcine proliferative enteritis (PPE)
are differential diagnoses, but can occur with swine dysentery.
Serologic testing isnotreliable for diagnosing individual pigs but
only for infectedherds.

Sanitation and effective drugs (tiamulin, carbadox, linconrycin) are

used for prevention and treatment. Acute outbreaks are treated with
water medication, followed by control through feed medication.

Severely affected pigs may benefit from injected antimicrobials.
Failure to control clinical disease by feed medication is generally the
result ofpoor feed consumption by individual pigs or formulation
errors. Resistance by S. hyodysenteriae to certain antimicrobials has
beendemonstrated in laboratory (invitro) testing. Eradication is

preferable to control because antimicrobials cost US $7 - $12 per
Pig-
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Spirochetal Colitis

Spirochetal colitis due to the presence ofweakly beta-hemolytic
spirochetes maybeclinically important. Theorganisms colonize the
colonandcause chronic colitis. Serpulina pilosicoliis probably the
best studied oftheseorganisms, and canbe differentiated from other
spirochetes biochemically andby PCR testing.
The characteristic lesion is a flaccid colon containing poorly

digested, fluid feces inthe late nursery - early grower phase. Mucosa
may be hyperemic withincreased quantities ofmucus. Diagnosis is
by isolation ofweakly beta-hemolytic S. pilosicoli and
histopathology. The small intestine should be examined for

pathogens and evidence ofchronic inflammation, since spirochete
growth inthe colon maybeenhanced by poor digestion or
absorption, aswellas from eating fermentable, less digestible diets.
Treatment and control is similar to that for swine dysentery.

Non-specific Colitis

Non-specific colitis occurs inpigs withpoor digestion or absorption
ofnutrients in the small intestine. Both may be the result ofrjrimary
small intestinal disease or inappropriate ration formulation or

composittoa Fermentable feedstuffs then reach thecolon, altering
thepopulations and types ofbacteria there. Fermenting starches and
proteins (amines) and bacterial products can irritate thecolon,
leading to mild, catarrhal colitis and decreased ability to absorb water
and salt.

Salmonellosis

Salmonellosis, first described over 100 years ago, re-emerged as a

major disease inUS swine inthe 1980's and continues to bea
significant cause ofhuman food poisoning. Enterocolitis inswine is
caused by a variety ofserotypes (usually S. choleraesuis orS.
typhimurium). Septicemia due to host-adapted S. choleraesuis isthe
primary concern inswine. Enterocolitis and diarrhea are more
common inyounger pigs (3 to 8 weeksold). Septicemia and
pneumonia are more common inolder pigs (6to 24weeks old).
Gross lesions are variable andnot specific. Fibrinous to ulcerative
enterocolitis may be present, but interstitial pneumonia,

splenomegalry. lyrnphadenopathv. and hepatomegallv are most
commoa

Diagnosis of septicemic salmonellosis is made by postmortem
examination and isolationofthe organism from spleen, liver,
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lymph nodes or lung. Histopathology often reveals multifocal
necrotizing hepatitis, as well as macrophagic interstitial
pneumonia in lungs.

Asymptomatic pigs can carry and shed Salmonella for an
indefinite period (at least 12 weeks). Detection of individual
carriers or demonstrating that a herd is free of infection is
difficult. Pharyngeal tonsil samples from nonmedicated weaned
pigs 5 to 12 weeks old may be the most reliable method of
demonstrating Salmonella in a herd. Serologic tests are not
routinely available. A mixed ELISA test, developed in Denmark,
is being evaluated.

Enteric salmonellosis oftenresponds to antimicrobials given in water,

coupled with scrupulous sanitation and sound husbandry. The
septicemic form requires injection of infected pigs and oral
medication forthe remainder of pigs at risk. Visibly sick pigs should
bemoved to a separate hospital pen. Disease outbreaks areoften
linkedto environmental and social stresses or the presence of

predisposing diseases. Control isachieved by sanitation, AI/AO
production, and careful attention to animal comfort. Fresh air, clean
water, palatable and accessible feed, and a comfortable, quiet place
to restare essential to pig health. Antimicrobials infeed may help
temporarily but will eventually fail. Autogenous or univalent wholecell bacterins are of questionable benefit. Two modified-live vaccines
have good efficacy.

Salmonella contamination offeed is a major safety and marketing

issue. Most serotypes found inpork products do notcause disease in
pigs. The swine industry will need to implement Salmonella
reduction programs to remain competitive intheworld market.
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Transmissible Parasites
Trichuris suis (Whipworm)

Whipworm infestation cancause mucohemorrhagic diarrhea and
poor performance. Infestation along withswine dysentery and
salmonellosis can cause more severe symptoms. Pigs eat eggs that
survive for long times inthe environment. After being ingested,
larvae migrate to the colonic mucosa for 2 to 3 weeks, causing
catarrhal colitis. Worms become visible 3 weeks after infection and

are patent at 7 weeks. At necropsy, larvae canbe found incolonic
mucosal scrapings during the first 3 weeksafter infection. Larvae
develop into worms inthe cecum andcolon. Fecal examination for
eggs is usually misleading. Control depends on timely useof
anthelmintics, such as ivomec and levamisol. Whipworm infestations
make it harder to treat swinedysentery and salmonellosis.

Ascaris suum (Roundworm)

Roundworm is a common intestinal parasiteofswine. It is

particularly found inswine raised on solid floors or inoutside pens,
and tends to be more severe in the late summer and early fell in the
midwest US.

There are usually no lesions inthe intestine, but the liver and lungs
often suffer significant damage dueto larval migration andthe
resulting hypersensitivity reactions. Enzootic pneumonia

(mycoplasma) ismade worse byroundworm migration. Diagnosis is
byobservation of typical lesions inliver and lung, or byfinding
roundworms in the smallintestine. Fecal flotation ofeggs is a reliable

test only after a 6-week prepatent period. Negative results do not
rule out infestation.

Sanitation combined with strategic deworming can save producers

considerable expense. Understanding the life cycle of nematodes and
the pharmacology ofanthelmintics canhelp when designing control
programs.
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Nodular Worms

Nodular worms are not usually diagnosed as a significant cause of
disease. Infestationsare more common in pigs raised in dirt lots.

They suffer decreased feed efficiency as a result of infestation. Pigs
born in cleanfacilities and subsequently exposed to large numbers of
eggs can suffer stunting due to liver and lung damage.
Grain mite eggs can resemble ova ofnodular worms in fecal
flotations. Inflammatory nodules are visible throughserosaofcecum
andcolon, and can easily be confused withnon-specific lesions of
dilated lymphoglandular complexes, which are evidence of colitis.

Macracanthorhynchus
hirudinaceous

M. hirudinaceous only rarely causes small intestinal disease. The
worm's headpenetrates into the intestinal mucosa, causing an
inflammatory response. Granulomas can develop and ruptureto
cause peritonitis. Diagnosis isbyobservation of adults worms within
the smallintestine. Treatment is usuallynot warranted, and no
treatments are effective.

Balantidium coli

B. colilive inthe large intestines of swine and people. Although the
host-parasite relationship isconsidered harmless (commensal),
worms are often found in necrotic debris from pigs with colitis. The

organism multiplies intheintestinal lumen and may expand existing
lesions bymaking an enzyme called hyaluronidase. Pigs with iron
deficiency anemia may have heavier infestations inthe colon.
Ruling out other causes of colitis isthe first step indiagnosis.
Histopathology of colon or fecal samples demonstrate typical
organisms. Treatment and control israrely indicated but has included
using copper sulfate or arsenicals.

Cryptosporidia

Cryptosporidia are nota significant cause ofdisease inswine but can
be found in cases ofchronic enteritis where sanitation is poor.
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Non-transmissible Diseases
Hemorrhagic Bowel Syndrome
(HBS)

HBS is a poorly defined, noninfectious cause ofsudden death("pen
death") in grower - finishing swine. Anapparently normal animal can
die in 30 minutes following abdominal discomfort, distention and
prostratioa

Necropsy reveals an anemic carcass with a dilated, flaccid, congested
intestine containing unclotted brownish blood. The contents of the
stomachand colon are usually normal. Gross examination can rule
out intestinal accidents (volvulus, torsion, incarceration) or gastric

ulcer. Theremaining possible diagnosis isporcine proliferative
enteritis (PPE).

Bacteriology assists in ruling out salmonellosis. Similarly,
histopathology canrule out PPEand salmonellosis. Other unusual
causes of hemorrhage inthe intestine include anticoagulant toxicity,
caustic chemicals, and ill-defined hypersensitivities to mycotoxins or
biologicalproteins.

Treating individual pigs isdifficult because the disease kills quickly.
Feed-grade antimicrobials have been tried. A consistent, plentiful
sourceofpalatable feed mayalso help.
Gastric Ulcers

Gastric ulcers (ulceration of pars esophagea or UPE), gastric
erosions and epithelial hyperplasia are common ingrow-finish swine.
Ulcers become significant when they bleed or pigs lose their appetite.
Producers will seepigs die suddenly or find anemic pigs with melena.
Helicobacters andgastrospirillae may be associated with UPE, but
no direct evidence ofcausation has been reported.

Necropsy reveals anemia andsometimes blood inthe stomach,
intestine or colon. Typical ulceration of the esophageal portion of the
stomach confirms diagnosis. Preulcerative hyperplasia and
keratinization are common, and can be followed by ulcerationin as

few as 2 days. Absence of blood clots inthe stomach does notrule
out gastric ulcer. Inexperienced diagnosticians can easily miss the
lesions.

Control isempirical usually byproviding a uniformly ground diet of
at least 700micron particle size. Producers canalso decrease various
stresses (including outbreaks of pneumonia andovercrowding), and
decrease fat or increase fiber content in the diet.
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Prolapsed Rectum

Rectal prolapse is generally the result of coughing, piling, or chronic
diarrhea. Straining—due to vaginitis, proctitis or urethritis from
mechanical irritation—may also predispose animals to prolapse.
Zearalenone or zearalenol in feed can increase rates ofrectal

prolapse, and certainantibiotics maybe associated with prolapse.
Genetic predisposition is reported but poorlydocumented.

Rectal Strictures

Scarring fromprevious rectalprolapses causes most rectalstrictures.
Salmonella typhimurium infection is associated with increased
frequency, apparently by cutting off blood supply to regions ofthe
rectum. Blood supply loss in the rectumcan onlyrarefy be
demonstrated. Megacolon is generally the result of strictures. Lupine
seed meal in feed has been associated with megacolon without rectal
strictures.

Dietary Hypersensitivity

The sudden onset ofdiarrhea is often related to changes in feed.

Whether hypersensitivity is due to true allergy is uncertain. Some
reports have linked hypersensitivity to pelleted feed containing
phytoagglutinin, andantimicrobials andanthelmintics have been
blamed. Diagnosis is by clinical signs, history, and ruling out other
causesofdiarrhea. Rapid improvement afterchanging the dietmight
also indicate hypersensitivity.
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Section

7
Enteric Disease

Management Strategies
Introduction

Swineproducers managepigs, facilities, labor and money. Disease
creates economic losses—in poor performance or death ofpigs,
extra labor, and money spent on treatment. To remain profitable,
swine producers must have a disease management strategy in place.

Segregated Early Weaning

Segregatedearlyweaning (SEW), alreadydiscussed in Section3,

'

can prevent disease if:

'

•

•

All dams are free ofa specific pathogen or all dams are
sufficiently immune to a pathogen so they are no longer
shedding the organism (SIV or TGE, for example).
All dams transfer passive immunitythrough colostrum,
which protects piglets from infection due to intermittent
shedding from sows. This applies to Serpulina
hyodysenteriae, Mycoplasma hyopneumoniae,
Actinobacillus pleuropneumoniae, porcine reproductive and
respiratory syndrome virus (PRRSV) and several other
agents.

•

Pigs are infected by dams and develop active immunitywhile
they are still being passively protected by the dam's
antibodies in milk. This works for less virulent, common

•

pathogens which are usually "early colonizers," such as
streptococci, Salmonella, rotaviruses and Escherichiacoli.
Other key elements ofbiosecurity, pig flow, and
management are in place.
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All-In/All-Out (AI/AO)
Production

AI/AO production completely empties a fecility, which canthen be
disinfected before restocking withthe next group of pigs. Thorough
sanitatton reduces the chance that pathogens in the environment will
survive to infectthe next group ofpigs. It also breaks contact

between groups of pigs so that uninfected pigs arenotexposed to
infected ones. All pigs must be removed from the fecility (all out) to
be effective.

Gilt Acclimation

Many programs seek to assure thatgilts and boars entering the
breeding herd are immune and no longer shedding pathogens, a
process known asacclimation and stabilization The goal isto
expose gilts to pathogens before they enter the breeding herd sothat
they can develop full immunity. It isalso good ifgilts are no longer
shedding pathogens that could infect subgroups ofnaive pigs within
thebreeding herd. Achieving herd immunity isextremely important
for allswine ferms, but it is a greater challenge in segregated rearing
systems because ofthelarge numbers ofpigs involved.
Table 7.1 outlinesthe steps in gilt acclimation.
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Table 7.1 Gilt Acclimation

Comments
1-5 Months

Selection

•
•

Based on genetic potential, underline and soundness
Use gilt developer rations, usuallyhigher in calciumand amino
acids

1-6 Months

Acclimatization

•

Separate from commercial finishing pigs

•

Expose gilts to organisms present in farrowing facility
•
•
•

•

Feedback of feces, tissues, fetuses and/or commingling with
cull gilts and sows
Boars should be handled the same as gilts
Allow at least 30 days for acclimation

Vaccination

•

Boost immunity with herd-specific vaccinations
• Agents in growing pigs (e.g., Erysipelas)
• Agents in sow herd (e.g., PRRSV, M. hyopneumoniae,
SIV)

6-7 Months

Isolation

•

Parasite control - As needed

•

Medications - As needed

No new introductions to gilt pool
Serological surveillance

•
•

Seronegativefor agents not present in sow herd
Seropositive for agents in the sow herd

"Cool down" period
•
No new introductions of gilts

• Allow time for shedding to decrease, usually 30 days
Pre-breeding vaccination - Farm-specific, parvovirus, erysipelas,
leptospirosis
7-8 Months

Breeding

In the US, gilt acclimation has been used to control PRRSV.
Although acclimation has not been uniformly effective, it has
had the added benefit of controlling other diseases.
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Vaccination Programs

Vaccination for pathogens not present in a herd is a waste of money.
Therefore, accurate diagnosis of a specific disease should occur
before a specific vaccination program begins. Several questions
should be considered before investing in a vaccination program.
Is the disease agent present?
Get an accurate diagnosis. Is the disease likely to remain in the
herd? Vaccination for E. coli is wise because the organism is
common, the disease kills and the vaccine is inexpensive.
Vaccination for rotavirus may not be wise, because the disease is
sporadic and highly responsive to management intervention.
Is the disease causing substantial economic loss?
Vaccinating for an agent that causes occasional death
{Actinobacillus suis) may cost more than the actual disease.
Vaccinating for agents of enzootic and common diseases that slow
growth and decrease feed efficiency (E. coli, M. hyopneumoniae)
may be very cost effective, even though the disease is less obvious.
Is the disease agent a primary pathogen?
Vaccination for secondary agents, such as Actinomyces pyogenes or
Streptococcus equisimilis is rarely effective.
Is there a vaccine available?

Reputable products, tested for potency and efficacy, are preferred.
Any agent that can be grown can be killed and used as a vaccine,
but many such products are not effective.
Does the vaccine contain theproper strain(s) ofthe organism?
Additional diagnostic testing may be required to answer this
question. Be sure you know the answer before vaccines are
purchased. For example, vaccination protection for APP is serotype
specific.
What is the cost and economic benefit ofvaccination?
Vaccination programs vary considerably. What works on one farm
may not work on another. Evaluation of product data should
include statistical analysis. On-farm evaluations should be
performed by scientific method and controls.

Are other, more cost-effective methods ofcontrol available?
Vaccination is never better than good management and biosecurity.
Is the vaccine safe?
Some vaccines can cause abortions, reactions, abscesses, or hinder
serologic testing in the future.
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When should the vaccine be given?
One must determine the optimal age ofpig or stage of gestation
Are boostervaccinationsrequired?
Ifa booster is recommended, it should be given after the proper period
oftime, usually2 to 4 weeks to get maximumprotection. Subsequent
boosters may be required in sow herds. Generally, the more boosters
that are required, the less effectivethe vaccine.

Can thefarm measure improvement or efficacy?
Many ferms use vaccineswithout knowing if they are necessaryor
effective. Records are necessary for monitoringthe results of
vaccination programs. These records can be used to monitorclinical
disease, medication costs, and economic benefit.

How long should the vaccine be used?
Some agents "disappear"after a period oftime and continued
vaccinationis a waste ofmoney. Continued monitoring ofherds is
usefulto determine if a particularagent is stilla threat or whether a
management or environmental modification has madethe vaccine no
longer necessary.

What route ofadministration shouldbe used?
Vaccinations must be givenby the route for whichthey are designed.
Routes (oral, intranasal, subcutaneous, or intramuscular) often influence
efficacy. Locationfor injections is important (usually neck)to avoid
damaging more valuable cuts ofmeat. Properneedle length, diameter,
and sharpness also must be considered.
Can thefarm handle the vaccine properly?
Is adequate refrigeration available? Whatis the productshelf-life? Can
openedbottlesofvaccine be stored?Is stafftrained to properly
administer the vaccine?

Vaccines can be produced for almost any antigen that can be cultured.
Yetjust because a vaccine can be produced does not meanit will
prevent or control disease. It is veryimportant to consider the cost and
benefitsofa vaccinationprogram before beginning one.
Table 7.2 outlines a vaccinationprogram for a breedingherd. Table 7. 3
outlines a program for piglets.
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Table 7.2 Vaccination Program for the Breeding Herd

Prebreeding: The purpose is to protect the sow and her unborn litter through pregnancy.
Usually, an initial dose at least 4 weeks before breeding is given followed by a booster dose in
gilts. Booster for sows at weaning. Vaccinate boars the same as gilts, then semiannually. Most
herds vaccinate for leptospiras,* parvovirus,* erysipelas,* and then other agents as needed
(pseudorabies, PRRSV, SIV, Japanese B, HCV).
Prefarrowing: The purpose is to transfer immunity to suckling pigs (via colostrum) and protect
them by maternal immunity during the suckling period. Give an initial dose 6 weeks and
booster dose 3 weeks before farrowing in gilts. In sows give boosters 3 weeks before
farrowing. Most vaccines given during this period are inactivated or killed products for safety
reasons. Vaccinate for E. coli* Clostridium perfringens* and then other agents as needed.
Give boosters to sows if actual disease occurs in pigs before 6 weeks of age.
• Good efficacy:
Mycoplasma hyopneumoniae, atrophic rhinitis (toxigenic
Pasteurella multocida, Bordetella bronchiseptica), erysipelas, SIV
Hemophilus parasuis, Actinobacillus pleuropneumoniae, killed
• Fair efficacy.
PRRSV, TGE, rotavirus, streptococci, Actinobacillus suis
"Vaccines appropriate for all farms.

Very young pigs may not respond well to vaccination because of
maternal immunity or age. An immune sow herd coupled with
segregated early weaning can successfully eliminate many of the
pathogens from the weaned offspring. Vaccination protocols are
highly variable, but generally less is better. Timing of vaccination
is dependant on expected level of maternal immunity (maternal
interference) and expected onset of infection in grow-finish pigs.
Table 7.3 Vaccination Program for Piglets

6 weeks: Initial priming dose of vaccine for erysipelas,* Mycoplasma hyopneumoniae*
9 weeks: Booster dose of vaccine for erysipelas,* Mycoplasma hyopneumoniae*
Vaccination for hog cholera virus (HCV), foot and mouth disease, and Japanese B virus in
suckling pigs is not necessary in the US but may be appropriate for some countries and
geographical areas.
Other vaccinations of piglets and pigs that are available in the US may include:
• Efficacy good: atrophic rhinitis at 1 and 3 weeks of age; Salmonella choleraesuis - one
dose MLV at 1 to 3 weeks of age; swine influenza - two doses
• Efficacy fair: Actinobacillus pleuropneumoniae - two doses; swine dysentery - two doses;
PRRSV - MLV at 1 to 3 weeks of age
• Efficacy poor/variable: Hemophilus parasuis - two doses; Streptococcus suis - two doses;
Actinobacillus suis and TGE - one dose MLV at birth or 2 doses killed; rotavirus - one dose
MLV at birth or 2 doses killed
*Vaccines appropriate for all farms.
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Table 7.4 summarizes current management, control and treatment
strategies for common enteric diseases of swine. The severity of
these diseases is related to dose and immunity. Control requires
management ofthe environment.

Disease Control and

Treatment

Table 7.4 Current Status of Selected Enteric Diseases in Swine

Management

Eradication

Vaccination

Treatment

Comments

FARROWING
E .coli

+ clean/AIAO

Clostridium

+

-

Coccidiosis
Rotavirus
TGE

+

-

+

-

+

+

NURSERY

-

+ good

+ fair

+ fair

+ poor

Sanitation / seal surfaces

-

-

+ poor
+ poor

Management and vaccination critical
Chronic may be secondary to coccidiosis
Ubiquitous / many "types"
Enzootic becoming more common
PRCV complicates diagnosis / serology

-

-

FINISHER

.GROWER

Rotavirus

+

-

E.coli

+

-

+ poor
+ poor

-

+ fair

Responds to sanitation and feedback
Responds to management, sanitation,

nutrition
TGE

+

+ poor

+

-

PRCV complicates diagnosis / eradication

desired

S. cholerasuis

+

S. "other"

+

-

PPE (ileitis)
Dysentery

+

-

+

+ good

+ fair
+ fair

Capitalizes on stress
Sanitation and biosecurity are important

.?

+ good
+ good

Lawsonia intracellularis

-

-

+

+ poor

Eradication preferred because of medication
expense
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Glossary
Acclimation and stabilization - A method used to expose / immunize
gilts to herd pathogens prior to entry into breeding herd.
Accrete - Add, as in accreting lean tissue or lean muscle acretion
Acute - Having a short and relatively severe course. Used to describe
symptoms, illness, or lesions.
ADG - Average daily gain. The average amount ofweight gained each
day by a growing pig.
Ad libitum - At pleasure, without restriction; referring to feed intake.
Agalactia - Absence or Mure ofmilk secretion
AI/AO (all-in/all-out) production - Completely emptying a fecility,
which can be thoroughly disinfected before restocking with another
group ofpigs. A swine management technique that breaks contact
between groups ofpigs so that infection does not spread from one
group to the next.
Aminoglycosides - A group ofantibiotics derived from various species
ofStreptomyces.
Angiopathy - Any disease ofthe blood vessels.
Antemortem - Before death.

Anthelmintics - Deworming agents.
Antibiogram - The results ofantimicrobial sensitivitytesting for
various antibiotics.

Antigen - Any substance capable ofprovoking an immune response.
Antiserum - A serum that contains antibodies. Injected into an animal
to confer passive immunity.
Apical - Located at the apex, top or uppermost part.
APP - Actinobacillus pleuroneumoniae, the organism responsible for
a common respiratory disease in grower-finisher pigs. APP is a leading
cause ofpneumonia and death in hogs.
Arsenicals - Any drug containing arsenic.
Atrophy - Wasting away.
Attaching and effacing E. coli (AEEC) - A lesion induced by certain
types of Escherichia coli.
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Autogenous - Describes vaccines madefromthe actual organism
isolated from a herd.

Average dairy gain (ADG) - The average amount ofweight gained
each day by a growing pig.
Bacterin - Suspension ofkilled or inactivated bacteria that stimulates
an immune response.
Biosecurity - Measures intended to prevent introduction or transferof
pathogens.

Capsule - A protective barrierformed by some bacteria that prevents
recognition by a host's immune system.
Carrier - An animal that harbors pathogens without having obvious
signs ofdisease.

Caseous - Resembling cheese, exudate with pus.
Catarrhal - Characterized by iriflammation ofthe mucous membranes.
Cell-mediated immunity - Immunity providedby cellsthat can
recognize infectedhost cells and killor remove them. Important in
resisting viral infections and intracellular bacterialpathogens.
Chyle - A milky substance taken up from the food in the intestine
during digestion.

Clinical signs - Visible indicators ofdisease, such as coughing,
gauntness, fever, diarrhea, lameness, inflammation, redness, etc.
Colibacillosis - Diarrhea due to infection with Escherichia coli.

Colostrum - The milk secreted in the first few days after parturition
Contains large numbers ofantibodies (IgG and IgA).
Commensal - One organism living in or on another organism without
causing harm.
Commingling - Mixing.
Creep - A protected area where pigletswillnot be crushed by their
dam, often used to provide heat, food or water to suckling pigs.
Cross-fostering - Moving a piglet from one dam to another.
Cross-reaction - The interactionofan antibodywith antigenthat did
not stimulate its synthesis, a type ofnon-specificreaction.
Dam - Female pig with piglets.
Deworming - Removingworms.
Diarrhea - Abnormallyfrequent passing of liquid feces.
Dilated - Stretched.

Diphtheritic - Having lesions similarto diphtheria, dry exudate and
necrosis on the surface ofa tissue (gut, tonsil, trachea).
Edema - Abnormally large amounts offluid in intercellulartissue
spaces.

Edematous - Affected with edema.
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Electrolytes - Ionic solutions used to replace fluid losses in sick
animals.

ELISA - Enzyme-linked immunosorbent assay. A diagnostic test.
Emphysema - Pathological accumulation ofair in lungsas bubbles.
Empirical - Based on experience.
Endotoxemia - Presence ofendotoxins in the blood. Can cause shock.
Enteritis - Inflammation ofthe intestine.

Enterotoxemia - The presence in the blood oftoxins produced in the
intestine.

Enzootic - Describesa disease oflow morbiditythat is constantly
present in a herd.
Epizootic - Describes a widelydiffused and rapidlyspreadingdisease;
a disease ofhigh morbiditythat strikes occasionally.
Etiology - A study offectors that cause disease, causativeagent.
Exposure - Contact ofan animalwith a microorganism
Exudate - Fluid, cells and cell debris as a result ofinflammation

Feedback - Exposing animals to a pathogen present in beddingor
feces in the hope that they will develop immunity.
Finisher - A pig or buildingin the final stage ofproduction before
marketing.
Flora - Microbial population.
Fluorescent antibody test (FAT) - A diagnostic method in which
tissue is stained with fluorescent dye and then examined under a
special microscope.
Fomite - Object that harbors a pathogen and may carry it from one
location or host to another.

Gastric ulcer (ulceration of the pars esophagea) - A lesion ofthe
gastric mucosa.
Gastrointestinal (GI) tract - The mouth, esophagus, stomach and
intestine; the digestive tract.
Gilt - A female pig that has not yet ferrowed.
Gestation - Pregnancy.
Granuloma - A mass ofgranulation tissue or chronic inflammation
Grower - A pig in the middle stage ofgrowth, between starter
(nursery) and finisher.
Hepatitis - Inflammation ofthe liver.
Hemolytic - Producing hemolysis or separation ofhemoglobin from
red blood cells.

Hemorrhage - Bleeding.
Hepatomegaly - Enlargement ofthe liver.
Host - The organism in or on which a pathogen or parasite lives.
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Humoral immunity - Immune protectionprovided by antibodies that
circulate in the body's fluids, primarily bloodand lymph.
Hyperemic - Engorged with blood.
Hyperplasia - Abnormal increase in the number ofnormal cells.
Hypersecretion - Excessive secretion.

Ileum - Lower portion ofthe small intestine.
Immune system - One component ofthe body's defenses.
Immunogenic - capable ofstimulating the immune system.
Immunoglobulin - A protein in serum with known antibody activity.
Incarceration - Unnaturalconfinement or entrapment ofa part.
Induced parturition - Artificial method of initiating birth.
Infection - Invasionand multiplication ofmicroorganisms in body
tissues.

Infiltrate - Material or cells that have moved into a tissue.

Inflammation - A local protective response, elicitedby injury,
characterized by pain, redness, swelling, and loss offunction.
Interstitial pneumonia - A chronic pneumonia, with increasein
interstitialtissue and decrease ofnormal lung tissue.
In vitro - In the laboratory.
Iron-deficiency anemia - Anemiacharacterizedby low or absent iron
stores.

Keratinization - Conversion into keratin, the principal constituent of
hair, nails and horny tissues.
Killed virus - Inactivated and preserved virus used in vaccines.
Lactation - Milk production.
Lacteals - The intestinal lymphsystemthat transports chyle.
Lamina propria - The mucous membrane coat between the
epitheliumand underlying structures or layers.
Latent carrier - An animalthat carries a pathogen and is capable of
shedding it but shows no sign ofdisease.
Lumen - The cavity in a tubular organ.
Lymph adenopathy - Disease oflymph nodes.
Lymphocyte - A cell originating in lymphtissue that participatesin
humoral and cell-mediated immunity.
Macrophage - Immune system cell whose job is to engulf and destroy
pathogens.
Malabsorption - Poor absorption, particularly ofnutrients.
Maldigestion - Poor digestion.
Megacolon - Abnormally large or dilated colon.
Melena - The passage ofdark or black feces, exposed to gastric acids.
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Meningitis - Inflammationofthe membrane that's that envelope the
brain and spinal cord.
Mesentery - A membranous fold that attaches various organs to the
body wall.
Metaplasia - An abnormal change in mature tissues.
MMA - Mastitis, metritis, and agalactia; problems encountered in
sows.

Modified live virus (MLV) - A living virus whose virulencehas been
reduced so that it can be used as an antigen in a vaccine without
causing serious illness.
Motility - The abilityto move.
Mucohemorrhagic - Containing mucus and blood.
Mycotoxin - A fungal toxin.
Naive - Describes an animal that has not been exposed to a specific
pathogen.
Natural resistance - Species-specific, inherited protection against
certain pathogens.
Necropsy - Pathological examinationofa body after death.
Necrosis - Cell and tissue death.
Neonatal - Newborn.

Nonsuppurative - Not producing pus or neutrophils.
Nursery - A pig in the first stage ofproduction.
Passive resistance - When antibodies from one animal protect another
animalfrom disease. For example, nursing young receive antibodies
in milk.

Pathogen - Disease-causing microbe.
Pathogenesis - A disease-causing process.
PCR testing - Polymerasechain reaction testing. A diagnostic test.
Peritonitis - Inflammation ofthe peritoneum, the serous membrane
lining the aMominal and pelvic walls.
Phagocyte - An cell equipped to engulf and destroy pathogens, such as
a neutrophil or macrophage.
Pharyngeal - Pertaining to the pharynx or throat.
Plasma - the liquid portion ofthe blood in which blood cellsare
suspended.
Polyarthritis -Inflammation of several joints.
Polyserositis - Iriflammation ofthe serous membranes.
ppm - Parts per million.
Priming - The first encounter between the immune system and a
pathogen, when the system is sensitized to that pathogen.
Proctitis - Inflammation ofthe rectum.

Prolapse - Falling down, sinking or displacement.
Prophylactic - Preventive.
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Pulse medication - Medication administered in successive, short
courses over a period oftime.

Resistance - The abilityto fight infection.
Risk Management - The use ofdisease prevention and treatment
strategies to minimize loss ofanimals and cost.
Segregated early weaning (SEW) - A swine production method
designed to capture efficiencies ofscale and control disease by
moving groups ofpigs through a production fecility.
Sensitivity - The abilityto identifypositive samples correctly.
Sentinel - An animal(s) known negative for a pathogen introduced to
a herd to monitor for infection, usually by seroconversion
Septicemia - The presence ofpathogens or their toxins in blood.
Sequential infection - When one infection follows another, usually in
a predictable order.
Seroconversion - The process ofdeveloping detectable antibodies to a
particular agent or antigen
Serology - The study ofantigen-antibody reactions in the laboratory.
Serosa - Any serous membrane.
Serotype (serovar, serovariety, serogroup) - Subdivision ofa
species, distinguished by individualantigenicity.
Serum - Clear portion ofany animal liquid;usuallyreferring to the
clear portion that separates from cells in clotting blood.
Shedding - Spreading pathogens, usually in urine, feces or respiratory
aerosol.

Shigatoxin - The exotoxin formed by Shigella dysenteriae type 1.
SIV - Swine influenza virus.

Specificity - The abilityto identifynegative samples correctly.
Spomlating - Capable offorming spores.
Splenomegaly - Enlargement ofthe spleen.
Stillborn - Born dead.

Subacute - Between acute and chronic, used to describe symptoms
and diseases.

Subclinical - Without clinical manifestations, used to describe the early
stages ofan infection or illness.
Superinfection - An infection that overwhelms the animal's defenses.
Systemic - Affecting the whole body.
TDS - Total disolved solids. Measure of water hardness.

Titer - Reciprocal of last positive dilution used to indicate the
concentration ofantibody in serum.
Titration - The process ofmeasuring titer.
Toxemia - Poisoning ofthe bloodstream resulting from the spread of
bacterial products (toxins).
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TMR - Total mixed ration.

Texemia - The condition resulting from spread ofbacterial products
(toxins) in the blood stream.
Toxigenic - Toxin producing.
Toxin - A poison.
Transmissible gastroenteritis (TGE) - A highly contagious intestinal
disease that attacks swine ofall ages but is particularly devastating to
piglets.
Univalent - Containing one antigen.
Uterus - The hollow organ in which the developing fetus is nourished.
Vaccination - Administering vaccine.
Vaccine - A substance that contains antigenic components from a
infectious organism that stimulate antibody production.
Vaginitis - Inflammationofthe vagina.
Villous - Covered with villi.

Viremia - The presence ofviruses in the blood.
Virulence - The pathogenicity ofa microorganism.
Volvulus - Twisting ofthe bowel.
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Section

Reference Materials
Farrowing House Production Manual (EXAMPLE)
A production manual should be concise, easily understood, and useful to employees actually doing the work. Each
farm will have unique problems and procedures that should be stated in the manual. Sections of the manual will
generally minimally address or state the management's position for the following:

Sanitation procedures
•
Piglets require a clean environment to remain healthy
•
Farrowing room preparation before placing sows
•
Cleaning, disinfection procedure, heat lamp placement
•

Farrowing room maintenance procedures

Biosecurity requirements
•
Boot wash / hand wash and frequency of replenishing
•
Traffic patterns for employees and pigs to minimize transport of pathogens
•
•

Material and supplies brought in, methods, sanitation
Animal, tissue, and refuse disposal procedures

Farrowing house environmental management
•
•
•
•

Preferred ambient (room) temperature of 24° C
Minimum ventilation rate (when cold) is 15 cmm/sow
Maximum ventilation rate should still avoid drafts on piglets
Heat lamps / supplement heat for the litter

Turn on heat day 111 gestation
•
Place to achieve 32° - 35°C in piglet rest area
•
Place over creep area 18" from back of crate
•
Gradually decrease temperature over lactation period
•
Sow cooling devices: operation and maintenance
Farrowing house procedure
•
Closely observe for signs of parturition
Sow should have a pig within 2 hours of onset of labor
•
•
Should have <1 hour farrowing interval between piglets
Obstetrics: clean, gentle, well lubricated, gloved hand
•

Processing newborn piglets (usually day 1 of life)
•
Trim navel cord, spray with disinfectant
•
•
•
•

Clip needle teeth (optional)
Inject 100 - 200 mg iron into neck muscle
Identify with notches, tags, or tattoo
Dock tails (optional) and disinfect
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Transfer of piglets / cross-fostering (1-3 days of age)
•

Minimize litter size variation

•
•

Minimize piglet size variation
Disease considerations (diarrhea, PRRSV, arthritis, pneumonia)
No transfer of sick pigs: medication (below)
No transfers during PRRSV outbreaks
No transfers after 3 days of age
No transfers before 2 hours of age
.ater transfers are avoided

Use of nurse-sows and procedure

Medication of piglets
•

Treatments

•

Diarrhea

•

Joint infections

•

Septicemia

•

CNS

•

Skin infections

Drug

Dose

Withdrawal

Per a farm-specific protocol

Examination / observation procedures
•

Observation of sows

•

Observation of piglets

Castration

•

Younger is better (5-10 days)

•

Procedure: describe or video

•

Inguinal hernia repair procedure

Sow feeding in farrowing
•
Goal: feed for maximum milk production to achieve higher weaning weights
•

•

Sanitation

•
Clean feed, clean feeders, fresh feed daily
•
Clean water available and easily accessible
Pre-farrow feeding
•
Ration changed from gestation to farrowing ration

•

Twice daily feeding, 2-3 lb each feeding

•

Avoid constipation

Post-farrowing feeding

Day

Number of feedings

kgs/feeding

Kgs feed/day

1

2

Farrow

2
2

2.5 to

1.5 to 2

2

2

1.5

2

3

2

1

3

4

2

2

4

5

2

2

4

6

2

2.5

5

7

2 or 3
2 or 3

3
3

6
6 or more

9

2 or 3

3

7 or more

10
11

2 or 3
2 or 3

3

7 or more

3

8 or more

Pre-farrow

8

12

2 or 3

3

8 or more

13

3

8 or more

14

2 or 3
2 or 3

3

9 or more

15

2 or 3

6

9 or more
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Creep feeding (optional)
•
Start about 10 days of age
•

Small amounts (1/2 cup) twice daily

Weaning procedure
•
•

Farm specific
Refer to section in manual for nursery management

Vaccination programs for sows
1.

General procedures, be specific
Product selection

Product handling
Product timing
Product limitations

Product safety
2.

Reasons to vaccinate
a.
Protect the sow

•

Erysipelas

b. Protect the unborn litter

•

Leptospirosis

•
•

Parvovirus
PRRSV

c.

To protect the newborn litter
E. coli
Clostridium
TGE

Erysipelas

Provide "stable immunity" in sows / decrease shedding of organisms to offspring
•

Rotavirus

•

Erysipelas

P. multocida type D

(Farm-specific recommendations)

Bordetella bronchiseptica
APP

PRRSV
SIV

Piglet and offspring vaccination
Goal: provide systemic immune protection to pigs through the grow-finish period
•

Timing is important

•

Avoid maternal interference

•

Immune competency

•

Product selection

•

•
Safety
•
Efficacy
Examples
Product

Atrophic rhinitis
Mycoplasma hyopneumoniae

1 and 3 weeks
3 weeks and 6 weeks
6 weeks and 9 weeks

Erysipelas
Records

•

Emphasize the need for accurate and complete records
•
Breeding records
•
Farrowing records
•
Pig and weaning records
•
Examples of data collection forms

Culling of sows occurs because of:
•
•
•
•

Poor performance
Breeding problems
Farrowing problems
Soundness: feet, legs, mammary glands, general health
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Practical Necropsy and Diagnostic Techniques

The goal of necropsy is to efficiently open and examine a carcass for evidence of abnormalities or
disease. Changes that can be observed in tissues by gross examination are called lesions. Many
tissue changes can occur as the result of postmortem changes (autolysis). Knowledge of normal
anatomical structures and the effects of autolysis greatly aid interpretation of tissues changes
caused by disease. Frequently misinterpreted tissues changes due to autolysis include passive
congestion or pooling of blood in tissues, most likely in lung and intestinal tissue, irregular red or
pale areas in liver due to autolytic bacteria or congestion, and gas-filled, dilated intestines.
A convenient way to keep materials for necropsy and sampling is to have the materials stored in a
kit form. A fishing tacklebox works well. A swine veterinarian's field diagnostic kit may include:
scissors

forceps
knife

black marker for marking samples
pH paper
vacutainer shields for blood collection

earplugs
blood tubes for serum
EDTA tubes

3 ml syringes with 1 x 20 ga needles
12 mL syringes
16 gax4" needles
16 gax 1.5" needles
20 gax 1.5" needles
vacutainer needles
smoke tubes

smoke tube bulbs

sharpening stone
large whirlpaks
small whirlpaks
jar of 10% formalin
disposable gloves
hog snare
falcon tubes
culturettes / dacron swabs

microscope slides
Necropsy of pigs is simple and fast if basic techniques are followed. Usually, multiple carcasses
are opened until it is clear that the lesion(s) observed are consistently present. Dead pigs are most
available, and depending upon diseases present, may yield useful information at necropsy. Primary
causes of disease may be overshadowed by secondary agents in pigs that have chronic disease.
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Consequently, when more than one disease process is occurring, it is desirable to euthanize
acutely affected pigs to detect primary pathogens.
A simple and efficient necropsy technique is as follows:
1. Place pig on its back.
2. Incise from axilla to between jawbones on both sides.
3. Incise inguinal region to perineum, freeing the femur from the acetabulum on both sides. The
pig should be lying on its back.
4. Make a "handle" from skin under the chin and incise below breastbone through costochondral
junctions.
5. Continue incision caudalfy, opening the abdominal cavity.
6.

Cut between the first two ribs on the midline.

7. Manually spread the chest open.

At this point, the thoracic cavity and abdominal cavity are open for inspection. Start a systematic
examination, proceeding from "sterile" organs first to "dirty" organs last. Collect appropriate
samples as you go.
1. Cut out the tonsils, trachea, lungs and heart (all together) and examine or collect samples.
• Tonsils can be removed with trachea and lungs and examined for tonsilitis.
• Tracheitis, inflammation of the windpipe.
• Pneumonia: palpate lung for firmness and consistency and slice into the lung across
airways.
• Open chambers of the heart and examine valves.
2. Examine, cut, remove kidneys and urinary bladder.
3. Examine and/or remove spleen and liver; collect specimens.
4. Find the cecum and attached ileum. Examine mesenteric lymph nodes.
5. Examine/remove small intestine, cecum, colon, stomach.

Optional, depending on clinical signs:
6. Examine joints by aseptically collecting synovial fluid (syringe or swab) and then opening
them.

7.

Examine brain.
•

Remove head.

•
•

Split head on midline in pigs <10 kg.
Use hatchet or cleaver to open skull in pigs > 10 kg by chopping transversely behind the
eyes and then sagitalfy to vertebra to expose brain.

• Saw the snout transversely at the level of the 2nd premolar and examine turbinates.
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Diagnostic Techniques

1. Fecal / cecal pH may indicate mechanism, hence cause of diarrhea in suckling pigs.
• pH >7.0: hypersecretion, likely E. coli.
• pH <7.0: malabsorption, more likely viral or coccidia.

2. Impression smears from smallintestine may demonstrate immature coccidia.
• Gently blot the mucosal surface of ileum with paper towel.
•
•

Press slide against mucosa.
Air dry and stain with Diff-Quick or Wright's stain.

•

Examine for merozoites.

3. Colon scrapings may demonstrate spirochaetes in suspected cases of swine dysentery.
• Use slide or knife to scrape affected colon mucosa.
•

Make thin smear on slide.

•
•

Stain with Victoria Blue or Crystal Violet for 20 minutes.
Examine at 400x for spiral-shaped organisms.

4. Villus atrophy typicalof viral or coccidia infection can be demonstrated in neonates.
•
•
•
•

Euthanize an acutely affected piglet.
Put 1 cm of ileum in test tube with plain water.
Wait a few minutes for villi to engorge with water.
Examine the preparation.
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Troubleshooting Feed Problems

The quality ofthe provided feed has a major impact on the health and performance of animals.
Deficiencies and toxicoses may cause specificdisease whereas compromised performance occurs with
improper ration formulations. In some cases feed-related problems may be included in a differential
diagnosis or "rule out" list when health and performance problems occur. Carefiil evaluation ofclinical
evidence, finding the feed as the common denominator, and selection ofrepresentative specimens and
appropriate laboratory tests can help confirm the cause ofthe problem.

Types of Health Problems Associated with Feed
1. Nutrient imbalances (Ca, P, vitamins, etc.)
• Rickets (growing pigs).
• Osteoporosis (sows).
• Mulberry heart disease / hepatosis dietetica.
• Parakaratosis (Zn deficiency).
• Many others.

2. Contamination with toxic compounds (errors or accidental)
Monensin (deadly to swine with concurrent tiamulin).
Insecticides.

Selenium.

Hydraulic fluid.
Arsanilic acid.

Salt (sodium ion toxicity).
3. Feed refusal (vomitoxin or unknown)

4. Moldy feed (taste, smell,nutrients, dust, palatability)
5. Mycotoxins (toxic compounds from fiingi)
6. Mislabeledfeed - prepared for wrong species, wrong ingredients
7. Residues, look for:
•

Sulfonamides.

•

Insecticides, heavy metals.
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Feed History

1. Where formulated and by whom
•

Commercial mill.

•

Onferm.

2. Time sequence ofthe new feed and onset ofhealth problem
3.

Constituents ofthis batch:

•

Drugs.

•

Additives.

•

Minerals, vitamins.

4. What was mixed or delivered just prior to this batch?

5. Anything unique or different about this batch?
•

Who?

•

What?

•

Where?

Evaluation of Feed

1. Sample collection
• A major factor affecting accuracy ofanalysis

•

Final sample mustrepresent the average composition ofthe feed or grainsampled to make
the analytical result valid!

•

Mycotoxin analyses in whole grains represent special sampling considerations. Because
mycotoxins are oftenhigh in a fewsingle kernels mixed throughout the grain, yourodds of
getting a representative sample are greatly increased withthe more sub-samples you collect

•

Collect multiple small sub-samples (use a grainprobe in bins or feeders, or a coffee can
passed through a moving stream ofgrain or feed). Mixthese well and then submit a

from multiple sites in the grain

•

composite ofthis pooled sample.
How big ofa sample?
0.5 - 1 kgs ofa ground mixed feed
2.5 -5 kgs whole grain

2. Feed sample preservation

•
•
•

Plastic okay for short-termstorage and transport ofdry feed. Must keep cool.
High moisture feeds - freeze or use paper or cloth bags.
Producer should consider freezing back a quart ofeach batch offeed.
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3. Physical characteristics offeed
• Particle size? - swine feed, dairy TMR.
• Color, ergot sclerotia, odor, oily?

Laboratory Evaluation of Feed

1. Nutrient analysis
• Ca, P, protein, salt, vitamins D, E, and A, other micro-nutrients.
• May indicate a mis-formulation.
• Chemical analysis for contaminants (OP's, Se, monensin, copper).
• Mycotoxin analysis (lab's methods?)
• Looking for actual toxin.
•

•

Zearalenone, anatoxin, vomitoxin, fumonisin, and others.

Mold spore counts.
• What do they mean? .. .not very useful.
• Not a good indicator ofmold growth, but an indication ofsporulation(reproductive)
stage.

2. Feed microscopy (microscopic examination)
• Identifies components offeed and sometimes formula.
• Can be very helpful.
•

•
•
•

Can tell a lot about a feed.

Particle size - use feed sieves to measure mean particle size in ground feed or TMR.
Bacterial culturing (Salmonella spp. and others).
Test feeding to a few animals.
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Water Quality for Livestock

Water has been called the most important nutrient. Water of adequate quantity and quality iscertainly
critical to successful swine production. Water may beoneof thecausative agents that should be
investigated when producers have a problem with poor performance and perhaps poor feed
consumption It isimportant to beable to estimate water intake, which varies considerably with age
and weight. A rule ofthumb isthat a pig will drink about 3 times what it eats or approximately 4 L per
50kg bodyweight. Lactating sows will consume anadditional 8-16 L daily.
Criteriafor evaluating water qualityusuallyinclude:

1. Physical standards are how water looks, tastes, and smells. Evaluations ofthese criteria are
somewhat subjective (aesthetic) and are obvious to humans but little isknown for pigs. Those
considerations oftaste, odor, color, and turbidity detectable by human evaluation usually require
additional testing to define the cause.

2. Microbiological standards are determined by microbiologic examination ofwater samples. The
general sanitary quality ofthe sample can be evaluated and some indication ofthe degree of
contamination ofthe water with the waste from human or animal sources determined. These

examinations do not attempt to isolate pathogenic bacteria butrather detect thepresence of
organisms that are indicators ofcontamination, usually either coliform bacteria orE. coli

specifically. US standards generally permit no more than 1000 organisms per 100 mL ofwater,
determined by plate counts.

Most pathogens eliminated from the body in feces or urine are transmissible incontaminated water.
Notable among these are E. coli, Salmonella, Vibrio, Leptospiras, enteric viruses, and nematode
ova.

Besides contamination withhuman and animal waste(potentially containing pathogens), other
bacteria of concern are ironbacteria, not because they are a direct health problem, but because they

create a foul-smelling slime that clogs pumps, fixtures, and nipples. Iron bacteria presence inwater
withhigh salinity (particularly sulfate salts) will also have odor.

3. Chemical constituents inwater are, withthe capabilities of today's analytic laboratories, quite easy

to measure. A bigger challenge may beinestablishing levels ofcontaminants that adversely affect
animalhealth and production

Salinity, also known as Total Dissolved Solids(TDS). is sometimes referredto as "water hardness."

Salinity, generally expressed in mg/L, is anexpression ofthe amount ofsoluble salts. The ions most
commonly involved insaline water are Ca, Mg, and Naasbicarbonate, chloride or sulfate salts. Water
containing >7000 mg/L should be considered unsafe for swine. Water "hardness" is sometimes
confiised with salinity but the two are not correlative. Hardness isexpressed asthe sum ofCaand Mg
reported in equivalent amounts ofcalcium carbonate. Water containing high levels ofsalinity could be
considered"soft" rather than "hard" if Na is high and Ca and Mg are low.
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Guidelines for Salinity in Swine Drinking Water
Salinity

Effect

<1000 mg/L
1000-3000 mg/L
3000-5000 mg/L

Safe. No health problems expected.
Satisfactory. Mild transient diarrhea.
Satisfactory. Transient diarrhea, scale build-up in pipes,
may inactivate medications.
Borderline. Do not offer to pregnant animals.
Unfit. Risk for pregnant swine, lactating swine, young pigs,
stressed animals, during heat stress.

5000-7000 mg/L
>7000 mg/L

>10,000mg/L

Unfit. Do not use for livestock.

Nitrates and nitrites are water soluble and may be leached from soil into groundwater. Animaland
human wastes, nitrogen fertilizers, decaying organic mater, and soil high in Nitrogen-fixing bacteriaare
sources ofcontaminationto poorly encased wells, poorly sealed wells, shallowwells, low-lying water
reservoirsand ponds. The upper limit for nitrate considered safe in human drinking water is 45 mg
nitrate/L, but the maximumrecommended for livestock is 440 mg nitrate/L. Up to 1200 mg/L has been
shown to have no effect on performanceofgrowing/finishing swine or reproductive performanceof
gilts.

Chlorine greaterthan 250-500ppm can cause a foultaste in water and maydecrease consumption.
Highironlevels in water can contribute to growthofbacteria that are not a health riskbut mayfoul
pipes and nipples or inactivate certain medications. Highconcentrations ofsulfate mayexert a laxative
effect, particularly inyoungweanlings. Extremes ofpH (<5 or >8) mayaffect solubility ofmedications
and additives to water or may inactivate them. HighpH can decrease ability to successfully chlorinate
water.

Other contaminants are occasionally present in water as the result ofpoint-sources (spills or dumping)
or accidental or purposeful contamination frompesticides, chemicals, heavy metals or fertilizers. The
following water quality guidelines for livestock have recently been proposed.
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Guidelines for Total Dissolved Salts in Swine Drinking Water
Category
Major Ions

Maximum Recommended Limit (mg/L)
TDS

3000

Calcium

1000

Chloride

1000

Nitrate+nitrite

100

Nitrite alone

10

Sodium

2000

Sulfates

1000

Ammonia

2

PH

5-8

Heavy Metals and

Aluminum

5.0

Trace Ions

Beryllium

0.1

Boron

0.5

Cadmium

0.02

Chromium

1

Cobalt

1

Copper

5

Fluoride

2

no guideline

Iron

0.1

Lead

no guideline

Manganese
Mercury
Molybdenum

0.003
0.5

Nickel

1

Selenium

0.05

Uranium

0.2
0.1

Vanadium

50

Zinc
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Troubleshooting Water Quality Problems

1. Water source history
•

Know the source ofthe water
•

Well

•
•
•

Pond

•
2.

Shallow: more problems with nitrates, coliforms
Deep: more problems with hardness, salinity
More problems with nitrates, surface water contamination

Gather some well information

•
•
•

Age: older impliesgreater likelihood ofproblems
Depth: shallow < 10 meters; deep > 100 meters
Type ofpump: submersible,jet, piston

•

Look for structural defects

•

Lack ofsanitary seal
• Extremely important to prevent surface contamination
• Cracked casing
• Surface drainage: located on high area where water runs away
• May need to contact well service professionals
How long has source been used?
• Any kind ofwater treatment used?

•

•

Chlorination

•

Softening

•

Other

3. Quantity ofwater flow?
• At well head: ranges from 3 to 30 gal/min
•

At drinkers

•
•
•

Nipple flow rates: recommendations based on animalweight
Cups: pigs waste less water; must be kept clean
Troughs: must be kept clean

Restricted water to growing pigs can cause decreased feed consumption and poor growth rates,
therefore water should be available ad libitum. Restricted water to the breeding herd will decrease
lactation ability, feed intake, reproductive performance, and willincrease the frequency ofurinary tract
infections. Water should be available a minimum of 3 times daily and preferably ad libitum.
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4. Laboratory evaluation ofwater
•
Sample collection
• One pint is adequate
• Use a clean container - glass is best
•

Collect untreated water near source

•
•

Run water for a few seconds to flush pipes
Keep cool, and rapidly transport to lab

5. Assays to include from water used in animal production
• Primary assay

•

•

Total dissolved solids (TDS)

•

Nitrates

•

Sulfates

•

Coliforms

Secondary assay (ifTDS is high)
Sodium

Magnesium
Chloride
Calcium
Potassium

Manganese
Iron
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Checklist for Physical Examination of the Breeding Herd
1. Physical condition
• Body weight and frame

2.

•

Cleanliness

•
•

Mammary glands
Vulvular discharge

•

Skin

•

Feet and legs

Feed

•

Amount consumed

•

Feed intake curves

•
•

Feeder design
Feed quality and quantity

3. Water quality and availability
4.

Environment

•
•

Temperature
Floor design

•

Crate design
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Checklist for Physical Examination of Piglets

1. Physical condition
•Piglet birth weight
•Litter size

•Weight and variation in weight
•Skin
•Locomotor condition
•Infectious disease
•Teeth

•Tails
2.

Feed

•Creep feed
•Water availability and sanitation
3.

Environment

•Temperature
•Drafts

•Floor design
•Management
•Flow

4. Building use
•Farrowing schedule
•Sanitation

•Cleanliness
•Downtime

•Washing procedure

72

REFERENCE

Checklist for High Preweaning Mortality

1.

Trauma

•
•
•

Facilities / equipment
Ambient temperature
Crate design

•

2.

Microenvironment

Predisposing illness
•
Chilling
•
Congenital anomalies
•

3.

Diseases

•

Starvation

•
•

Undersized pigs
Weak pigs

Facilities / equipment
•
Farrowing flooring
•
Gestation housing
•

4.

5.

6.

Microenvironment

Management
•
Creching
•
Cross-fostering

•
•
•

Fractionated weaning
Gestation feeding
Induced farrowing

•

Alimentation

Sow / litter / pig factors
•

Genetics

•

Litter size

•
•
•

Piglet birth weight
Piglet weight variation
Parity

Starvation

•

Chilling
•

Floor surface

•

Crate design

•

Drafts

•

Supplemental heating

• Dysgalactia
• Management
•

Alimentation

•

Cross-fostering

•

Nurse sows

•

Split suckling

• Predisposing illness
• Congenital anomalies, low viability
•

Disease
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Checklist for Low Preweaning Weights

1. Birth weights low
•

Genetics

•

Gestation length

•

Litter size

• Parity
•

Nutrition

2. Average daily gain (ADG) of suckling pigs is low
• Nutrient ingestion low
• Milk production low
•

•

Entire chain

• Systemic signs
• Bacteremia / septicemia
MMA-syndrome
• Non-systemic signs
•

Feed intake

•

Nutrient density

•

Thermal stresses

•

Water intake

• Mycotoxins
• Single or multiple glands
• Congenital
•

Genetics

•

Mastitis

•

Trauma

• Reduced suckling
• Birth weight
• Chilling
•

Debilitations

• Constituent quality
•

Feed intake

• Nutrient density
3. Conversion efficiency (milk+creep feed) low
• Chilling
•

Debilitation

•

Diarrhea and disease

•

Genetics

• Malabsorption
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Checklist for High Stillborn Deaths

1.

Noninfectious causes
•

Environment

•

Ambient temperature

•

Carbon monoxide

•
•

Evaporative cooling
Farrow crate design

2.

Management
• Attended farrowings
• Induced farrowings

3.

Nutrition

•

Gestation energy

•

Micronutrients

4. Sow/ litter / pig factors

5.

•

Birth order

•
•
•
•
•

Delivery interval
Farrowing duration
Gestational length
Parity
Piglet size/weight

•

Sow size

Infectious causes

•

•

Reproductive pathogens
Leptospirosis

•

PRV

•

PRRSV

•

Viremia / fever

•

Systemic pathogens

•

•

SIV

•

PRRSV

Septicemia / fever / endotoxemia
•

Salmonella choleraesuis

• Erysipelas
•

Actinobacillus

•

Other bacteria
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Antimicrobial Use in Swine: A Brief Overview

Kent J.Schwartz, DVM, MS
In the past 50 years, antimicrobials have been widely used for treatment, prevention, and control of
swine bacterial diseases. In addition, certain antimicrobials also enhance growth and/or feed efficiency
when fed at subtherapeutic levels. The use of medications (antibiotics, antimicrobials) to control disease
is being increasingly scrutinized because of fears of residues as well as the potential for inducing
antibiotic-resistant organisms that can infect humans. This, as well as cost and efficacy, has driven

producers to be more selective in choosing medication strategies for swine and to search for alternatives.
Those alternatives include eradication of the agent from a herd (Serpulina hyodysenteriae, Actinobacillus

pleuropneumoniae), strict biosecurity to prevent introduction of agents ( S. hyodysenteriae, A.
pleuropneumoniae), vaccination (E. coli, Mycoplasma hyopneumoniae, Erysipelas rhusiopathiae,
Serpulina hyodysenteriae, Salmonella choleraesuis) or improving air quality, ambient temperature
fluctutations, environment (Streptococcus suis, Hemophilus parasuis, E. coli, Salmonella spp.).
Unfortunately, bacterial diseases often remain in herds, causing disease, ill-thrift, and death.
Antimicrobials remain extremely useful for disease treatment, for growth enhancement, and occasionally
disease prevention.

TREATMENT

Treatment is the application of medication to pigs clinically affected with bacterial disease. Antimicrobials
do not "cure" an animal of bacterial disease but only suppress the bacterial growth to allow the animal to
fight the disease agent with inflammatory response and immune response. Attention to details of
housing, environment, nutrition, parasites and pig flow allow antimicrobialsto be more effective in
disease control.

The basic tenets of successful antimicrobial therapy are:
1. Initiate therapy EARLY in the course of disease

Treat Early

2.

Use the Right Drug

Choose the correct antimicrobial (Tables 1 and 2)

3. Use the proper (effective) dose, route, and frequency of administration...Use the Right Dose
4. Treat for the proper period of time
Treat Long Enough
5. Observe proper withdrawal of antimicrobials before slaughter
Observe Withdrawal
Times

Treat Early

Best results are achieved when animals are medicated early in the course of disease. Chronic disease

generally responds poorly and slowly to therapy, because the animal has become debilitated, is not
eating, has extensive tissue damage, has exhausted its inflammatory and immune response, and has a
larger bacterial or toxin load.
Use the Right Drug
Antimicrobials used for treatment of disease are selected on the basis of: the causative organism

(requires accurate diagnosis), the organism susceptibility (requires antibiotic sensitivity or
historical data), and the tissue distribution (pharmacodynamics) of a particular antimicrobial. The site
of infection must be known. Also required is a knowledge of where the drug goes in the body, the drug's

absorption, distribution, solubility in lipid or aqueous solvents, and method and rate of excretionfrom the
body. The route of administration must be considered as well. Many antimicrobials are not well absorbed
from the intestine, therefore, they are of littlevalue in treating systemic infections. For example the
aminoglycosides (neomycin, streptomycin, gentamycin, kanamycin) given orally are of no value for
systemic infections (Salmonella choleraesuis) but often are quite effective for enteric infections
(Salmonella typhimurium, E. coli). Some medications cannot penetrate to jointfluids, lungs, or brain,
whereas others (lincomycin) penetrate well. Some medications are very rapidly excreted or metabolized
and require multiple doses each day to maintain an effective blood or tissue level. Veterinarians spend a
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great deal of time learning the pharmacokinetics and pharmacodynamics of antimicrobials. It is beyond
the scope of this summary to discuss these factors in detail.
Use the Right Dose
The goal of therapy is to achieve a concentration of antimicrobial at the site of infection that is inhibitory
to the pathogen present. Best therapeutic efficacy is usually by administration of higher dosage rates,
unless data are available to suggest lower rates. Intermediate sensitivity can be overcome by increasing
dose.

Treat Them Long Enough

A 3-day course of therapy would be minimum for an acute bacterial infection. Human medicine
generally prescribes medication to continue for at least 3 days after cessation of clinical signs.
Depending on disease and populations of pigs, therapy in water is generally for a 5-day period and
injectable medication for 3 days.

Treatment of animals with clinical disease by feed medication is often unrewarding because sick animals
do not consume enough feed to receive the proper dose of medication. Medication of feed with
therapeutic levels of antimicrobials may be helpful in preventing disease in animals that are still eating,
and this strategy is often coupled with either injection of clinically affected pigs or as a follow-up to water
medication.

Observe Withdrawals and Labeled Uses

The global marketplace is acutely aware of food safety perceptions. People expect residue-free pork.
Although the perception of increased antimicrobial resistance because of animal uses is generally not
justified scientifically, the pork industry must strive to use antimicrobials appropriately and prudently.
Records should identify treated animals, medication and dosage, and withdrawal times.
GROWTH ENHANCEMENT

One major economic benefit derived from antimicrobials is the effect on average daily gain and feed
efficiency. Numerous studies have documented increased performance by feeding certain antimicrobials
at subtherapeutic levels. A summary by Hayes of over 60 trials found:
Table 1

Effect on Growth Rate (% Improvement)
Weight of Pig:
ASP-250
Mecadox

< 35 lb
22
18

Tylan Sulfa
17
Pen-Strep
14
Tylosin
14
Average Response: 15

> 125 lb

35-125 lb

ASP-250

17

Mecadox

15

Tylosin
Tetracyclines
Virginiamycin

10

Tetracyclines
Virginiamycin
Tylosin
Pen-Strep

10

Bacitracin

10

6
5
4
3
2

4

11

Table 2

Effect on Feed Efficiency (% Imprc)vement)
Weight of Pig:

< 35 lb

> 125 lb

35-125 lb
6

Virginiamycin

3
2

2
1
1

8

Mecadox

Mecadox

8

Virginiamycin

6

Bacitracin

ASP-250

7

ASP-250

6

Tylosin
Tetracylines

4

Tetracyclines
Pen-Strep
Tylosin

Penicillin

Lineomycin
7
Pen-Strep
7
Average Response: 8

4
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Comments

1. These trials do not consider disease effects, although most were in "healthy" pigs.
2. Most of the beneficial effect on growth is during the growth phase (up to 160 lb).
3. Ad libitum feeding required; some of the effect is due to increased feed intake.

4. The presence of enzootic diseases may influence drug selection. Enzootic disease agents
and pressure differ markedly, depending on the particular farm or production system.
5. Subtherapeutic levels are not therapeutic (but may have some preventative effect).
PREVENTION or CONTROL

The use of antimicrobial strategies alone to prevent or control disease will eventually fail due to
resistance or complacency. Antimicrobials are an aid in prevention and control of diseases. Prudent use
of vaccinations, coupled with sound principles of husbandry and pig flow are essential for successful pig

production. Pig production without the use of antimicrobials is a worldwide trend but some are still used
extensively. In the opinion of the author, the most frequently used (not alwaysthe most efficacious)
feed-grade antimicrobials for treatment and control of clinically apparent diseases are found in Table4.
Other Comments

1. Colistin is not absorbed from the intestinal tract. It is frequently used for Pseudomonas infections in
humans, is highly toxic parenterally, and not used in animals in the US.

2. Organic arsenicals have fallen from favor in the US due to resistance of pathogens and toxicity.
They are occasionally used as growth promoters.

3. In the US, antimicrobials used therapeutically are targeted for specific disease agents rather than
"broad spectrum." Accurate diagnosis is extremely important.

4. Many pathogens have variable sensitivity to antimicrobials. Isolation of the offending agent allows
antimicrobial sensitivity testing for proper antimicrobial selection.

5. Many orally administered antimicrobials are not absorbed from the gastrointestinal tract and,
therefore, are of little value for systemic infections.
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Table 3

Antibiotic Sensitivity Data and Estimates*
Pathogens
Agent

E. coli

Salmonella

For Enteric Bacterial

Lawsonia
intracellularis

Brachyspira
(Serpulina,
Treponema)

Clostridium

Isospora/E

perfringens

imeria

Availability:
l=injectable,

(coccidia)

W=water,

Dose

F=Feed

spp

Percent Sensitive*
amikacin

98

98

low

low

low

0

2mg/kg

1

ampicillin

75

40

moderate

low

low

0

10mg/kg

1

high

0

50ppm

F

carbadox

high**

high

high

high

ceftiofur

98

94

high

low

low

0

2mg/kg

1

cephalexin

95

70

unknown

low

low

0

5mg/kg

l,W

ciprofloxacin

90

95

high

low

low

0

2mg/kg

1

gentamycin

98

95

low

low

low

0

1mg/kg

1, W, F

kanamycin

90

70

low

low

low

0

5mg/kg

1

0

10mg/kg

1, W, F

lincomycin

low

low

high

high

high

neomycin

60

80

low

low

low

0

20mg/kg

W,F

nitrofurans

80

80

low

low

low

0

Prohibited

W, F

I.W, F

spectinomycin

35

70

low

low

low

0

20mg/kg

tetracycline

10

20

high

Low

low

0

10mg/kg

1, W, F

0

0

high

high

high

0

120ppm

W, F
1, W

tiamulin

trimethoprim-sulfa

tylocin
virginiamycin

85

90

low

low

low

maybe

10mg/kg

0

5

high

high

high

0

100ppm

I.W, F

low

low

high

moderate

high

0

25ppm

F

* Numerical data from Iowa State University Veterinary Diagnostic Laboratory.
Others are estimates based on available data and field experiences.

** High > 65%, moderate 35% - 65%, low < 35%
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Table 4 Antimicrobials Administered Orally (in Feed or Water), Absorption, Common Uses, and Efficacy

Antimicrobial

Asorption from Intestine

Amoxicillin

good

Efficacy Against
Streptococcus

good

Actinobacillus

fair

Pasteurella

good
good

Hemophilus

Ampicillin

good

E.coli

fair

Salmonella

fair

Streptococcus

Hemophilus

good
good
good
good

E. coli

fair

Salmonella

fair

Actinobacillus
Pasteurella

Apramycin
Cephalexin

Carbadox

none

good

none

Salmonella

poor

E. coli

poor

Streptococcus
Actinobacillus

good
good

Salmonella

fair

E.coli

fair

Pasteurella

good
good
good
good

Hemophilus
Serpulina
Lawsonia

Gentamycin

none

Salmonella

fair

E. coli

fair

E. coli

good
good

Salmonella

Lincomycin

good

Serpulina (swine dysentery)

poor

Mycoplasma
Serpulina

good
good
good
good

Lawsonia

Streptococcus

Penicillin

Neomycin

poor

none

Actinobacillus

fair

Pasteurella

fair

Hemophilus
Streptococci

fair

Actinobacillus

fair

Pasteurella

fair

Hemophilus

fair

E. coli

Hemophilus

good
good
good
good
good
good
good
good
good
good
good
good

Pasteurella

fair

Actinobacillus

Lawsonia

good
good
good

Pasteurella

fair

Mycoplasma

fair

Salmonella

Spectinomycin

poor

E. coli

Tetracyclines

good

Hemophilus

Tiamulin

good

Salmonella
Pasteurella

Serpulina
Lawsonia

Streptococci
Mycoplasma
Actinobacillus

Tilmicosin

good

Mycoplasma
Tylosin

good

good
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Table 5 Strategic

No clinical disease

Atrophic rhinitis
E.coli

Salmonella

Swine dysentery

Ileitis

Mycoplasma hyopneumoniae

Enzootic pneumonia (Mhyo+Bacteria)

Actinobacillus pleuropneumoniae

Streptococcus suis

Hemophilus parasuis

non Feed-Grade Antimicrobials in the US

Nursery

Grower

Finisher

Apralan
Virginiamycin
Flavomycin

Bacitracin

Bacitracin

Virginiamycin

None

ASP/CSP

Not appropriate

Not appropriate

Carbadox

None

None

Spectinomycin

Neomycin

Nitrofurazone

Carbadox

Carbadox

Carbadox

Neomycin
Spectinomycin

Neomycin
Spectinomycin

Neomycin
Spectinomycin

Nitrofurazone

Nitrofurazone

Nitrofurazone

Carbadox

Carbadox

Carbadox

Lincomycin

Lincomycin

Lincomycin

Tiamulin

Tiamulin

Tiamulin

Tylosin
Lincomycin

Tylosin
Lincomycin

Tylosin
Lincomycin

Carbadox

Carbadox

Tiamulin

Tetracycline

Tiamulin

Tetracycline

Tiamulin

Tetracycline

Lincomycin

Lincomycin

Lincomycin

Tiamulin

Tiamulin

Tiamulin

Tetracycline
Tylosin

Tetracycline
Tylosin

Tetracycline
Tylosin

Lincomycin

Lincomycin

Lincomycin

Tiamulin

Tiamulin

Tiamulin

Tetracycline
Tylan/Sulfa

Tetracycline
Tylan/Sulfa

Tetracycline
Tylan/Sulfa

ASP/CSP

ASP / CSP

ASP / CSP

Tilmicosin

Tilmicocin

Tilmicocin

Tetracycline

Tetracycline

Tetracycline

Penicillin

Penicillin

Penicillin
None

Tiamulin

Tiamulin

ASP / CSP

ASP / CSP

Tetracaine

Tetracycline
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Penicillin sp.
Mucor spp.
Humicolor sp.

Common sweet

Dicoumarol

clover (Melilotus
officinalis)

"slobbers syndrome," salivation, anorexia,

Rhizoctonia leguminicola

Red clover

Slaframine

liver

hemorrhages due to anti-Vitamin K effect in

diarrhea

Horse: depression, leukoencephalomalacia,
and hepatosis
Swine: hepatosis, acute dyspnea associated
with pulmonary edema & hydrothorax, sows
may abort

Fusarium moniliforme

heat intolerance

tremors, agalactia due to reduced prolactin

gangrene of the extremities, convulsions, ataxi,

when source removed

tremors, convulsions, low mortality, recovery

enlargement

estrogenic, vulvovaginitis, infertility, mammary

feed refusal, diarrhea, weight loss, necrotic
dermatosis, lympholysis, thymolysis, some data
show reduced milk production

similar to ochratoxin

nephrotoxicosis with polydipsia and polyuria,
weight loss, anorexia

residues are regulated

Acremonium coeniphialum

Penicillin cyclopium,
Aspergillus spp.
Claviceps purpurea

Fusareum roseum

Fusarium sporotrichioides

Penicillin citrinin

Penicillium viridicatum

Aspergillus ochraceous

DISEASE MANIFESTATIONS

hepatotoxicosis, cholangiohepatitis,
hemorrhage, coagulopathy, slow growth, poor
feed conversion, reduced milk production, milk

Corn

Fescue forage

Ergovaline

FUNGUS

Aspergillus flavus
Aspergillus parasiticus

Fumonisins

Cereal Grains

Rye,

Corn, Peanuts,
Pecans, Walnuts

Wheat

Sorghum,

Corn,

Sorghum

Wheat,

Barley,

Barley
Corn,

Wheat, Rye, Oats,

Peanuts

Cottonseed,
Com,
Peanuts,
Sorghum
Com,
Wheat,

SUBSTRATES

alkaloids

Tremorgenic mycotoxins
(Penitrems fumitremorgen)
Ergotamine and related

(F-2) and zearalenol

Zearalenone

(vomitoxin, DON)

e.g., T-2 Toxin,
diacetoxyscirpenol,
deoxynivalenol

Trichothecenes

Citrinin

Orchratoxin A

G1 &G2

B1.B2,

Aflatoxin

Table 6 Common Mycotoxins That Affect Livestock
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Senior Thesis Project
Assignment: Proofread OrthoEdge.

Purpose: To proofread OrthoEdge, an internal newsletter focusing on competitive,
product, and company (Zimmer) information.
Audience: Sales associates. Tone is conversational.

Skills Required: Proofreading. Correct use of proofreading marks. Fact checking.

Client: Zimmer Division of Bristol-Myers Squibb Company
Format: 12-page, tabloid size
Style Manual: None
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Delivering Silver Bullets from Marketing's Desk to Sales jgads

WHAT'S INSIDE

OrthoEdge—
All the news You Can Use

Hip
Take Aim At Crossfire.,...
f
How Beneficial Is. the Howmedica

OrthoEdgehas just one

Definition PM Hip Stem's PMMA
Pie-Mantle?

2
4

;..

"

Vac1 Vl Vacuum Mixing System

7

effective against them.

effectiveness.

unless it makes a differ

5

ence in your next sales

The News Is Out on Calcicoat*' Ceramic

.Coating!
7
The 24-Hour Commitment
7
Frequently Asked Questions The Quick-

force

should be practical,.,
timely and accurate.That',

.Sign UpSurgeons Now for Mayo2000

Meetings

themas soonas they're detected, we can put a stop
to them quickly or come up with a strategy that's

Everyone agrees that it

Introducing the VerSys* Heritage Hip
Prosthesis

goal—to increase sales

the field. This newsletter won't be justcompetitive,

ing. In this interview,

although competition will be a significant focus. I

Kent Pedersen, Vice

President/Franchise Marketing, shareshis thoughts
on our new venture.

Knee
SignUp Surgeons Nowfor Mayo 2000

petitiveinformation. But howwepositionourselves
againstcompetition is one of the most important

,

5

Looking fora Silver Bullet—It's Poly!,..2

toolsthatwecan giveoursalesorganization. Typi

WithPatientsAskingfor UKA,YourSur

cal competitiveinformation—solidinformation,sell

close an account.

The other objective is to replace a lot of the
weeklymail that we're currentlysending.So instead

of sending separatepiecesfromproductmanagers,
we can consolidate news so you get all the informa
tion in one document. OrthoEdge should be indis

5

The Anatomically Rotated Articular
Surface (ARAS).
5

.works asIenvision, therewillbegreatvalueingood,

What is our biggest competitive challenge?
For us the greatestnear-termchallengeis maintain
ing momentum. We bottomed out in 1997, and then
began to stabilizeand grow marketshare. Now we're

Countering the New Osteonics Scorpio

solid competitive information.

on a nice, upward slope. Our challenge is to keep

3

CulturalInfluenceson Rangeof Motion
4.

Revisions R Us ....„.„...

Knee

6

reason because we never have. If this newsletter

I alsodon't like not playing on a level playing
field. And right now I don't believe we are. We have

threecompetitors out therethat are actively using

Fracture

competitive information to sell against us. Yet we
are not using like information to sell against them.

Management
ZimmerCableReadyvs. Dall-Miles
1
Congratulations on Fx Conversions.... 2
A Zimmer Shoulder to Lean On
One Hex You'll Want

She WoiksHard for the Money

3
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The Lowdown on 7«"*~---*-: "-:.—••-•

I**Plating System

Norare we taking a position to force themto stop
whatthey'redoing. So it's notfair. I always playto
win, and I want to play this one to win. I want to set
the thresholdfor a good, solid, quality newsletter,
so that we sharewhat's goingon in various partsof
thecompanywiththewholecountry.If wecan iden
tifyaggressive trends ina particular regionandshare

-:

Coffee Break Questions

7

pensable.

that going. We're fortunate that our distribution or
ganization was restructured in 1997. Other consoli

dating companies are now facing those same kind
of changes, and Stryker and Howmedica have been

slow to initiatesignificant change. The uncertainty
in other organizations is an opportunityfor us. Our
goal is to keep the momentum going. We've had
helpful product launches in 1999. Our distribution

organization is solid and performing exceptionally
well. We need to keep providing current, relevant
information so thatweseizeopportunities andcapi
talize on each one. Momentum now is real impor
tant, becausewhenothercompaniesdo get their acts
together, the competition will be even stiffer.

How to Get Side-by-Side ReamerTrials

?

want to share success stories. What were the suc

cessful tactics?To know someonelanded a big ac
count is nice, and we appreciate that, but that won't
helpanyoneelse come up withthe rightstrategyto

ing tactics, or promotional programs—stated in a
professional manner is very valuable.
Ourcompetition writes whattheythink withvery
littleregard whether we willreact...andwithgood

geons Might Too

4y&°"

rhetoric applies to what's timelyand necessary in

call, it isn't worth print

On sharing competitive information...
Zimmer is very conservative when it comes to com

Meetings

On the real action...

The action is out there... not in Warsaw. I don' t want
to believe our own rhetoric. I want to make sure our
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HIPS

Tips

Zimmer Cable Ready

Calendar

vs. Dall-Miles

By Dave Anderson

By Warren Chapman

A paperpresented recenUy at theHarvard HipCourse
and submitted to the Orthopaedic Research Society
(ORS) for presentationat the AAOS2000 meeting

Websites

Updates

What benefitsof the Zimmer Cable-Ready* Cable
Grip Systemcan help you sell againstHowmedica's
Dall-Miles Cerclage Cable System?
Re-tension of Cables

The Cable-Ready System allows a surgeon to
re-tension cables before committing to the final
position. The Dall-Miles System does not have
Retensioning Bits.

Take Aim at Crossfire

will help you take aim at Crossfire™ Acetabular

Components from Stryker/Howmedica/Osteonics.
Investigators at the Orthopaedics Biomechanics

Laboratory at Massachusetts General Hospital
examined the wear characteristics of four commer

cially available crosslinked polyethylenes^
Crosslinking of polyethylene is known to improved
its abrasion resistance.

N*'

Investigators obtained samples of Longevity*

Implant Options

The Long GTR and Cable-Pin are unique to the
Zimmer system. Dall-Miles doesn't offer either.
Cable Strength
Zimmer's multi-strand cable is smoother than the

DallMiles,whichcancausea Giglisaweffect.Ouch.

(Zimmer), Durasul™ (Sulzer), and Crossfire™

(Stryker/Howmedica/Osteonics) components from

theirmanufacturers. Marathon™ (DePuy/J &J) poly
was fabricated in the Biomechanics Laboratory.
Samplesof each materialweretestedin bothunaged
and aged conditions, with aging intended to sir
late long-termshelf storage, specifically the effect
of oxygen on polyethylene.

continued on page 3
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Looking for
the Silver
Bullet-

It's Poly!
By Scott Bowman
In 1949 George Trendle needed a dramatic new show
to save radio station WXYZ in Detroit. Trendle's hero

rode a white horse with silver shoes named Silver.

And the Lone Ranger, as the hero was known, used
silver bullets.

In 2000your silver bullet—designed to stop the
competition flat in its track—is 1900 resin polyeth
ylene(net shape, of course).Afterall, we're facinga
competitive werewolf, sporting a hew prosthetic fe
mur, and bragging about a pseudo feature that either
mimics the NexGen* Complete Knee Solution or at
tempts to match our IB II clinical results.

Orthopedics Today Polyethylene Glossary (Oct.
1999)says, "In several retrieval studies,components
manufactured from 1900 resin have shown signifi
cantly lower levels of oxidation following steriliza
tion by gamma irradiation in air." Sterilization and

packaging methods can affect the quality and long-

How Beneficial Is the Howmedica

Definition PM Hip Stem's PMMA
Pre-]\lantle?
ByDaveWeidenbenner

Thepre-mantle on theHowmedica Definition PMhipstem is bonded onto thestem during produc
tion and serves tocenter theproximal stem inthe medullary canal. We decided totesttheintegrity of
thepolymethylmethacrylate (PMMA) pre-mantle and findoutjust howgoodit is.

What We Did

JB ••

^m>••.

We removed thestem from its presterile packaging andfound noevidence of crazing, cracking or
delamination. Then werinsed thestem in deionized water anddried it.Thestem wasimplanted into
a preparedcompositefemurusingHowmedicaSimplexP bonecement vacuummixed withthe mono

merchilledto0°C.(Vacuum mixing withchilledmonomer is themosteffective technique forreduc
ing porosity and increasingthe mechanical properties of in-situ cement.1-2) The femur was filled

retrograde using a cement injection gun. No plug wasused sincethe foam coreof thecomposite
femur prevents cement from extruding distally. Thefemur waspressurized before steminsertion and
thestem was inserted 4 minutes after thestartof mixing, when thecement was in theearly dough
stage of polymerization. Aftercuring for 12 hours,the femur and implantedstem were soakedfor 3
monthsat 37°Cin Ringer'ssolutionto simulateimplantation in the body.Cross-sections of the femur
and stem were then cut with a water-cooled blade,preparedwithoutsolventsto minimizemechanical
damage, and hand polished to a mirror finish.
What We Found

term performance ofpolyethylene. However, gamma
irradiation in a nitrogen environment minimizes oxi

dation while improving other material properties
throughcrosslinking. That's our poly they're talking
about!

And you should be talking about it too. Properly
designedand manufacturedimplantsmadefromcom
pression-molded poly have been used in vivo for more

than 15 years. Poly will likely remain the material of
choice for these implants for many years. So next

time you're looking for the silver bullet,pull out the
Zimmer 5-Point Polyethylene Performance Factors.

Congratulations on Fx
•Jf—-

Conversions

Between July 1 and
December 20,1999,
sales associates

successfully converted
21 centers to Zimmer

fracture systems.

Crazes arevoids separated byfibrils. Crazing itselfisaform ofstress reduction. This section demon
strates crazing in thepre-mantle zone. The pre-mantle wasrelieving itselfof stresses inherentfrom

Kudos to Zimmer
White and Zimmer

the manufacturing process.

Frye, which converted
three centers each, and

to Zimmer Carolinas,
Zimmer Maxon, and
Zimmer Rowland,
which converted two

Examination of the sections revealed numerous crazeswithinthe pre-mantle, and their orientation
indicatedthat they had formedat the timeof implantation. The combinationof residualstressin the
pre-mantle and free monomer in the early doughstageof the cementapparently activated thecraz

ing. Crazes arevoids separated byfibrils. Cracks arevoids with nofibrils connecting the opposing
surfaces.Crazing reduces stress. The pre-mantlewas relieving itself of stresses inherent from the
manufacturing process.
What This Means

The clinical impact of the pre-mantle crazing we saw is notclearat this time. Someinvestigators

believe that cracks orvoids inthe cement aredetrimental totheclinical performance ofanimplant.3- •**-

J^fazes are different from cracks orsingle voids. Yet minimizing any disruptions inthe cement isa
"reasonable goalfor cemented hip arthroplasty. One thing's for certain—the pre-mantle introduces
another variable into the cemented hip equation.

centers each. These

conversions are proof
positive that you don't
have to give away
fracture systems or
split the business with

1.Wixson RL,Lautenschlager EP, Novak MA.Vacuum mixingof acrylic bonecement. JArthmp. 1987;2:141-149.

2. Lidgren L. Bodelind B, Mollcr J.Bone cement improved by vacuum mixing andchilling. Ada Onhop Scand. 1987;57:27-32.
3.Jacobs JJ, Sumner DR. Galante JO. Mechanism of bone loss associated withtotal hipreplacement. Orlhop Clinics ofN
Am. 1993;24:583-590.

4.Anthony PP, GieGA,Howie CR.etal.Localized endosteal bone lysisinrelation to the femoral components of cemented total
hip arthroplasties. JBJS. l990;72[B):971-979.
5. JonesLC. Hungerford DS. Cement disease.Clin Orlhop. 1987;225:192-206.

6. Muller RT,Heger I,Oldenburg M.Themechanism of loosening incemented hipprostheses determined for long-term results.
ArchOrlhop TraumaSurg. 1997;116:41-45.

7. Vcrdonschot N. Huiskes R.Cement debonding process of total hiparthroplasty stems. Clin Orlhop. 1997;336:297-307.

competitors!
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"Take Aimat Crossfire"continuedfromfront caver

A Zimmer Shoulder to Lean On
By Scott Holdsworth

pick up bar graph from abstract

Release of the Bigliani/Flatow™ Shoulder opens a window of opportunity to sellagainst competing
shoulders. The shoulder has two majorareasof focus—an innovative variable conformity glenoid
component and surgeon-friendly instrumentation.

Designed to enhance cementfixation and minimize polyethylene wear, the glenoid component's

variable conformity helps toensure stability through a range ofmotionlwhile reducing edge loading
andassociated wear. Peggedandkeeledcomponents offerintraoperativeflexibility. Anoffsethumeral
headsystemis designedto replicateanatomical relationships and restoremobility.
Precise,low-profile instrumentation, designed byshouldersurgeons/or shouldersurgeons, makes
reproducible results a reality.

Shoulder Days
You can encourage interested surgeons to visitColumbia-Presbyteriajfor Mt. SinaiHospitals in New
York City for "ShoulderDays."They'll havea chanceto see shoulder surgery at a regional centerof
excellenceand talk to theirpeers aboutthe Bigliani/Flatow Shoulder. The OrthopedicLearningCenter

in Chicago isalso sponsoring shoulder-specific courses in April anrjpctober, 2000. Orsurgeons coidd,

drop into Zimmer's Mobile Learning Center for sawbones demonstrations. Check with Scou HoldSwoith
for dates and times.

POD wear rate comparison ofthe crosslinked UHMWPE's
in unaged and aged forms.

Artificial aging of the Marathon-type, Longevity
and Durasul materials did not show any appreciable
oxidation, and thus no change in their wear behav
ior. However, Crossfire polyethylene showed signifi
cant oxidation after aging, which was also reflected
in its wear behavior.

The authors noted that the wear rate of unaged
Marathoh-type material was higher than that of
unaged Durasul, Longevity and Crossfire samples
due to the lower radiation dose used in the manufac

Results, Results, Results
In MayZimmerwill begina multi-center globalstudyof Bigliani/Flatow Shouldercases.The goalis
to collect24-monthfollow-updata. Of course,clinicalresultsare the proofof the product,so we'll be
watching this study closely.

ture of the Marathon-type material.
They also noted that artificial aging of the Mara
thon-type, Longevity and Durasul materials did not
show any appreciable oxidation, and thus no change
in their wear behavior. However, Crossfire polyeth
ylene showed significant oxidation after aging, which
was also reflected in its wear behavior. In fact, the

With Patients Asking for UKA,
Your Surgeons Might Too
By Mark Price

wear rate and oxidation level of aged Crossfire
samples were even higher than those of the aged con
ventional poly that served as a control. They con
cluded, "This observation raises significant concerns
on the long-term stability of the gamma sterilized
highly crosslinked UHMWPEs."
During the discussion after this paper was pre
sented at the Harvard Hip Course, the Osteonics rep
resentative objected to the test, arguing that since their
product is packaged in nitrogen gas, oxygen is not
available for oxidation.

I encourage you to use this abstract and the pre
sentation at the AAOS to sell against Crossfire poly.
If you have questions, please call.

naasa
"Zimmer CableReadyvs.Dall-Miles"continuedfrom
front cover
Cable Plate Profile

In the Zimmer System the cable is passed through

&

\offel

TKA

UKA

PercentofXxcellent results: UKA v.v TKA

Several calls from the field indicate that patients are asking for unicompartmental knee arthroplasty
(UKA).They believe that UKAcauses less postoperativepain and speedierrehabilitation.In fact, these
patientshave heard that UKA is an outpatientprocedure. In some markets, rural hospitals are being
marketedas cutting edge "centers of excellence" becauseorthopaedicsurgeonsare performingmini
mally invasive UKA with patients being discharged in less than 24 hours.
Why woulda surgeonconsiderUKA?According to Newman et al., "Unicompartmental knee ar
throplastygives better results than total knee arthroplasty and that superiorityis maintained for at least

the plate^which reduces the potential for
micromotion.'Dall-'Mlles has • higher profile with a '
body that mounts on top of the cable plate.
Zimmer had the first tensioner that measured the

amount of tension. Dall-Miles is catching up but still
has many tensioners with no scale in the field.

•

Deep vein thrombosis is more common following total knee arthroplasty(TKA) than UKA.

If these competitive advantages sound familiar, they
should because they are part of the Cable-Ready
Cable Grip System Distinctives. Check out the
Distinctives kit for more great selling points.

•
•
•
•

TKA frequently requires postop manipulation; UKA does not.
Flexion is gained more quickly with UKA.
UKA results in shorter hospital length of stay.
Knee scores for UKA are superior to TKA.

•
•

More UKApatients rate their knees as excellent following surgery.
UKA offers superior range of motion (ROM) at 5 years postop.

JHUiM T •J»5BJLU> in;

5 years."1 Here are some additional reasons:

• UKA offers lower morbidity, specifically blood loss and pulmonary embolism.

*

Ability to Monitor Tension

One Hex You'll Want
By Warren Chapnutn

1. NewmanJH, AckroydCE. Shah NA. Unicompartmental or total knee replacement?JBJS. 1998;80-B:862-863.

Minimally Invasive Surgery (MIS)
with the MG/Uni
By Mark Price

How do you make any plate, screw or cannulated
•screw into a cable construct? The answer is Zimmor'fC

ingenious new Hex Button,_^/.Jij.<; IVV %;\ yv\tv\jw
The button, seated in the hex recess of any bone
screw, anchors an eyelet through which cable can be
passed. So Hip Screws, Periarticular Plates or stan
dard ECT plates now adapt to cable constructs. The
Hex Button is available in stainless steel or commer

cially pure titanium in 2.5mm, 3.5mm and 5.0mm
diameters. The button is sterile packed in singles or

The MIS MG/Uni project involves redesigning present knee instrumentation to facilitate less invasive

boxes of 10.

unicompartmental knee arthroplasty (UKA). The modified instruments along with an improved MIS

Check out our new Hex Button at the AAOS

technique provide a competitive edge for Zimmer in UKA. The 98% clinical success rate of the MG/

in Orlando and don't forget to tell your customers

Uni at 6 to 10 years is documented in the Oct., 1999, issueof Clinical Orthopedics andRelated Re

about it!

search. Be sure to talk to your surgeons about these impressive results.

«•
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Introducing the VerSys® Heritage Hip Prosthesis
By TomTroup

Why introduce the full primary VerSys Heritage Hip

The VerSysHeritage Prosthesis builds on the suc

cess of Charnley's first-generation stem design but
incorporates additional intraoperative versatility. This
new VerSys System component capitalizes on the

Prosthesis now?

To quote from the proceedings of the 1998 Hip
Society Meeting, "If a polished cemented stem
debonds from the cement, the likelihood of revision

current market trend toward polished femoral com
ponents with a stem geometry that has excellent,
long-term results.
VerSys Heritage Stem evaluations began in May
1999, and surgeons have already converted from the
DePuy Endurance, J & J Ultima, Osteonics Omnifit,
and Howmedica Strata stems. Perhaps your surgeons

due to osteolysis is very low." Obviously, with an
aging population, surgeons must think about the pos
sibility and ease of revision. Studies have also shown
that polished cemented stems perform very well over
long periods of time. For example, the first-genera
tion flat/back hip stem developed by Sir John
Charnley has had well-documented, long-term, ex
cellent results. Charnley's original stem had rectan
gular cross-sectional geometry and a polished sur

will be next!

For more information, review the VerSys Heri

tage Stem DistJ/ic+iV2fJ k£JI" ,

face.

A

Charnley Stem

Cultural Influences

She Works Hard for the Money

on Range of Motion

Lib Olson Sells a Complete M/DN™ Fixation System -/W J* 8>8> &0O
By Sarah Staples

By Adam Sampson
.
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First-Generation
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is 110° to 115°.1J Yet for the average person from

Japan or the Middle East, average range of motion
(ROM) is 130° to 155°. So while TKA is highly suc
cessful in the United States, it might actually limit
ROM for some international patients. The quality of
the surgical outcome is certainly affected by patient-

related, implant-related and surgeon-related factors.2
Patient-related factors include physical condition,
age and activity, which is often culturally influenced.
For example, Japanese regularly practice seiza, a
form of sitting that requires deep knee flexion. The
Japanese also pay close attention to the beautiftcation of gardens, with much detailed work performed
in a fully squatting position. In Muslim countries
(predominantly South Asia and the Middle East),
prayers occur at least three times daily. These require
deep knee flexion. Traditional western style TKA
may inhibit these familiar activities.
Achieving greater ROM with TKA might seem
unimportant if not for the internationals who flock
to the U.S. for treatment and the country's own grow
ing immigrant population. Institutions, such as the
Mayo Clinic and Duke Medical Center, are known

throughout the world as centers of excellence. Typi
cally, TKA is paid for in advance with U.S. dollars.

c- iF

c

.

Ai

-

•• u

•*.

ullary
llaryFixation
Fixation System/Heropportunity
System/Her opportunity began\
began with

the arrival of a new trauma surgeon, even though he
was strong on Synthes. She introduced herself and

arranged for him to attend the trauma portion of
Zimmer's annual course at Vail. There he developed
relationships with Lib's distributor, Tim Hooton,
other Zimmer personnel and his peers. On returning
to Florida he agreed to trial the M/DN system, im
planted a nail and liked it. Yet the hospital was al
ready committed to Richards and Synthes systems.
So Lib bided her time. "I've been calling on both
hospitals in town for 12-1/2 years and I knew our
relationship was important. They saw me regularly
because I already had the total joint business. So I
just stayed in touch."

• First, she emphasized how easy the M/DN sys
tem was for OR staff. "You've only got two trays
and parts are all color-coded. The design is so logi
cal that anybody should be able to learn it quickly."
• Next, she pointed to surgeon benefits. "For sur
geons, it's the instruments that count. Drill bits are
critical with nail systems. Our pointed drill bits don't
slide or skip and make distal targeting so much
easier."

• Finally, she broke down the quote so that pa
tient charge items were clearly marked. "Hospitals
should understand that implants are patient charge
items, so much of their initial investment in a trauma

system will actually be recovered. We should be ex
plaining costs, not just consigning or discounting sys
tems."

Lib says another key element contributed to her

Her break came when most of the trauma sur

geons switched hospitals. Inexperienced staff needed
a simple system and the new trauma surgeon had been
favorably impressed by Zimmer and its M/DN nails.
"Plus, the OR supervisor and hospital administra
tion knew I would take care of them," says Lib. "I
was available to in-service our products and they
could always call with questions."

success—listening. "Sales people are always busy
talking, but they need to listen too. Gaining infor
mation is a big part of our job. I try to be aware of
what's happening, because there will always be op
portunities. I knew this hospital needed a simple sys
tem and good customer support. I was ready and
waiting with a Zimmer system when the time came."

Lib focused on three key} messages when sell

ing the system.:',* flj^

***

>r^

These institutions are sensitive to cultural differences

and have gone the extra mile to accommodate pa--,
tients and their families. Still, current knee implant
designs lack sufficient flexion for many of their pa-"'

tients. J||

jH

In addition, there are large subgroups of Japanese
and Middle Eastern descenUn the U.S. According to
the Population Bulletin, die Asian American popu
lation will double by 2010.'Almost 70% of the Asians
counted in the 1990 Census were either immigrants,
who came to the U.S. after 1970, or the children of

these immigrants. Most Asian Americans reside in

PJ:M4JI
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Keep it Simple! „
The Lowdown on 5

imcr

Periarticular

Plating System
By Mark Phillips

California, New York and Hawaii.

All of these potential candidates for TKA would
benefit from a knee implant with greater flexion than
current designs.

v

1. Insall, JN. Current knee implant designs lack suf
ficient flexion for certain cultures. Orthopaedics
Today. 1999;Aug:
.
2. Hezfy MS, Kelly BP, Cooke TDV. Kinematics of
the knee joint in deep flexion: a radiographic assess
ment. Med Engineering Physics. 1998;20:302-307.
3. Population Reference Bureau Publications—
Immigration to the United States.Web site. Available
at: http://www.ins.doj.gov/graphics/about/statistics/

Periarticular fractures of the knee are complicated enough that surgeons shouldn't have to struggle with
implants and instruments. That's why our Periarticular Plating System is designed to keep it simple.
• Contouring is easy and quick because plates are pre-contoured. The plate thickness decreases toward the
joint line so additional contouring is easier too. And the screws are self-tapping, which saves time by
eliminating a step in preparation.
• A complete instrument set and well-organized sterilization tray facilitate rather than frustrate
implantation.
• To minimize soft tissue irritation, low-profile bone screws seat nearly flush with the plates.
Keep your pitch to a surgeon simple too. Review these points and, most importantly, expect to sell

Zimmer^ Periarticular Plating System!

A

O

X

index.htm. Accessed October 4, 1999.
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Revisions R Us
By Mark ProJger

Revision surgery has captured surgeons'attention
and the NexGen® Complete Knee Solution

System isleading the way. The NexGen system
offers a variety of implant and insfrumeril options
that enable surgeons to meet even the most
difficult challenges of revision surgery.
The revision column of Ortholulge will cover

new implants and instruments,surgical tips, sales

Similar mismatches can also occur on the

femoral side. Many surgeons elect to move femo

ral componentslaterallyto optimizepatellartrack
ing. When using a press-fit femoral component,
the result was often a less-than-optimal position

of the cutting block and subsequent femoral
resection (Fig. 3). ::
&8&gl%>fa&mmt&s&&f

Sign Up Surgeons
Now for Mayo 2000
Meetings
By Kevin McCallum
If 1999's experience is any indicator, interest in the
MAYO" Conservative Hip Prosthesis continues to
be high. Approximately 68 surgeons completed Dr.

(S>

MorreyV instructional course at the Mayo Founda
tion in Rochester, Minn;, during 1999. Surgeons can

success stories, and case studies from surgeon
consultants. We also need your help in suggesting

implant Mayo hip stemswithout attendingthecourse,
but the instructional courses are designed for those

topics orconcerns. Thegoal ofthis^* column isto

„who;prefer,an in-depth view of the product and

give you the best, most up-to-date, useful infor
mation so that you can convert surgeons using
competitive products. The NexGen system offers
many advantages. So let's investigate the hot top
ics and review sales tactics that are proving to

.Its use

•' *Act»<]uickly to enroll your surgeons for these
Mayo courses in 2000.

February 3 - 4

April 27 - 28

July 20-21

Nov 16-17

deliver success.

The offset stem can be dialed into the best

Offset Stems

Before offset stems, surgeons were forced to make

substantial compromises between implant size and
bone coverage. When a surgeon uses the tibial or

y

femoral canal for placement ofapress^-fit stem,

Restoring Natural Anteversion

position for a particular patient (Fig. 4).Consult
the Dec. 14, 1998, Weekly Mail and the Offset
Stem Extension Distinctive Set for a more com

plete explanation.

the position of the tibial tray or femoral compo
nent is often malaligned (Fig. 1).

<Photo: Restore Natural Anteversion

slide from Kevin's presentation>

g. 1 from Mark's file>

A high femoral osteotomy allows the Mayo stem to follow
the angle of the natural femoral neck, restoring natural
anteversion.

If you haven't taken the pltmge against the
On the tibial side, surgeons have often selected
oversized tibial trays, creating soft-tissue impinge
ment, or undersized trays, resulting in poor tibial
support and subsidence. An offset stem allows the
surgeon to dial in the correct position of the tray,
ensuring maximum cortical rim coverage with full
bony support (Fig. 2).

stems represent a unique Zimrner advantage. Our
competitors are already catching on to the appe,

One surgeon who attended the course shared this
important observation about restoring anteversion.
"The Mayo stem will restore the natural anteversion,
cause it is inserted in the femoral neck with a higher

Howmedica Osteonics nave been showing their
offset adapter for the Total Stabilizer and J&J/
DePuy have a stem capable of varying single

ral neck. This could be an advantage compared to
straight stem designs that require anteversion to be
ually dialed in during rasping and stem insertion."

competition in their revisioii accounts, offset

ofthe offset and desin|ingfversion oftheir o

plane adjustmets. now is the time to remind sur
geons that Zimmer is leading the way to new tech

nology in Revision Total Knee Arthoplasty.
<F ig. 2 from Mark's file>

The NexGen Anatomically Rotated
Articular Surface (ARAS)
By David Fatke

'steotomy andit followstheangleof the naturalfemo

Clinical Data
Our most frequent request is for clinical data on the
Mayo hip. Dr. Morrey has submitted his clinical data
for publication in the international edition of the Jour
nal of Bone and Joint Surgery. Expect to see the fi
nal article soon. In the meantime, Dr. Morrey will
accept surgeon calls regarding his clinical results.
Please schedule these calls through Pam Fancil
(4342) or Kathy Singrey (4713).

New Distinctive Tool
Card Available Soon

The Anatomically Rotated Articular Surface (ARAS),

a cruciate-retaining (CR) tibial articulating surface

^

With the new ARAS tool card, you can quickly and
graphically communicate the advantages of the Ana
tomically Rotated Articular Surface. As you develop
your selling strategy, keep the following points in

first introduced with the MGII, is also available in

the NexGen CR product line. Designed by Thomas
Winters, M.D., of the Matthews Orthopaedic Clinic,
Orlando, Fla., ARAS has the same articular geom
etry as the standard CR surface. However, the proxi
mal articular surface is externally rotated 6y from

coverage, while still permitting duplication of the

• NexGen ARAS allows the surgeon to achieve
anatomic rotational alignment while obtaining maxi
mum cortical bone coverage.
• Dr. Winters has shown that using an anatomi
cally rotated articular surface reduces the necessity

normal external rotation of the knee.

for lateral releases.

rcenter. This allows the sui'geutl TtTposition the
tibial base plate to achieve maximum cortical bone

Proper Alignment vs. Bone Coverage
Optimal tibiofemoral articulation and patellofemoral
tracking are achieved by aligning the tibial compo
nent with the tibial tubercle. However, external rota

tion of the tibial component may result in postero
lateral and anteromedial overhang or the use of a
smaller component to eliminate excessive overhang.
The NexGen ARAS overcomes these concerns

by allowing the surgeon to maximize cortical bone
coverage with the tibial tray while obtaining the de
sired external rotation via the articulating surface.

^

Uoi,

mind.

caption

• Target competitive surgeons currently using
Profix from Smith and Nephew, which incorporates
a lOy externally rotated surface.

•The NexGen ARAS is available in 10, 12 and
14mm thicknesses for size 3 through 10 tibial trays
and C through H femoral components.

K/

KNEES

Countering the New Osteonics Scorpio Knee
By Scott Bowman

i

TlienewScorpioTotalKneeSystembrochure makesa *•' NexGen CompleteKneeSolutionDesign_i Rationumber of claims that represent major changes from
the Series 7000. In the grid that follows, we counter
these claims with brief but detailed responses from the

nale. Each Scorpio claim is balanced by a NexGen response, followed by some questions to consider. Use
these questions with surgeons who are considering or

using the Scorpio Knee. When you evaluatethe claims
made by Osteonics, you realize again that the NexGen
System Complete Knee Solution is defined by a trusted
tradition and a focused future.

Scorpio CR & PS vs. NexGen CR & LPS
Scorpio Claim

NexGen Response

Deepened patella groove eases tension

Similar to NexGenCR and LPS design. NexGenavg. ROM

across extensor mechanism, facilitat

is 124° for CR and 121° for LPS. No claims about ROM for

ing deeper flexion.

Scorpio. Scorpio brochure is comparing patella groovedepth
to tlie IBII not the NexGen.

Single femoral A/P radius from 15°
hyperextension to 75° flexion, based on
epicondylar axis, better reproduces
knee kinematics than a multi-radius

design. Scorpio calls this the functional
ROM.

The I/B knee has over 20 years of clinical success; NexGen
has carried on this lineage. NexGencomponents have frontal
and sagittal conformity during the walking gait cycle. An
other demand for functional ROM is rising from a chair.This
requires at least 90° to 110° flexion. It is also noteworthy that
tbe NexGen CR has different radii of curvatures on the

If the Scorpio patella groove is not as deep or extended
as far as the NexGen, will it support the patella in deep
angles of flexion?

Does the Scorpio design claim an average ROM 7
Does tlie single radius of tbe Scorpio allow for sagittal
conformity throughout the gait cycle?

The Scorpio articular surface geometry appears rela
tively flat in the sagittal plane. Could it result in high
tibiofemoral contact stress throughout tlie gait cycle?

condyles, which allow for the screw-home kinematics as dem

onstrated by Eckoff et al. Where is the clinical proof?
Scorpio reference paper entitled "The
Axes of Rotation of the Knee" by A.
Hollister et al., CORR 1993. The study
concludes that the contours of the pos
terior femoral condyles are circular
when perpendicular to the epicondylar
axis. Therefore, this feature has been

incorporated into the design of the
Scorpio femoral component.

Issues with paper
Dr. Hollister specializes in hand surgery.
1. Only six knees studied w/ retained ACL and PCL.
2. Axis of tibia perpendicular to anatomic varus of tibial pla

Are all patient anatomies the same?
Was the surgical technique anterior or posterior ref
erence ?

With in-between sizes, do you upsize or downsize ?

teau, not perpendicular to mechanical axis, which most
implant system surgical techniques use.
3. Location of epicondylar axis centers difficult to locate and
different from the drilled axes by 4.6mm.

4. Measurements takenfrom the medial condyleonly.
There are many factors with regard to reestablishing the
epicondylar axis of rotation:
• Patient anatomy variations
• Surgical technique: anterior or posterior referencing
• A/P size of femoral component
• If in-between sizes, upsize or downsize
All of these factors make it almost impossible to reestablish
the center of rotation about the epicondylar axis.

4° posterior slope built into the tibial
insert enables deep flexion.

NexGen 7° posteriorslope with avg. ROM 120°plus 7° tibial

Anatomical slopes are set at 6° to 9° posteriorly.How

cut is more anatomic and preserves bone.

does altering anatomic slope affect soft tissue and the
kinematics of the knee?

What is the thickness of the Scorpio posterior poly?
Built in internal/external rotation of up
to +15° allows for variation in patient

NexGen CR has built in ±15° and the LPS has ±12°.

knee motion.

High lateral anterior patella flange.
Scorpio CR and PS have the same M/L
frontal radius, which is relatively flat

NexGenpatellar flange is thin and nanow to help reduce stress

Would a high patellar flange influence lateral release

on the extensor mechanism and reduce lateral release rates.

rates?

NexGen CR and LPS have design-specific geometries to ac

If tlie flat frontal curvatures are not design-specific,
could they be susceptible to edge loading?

commodate CR and LPS articulation. The CR has a broad

frontal radius that works in conjunction with the PCL, and
the LPS has deeper dished frontal radii to accommodate liftoff
during PS articulation. Both designs maximize contact area
while allowing for proper kinematics. NexGen CR and PS are
design-specific and clinically proven.

Flat on flat was not the answer in the 80's. How can it
be now?

The Scorpio patella groove has been
deepened. The patella button is a Mexi
can-hat type design with a concave rim.

NexGen is a modified dome that provides conformity and
proper kinematic tracking as demonstrated in over 130,000
knees implanted in the US to date.

Six sizes of femoral components.

Eight sizes of femoral components allow for increased

Tlie patient-size distributioncurve should be equally di

patient specificity.

vided by the number of size alternatives offered by the
implant system to optimize patient outcomes. Does the
limited size offering of die Scorpio address this issue?

Six sizes of tibial components.

Ten sizes of tibial components allow for increased patient
specificity.

Posterior stabilized femoral and tibial

Standard size CR femoral components have total
interchangability with all tibial plate sizes.
Standard size LPS femoral components are interchangeable
with at least four sizes of tibial trays. This allows for better
implant-to-patient fit.

components can be interchanged one
size up and one size down.

No mention in brochure about poly
ethylene.

Does the Scorpio patella design offer the required con
formity and kinematic tracking?
- '*

Will the concave design make it more susceptible to
edge loading?

In today's cost-sensitive environment, matching im

plants to the patients' demand level is becoming in
creasingly common. Can a system that only offers one
size up and one size down meet today's demands?

the "Gold Standard."

Why would a "total knee system" not include discus
sion about the articulating surface material?

NexGen LCCK allows seamless transition from CR to CRA

What is the definition of a complete knee system?

Zimmer net-shape molded poly, N2 packaged UHMWPE, is

At this time CCK revision requires the
Series 7000 system.

to LPS to LCCK.

Passport Posterior Ref. Instruments
Passport Anterior Ref. Instruments

Multi-reference 4-in-1 (anterior or posterior ref.)
Epicondylar (anterior or posterior ref.)

Tea or coffee? What is tlie advantage to limited in
strumentation?

Intramedullary (anterior ref.)

Micro mill 5-in-l (anterior ref.)
5-in-l sawblade (anterior ref.)
Revision instruments

Increased options

&

HIPS

/

The 24-Hour
Commitment

Questions

Coating!

By Jim Smith

By Warren Chapman and mark Phillips

By Kevin McCallum

One of the basic responsibilities of the Marketing
Group is to provide timely answers to your questions.

You're sitting in the surgeons' lounge waiting for the

Congratulations! We've seen significant growth on
our Calcicoat VerSys Stem and Trilogy Cup fiber
metal products. Hydroxyapatite (HA) and tricalcium
phosphate (TCP) coated stems accounted for %of
total VerSys fiber metal stem sales in
•
That means the news is getting out.

We are working hard to be accessible, but we also

Who's selling VerSys Calcicoat stems?

realize (hat we can do better. So our commitment is

to give you a same-day response, if possible, or.
respond at the latest within 24 hours.
Youcan reach us by phone or by e-mail. If you're
calling, here's the procedure.

>f

The top 10 distributorships are:
1

2

Call the product manager responsible for your area
or produoter product in question.

tailed message and your personal mail box number
• In emergencies:
• Call the appropriate product manager.

6

7

ment or the company operator.

8

9
10

Focus on
Distinctives
Remember to focus on the important features when
presenting Calcicoat coatings. The Distinctives Kit
highlights:
• Titanium fiber metal ingrowth surface with 13year clinical results
• Applied to good implant designs—Trilogy cups
and VerSysfiber metal stems

• Thin coating of HA/TCP that essentially maintains

pore size and porosity!

next case or catching a cup of coffee in the hallway.
Then a surgeon walks by. After chatting about golf
and his family,try one of these sales-stimulatingques
tions.

When I bring the cable in for your next proximal

femoral fracture, can I bring a hip screw too?

Remember, we now have keyed and keyless Versa:")
Fx* II Femoral Fixation Devices. And with the
Bounty Program in effect, it's a great time to sell
Versa-Fx!

For surgeons who use the Blomet compression hip

uct specialist or secretary.
• If the product specialist or secretary is busy, "pound
out" again until you reach someone in the depart

5

• If you finally reach the company operator, ask to
be transfened to the cellular phone of the product
manager you are trying to reach.
All of us in Marketing are committed to making
timely communication a critical element in winning
in the marketplace!

screw...Have you considered the thickness of the
plate?
The Versa^Fjc.system has a low profile design to re

duce soft tissue impingement and initation.
Ask the purchasing agent...What type of hip
screws are you using?

If you're sharing the business because you didn't have
both keyed and keyless screws, now's the time to
ask for the other part of the business.

Frequently
Asked

Questions
About the

Quick-Vac™
Vacuum

•••

W« <S'V

Mixing System
By Bob von Seggern

white cylinder located next to the
tibial pressurizers?

Use the encased fiber metal sample'with trier

'* A. The cylinder prevents voids irilhe'

nifying glass on your next sales call. The Calcicoat
brochure 97-2100-61 -00 and the Calcicoat data sheet*

bone cement by keeping the femoral
pressurizer from sliding proximally on

97-2100-062-00 are excellent leave-behinds for your

the nozzle.

/ethylene

surgeons.

Osteonics has enjoyed success in the HA segment
with little competition. Now it's your turn to offer
surgeons Calcicoat HA/TCP coating on a titanium

fiber metal ingrowth surface. So let's get the news
out!

FRACTURE

Q. Does a collapsed vacuum indica
tor mean that the desired 21-22 mmllg

of vacuum is present?
A. No. Remember that a collapsed
vacuum indicator only indicates that a
vacuum is present. It does not indicate
the amount of the vacuum.

How to Get Side-bySide Reamer Trials

Q. How many pulls on the hand-held
vacuum pump are required to create
the desired amount of vacuum?

By Jon Hill
Here's an easy way to get your surgeons to compare
Zimmer and Synthes reamers during surgery. Roll
several mid-size reamers into a Synthes AO case. The
surgeon will begin reaming with Synthes reamers but
graduate to the Zimmer reamers. He'll get a real feel
for the performance advantages of the Zimmer
reamer. Plus, you'll save money because you don't
have to provide a full set of Zimmer reamers for a
case.

A. 15.

Q. Will the current Miller nozzles fit

on the new cartridge?
A. Yes.

Q. Who are the sales leaders for the
Quick-Vac system?
A. Tri-State

Lieffring
If the surgeon is impressed by the trial but wary
of the capital expenditure, remind him (and his pur
chasing department) that Zimmer offers a 6- or 12month same-as-cash deal. So he can have the Zimmer

reamers today, but pay for them when his budget pro
cess permits.

(£&

• If the prodScTrnanager doesn't answer,leave a de

• If you get phone mail, "pound out" by pressing
"0" and then "#." You will be transfened to a prod

3
4

/

Coffee Break

The News Is Out on
Calcicoat® Ceramic

Reed

Colbourne

S
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Selling Against the New Jersey Low-Contact Stress (LCS)
Total Knee System
By Mark Price, with helpfrom Ray Hinch ofZimmer-Page and ToddDavis
In selling the New Jersey Low-Contact Stress (LCS)
Total Knee System, DePuy/J & J appears to be rely
ing on three key claims.

The LCS is easier to implant than a
fixed bearing knee.

UrJ
( f***j,

With this in mind, let's examine the reported ROM

the NexGenPS component.*

for the LCS.

DePuy's LCS clinical success hasbeen achieved

• Dr. Jim Stiehl and colleagues reported that patients
receiving a DePuy LCS PCL-sacrificing device
who had > 105° preoperative ROM lost 1° postop
eratively (American Journal of Knee Surgery,

with Enduron™ ram-extruded polyethylene that
used to be gamma sterilized in air. In 1997, DePuy
switched sterilization technology to a gas plasma

1997).

This claim is based solely on the fact that with a
• Dr. John J. Callaghan recently reported that his
rotating tibial articular surface, the orientation of the
LCS PCL-sacrificing patients averaged 110°
tibial tray is less critical. Although positioning the
preoperatively, but only achieved 102° at 12-year
tibial tray is undoubtedly easier, tray position is only
follow-up, an 8° loss (1998 Current Concepts
a small part of what makes a total knee easier too . ^ meeting,
meeii
Orlando, Fla.).
implant.
fdeJU
does NexGei) J£QM compare? Dr. Kim Bertin
It is widely acknowledged that posterior stabi \—HtJwdc
reports thaTriis patients achieved an impressive
lized (PS) knees are less difficult to implant1 Easier
121.3° average ROM two years postoperatively.6
implantation is based on the PS's ability to protect
against subluxation and to improve stability through
These patients had a preoperative average ROM of
increased conformity (dishing) at the femoral/tihial
112°, similar to Dr. Callaghan's patients. On the ba-

technique. This change indicates DePuy's acknowl
edgment that gamma sterilization was an inferior
polyethylene sterilization technique. You can also
point out that gas plasma sterilization does not pro
vide the reduced wear benefits of crosslinking as
sociated with our NexGen net-shaped poly.

(M)

Although DePuy's LCS is the "only mobile bearing
game in town" and their claims may sound impres
sive, do not lose sight of the facts! Be proactive and
discuss these issues with your surgeons before the
DePuy rep arrives. Then DePuy will be forced to
defend their position.

interface. Conversely, there arereports thattheLCS g*«is ofthese two studies, the NexGen system produced
has had bearing dislocations,2"4 and spin-outs can "v superior ROM compared with the LCS system,

occurwhen thekneehasnotbeenproperly balanced^"
In fact, many surgeons admit that a mobile bearing
knee is more technically demanding to implant than
its fixed bearing counterpart. Dr. Dennis Burke of
Massachusetts General Hospital says that the LCS
increases his tourniquet time by as much as 15

If surgeons challenge you on ROM, ask if they
have any documented proof of LCS ROM results.
We have not seen any published articles to date on
LCS outcomes in young, active patients, and the re
ported ROM with this knee is clearly insufficient
for this population.

Still, instrumentation remains the deciding fac
tor in ease of implantation. For this reason, the
NexGen* System provides five unique femoral

The LCS design reduces polyethylene

preparation systems. Such surgical flexibility is con
sidered by many of our users to make the knee easier

DePuy has provided no proof that the LCS reduces

to implant.
Don't let the claim of easy implantation go un

challenged. If easy implantation is an issue for your
surgeons, suggest they consider a fixed bearing, PS
design, such as the NexGen Legacy LPS, combined

i&y

with their choice of NexGen instruments.

The LCS is designed for the young,
active patient.

wear.

1. Insall JN. Surgery of beKnee. Vol 2, ed 2.
M^\

: •/

[

: 1993:838-839.

ing elements after New Jer ey Low-Contact Stress
total knee arthroplasty. CI n Orthop Related Res.
1990;254:211-215.

3. Bert JM. Case report, del lyed failure of meniscal
bearing elements in total kn< e arthroplasty. JArthrop.

polyethylene wear. The only data offered suggest that
the LCS design increases contact area at the
tibiofemoral interface, thereby reducing contact
stress. Yet reducing contact stress doesn't necessar
ily result in less polyethylene wear. In fact, a more
accurate hypothesis might be that increasing con
tact area can actually lead to increased volumetric

1998;39(1):153-160.
5. Insall JN. Adventures ii mobile-bearing knee de

wear.

sign. Orthopedics.1998;2I(9):1021-1023.

Even Dr. Insall has made this claim when talking

This claim can be attacked several ways.
• The large contact area of the LCS that DePuy pro
motes is found only with the knee in extension.

about potential benefits of a mobile bearing design.5

Beyond 35° of flexion, the LCS behaves as a total

However, for younger patients requiring a total knee
system, Dr. Insall's first requirement is maintaining
adequate range of motion (ROM). By that he means
ROM at least equal to that of the unaffected con

condylar design with contact loss. Dr. Insall ob

tralateral side.

GoodSelling! ^£**>VCkll\ ^V/^sWe
2. Bert JM. Dislocation/subh xation of meniscal bear

minutes.

\ty>

Thank you for reading and using this information
with your surgeons.

serves, "The low-contact stress (LCS) model has a

1996;11(5):611-612.

4. Huang CH, Young TH.JLee YT, Jan JS, Cheng
CK. Polyethylene failure in New Jersey Low-Con
tact Stress total knee arthroplasty. J Biomed Mat Res.

6. Bertin KC. NexGen to al knee arthroplasty, de
sign rationale and early cli lical results. Warsaw, Ind:
Zimmer, 1998. Pub no 97 5972-16.

7. Insall JN. Surgery oj the Knee. Vol 2, ed 2.

N ^

:

1

: 1993:698.

8. Postak PD, Heim CS, Greenwald AS. Tibial pla
teau surface stress in TKA: a factor influencing poly

femoral component of decreasing radius pqsteri- * mer damage series IV—PCL substituting designs.
orly; (andthat) congruency is less when the knee IPaperpresented at: AnnualMeeting qf theAmerican
is flexed so the contact area decreases in flexion,

Association of Orthopedic Surgeons,1996;

/

therebylosinga majoradvantage."7 In fact, beyond
35° of flexion, the LCS has less contact area than
I T
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Keep 'Em Moving: Knee Instrument
Lubrication Reminder
By Nancy Pakieser
Godd care and maintenance of NexGen® Knee Sys
tem Instrumentation is the key to obtaining long ser
vice from this critical asset. Lubrication is especially

important for instruments with moving parts. NexGen

instruments that specifically requireroutine'lubrication include: the Adjustable IM Guide 5978-04; Ar
ticular Surface Inserter 5977-20; Articular Surface

essary to lubricate instruments right out of the pack
age, particularly if they have been sitting for any
length of time. Notify your hospital accounts of this
need. By providing your accounts with this informa
tion and encouraging them to properly lubricate their
instruments, you can expect many years of troublefree performance.

Remover 5977-21; and the E/M Tibial Cutting Guide
5967-60.

If an instrument becomes difficult to turn or ma

nipulate:

There are many products available to assist in
maintaining reliable instrument function, but not all
products are applicable to NexGen instrumentation.
Because NexGen instruments are steam sterilized, it

is essential that only a water-soluble lubricant, such

1. Rush the instrument with instrument milk, espe

cially around ball plungers, hinges and other mov
able areas.

as instrument milk, be used. Mineral oil or silicone

2. Work or turn the mechanism several times.
3. Rinse with warm water.

lubricants should never be used. Instrumentation

4. Repeat previous steps as necessary.

does not need to be lubricated after every use and
should be treated as any other hinged, rotating or ar
ticulating instrument. It
km;
many cases it may be nec

5. Return instrument to Zimmer if it is still difficult
to use.

I

Calling All Bounty Hunters!
There's extra money in fracture systems, hips and knees for successfulbounty hunters. Fulldetails of
Zimmer's Bounty Program 2000 are available from Warren Chapman, Todd Davis and Dave
Weidenbennet. But here's the bottom line...

Fracture

Hips

$l,0007Conversion

Up to $3,000/Surgeon
When your surgeon implants three fracture
stems, cemented stems or porous stems, you're

This programrewards you and yourcustomerfor
converting to the Versa-Fx®II Femoral Fixation
System. Your target account must be doing at least
five hip screw procedures a month using 50%
competitive product and must agree to a 90-day

eligible for a bonus. That's three hips from one
column.

Fracture Stems

for $500 and your account will receive a Periar

$500/Surgeon
(3 Surgeries)
VerSys LD/FX Cemented
VerSys LD/FX Press Fit

Tray. After a competitive conversion, you'll re
ceive an additional $500 and your account will
be tlie pioud owners of a Periarticular Distal
Femora! Starter Kit and Implant Tray, and a Peri
articular Screw Tray. Note that both of you ben
efit even if the account doesn't convert. Plus,

you'll stimulate interest in periarticular products
in the process.

NexGen Complete Knee Solution
$1,000 to $l,5u07Surgeon
Convince a comjietitive surgeon to implant either

three primary or revision NexGen knees and
you're in the money. Convince them to do both
and you're in even bigger money. No mixing of
primary and revision implants, though.

Primary Knees
$1,000/Surgeon
(3 Surgeries)

Cemented Stems

$1,000/Surgeon
(3 Surgeries)
CPT Hip System
VerSysCemented
VerSys Heritage Hip ProsUiesis
Porous Stems

5$1,500/Surgcon
(3 Surgeries)

Mayo Conservative Hip Prosthesis*
VerSysFiber Metal MidCoat
VerSys Fiber Metal Taper
VerSys6" Beaded MidCoat
Versys6" FullCoat
VerSys 8" FuUCaM

NexGen CR

Zimmer Anatomic
Zimmer Anatomic CP

NexGen Legacy LPS

ZimmerAnatomic, BR

'NexGen CRA
NexGen LCCK

Zimmer's eyes and ears in the field. To help us
collect and disseminate competitive information,
we've instituted the Eyes and Ears Award.
Here's how it works. When you come across hot

competitive information, document it and forward it
to the appropriate manager in Warsaw. We're not
looking for hearsay. We need names, dates, times, or
publications.We'll share the best information nation
award.

Golfing with Back
Pain: A Physician's
Approach
An estimated 80% of golfers will experience an epi
sode of moderate to severe back pain. And 5% will
injure their backs so severely that surgery becomes
necessary. Whether you're a golf pro or weekend
duffer, this video tape can help you avoid injury and
reduce back pain. Orthopaedic surgeon Bruce Dall
and PGA proJim Lipkowitzdemonstrate swing modi

fications for golfers with aching backs, and healthy
swings that help prevent injury.
For more details,
www.healthyfun.com.

check

out

http://

Ortho Smarts

Revision Knce.s

$1,500/Surgeon
(3 Surgeries)

Award
When it comes to competitive information, you are

wide and honor the best "Eyes and Ears" with a small

trial. After the first procedure, you'll get a check'
ticular Proximal Tibial Starter Kit and Implant

Eyes and Ears

DetaiLs, DetaiLs
Of course, there's always paper work.
(Somebody's paying you to do it!) You mustuse the correct forms to enroll each surgeon and
forms must be submitted promptly,Consult pre-:.;
vious mailings tor definitions of competitive <

surgeons and full details of each bounty pro
gram. Then get selling'

BySarahStaples

Test yourorthopaedicknowledgeby answering
this simple question.

What is the longest and usually strongest bone
in the body?

Now, to add to the challenge...
What are the six smallest bones in the body?
Look for the answers in the next issue of
OrthoEdge,

Be Prepared for
Academy
March 15 -19,
2000

in Orlando, Fla.
Alittle advance preparation before Academy can help

you capitalize on productive selling time. Log onto
http://www.aabs.organd click on the Annual Meet
ing button.Then cruise throughthevarious offerings
for opportunities you can leverage into sales.
Before attending, you can recommend scientific
sessions, presentations or CME courses that might
sway surgeons who are considering Zimmer prod
ucts. Or let surgeons from your territory know of your
availability during the meeting. You might even print

outappropriate abstracts andleave them wiUr your
prospective customers.
After Academy, follow up with your surgeons to
find out what they learned and reinforce the positive
impression they got of Zimmer products and people.
So keep looking and listening!

<y

Sales Training

Livelink
Roll-Out

Internet/Computer-Based Sales Force
Training
By Bruce Barton

Advancements in long-distance learning technology
will be providing us with numerous new training
opportunities for our field sales force. Given esca
lating travel costs and "out-of-territory" time to at
tend training programs, we have been looking at al
ternative ways to deliver on-time training to the field.
Based on recent feedback, we have done a good job

By Angle Hile

: ::

jBff

classroomtraining,it will give us endless opportu

and out-of-tenitory time, we have not conducted
enough programs for the more tenured sales associ

force. Some potential programs would include:

ates.

• Competitive updates on all products to be con
ducted on a regular basis

ment is actively pursuing the world-wide web and
CD technology as viable mediums to deliver indi
vidualized and group training programs to the field.
We have recently acquired technology where live
interactive training programs will be delivered to the
sales force via the Internet. Using the technology will
allow us to conduct live, virtual classroom-type in
struction to you simultaneously around the country.
You will only need access to the Internet. You will
be able to participate in the programs from your
homes or offices. Classes will also be archived to

allow people who could not participate "live" to view
the class at a later date. Because this is truly a live,
virtual classroom, you will be able to interact with
the instructor(s) and each other. You will receive
immediate answers to your questions.
We are creating a "Zimmer University" where you
will be able to access all our web-based programs

through the Zimmer Intranet. By using web-based
and computer-based training, the sales force will be
able to:

• Participate in shorter, more focused training ses
sions, more frequently.
•

Reduce travel costs.

• Reduce out-of-territory time to attend programs.

Livelink, an intranet site that connects you directly //'-with weekly mails, sales reports, surgical techniques,
distinctive tool kit materials, company communica
tions, managed care info, logos and graphics, and
case layouts. Because LiveLink is administered in
ternally, you don't even have to load any software

'. Although this technology will not totally replace

training new-hires and sales managers. However,
because of travel limitations, e.g., travel expenses

The Education,Training & Development Depart

Where can you search for, display, download, and
print exclusive Zimmer content? The answer is

• Receive complex product and sales information
in a more timely and effective manner,
• Receive live and interactive training programs at
home or office during non-selling times, e.g., eve
nings, weekends, etc.:

on your computer.

nities to conduct additional training for the sales

• New-hire pre-class programs
• New-hire post-class reinforcement programs
• Sales skill training for existing sales forces
• Clinical case studies
• Sales case studies

• Advanced sales management case studies
• Product updates
• Distributors will be able to use the instructor soft

ware to conduct sales meetings

LiveLink rolled out to an initial group of 33 sales
force participants, with another 100 added in

• Surgeon-to-surgeon meetings
• Clinical programs conducted by surgeon consult
ants and designers (e.g., in discussion of complex
cases, grand rounds, etc.)

December. Your distributor knows who's connected.

By March 2000 roll-out should be complete.
We want you to have timely information elec
tronically. So we add new content weekly—if not
daily! If you haven't seen the Intranet, we will be at
AAOS and upcoming Medical Education meet
ings—stop by and see what's available.
If you have questions, please contact me or refer

• Product launches

Our first program to be conducted early first quar
ter 2000 will be for those who require documenta
tion/verification that they have been trained in oper

ating room protocol, sterile technique, bloodbome
pathogens, and other AORN standards.
Look forward to some exciting "on-line" train
ing programs in the future from the Education, Train
ing & Development Department. If you would like

to the Zimmer e-Business booklet, which indicates

the contact person for specific content.

Competitor Web Site to Watch

more information or have ideas for programs, please
call Dan Krupp or Bruce Barton in the ET&D De

Sulzer Medica

(www.sulzer.com or www.durasul.com)
Discusses Durasul polyethylene, including wear

partment.

results, charts, and claims.

Longevity article from Craig N

Web Resources for You and
Your Doctors
4arthritis.com

(www.4arthritis.com)

Loaded with patient education information and
links to recognized organizations.
i
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Doctors Guide to Arthritis and Resources

(www.psIgroup.com/arthritis.htm#disease)
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lit1 i JtOl/l/t
articles, patient education informa-

¥ fton,%ficNmKs todiscussion and newsgroups.
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Much of the patient education information is
provided by the Arthritis Foundation.
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Medical Education Dates
Regional
Date

Meeting

Location

Jan IMS
Jan 20-28

Harborview Meeting

SanibclHarbour Resort Ft. Myers, FL
Vail, CO

Feb 24-27

Whistler Orthopaedic Symposium
Rush-Presbylcrian St. Luke'sMedical Center -

Feb 28-29

14th Annual Vail Orthopaedic Symposium

Division

Exhibit

Dipt. Rep/
KevContact

US

F

6'Table

Conventions

GLOBAL

F, II, K, PC,

I0"x40" Exhibit

MED - PF/JB

None

SherylConlcy

Global

Chateau Resort,Whistler,CANADA

CANADA

H,K,F

St. Luke'sMedical Clr, Chicago, 1L

US

11,K

1

MED-TH

ChicagoLearning Center
Mar 2-3

Mayo Hip

MayoClinic,Rochester, MN

US

H

MED - KS

Mar 15-19

AAOS

Orlando,FL

US

H, K, F, PC

Conventions

Mar 21-22

Columbia Shoulder Days
MayoElbowDays

Columbia Presbyterian, NewYork, NY
Mayo Clinic, Rochester, MN

GLOBAL

F

MED - PF

GLOBAL

F

MED-PF

AprTBD

ISK - Midwest

Midwest

US

K

MED

Apr 3

OLC Shoulder Course

AAOS, Roscmonl, IL

US

F

MED-PF

Apr 10-11

Rush-Prcsbytcrian St. Luke'sMedical Center Chicago Learning Center
MayoClinic - Upper Extremity -Trauma

St. Luke'sMedical Or Chicago, IL

US

H,K

MED-KS

Phocniz, AZ

US

F

Mar 30-31

Apr 13-15

MED-PF

Conventions

Apr 14-l(i

GTA Regional

Kansas City, KS

us

F

MED-PF

Apr 27-28
May TBD

Mayo Hip
Trauma Update(Zimmer)

MayoClinic, Rochester, MN

us

H

MED - KS

Baltimore, MD

us

F

MED - PF

May 12

ISK - New York

New York, NY

us

K

MED-JB

May 17-21

AsiaPacific Ortho Symposium (APOS)

Cairns, AUSTRALIA

GLOBAL

H,K

MED-MS
MED-

May 19-20

West Palm Beach

PGA Resort, West Palm, FL

US

H,K

May 21-24

Greenwald - Current Concepts - Spring Course

Rio SuitesHotel, LasVegas, NV

us

H,K

MED-

June 1-2

MayoElbowDays

MayoClinic, Rochester, MN
HotSprings, VA

GLOBAL

F

MED - PF

June 14-17

AmericanOrtho Association(AOA)

us

Corporate

Med Ed

June 18-25

RenaissanceHotel, Baltimore, MD

us

F.H.K

MED-PG

June 20-21

lohn Hopkins Board Review Course
Columbia Shoulder Days

Columbia Presbyterian, New York, NY

GLOBAL

F

MED-PF

June 23-25

5th Annual Alaska

Sitka, AK

us

H,K

MED-TH

June 26-27

Rush-Prcsbylerian St. Luke'sMedical Center -
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Senior Thesis Project
Assignment: Prepare an abstract of "Cleaning Up the Mess: New Approaches to the Old
Problem of Thrombus in Coronary Interventions."
Purpose: To share current research and clinical information with primary care and
referring physicians.
Audience: Readers of Perspectives in Research, an in-house publication for staff and
referring physicians affiliated with Borgess Health Alliance.

Skills Required : Comprehending and summarizing primary material. Ability to follow an
established format.

Client: Borgess Health Alliance

Style Manual: AMA with some modifications

<Title>

Cleaning up the Mess: New Approaches to the Old Problem of thrombus in
Coronary Interventions
<Author>

Tim A. Fischell, MD, FACC

<Copy>

The success rate for precutaneous transluminal coronary interventions (PTCI) has
steadily increased over the past decade. However, the presence of thrombus-laden
coronary lesions increases the risk of dangerous complications to this procedure,

including no reflow, myocardial infarctions, and even death. Recently, several new
technologies have been developed to eradicate thrombi.
The Food and Drug Administration, FDA, has recently approved the Possis
Rheolytic™ thrombectomy catheter for use in the native coronary circulation and
degenerated saphenous veins. Many physicians and radiologists are already familiar with
this device and use it for treatment of intracoronary thrombi when performing a

precutaneous transluminal coronary angioplasty, PTC A, or stent. However, new devices
are being tested for the market.

One of the most novel devices is the Angiojet Rheolytic-Thrombectomy System
(Possis Medical, Inc., Minneapolis, MN). This device uses high-velocity saline jets to
create a "localized Bernoulli effect." That allows for removal of an organized thrombus.
Unlike other devices, this one is flexible and deliverable to the epicardial coronary
arteries. There are some downfalls to this device. For instance, there is risk of distal

vessel occlusion from large thrombotic particulate debris. Other limitations include:

capital costs, hemolysis and difficulty using the 5 French device. However, the
advantages have been shown to outweigh any potential disadvantages.

A randomized study compared the Angiojet to intracoronary urokinase. The
study revealed that Angiojet was superior to urokinase in several aspects, including a
reduced in-hospital major adverse coronary event, MACE, (13.9% vs. 32.5%) and
reduced bleeding complications (5.0% vs. 11.8%), reduced 30-day MACE (15% vs.
33.1%) and a reduced length of stay (2.5 days vs. 3.5 days). The Angiojet has proven
safe and effective in the treatment of thrombotic lesions.

There are also a number of other devices in various stages of clinical development
that are designed to either remove or collect thrombotic debris during PTCI. One of these
devices is an ultrasonic thrombus ablation probe developed by Acolysis (Morrisville,
NC). While it is very efficient at breaking up a thrombus, it cannot remove the debris.

The PercuSurge system (GuardWire™, PercuSurge, Sunnyvale, CA) uses a balloon and
wire system which is compatible with existing angioplasty equipment. This device is

able to physically remove most of the thrombotic debris released during intervention. It
is currently used in clinical trials, and may be available for clinical use in the United
States within a year.

Not to be forgotten is the importance of pharmacological approaches. No re flow
is the most serious complication causing morbidity in thrombus laden lesions.

Intracoronary administration of pharmacological agents such a verapamil, diltiazem and
adenosine has been effective in reversing no reflow. A "cocktail" of pharmacological
agents may prove even more effective in reversing no reflow.
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Cleaning up the Mess: New Approaches to the Old Problem of
Thrombus in Coronary Interventions

Tim A. Fischell, MD, FACC
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The success rate for percutaneous transluminal coronary interventions (PTCI) has
steadily increased over the past decade. However, the presence of thrombus-laden

coronary lesions increases the risk of dangerous complications to this procedure^
including no reflow, myocardial infarctions, and even death. Recently, several new
technologies have been developed in-ordetto eradicate any present thrombi.

*^viacK^" \ The^FD^ has recently approved the Possis Rheolytic™ tr^romobectqmy catheter
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^or use *n ^e native coronary circulation and degenerated saphenous veins. Many
physicians and radiologists are already familiar with this device and use it for treatment

ofany intracoronary thrombi when performing a(PTGA) or stent. However, new devices f j,<xn<. bu ww nai

are being tested for the market.
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One of the most novel devices is the Angiojet Rheolytic-Thrombectomy System
(Possis Medical, Inc., Minneapolis, MN). This device uses high-velocity saline jets to
create a "localized Bernoulli effect." Thk allows for tfee-aetual removal of an organized
thrombus. Unlike other deices, this one has shown to be flexible and deliverable to the

epicardial coronary arteries. There are some downfalls to this device. For instance, ttns<device cannot eradicate larger particles (more than 10um) that can cause distal arteriolar

obstruction. Other limitations include: capital costs, hemolysis and difficulty using the 5
French device. However, the advantages have been shown to outweigh the
disadvantages.
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A randomized study compared the Angiojet to intracoronary urokinase. The
study revealed that Angiojet was superior to urokinase in several aspects including a
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reduced Tin-hospital(MACEA(13.9%
vs. 32.5%), reduced bleeding complications (5.0% vs.
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11.8%), reduced 30-day MACE (15% vs. 33.1%) and a reduced length of stay (2.5 days

vs. 3.5 days). -This data-shows-that the Angiojet have proven te-be-a safe and effective \k¥?
A

treatment in the treatment of thrombotic lesions.
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There are also a number of devices in the various stages of clinical development
that are designed to either remove or collect thrombotic debris during PTCI. One of these

^^devices is an ultrasonic thrombus ablation probe developed by Acolysis (Morrisville, NC).
While it very efficient at breaking-up a thrombus, it cannot remove the debris. The
PercuSurge system (GuardWire™, PercuSurge, Sunnyvale, CA) uses a balloon and wire
4

system*which is compatible with existing angioplasty equipment. This device is able to
physically remove most of the thrombotic debris released during intervention. This
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device is currently used in clinical trials, and ir may be available for clinical use in the

United States within ayear.
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Not to be forgotten is the importance of pharmacological approaches. No f^how
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is the most serious complication causing morbidity in thrombus^laden lesions.
v

Intracoronary administration of pharmacological agents such as verapamil, diltiazem and
s

adenosine havebeen effective in reversing no reflow. In tho future, it may be shown tha^-^

Cut) -(^e=rBaa™S 5"cocktail" ofpharmacological agents -isreven more effective4ndreversing no
reflow.
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Overall, it has been shown that there are many new advances in devices to
obliterate intracoronary thrombic lesions. Currently, the most novel is the Angiojet
System, but with increasingly new technology, it may soon be outdone by its competitors.

Cleaning Up the Mess: New Approaches
to the Old Problem of Thrombus in

Coronary Interventions

Tim A. Fischell, MD, FACC

The Journal of Invasive Cardiology

Volume 11, Number 8, August 1999

Reprinted by permission from The Journal of Invasive Cardiology
Copyright© 1999 by Health Management Publications, Inc.

L

yJKr^

•

FISCHELL

hemodialysis access graft lesions,5 in peripheral arterial

0.014" wire with a balloon near the distal end. This wire

lesions, and in native and SVGs.6 8 The VeGAS 2

is compatible with existing angioplasty equipment. The

study" was a randomized study (n = 352) comparing

wire can be passed through the thrombotic lesion and

the Angiojet to intracoronary urokinase for the treat

advanced to the distal vessel. The balloon is inflated

ment of thrombotic lesions in native vessels and in

and the PTCI is performed over this GuardWire. Fol
lowing the intervention, an aspiration catheter is
advanced over this wire and is used to suction out any

saphenous vein grafts. The patients were similar in
terms of lesion length, extent of coronary artery dis
ease, lesion complexity and other baseline characteris
tics. Approximately half of the lesions treated were in
degenerated vein grafts. In this study, the Angiojet

loose thrombotic or atheroembolic debris that was

released into the closed space created by the balloon
occlusion. This device has been used successfully in

appeared superior to urokinase In several important

pilot series in SVGs, lowering CPK elevations from

endpoints, including reduced in-hospital MACE
(13.9% vs. 32.5%o), reduced bleeding complications
(5.0% vs. 11.8%), reduced 30-day MACE (15% vs.
33.1%) and reduced length of stay (2.5 days vs. 3.5

historically high levels to 12.5%. The advantage of this

days). These data, combined with the data from the

paper by Henry et al., suggest that the Angiojet pro
vides a reasonably safe and effective treatment option
for the adjunctive debulking of thrombus in coronary
interventions. No data are currently available compar
ing this devicetoiuTernative, and perhaps more effec
tive pharmacologic treatment with glycoprotein Ilb/IIIa
platelet inhibitors.

Alternative Treatment Options for Thrombotic
Lesions

system is the potential to physically remove most of the
debris released during intervention. One significant dis
advantage with this system is the need to work quickly,
with multiple exchanges, while there is ischemia
induced by the distal balloon occlusion. On the positive
side, the mean occlusion time was only 2.5 minutes in
the pilot series. This device may not be well suited to
treatment of the native epicardial vessels due to the
presence of numerous side branches that would receive
the debris proximal to the distal occlusive balloon. This
device is in clinical trials in the United States and may
be available for clinical use within the next year.
Another clever device-related approach to this prob

lem utilizes^tbpopncept of a distal expandable and

retractable^filter^MuItiple devices are in development
Device-related approaches. There are a number of

ilternative devices, in various-stagesLijfxlinical devel
opment, designed to eithe/remove or collejcHhrombotic debris during PTCI. ThemtrasoriIc~thrombus ablation
)robe developed by Acolysis (Morrisville, North Car

olina) is perhaps the best tested alternative mechanical
\\sj ttirombus debulking device.""1 This device utilizes high
frequency (41.9 kHz) ultrasonic energy to vibrate a
small metal tip at the end of a 4.5 Fr catheter. This
energy creates a cavitational force that breaks up the
thrombus into small pieces. Unlike the Angiojet, there
is no mechanism for removing the debris from the
body. In vitro studies with this device suggest that this

from Cordis/Angioguard, Microvena, Boston Scientific
SCIMED and others. These devices typically utilize a
self-expanding nitinol umbrella covered with a microporous membrane that expands after delivery to the
distal bed. Similar to the PercuSurge system, this type
of filter-wire is used to deliver the balloon and/or stent

to the lesion target site. The filter has the potential
advantage ofallowing distal blood-flow,while collect
ing the larger embolic debris. After the intervention,
the filter basket is retracted and the debris is physically
removed from the body. These devices are appealing
and may allow safer treatment of native vessels,
carotid arteries and SVGs.

cavitational force creates microembolic debris in the

5-10 urn range that is capable of passing through the
coronary microvasculature. This device has been used

quite successfully in pilot trials in Europe as an adjunc
tive treatment for patients with acute myocardial infarc
tion and in degenerated SVGs. The device is currently
being evaluated in clinical trials in the United States for

the management of thrombus in acute myocardial
infarction and for the treatment of thrombus-laden

SVGs. FDA approval of the device could come as early
as 2000.

There are two other major device-related approaches
now in various stages of testing to try to deal with intra
coronary thrombus. The PercuSurge system (GuardWire", PercuSurge, Sunnyvale, California) consists of a
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Pharmacologic approaches. Although there will
clearly be a role for devices in high-risk thrombotic
lesions, some newer pharmacologic approaches to the
prevention and/or reversal of microembolic complica
tions warrant discussion.

No reflow is the most serious and common compli
cation causing morbidity and mortality in the treatment
of thrombus laden lesions. The etiology of no reflow or
slow flow after angioplasty of thrombus containing
lesions grafts is likely two-fold. It is probable that in
some cases there is a mechanical component of small
vessel obstruction from distal embolization of the

thrombus from the dilated lesion site. Perhaps more
importantly, there is evidence that the majority of the

The Journal of Invasive Cardiology

New Approaches to the Old Problem ofThrombus in Coronary Interventions
high distal vascular resistance is caused by intense

2. Myler RK, Shaw RE, Stertzer SH, et al. Unstable angina and

microvascular vasoconstriction."I3

coronary angioplasty. Circulation l990;82(Suppl II):88-95.
3. De Feyter PJ, van den Brand M, Jaarman G, et al. Acute
coronary artery occlusion during and after percutaneous
transluminal coronary angioplasty: Frequency, prediction,
clinical course management and follow-up. Circulation

Intracoronary administration of verapamil (100-900
ug) appears effective in improving antegrade blood
flow in this condition in 67-89% of cases.11 Intracoro
nary diltiazem (0.5-2.5 mg) may be even more effec
tive than verapamil in reversing no reflow. In one

1991;83:927-936.

4. Henry TD, Setum CM, Wilson GJ, et al. Preclinical evalua

tion of a rheolytic catheter for percutaneous coronary

small series, flow was normalized in 23 of 24 cases

artery/saphenous vein graft thrombectomy. J lavas Cardiol

(95%). There are also pilot data showing that nicardip
ine and intracoronary nitroprusside, an NO donor, may
be effective in reversing no reflow. Finally, a recent
report by our group demonstrated marked and rapid
efficacy using a technique of repetitive forceful injec

1999;11:475-484.

5. Ramee SR, Collins TJ, Karsan A, et al. Percutaneous rccanal-

ization of thrombosed hemodialysis access site using rheolyt
ic thrombectomy: Acute results (Abstr). Circulation
1994;90:1-10.

6. Ramee SR, Schatz RA, Carrozza JP, et al. Results of the

tions of intracoronary adenosine with a small volume
(3 ml) syringe.14 In our updated series with more than
20 patients, 95% of patients had restoration of TIMI 3
flow, with a mean treatment time of 3.5 minutes to
reverse the no reflow event. It is possible that a combi

VeGAS I Pilot Study of the Possis coronary AngioJet'
thrombectomy catheter (Abstr). Circulation 1996;94:1-619.

7. Hamburger J, Bekke M, di Mario C, etal. The Euro-ART study:
Ananalysis of the initial European experience with the AngioJet"
rapid thrombectomy catheter (Abstr). J Am Coll Cardiol
1997;29:1864.

I. Ramee SR, Bairn DS, Popma JJ, et al. A randomized, prospec

nation cocktail of intracoronary pharmacologic agents,
each with different mechanisms of action (e.g., adeno
sine, diltiazem and nitroprusside) could prove even

tivemulticenter study comparing intracoronary urokinase torhe
olytic thrombectomy with the Possis AngioJet catheter for
intracoronary thrombus: Final results of the VeGAS 2 trial

more efficacious in reversing no reflow.
In summary, the Angiojet system described in this

issue of the Journal appears to be a promising new
tool for the interventional cardiologist facing the

(Abstr). Circulation 1998;98:1-86.

». Arinani M, Fishbein MC, Chae JS, et al. Dissolution of periph
eral
10.

treatment of a thrombus-containing lesion. Several
other new devices are on the horizon, which will

actively compete with the Angiojet in this high-risk
patient population. Newer pharmacologic approaches
for the prevention and reversal of no reflow may limit
the use of these mechanical devices to the subpopulation of lesions containing a large thrombotic burden.

thrombi

by

ultrasound.

Circulation

Rosenschein U, Gaul G, Erbel R, et al. Percutaneous translumi

nal therapy of occluded saphenous vein grafts: Can the chal
lenge be met with ultrasound thrombolysis? Circulation
1999;99:26-29.

11. Wilson RF, Laxson DD, Lesser JR, White CW. Intense

microvascular constriction after angioplasty of acute thrombotic
coronary arterial lesions. Lancet 1989;1.807-811.

12. Kloner RA, Ganote CE, Jennings, RB. The "no-reflow" phe
nomenon after temporary coronary occlusion in the dog. J Clin
Invest 1974;54:1496-1508.
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i\ Commentary

Cleaning Up the Mess: New Approaches to the
Old Problem of Thrombus in Coronary
Interventions
Tim A. Fischell, MD, FACC

The overall procedural (success ratejj^percutaneous
transluminal coronary interventions (PTCI) has
improved steadily during the last decade. This
improvement is largely attributable to advances in

(device technology (most notably the coronary stent) as
irell as maturation of the technical aspects of treating

^complex disease. Despite these improvements, coro
nary interventionalists continue to face difficult chal
lenges in the treatment of the thrombus-laden coronary
lesion. The presence of intracoronary thrombus prior to
PTCI is associated with a substantially increased risk
of serious complications, including no reflow, myocar
dial infarction and death.13

In this issue of the Journal of Invasive Cardiology,
Henry and colleagues4 have provided encouraging in
vitro and preclinical in vivo data demonstrating the
potential efficacy of the Possis Rheolytic™ thrombec
tomy catheter for the mechanical debulking of intralu
minal thrombus. This thrombectomy device is familiar
to the majority of interventional cardiologists and radi
ologists, and has been recently approved by the FDA
for clinical use in the native coronary circulation and in
degenerated saphenous vein grafts. This device is one
of several new technologies developed for the adjunc
tive treatment of intracoronary thrombus in the setting
of PTCA and stenting.

See Henry et al. on pages 475^484
The Angiojet system. The Angiojet RheolyticThrombectomy System (Possis Medical, Inc., Minneapo
lis, Minnesota) is a novel device that uses high-velocity

saline jets to create a "localized Bernoulli effect" to
^-aUowJhfi-jpechanical removaliiLort^anizeiLthxombijs.
This device has a number of desirable features for this
From the Heart Institute at Borgess Medical Center, Kalamazoo
Center for Medical Studies, Kalamazoo. Michigan.
Address reprint requests to: Tim A. Fischell, MD, Heart Institute
al Borgess Medical Center, 1521 (kill Road. Kalamazoo, Ml 49001.
E-mail: tafl@nct-link.net
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application. It appears to be reasonably flexible and
deliverable to the epicardial coronary arteries. Based
upon the data presented in the current study, this device
appears very efficient in thrombus removal.
Interestingly, the effluent debris size as measured in
the in vitro study (4-10 um) is similar to the debris
described following atheroablation with rotational
atherectomy, which is well tolerated in the large majori
ty of cases. However, one must be a bit cautious in
interpreting these data. As pointed out in Henry's arti
cle, only 2-12% of the embolic debris particles (as
counted in a Coulter counter) were larger than 10-12
um with the Rotablator. Although this appears reassur

ing, when one examines the Rotablator data, it is not
always appreciated that the 2-12% of particles larger
than 10 um make up more than 50% of the plaque vol
ume that is ablated. In other words, there are millions of

dust-like particles that constitute a very small plaque
volume and, perhaps, a few thousand particles that are
large and can cause distal arteriolar obstruction and
non-Q wave myocardial infarction. It is possible that a
similar relationship may exist with the RT device and
other thrombus debulking devices. Thus, distal vessel
occlusion from large thrombotic particulate debris
remains a potential risk with this type of device. Other
limitations of this technology may include capitalcosts,
hemolysis and difficulty in advancing the .5 French
device through the obstructing lesion. In many cases of
native and saphenous vein graft obstruction, there can
be a large thrombus burden distal to a high-grade ather
osclerotic lesion, which may not be easily accessed
with the RT device without pre-dilatation. There may
also be issues regarding the RT's effectiveness in the
removal of atheroembolic debris during the treatment
of degenerated saphenous vein grafts (SVGs).
Despite these potential limitations, the Angiojet
Rheolytic Thrombectomy System has proven safe and
effective in the treatment of thombotic lesions. This

device has been used successfully in the treatment of

485

Senior Thesis Project
Assignment: Prepare an American Society of Health Systems Pharmacists (ASHSP)
form for reboxetine mesylate tablets, a new antidepressant.
Purpose: To summarize pertinent information about a drug for the ASHSP database.
Audience: Health system pharmacists.

Skills Required : Ability to extract and organize information from the product's proposed
package insert in the format specified by ASHSP. Basic understanding of specialized
vocabulary. Familiarity with WORD software.
Client: Pharmacia & Upjohn
Format: WORD document

Style Manual: AMA

VESTRA AHFS Form
Job No. PTX

Final Approved Copy, February

, 2000

Source i
<Title>

Product Information Form for AHFS Drug Information*
<VESTRA logo>

<Copy>

1.

AHFS Classification Number

28:16.04

PI-1A

PI-19A

2. Generic Name (list USAN and CAS registry numbers)
reboxetine mesylate tablets
3.

Trade Name and Manufacturer

VESTRA; manufactured for Pharmacia & Upjohn by Pharmacia & Upjohn S.p.A.,
Ascoli, Piceno, Italy.
4. NDA Number and Date of FDA Approval
NDA _;
, 2000
PI-1B,C

5. Physical Properties of the Chemical Entity
Reboxetine is a white to off-white crystalline powder. It is freely soluble in water
and methanol. Its empirical formula is C12H23N03CH403S. The molecular
weights of the free base and the mesylate are 313.40 and 409.50, respectively. It is
a racemic mixture of two enantiomers.

PI-IE

6.

Chemical Properties

a)

Describe any structural similarities of the drug to other available compounds
or groups of compounds. Describe any structural differences and their
consequences when compared to these other compounds.

VESTRA Tablets contain reboxetine mesylate, a structurally novel antidepressant
chemically unrelated to the tricyclic or tetracyclic antidepressants, the monoamine
oxidase inhibitors, or the selective serotonin reuptake inhibitors.

PI-18A

b)

List the pATa(s) of the drug.

c)

Describe any physical or chemical incompatibilities, which may exist;
describe the specific conditions of the incompatibilities and their
consequences. Important compatibilities should also be noted.

d)

List the stability of the drug to temperature, light, and moisture.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).
e)

List the pH range over which the drug is stable in specific solutions.

VESTRA AHFS Form
JobNo.PTX

Final Approved Copy, February

, 2000

Not applicable.

f)

List the pH of commercially available liquid products and/or reconstituted
products (parenteral and/or oral).

Not applicable. Reboxetine mesylate is available only in oral tablet form.
g)

List the osmolarity/osmolality of commercially available solutions of the drug
and/or common dilutions of reconstituted solutions (parenteral and/or oral).

Not applicable. Reboxetine mesylate is available only in oral tablet form.

h)

Describe the diluent for parenteral or liquid oral products(s) if provided with
the commercial package. List the pH of this diluent.

Not applicable.

i)

List the actual amount of active ingredient in the vial and total volume of
solution after reconstitution. If various methods of reconstitution can be

followed, describe the volume to be added, final volume of solution, and
approximate final concentration per mL for each.

Not applicable.
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j)

List the recommended storage conditions for commercially available

produces).
Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).

k) List the expiration dating periods for commercially available product(s).
months

1) List the recommended storage conditions for reconstituted product(s). Provide
information regarding the effects of refrigeration and freezing and other
environmental conditions (eg, microwave thawing) on the stability of the
product(s).
Not applicable.

m) List expiration dating periods for reconstituted drug.
Not applicable.
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n) List any excipients contained in the commercially available product(s) and
their purpose. Describe any potentially significant consequence of their
presence.
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Inactive ingredients consist of dibasic calcium phosphate dihydrate,
microcrystalline cellulose, crospovidone, magnesium stearate, and silicon dioxide.

o) List the stability of the drug if further diluted following reconstitution; specify
the diluent, final concentration in solution, temperature, time period, and
recommended storage conditions.

Not applicable.
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7.

Pharmacologic Classification

a)

State the pharmacologic class to which the drug belongs and any similar or
distinct properties it possesses in comparison to existing drugs.

Reboxetine mesylate is a structurally novel antidepressant for oral administration.
It is chemically unrelated to tricyclic or tetracyclic antidepressants, the monoamine
oxidase inhibitors, or the selective serotonin reuptake inhibitors.

PI- 1G

b)

State the mechanism of action; if the mechanism of action is unknown, so
state. If applicable, the mechanism of action may be compared with that of
another drug or class of drugs.

The mechanism of action of reboxetine, although not fully elucidated,

appears to be linked to potentiation of noradrenergic activity in the central
nervous system resulting from selective inhibition of CNS neuronal reuptake
of norepinephrine (NE). In vitro binding studies in animals and functional
studies in human transporters suggest that reboxetine is a potent inhibitor of
NE reuptake, while having a 64-to-133-fold weaker potency on serotonin
reuptake and negligible effects on dopamine reuptake. In agreement with
this, an m vivo study in rats showed a 30-fold greater potency of reboxetine
in a noradrenergic brain region (*locus coeruleus) compared with a
serotonergic region (dorsal raphe nucleus). In contrast to tricyclic
antidepressants, in vitro studies have shown that reboxetine has a slight
affinity (K; 1-5 uM) for serotonergic 5HT2C, histamine Hi, and muscarinic
cholinergic receptors and no significant affinity (Ki > 5 uM) for adrenergic

(=11, =j 2 or—), dopaminergic (D2, D3, or D4), or serotonergic 5HT1A or
5HT2a receptors. Pharmacologic activities at these receptors are hypothesized
to be associated with the various anticholinergic, sedative and cardiovascular
effects seen with psychotropic drugs. Chronic administration of reboxetine to
animals was found to downregulate brain noradrenergic receptors, as has
been observed with other clinically effective antidepressants.
c)

List the potential unlabeled (investigational) uses for the drug based on an
expanded description of its pharmacologic activity (preferably in humans),
unless federal and/or state regulations prohibit such a discussion.

Not applicable.
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d) List bacterial, fungal, viral, and/or other microbial spectra and clinical
effectiveness (ie, both in vitro and in vivo activity) for an antimicrobial agent,
comparing properties to other agents.
Not applicable.

e)

PI-2H

List pharmacokinetic data for absorption, distribution, metabolism, and
excretion of drug.

i)

Absorption: Include information on the extent and rate of absorption
of the drug by the usual routes of administration; the factors that
might affect rate or extent of absorption; the therapeutic, toxic, and
lethal blood concentrations; the period of time required for onset,
peak, and duration therapeutic effect. List bioavailability data for the
common routes of administration and dosage(s) of the drug; include
information describing the respective AUC (area under the
concentration-time curve) and how it and other parameters of
bioavailability were determined.

Reboxetine is rapidly and extensively absorbed following oral
administration. Mean maximal concentrations of 125 ng/mL are
achieved within 1.5 hours after administration of a 4-mg tablet. The
absolute oral bioavailability is about 94%. Administration of
reboxetine with a meal decreases the rate, but not the extent, of
reboxetine absorption.

ii)

Distribution: Include information on the usual distribution of the

drug in body tissues and fluids (especially those tissues or fluids
where the drug might be employed for therapeutic effects, eg,
prostatic fluid); the drug's propensity to cross the blood-brain barrier,
placenta, or appear inhuman milk; the protein binding; and
volume(s) of distribution of the drug.

The volume of distribution of reboxetine at steady state following
intravenous administration is 26L and 63L for R and S-enantiomers,
respectively. Reboxetine is 97% bound to human plasma proteins

(with higher affinity for =1 -acid glycoprotein than albumin).
Patients should be advised to notify their physician if they are breast
feeding.
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iii) Metabolism: Include information on site(s) of metabolism and extent
ofbiotransformation, and on the metabolic products and their
activity.
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Reboxetine is extensively metabolized after oral administration,
including hydroxylation of the ethoxyphenoxyring, 0-dealkylation,
and oxidation of the morpholine ring. The drug is predominantly
metabolized in vitro via cytochrome P4503A (CYP34A). In vitro
studies have shown that reboxetine does not inhibit the activity of the

following isoenzymes of cytochrome P450: CYP1A2, CYP2C9,
CYP2C19, and CYP2E1. Reboxetine inhibits both CYP3A4 and
CYP2D6 with low binding affinities. In an in vivo study, reboxetine
showed no effect on the pharmacokinetics of alprazolam, a model
CYP3 A4 substrate. Likewise, reboxetine had no effect on the in vivo

metabolism of dextromethorphan, a model CYP2D6 substrate.
Therefore, interactions between reboxetine and other compounds
metabolized by these enzymes are unlikely.
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iv) Excretion: Include information on routes of elimination from the
body, factors affecting elimination, and form in which drug is
eliminated. Include information on the half-life of elimination and

factors affecting it; include the method, route, and dosage used in this
determination, as well as important patient parameters (eg, normal
renal function).

The systemic clearance of reboxetine is 43 mL/min. About 10% of a
dose of reboxetine is excreted unchanged in urine.

Senior Thesis Project
Assignment: Prepare an abstract for the 16th IPVS Conference in Australia.
Purpose: To summarize original research submitted for an oral presentation or
scientific poster.
Audience: Veterinarians and pork producers.
Skills Required: Ability to extract key information from a field experience report Basic
understanding of specialized vocabulary. Familiarity with WORD software and use of
abstract templates. Fact checking.

Client: Pharmacia & Upjohn Animal Health
Format: 1-page, 2-column, as specified by IPVS
Style Manual: IPVS
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Introduction

Discussion

Bacterial infections of piglets can cause mortality and be detrimental to

The higher end of label dose was chosen to determine the effectiveness of
Naxcel against both their E. coli and Streptococcussuis infections. The
lower end of label dose may be equally effective, given the low MIC
required for Streptococcussuis. At the time this report was written, the
farm was using Naxcel injection at processing and doing trials to
compare the lower vs. higher Naxcel doses. During the trial, the farm
averaged 2.3 litters/sow/yr and had an average of 10.2 pigs born alive
(with 10.2 as the goal). A reduction in preweaning mortality of 5.17%
means an additional 1,455 pigs weaned annually. Weaned pigs were
valued at $23. This would result in $33,465 additional income from pigs
sold. The Naxcel cost $0.076/pig or $2139.55/year. If labor cost
$0.03/injection, the annual cost of treatment would be $844.56. For every
dollar invested in Naxcel, this farm's return on investment (including
labor costs) was $10.21. Overall, use of Naxcel proved to be very
effective. It reduced preweaning mortality in terms of room-to-room
variations, improved average weaning weights by 1.77 lbs, and reduced
the variation in weaning weights.

the profit of a farm. Some cost-effective vaccines have been shown to
reduce the number of fatalities. A 1200-sow farrow-feeder farm in the

United States was chosen because it periodically experiences excessive
mortality related to Streptococcus suis type 2. Most noticeable in the
nurseries, these infections caused the pigs to develop a rough hair coat,
swollen joints, encephalitis, and even mortality. Most mortalities
occurred at 3-4 weeks post-weaning. This study was devised to evaluate
the efficacy of Naxcel injections in reducing preweaning mortalities and
improving the weaning weights of piglets.
Materials and methods

Each farrowing room holds 20 crates. Four farrowing rooms served as
Control Group 1 (rooms 6, 7, 8, and 9 with a total of 862 pigs). Four
more farrowing rooms that followed the Naxcel injections served as
Control Group 2 (rooms 14, 15, 16 and 1 with a total of 934 pigs). The
Treatment Group included piglets (a total of 897 pigs) born to or
fostered onto all sows that farrowed in rooms 10, 11, 12 and 13. Sows
were offered feed up to 5 times a day in late lactation. Four pounds of
feed were offered at each feeding. Creep feed and milk replacers were
not made available until pigs entered the nursery.

Processing occurred on day 3. During a normal processing, tails were
burned off using a debeaker, both ears were tattooed, all pigs received
1 mL of iron, and male pigs were castrated. Needle teeth and navel
cords were not clipped. Cross fostering was allowed within a room the
first 48 hours after farrowing. Fall-behind pigs were pulled daily and
placed on a nurse sow. In addition to this, one 4-gram vial of Naxcel
Sterile Powder was diluted into 500 mL of sterile water yielding a final
concentration of 8 mg/mL. Pigs in the Treatment Group were injected
in the neck with 1 mL Naxcel (8 mg/pig of cetiofur equivalent) at
processing. The pigs were estimated to average 3 pounds at birth and
piglets were weighed at weaning. The average weaning age during this
trial was 17 days. There was no difference in weaning ages between
treatment and control groups. The data was analysed by procedures
recommended by Daniel (1).

Results

Trial results are summarized in Table 1. Ceftiofur injection at processing
reduced preweaning mortality by 5.17% on average, or 33%. Preweaning
mortality was also reduced. Ceftiofur-injected pigs weighed 1.77 lbs
(0.80 kg) more at weaning on average than pigs in Control Group 2.
Table 1. Trial Results

Control

Control

Group 1

Group 2

Group

Number of pigs
Pigs weaned

862

934

879

736

774

801

Preweaning

14.62

17.13

10.70*

Not measured

9.85/4.47

11.62/5.27

Ceftiofur

mortality (%)

Weaning
weight (lbs/kg)

"Statistically significant difference

Conclusion

Naxel is effective at reducing preweaning mortality and improving
weaning weights of piglets.
References

1. Wayne W. Danial (1987) Biostatistics: a foundation for analysis in

thehealth science. 4th edition. John Wiley andSons, Inc.
The study was funded by the Australian Pig Research and Development
Corporation.
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$0.03/injection, the annual cost of treatment would be $844.56. For every
dollar invested in Naxcel, this farm's return on investment (including
labor costs) was $10.21. Overall, use of Naxcel proved to be very
effective. It reduced preweaning mortality in terms of room-to-room
variations, improved average weaning weights by 1.77 lbs, and reduced
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Bacterial infections of piglets can cause mortality and be detrimental to
the profit of a farm. Some cost-effective vaccines have been shown to
reduce the number of fatalities. A 1200-Sow farrow-feeder farm in the
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United States was chosen because it perYodically experiences excessive
mortality related to Streptococcus suis type 2. Most noticeable in the
nurseries, these infections caused the pigs to develop a rough hair coat,
swollen joints, encephalitis, and even mortality. Most mortalities
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devised to evaluate the efficacy of Naxcel injections in reducing
preweaning mortalities and improving the weaning weights of piglets.
Materials and methods

Each farrowing room holds 20 crates. Four farrowing rooms pnor.te<_r\
•^g-llm ddministration-of Ndxecl served as Control Group 1 (rooms 6, 7, 8,
and 9 with a total of 862 pigs). Four more farrowing rooms that
followed the Naxcel injections served as Control Group 2 (rooms 14,
15, 16 and 1 with a total of 934 pigs). The Treatment Group included
piglets (a total of 897 pigs) born to or fostered onto all sows that
farrowed in rooms 10, 11, 12 and 13. Sows were offered feed up to 5
times a day in late lactation. Four pounds of feed were offered at each
feeding. Creep feed and milk replacers were not made available until
pigs entered the nursery.
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Processing occurred on day 3. During a normal processing, tails were
burned off using a debeaker, both ears were tattooed, all pigs received
1 mL of iron, and male pigs were castrated. Needle teeth and navel
cords were not clipped. Cross fostering was allowed within a room the
first 48 hours after farrowing. Fall-behind pigs were pulled daily and
placed on a nurse sow. In addition to this, one 4-gram vial of Naxcel
Sterile Powder was diluted into 500 mL of sterile water yielding a final
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x©fleentratirM6T§mg/mL. Pigsiathe Treatment Group were injected
in the neck with 1 mL Naxcel (»mg/pig of cetiofur equivalent) at
processing. The pigs were estimated to average 3 pounds at birth and
piglets were weighed at weaning. The average weaning age during this
trial was 17 days. There was no difference in weaning ages between
treatment and control groups.
Results

AdministeringNaxcel at processing reduced preweaningmortality^y

5.17% on average.
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Table 1. Naxcel Trial Ancillary Variables and Mortality by
Farrowing Room
The trial results were presented on Table 1 with ancillary variables and in

jable 2with preweaning mortality. Naxcel injection at processing reduced
preweaning mortality by 5.17%on average or 33%.Naxcelalso reduced
the variation in preweaning mortality from room-to-room (Table/1).
Table 2. Naxcel Trial Mortality by Treatment Group

Table 2 represents the percentage of mortality for Control Groups 1 and"

\/jC) 2, andfortheJjeatment group. It wa3 found thatjhe group treated with
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Naxcel had thelowest percentage of preweaninglnortality at 10.70%.
This is 3.92% lower than Control Group 1 and 6.43% lower than Control
Group 2.
Discussion

The higher end of label dose was chosen to determine the effectiveness of
Naxcel against both their E. coli and Streptococcus suis infections. The
lower end of label dose may be equally effective, given the low MIC
required for Streptococcus suis. At the time this report was written, the
farm was using Naxcel injection at processing and doing trials to

compare the lower vs. higher Naxcel doses. During the trial, the farm

averaged 2.3 litters/sow/yr and had an average of 10.2 pigs born alive
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Materials and methods

Each farrowing room holds 20 crates. Four farrowing rooms prior to
the administration of Naxcel served as Control Group 1 (rooms 6, 7, 8,
and 9 with a total of 862 pigs). Four more farrowing rooms that
followed the Naxcel injections served as Control Group 2 (rooms 14,
15, 16 and 1 with a total of 934 pigs). The Treatment Group included

piglets (a total of 897 pigs) born to or fostered onto all sows that
farrowed in rooms 10, 11, 12 and 13. Sows were offered feed up to 5
times a day in late lactation. Four pounds of feed were offered at each
feeding. Creep feed and milk replacers were not made available until

pigs entered the nursery.
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Processing occurred on day 3. At processing, tails were burned off
using a debeaker, both ears were tattooed, all pigs received 1 mL of
iron, and male pigs were castrated. Needle teeth and navel cords were
not clipped. Cross fostering was allowed within a room the first 48
hours after farrowing. Fall-behind pigs were pulled daily and placed
on a nurse sow. One 4-gram vial of Naxcel Sterile Powder was diluted
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of cetiofur equivalent) at processing. The pigs were estimated to
average 3 pounds at birth and piglets were weighed at weaning. The
average weaning age during this trial was 17 days. There was no
difference in weaning ages between treatment and control groups.
Results

Table 1. Naxcel Trial Ancillary Variables and Mortality by
Farrowing Room
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Table 2. Naxcel trial Mortality by Treatment Group
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processing and doing trials to compare the lower vs. higher Naxcel doses.
At the time of the trial, the farm averaged 2.3 litters/sow/yr and had an
average of 10.2 pigs bom alive (with 10.2 as the goal). A reduction in
preweaning mortality of 5.17% means an additional 1,455 pigs weaned
annually. Weaned pigs were valued at $23. This would result in $33,465
additional income from pigs sold. The naxcel cost $0.076/pig or
$2139.55/year. If labor cost $0.03/injection, the annual cost of treatment
would be $844.56. For every dollar invested in Naxcel, this farm's return
on investment (including labor costs) was $10.21. Overall, use of Naxcel
proved to be very effective. It reduced preweaning mortality in terms of
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AdministeringNaxcel at processing reduced preweaning mortality by
5.17% on average.ei^^o.

The trial results were presented on table 1 with ancillary variables and in
table2 with preweaningmortality.Naxcel injectionat processingreduced
preweaning mortality by 5.17% on average or 33%. Naxcel also reduced
the variation in preweaning mortality from room-to-room (Table 1).
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SUMMARY

2.1 Abstract

This study compared the effectiveness of ceftiofur sodium on reducing preweaning mortality
and improving weaning weights. Pigs (n= 897) received ImL ceftiofur sodium (reconstituted

as 8 mg ceftiofur/ml) IM at processing which occurred at 3 days of age. Preweaning
mortality for the Naxcel injected pigs was 10.70%. Preweaning mortality for the non-treated
groups was 14.62% for control group 1 (n = 862) and 17.13% for control group 2 (n=934).
The Naxcel treated pigs weighed an average of 11.62 lbs at weaning. Pigs in control group 2
weighed an average of 9.85 lbs at weaning.
Naxcel program proved to effectively reduce preweaning mortality in terms of room-to-room
variations. It improved average weaning weights by 1.77 lbs, and reduced the variation in
weaning weights. Economically, in this Naxcel program, for every dollar invested, one could
expect $10.21 returned, including labor.
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2.2 Tabular Summary
Product name: Naxcel Sterile Powder

Generic name: Naxcel

SECTION: Clinical Efficacy

Reference:

Study type:

Investigating laboratory: none

Study period (years): 1999
Challenge or natural infection: natural
Species/strain: swine
Duration of treatment: one injection at 3 days of age
Total number of animals: 897 injected - 801
weaned, 1796 control pigs - 1510 weaned
Observation period after the end of dosing: birth to weaning
Route of administration: intramuscular injection
Age (average): 3 days
Control formulation: none
Body weight (average) at start: estimated to be 3 lbs.
Treatment formulation: One bottle of Naxcel

sterile powder was mixed with 500 mL of sterile
water. Pigs were given 1 mL in the neck at 3

days of age
Purpose: To evaluate the efficacy of Naxcel injections in reducing preweaning mortality and improving
weaning weights of piglets on a 1200 sow farrow-to-feeder farm that periodically experiences excessive
mortality related to Streptococcus suis type 2.
Results

Farrowing House Rooms
Pigs Born or fostered on

Pigs weaned
Preweaning Mortality(%)

Control 1

Control 2

Naxcel

6, 7, 8, 9

14, 15, 16, 1

10, 11, 12, 13
897

862

934

736

774

801

14.62%

17.13%

10.70%

Conclusion:

A single injection of 1 mL (8 mg/ml) of Naxcel at processing (day 3) reduced preweaning
mortality. The mean weaning weight for the Naxcel treated group was 1.77 pounds heavier
than the mean weaning weight of Control group. Naxcel program proved to effectively
reduce preweaning mortality in terms of room-to-room variations. It improved average
weaning weights by 1.77 lbs, and reduced the variation in weaning weights. Economically,
in this Naxcel program, for every dollar invested, one could expect $10.21 returned,
including labor.
Study in compliance with GLP: yes
Study in compliance with GCP: yes

no x
no x
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INTRODUCTION

This trial took place on a 1200 sow farrow-to-feeder farm in the United States. This farm is
one of many owned by a large corporate swine integrator. This particular farm was chosen
due to periodic flare up of Streptococcus suis type 2. The Streptococcus suis infections were
most noticeable in the nurseries, with peak mortalities occurring at 3 to 4 weeks post
weaning. Pigs developed a rough hair coat, a small percent developed swollen joints (3%),
and several larger pigs displayed signs of encephalitis. Toxogenic E. coli had not been
diagnosed on this farm. The farrowing house was experiencing a yellow, watery scour in
approximately 5% of the litters when this trial began.

5

OBJECTIVES

To reduce pre
preweaning mortality and improve weaning weighs by injecting pigs with Naxcel®
at processing.

6

MATERIALS AND METHODS

Each farrowing room holds 20 crates. Four farrowing rooms prior to the administration of
Naxcel served as Control Group 1 (rooms 6, 7, 8, and 9 with a total of 862 pigs). Four more
farrowing rooms that followed the Naxcel injections served at Control Group 2 (rooms 14,
15, 16 and 1 with a total of 934 pigs). The Treatment Group included piglets (a total of 897
pigs) born to or fostered onto all sows that farrowed in rooms 10, 11, 12, and 13.

Sows were offered feed up to 5 times a day in late lactation. Four pounds of feed were
offered at each feeding. Creep feed and milk replacers were not made available until pigs
entered the nursery.
Processing occurred on day 3. At processing tails were burned off using a debeaker, both
ears were tattooed, all pigs receive 1 mL of iron, and male pigs were castrated. Needle teeth
and naval cords were not clipped. Cross fostering was allowed within a room the first 48
hours after farrowing. Fall behind pigs were pulled daily and placed on a nurse sow.
One 4-gram vial of Naxcel Sterile Powder was diluted into 500 mL of sterile water yielding a
final concentration of 8 mg/mL. Pigs in the treatment Group were injected with 1 mL Naxcel
(8 mg/pig of ceftiofur equivalent) at processing. The pigs were estimated to average 3 pounds
at birth and the rooms were weighed at weaning. The average weaning age during this trial
was 17 days. There was no difference in weaning age between treatment and control groups.

The hypothesis testing of the difference between the Treatment Group and the Controls
followed the procedures recommended by Danial (1).
6(11)
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RESULTS

The trial results were presented in Table 1 with ancillary variables and in Table 2 with

Prewean mortality. Naxcel injection at processing reduced preweaning mortality by 5.17%
on average or 33%. Naxcel also reduced the variation in preweaning mortality from roomto-room (Figure 1).

Naxcel injected pigs weighed 1.77 lbs. more at weaning on average than pigs in Control
Group 2. Although not recorded, the most noticeable difference by observation was the
uniformity in sizeof the Naxcel treated pigs when compared to either control group. The
farm was over budget with this program.

8

DISCUSSION

A Naxcel injection was chosen at day 3 in this trial, because this was when the farm was
picking up pigs to do routine processing. The higher end of label dose was chosen to
determine the effectiveness of Naxcel against both their E. coli and Steptococcus suis
infections. The lower end of label dose may be equally effective, given the low MIC

required for Streptococcus suis. At the time this report was written, the farm was using
Naxcel injection at processing and doing trials to compare the lower vs. higher Naxcel dose.
At the time of the trial, the farm averaged 2.3 litters/sow/year and had an average of greater
than 10.2 pigs born alive (with 10.2 as the goal). A reduction in preweaning mortality of
5.17 percentage points means additional 1,455 pigs weaned annually. Weaned pigs were
valued at $23. This would result in $33,465 additional income from pigs sold. The Naxcel
cost $0.076/pig or $2139.55/year. If labor cost $0.03/injection, the annual cost would be
$844.56. Forevery dollar invested in Naxcel, this farm's return on investment (including
labor costs) was $10.21.

Overall, use of Naxcel proved to be very effective. It reduced preweaning mortality in terms
of room-to-room variations, improved average weaning weights by 1.77 lbs., and reduced the
variation in weaning weights.

9

CONCLUSIONS

Naxcel program proved to effectively reduce preweaning mortality in terms of room-to-room
variations. It improved average weaning weights by 1.77 lbs., and reduced the variation in
weaning weights Economically, in this Naxcel program, for every dollar invested, one could
expect $10.21 returned, including labor.
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Table 1. Naxcel Trial Ancillary Variables and Mortality by Farrowing Room
Sows

Pigs

Net

Pigs

Prewean mortality

Farrowed

Born

Foster

Weaned

(%)

6

20

216

-17

182

8.54

7

20

197

30

193

14.98

8

17

183

24

171

17.39

9

19

208

21

190

17.03

10

22

214

33

220

10.93

11

18

200

11

187

11.37

12

19

199

25

198

11.61

13

18

205

10

196

8.84

14

22

209

35

221

9.43

15

20

223

40

192

27.00

16

18

196

20

178

17.59

1

15

180

31

183

13.27

Room

Table 2. Naxcel Trial Mortality by Treatment Group
Group

Treatment

Farrowing

No. Sows

Born alive

Prewean

room

farrowed

per sow

mortality (%)

Control 1

No

6, 7, 8, 9

76

10.57

14.62

Treatment

Naxcel at day 3

10, 11, 12, 13

77

10.62

10.70*

Control 2

No

14, 15, 16,1

75

10.77

17.13

* statistically significant difference
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Figure 1. Prewean Mortality in Naxcel Prewean Program
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Writing abstracts
Jerry D. Eastman, MS, and E. Roseland Klein
Introduction

In biomedical journals, an abstract provides readers

with apreview of the contents of an article. Aconcise,

abstracts contain words the author has coined (for ex
ample, chenic acid for chenodeoxycholic acid). Such

well-written abstract enables readers to discern the con

practices place an unnecessary burden on the reader.
An abstract is often separate and distinct from the ar

on that basis, whether to read the entire article. An ab
stract usually appears at the beginning ofan article and

must, therefore, be understood without reference to the

tent, determine its relevance to their work, and decide,

mirrors its format.

There are two general categories of abstracts, infor
mative and indicative: informative abstracts provide
specific information and indicative abstracts provide
general information. Abstracts of research papers in
nost biomedical journals are informative and have the

rollowing format: a statement of the purpose or the re
search question, a description of the methods used, a
brief compilation of results, and the conclusion or an

swer to the research question. Abstracts of review papers in biomedical journals (or chapters in books) are in| dicative and have a slightly different format: a
statement of the subject and a description of how the

facts are organized.
Some journals that report clinical research have

| asked authors to prepare informative abstracts in an

other guise, that is as "structured abstracts/' which are
designed to aid practicing physicians. Structured ab

stracts are organized differently and are more detailed
than informative abstracts.

Certain conventions apply, however, to the content

jof all abstracts for journal articles. The information is

usually presented in a single paragraph that has a word

limit requested by the journal (usually about 250

..words). Abstracts generally should not contain abbrevia-

ticle it represents (for example, in online databases) and

article. An abstract must include enough detail so that

the least-informed reader can understand the impor

tance of the research. Several formats have been devel
oped to aid authors in mamtaining the correct structure

for biomedical research papers. One such format is the
IMRAD formula, an acronym for Introduction, Meth
ods, Results, andDiscussion. Because the structureof
an abstract parallels the structure of the paper, such an

acronym can also be an aid for writers and editors of ab
stracts. In this chapter, we will discuss how to write in

formative and indicative abstracts for journal articles, as
well as abstracts for meetings. Within each of these sec
tions, we will discuss content, length, and style.
Informative abstracts
Content

An informative abstract accompanies an original re
search manuscript. It states the research question (Intro

duction), includes adescription of the methodology

used (Materials and Methods), the data derived from the

study (Results), and the answer to the research question
(Discussion). Such sentences can sometimes be taken

from the manuscript, if the manuscript iswritten before
the abstract. The acronym, IMRAD, can be a helpful de
vice for those just learning the order of information in
an abstract.

tions or symbols other than those that are recognized as

standard, for example, those for the Systeme Interna

Introduction: Ifyour manuscript title does not tell the

tional (SI) units and their products. If, however, along
descriptive phrase (for example, UV laser desorption

reader what question the research was designed to an
swer (for example, "Sodium and Potassium Transport

^es within an abstract, an abbreviation is appropriate.
P*t Abstracts should not contain jargon, that is, short-

ment of the question or hypothesis (for example, "To
show that sodium and potassium are transported and
absorbed along the length of the inner medullary col
lecting tubule, we performed parathyroidectomies on
adult male rats."). By stating the question or hypoth

juose in the "specialty," and it may be mistranslated by

tion contained in the abstract.

fcrne-of-flight mass spectrometry) must be used several

stracts should not contain citations of references (or

erences themselves), tables, or figures, and should
f*fcr contain information that is not included in the

gtt terms or phrases. Jargon is often understood only by
pdcrs whose first language is not English. Nor should

in the Rat"), the abstract must contain a clear state

esis, you have preparedthe reader for the new informa

Methods: When you describe the methods, include
the population (human or animal) studied, the tech-

Style

The Sd^iiig style in the abstract should be similar to

niques and equipment used, drugs or other agents ad- v^he stytegxtithe manuscript. Use the first person to de
ministered, and the statistical methods used to ana
lyze the data.

scribe your work unless the journal specifically prohib- "&
I
its it (feexample, "We administered surfactant.").

Results: Describe the data obtained in the research;

Write the abstract in complete sentences, and use tran
sitional words and phrases to maintain coherence. Each
sentence"should contain a single thought expressed

summarize only the most important findings. The data
should appearin the same order as you earlier (in the
Methods section) described the methods that produced
the data. If you revise data in the text or tables, be cer
tain that you also revise those data in the abstract.
Discussion: Complete the abstract with a sentence
that summarizes your findings ("Parathyroidectomy
increased sodium and potassium absorption along
the length of the inner medullary collecting tubule
in the rat."). You may also wish to include a sen
tence that describes or speculates on the significance
of your findings.

Another type of informative abstract, the structured
abstract, is requested by some clinical journals. Struc

clearly and concisely. In an attempt to write concisely,;
authors?sdmetimes write so cryptically that meaning

obscureulj^th practice, it is possible to find a balanc

betweexl^iteuining that the reader knows everything

you kn^^id giving too much detail.) When possible;!!

use verte^a the active voice, because they contribute tcfcj|JSf
clarity-Sapbrevity.
An informative abstract is generally written in one

paragrapr^itherefore, the topic sentence is important and
should state.clearly the purpose of the research. In an at

tempt to;^ay withinthe word limit, many authors have
resortedifean extensive use ofabbreviations. As a general

tured abstracts differ from standard informative ab

rule, abhrepations and symbols should not be used in ab
stracts, exceptfor those that represent SIunits and their

stracts in that they have specific section headings and

products;(for example, kg, umol). Nevertheless, other ab

were designed to report only original data from clinical
investigations with human subjects, specifically clinical

breviations/abound, and readers sometimes have to create

a key toMe.abbreviations before they can understand the

trials. The format should enable physician readers "to

abstractive admonish you to use few abbreviations

judge quickly the applicability and validity of the find

(maximumkrf'.two) so that the reader's attention is focused

ings of an article for clinical practice." The section
headings recommended are (1) Objective, (2) Study de
sign, (3) Setting, (4) Patients or other participants, (5)

on the message rather than on remembering what the abbreviationslstand for. The problem is compounded if a

Intervention(s), (6) Main outcome measure(s), (7) Re

manuscnp^ontains abbreviations coined by the author
that are not-memorized readily (forexample, tissue lactase

sults, and (8) Conclusion(s). If you use the section head
ings, you can often write phrases rather than complete
sentences, thereby conserving space. The inventors of

activityS^reviated as TLA). If you are tempted to use

the structured abstract, the Ad Hoc Working Group on

importence-of your work.
When arHmit is placed on the number of words per

Critical Appraisal of the Medical Literature (Interna
tional Committee of Medical Journal Editors, 1991), un
derstand that the use of section headings might not ap

more thmsone or two abbreviations, remember that you

are forcin^the reader to do more than comprehend the
mitted in a piece ofwriting, choosing the correct word
to conveyjthe intended meaning is important. You prob

the subheads.

ably wijpipt make the final choice ofwords until the
abstracting been revised many times. Huth (1987),
Schwager}l991), and Zeiger (1991), among others, have

Length

are excellent references.

peal to all editors; they suggest the possibility of
including the content for each subhead, but omitting

discussecLaccurate usage and offermany examples; all
The length of informative abstracts is determined by
the journal, as usually stated in its "Instructions to Au
thors." The "Uniform Requirements for Manuscripts
Submitted to Biomedical Journals" (International Com
mittee of Medical Journal Editors, 1991) recommend
150 words for unstructured abstracts and 250 words for

structured abstracts. (The 250-word limit is based on
the word maximum of the National Library of Medicine
MEDLINE database for abstracts of articles of fewer

than 10 pages.) Most journal editors tolerate abstracts
with a few more than the exact number of words recom

mended but will request that the abstract be shortened
if the word number exceeds the limit by 15 to 50 words.
If you can provide sufficient detail in fewer than 150 or
250 words, however, a shorter abstract is appropriate.

Indicative abstracts

Contents/
An indicative abstract is written for review articles

and chapters, that is, documents that review the current
publishecLresearch on a given question. Indicative ab
stracts describe the scope of the document, the principal
subjects discussed, and how (and to what extent) the
topics will:be addressed. An indicative abstract provides
a general:overview of the document.
The structured abstract format for a clinical review

article includes more than a description of the scope

and the topics to be discussed. Recommended for inclu
sion are the following:
• A statement of the purpose or objective of the
article

• A summary of data sources
• The number of studies selected for review (and
how they were selected)

• Data extraction (the rules used and how they
were applied)
• Results of data synthesis

• Conclusions (including potential applications
and research needs)

Content

The guidelines for the content of abstracts written for
meetings are the same as those for manuscripts.
Introduction: Describe in one or two sentences why
the work was done. State the research question.

Methods: Describe the population studied, the tech

niques used, and how the data were analyzed.
Results: Summarize the important findings. Tables

Length

Again, the length of an abstract is determined by the
journal. Although indicative abstracts are usually
shorter than informative abstracts, the word limit for
the structured form is 250.

and graphs can be used in abstracts written for meet
ings as a means to emphasize the results. A table or
graph is not a substitute for the results, but a means
by which to display the results.
Discussion: Abstracts for meetings can include a

statement of the implications of the findings.

Style

The writingstyle for indicative abstracts does not dif
fer from that of informative abstracts. The ultimate goal

Length

Abstracts for a meeting are usually prepared on spe

is to communicate to the reader why you have written

cial forms distributed by the organization that sponsors

the article and how you have organized the information.

the meeting. The size of the form and instructions for

Hints for writing abstracts

word limit, therefore, is imposed by the size of the box

for journal articles
• In Essentials of Writing Biomedical Research Pa

pers, Zeiger (1991) includes an excellent note in
which she tells readers how to count words (count

.each word as one), abbreviations (e.g., count either
P or g as one word), and numbers (count 0.003 as
one word). Symbols (for example, ± or <), however,
are not counted.

• When reporting numerical values, use SI style:

print symbols in lower-case Roman letters (kg); do
not use periods (g); leave space between numeral
and unit (5 g).
• Use SI units and their standard abbreviations to re

port laboratory data. SI convention requires (for the

preparing it vary from one organization to the next. The
printed-on the form. When the abstracts areprinted (ei
ther in a journal or a meeting program), they are reduced
in size so that four to six abstracts fit on a page, and

they are reproduced exactly as you submitted them, er
rors and all. To avoid print too small to read, many soci
eties request a specific type font or size, and further,
they request that space between lines not be reduced or
that other means to get more words inside the printed
box not be used.

Style
Remember that the information in an abstract writ

ten for a meeting does not have a manuscript to which a
reader can refer for clarification. Therefore, you must

sake of mathematical clarity) that when you report

guide the reader through the abstract. Transition words

complex compound units, you use exponential no
tation in place of multiple solidi (slant lines) for an
expression (for example, g.kg^.d1, not g/kg/d). You
may also write the expression with a solidus and a

mends "using signals to indicate the parts of the ab
stract." She suggests using such phrases as "we found

center dot, that is, g/(kg.d).

• Members of the Working Group who originally

proposed the structured abstract format have gone
one step further and included a glossary of
methodologic terms to enable you to avoid ambi
guity in your clinical writing (see Haynes et al.,
1990).

Abstracts written for meetings
A well-written abstract is often the means by which

scientists justify their attendance at meetings. Some of
these published abstracts, however, are incomprehen
sible paragraphs composed of jargon and abbreviations
that require rereading and a decoder ring to be under
stood. Abstracts for meetings are intended to attract

others to your oral presentation or poster, not to impose
a burden that may ultimately cause reviewers to reject
your submission.

should be used to bridge sections. In Essentials of Writ
ing Biomedical Research Papers (1991), Zeiger recom
that" or "we conclude that" to signal the reader that re
sults or discussion will be described.

Hints for writing abstracts for meetings

If you are writing orare responsible for preparing ab
stracts for submission to a meeting, a goodword pro

cessing program is very helpful. WordPerfect, for ex

ample, enables you to establish precise margins (left and
right, top and bottom) so that your abstract will fit ex
actly in the box on the abstract form. This procedure
also enables you to see how many lines you have avail
able to fill with text or how many lines over the limit
(that is, below the box) you have written.

Editing abstracts
Many ofyou may not write abstracts, but rather are

responsible for editing the abstracts of others. The rules
for editing an abstract are similar to those outlined
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above for writing an abstract. Because you are not di
rectly involved with the research, as editor you must
pay special attention, not only to the clarity of each in
dividual sentence, but also to the overall organization of
the abstract. Does the abstract follow the IMRAD for

Day RA. Howto write andpublish a scientific paper, 3rd ed. Phoenix:
Oryx Press, 1988.

Day RA. Scientific English: A guide for scientists and other profes
sionals. Phoenix: Oryx Press, 1992.
Haynes RB, Muirow CD, Huth EJ, Altman DG, Gardner MJ.More in
formative abstracts revisited. Ann Int Med 1990;113:69-76.

mat? Within each section of the abstract, does the se
quence of events parallel the sequence in the same sec
tion of the manuscript? Finally, as editor, you must
keep in mind that the abstract will be read by many
people who are not specialists in that field. If the lan
guage of the abstract is too technical for a nonspecialist
reader, you should work with the author to reduce its

Huth EJ. How to write and publish papers in the medical sciences.

technical language and to increase its intelligibility for
the educated, nonspecialist reader.

Lippert H, LehmannHP. SIunitsin medicine: An introduction to the
international system of units with conversion tables and nor
mal ranges. Baltimore: Urban and Schwarzenberg, 1978.
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incomplete sentence
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more direct and easier to follow.
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be written in the imperative mood (the subject you oeing understood
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Clinical Statistics for Non-

Statisticians
(AKA STAT 101)

Course Outline
Statistics and Clinical Trials

Population and Samples
Summary Statistics
Randomization

Hypothesis Testing
Confidence Intervals

Objectives of the Course
• Increase your understanding and
appreciation of the role of statistical science
in clinical trials

• To understand the process of making
estimates (inference) from patients in
clinical trails

• To understand core statistical principles

What is Statistics?

i

The art and science of collecting, analyzing,
and interpreting quantitative data.
The science of uncertainty

A science that is utilized in the design and
analysis of experiments in order to make
appropriate inferences (decisions) with
confidence.

What is a Clinical Trial?
Clinical trial - a prospective study comparing the
effect and value of a treatment against a control,
in human subjects (Comparison)
Prospective study - Subjects assigned a study
treatment and then followed forward in time

Regulatory agencies want clinical trials to be
adequate and well-controlled

Good Clinical Trials
Meet strict ICH guidelines with respect to
Randomization and Bias reduction

♦Blinded assessment of response (unbiased)
•Patient population
•Validation of analysis processes
•Data collection standards

•Prospectively defined comparisons
•Stated patient inclusion/exclusion criteria
•Must be expressed in written protocol

Statisticians Role in Clinical

Drug Development
• Development Plan
• Protocol Design
• Primary Question
• Study Design
• Patient Population
• Bias Reduction

• How many Patients

• Case Report Form and Database
• Statistical Analysis and Interpretation

Clinical Trial Questions and Data

A Clinical Trial Example
Suppose:

You are planning a clinical trial aimed at
establishing a marketing advantage for
Atorvastatin over Simvastatin.

<0>

Example - Objectives
What do you want to show? That Atorvastatin...
• Controls serum lipids better than the
competitor?
• Controls cholesterol better than the

competitor?
• Better controls specific types of cholesterol?

• Is cheaper to achieve the same effect?
• Is safer in achieving the same level of control?
• Makes it easier to manage the patient?
• Some combination of the above?

Objectives to Hypotheses
These Objectives must be transformed into
prospectively defined comparisons:
Objective:
Atorvastatin controls LDL-C better than Simvastatin

Hypotheses:
What is the parameter?

Mean Change in LDL-C from baseline to
follow-up
What we are trying to show is

Mean Change in LDL-C is greater for Atorvastatin
than for Simvastatin

Study Designs
Once the primary research question has been determined
an appropriate design must be chosen. The most
appropriate design is dependent on a number of factors- .
Examples of two types of designs include

• Parallel -AvsB
• Crossover - A and then B vs B and then A

tiuai
•Ml.

Parallel Group Design
Treatment 1

<

Treatment 2

Is the most often used and simplest design for clinical trials

• Randomly assigns a treatment to each patient and then follows
that patient for a specified period of time

• Assumes thatpatients assigned thestudy drugarenot
systematically different from patients assigned the control drug
♦

Does notgivea sense forindividual patient dose-response since

each patient is exposed to only one regimen

Cross-Over Design
X
• Allows patients to be used as their own control; can directly
assess on which drug each patient does better
• Has reduced between-patient variability; needs smaller sample
sizes because each patient is used twice

• Has a big assumption that patients return to their initial state at
the start of the next treatment period
• Are usually successful with short acting drugs that treat the
symptoms but not the disease or with stable conditions that require
constant medication (e.g.. anti-hypertensives)

Design, Objective

How to summarize

And Hypothesis

and make appropriate
comparisons

Design+objectives+precise parameter definitions determines the
type of statistical model to describe the data

Populations and Samples - Outline
• Populations and Samples
• Patient Population
• Sample Population

• Generalizability: role of blinding and
randomization

Populations and Samples
Statistical View

Clinical Trial View

Patient Population
Definition: A group of people with a
characteristic in which we are interested

We are not able to identify all people in the
Patient Population
• Role oflnclusion/Exclusion criteria

Describing the Patient Population:
• Statistical Model

• population parameters ("true value")

Sample Population
• Definition: A group of people who come to
the sites and are entered into the study.
• Describing the Sample Population:
• Inclusion/Exclusion criteria

• Data from Sample Population Described:
• graphically
• sample parameters ("estimator")

Sample Population
Infer from sample population to patient
population
Sample information will be close to (but not
the same as) population information
How close is sample information to
population information?

Populations and Samples
**ace*

Representativeness
Sample Population should be representative
of Patient Population
• Representative means similar characteristics
Strict use of Inclusion/Exclusion criteria

helps to provide representativeness
We can infer from a representative Sample
Population to a Patient Population

Estimation
• Sample
Population

Patient

Population
Summary

—•

Summary
Estimates

• Sample
Population

(but is not)

•

>

Patient

Population
Percent

Percent
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How good is the Estimate?
Bias-

Effect of deviating from the true
Value

No Bias

Biased

Populations and Samples
• Patient Population is what we want to know
about

• Sample Population is what we know about
Infer from what we know (Sample
Population) to what we want to know about
(Patient Population)

Generalizability: Role of Blinding
Blinding is needed to limit bias in conduct
/interpretation of a clinical trial (ICH guideline)
Bias is due to influence of Rx knowledge on:
recruitment, allocation, care, assessment of end-

points, withdrawals, analyses, etc.
Types: double-blind, single-blind, open label

Generalizability: Role of Blinding
(cont'd)
• Double blind is optimal, but not always
possible. Need SOPs to cover release of codes
• In some cases only single blind or open label
are practical / ethical
• Use a centralized randomization method [keeps sick
(not sick) patients from all going in the Rx (Pb) group]
• Clinical assessments made by medical staff who are not
involved in treating patients and are blinded to Rx.

Generalizability: Role of Randomization
• Introduces a deliberate element of chance (connection

between Patient Population and Sample Population)
• Provides sound statistical basis for inference and
evaluation of Rx effects

• Produces Rx groups with generally similar prognostic
factors (unbiased comparison)

• Stratify by: Center; Important (limited) prognostic
factors

• Inclusion/exclusion criteria and randomization ensure

representativeness and generalizability

»

Stratification
• by baseline prognostic factors believed to be critical to the
outcome of treatment (e.g., severity of disease, age, sex, etc.) may
be needed to ensure balanced treatment allocation within strata

• becomes more important as trial size becomes smaller

• can easily be carried too far; the use of more than two or three
stratification factors is rarely successful at achieving balance, and
is logistically troublesome
• may not be as efficient; if the risk factor is continuous, e.g.
baseline LDL-C, it is more efficient to adjust for it as a covariate

Randomization: How is it done?

Randomize subjects: sequentially, in blocks
Blocks:
• Size is a multiple of the number of Rx groups
• Not too large - to limit possible imbalance
• Not too short - avoid predictability towards the end
of the sequence in the block

10

Examples of Randomization
•Simple Random Sampling (Block size 2)
A

B

B

A

A

B

A

B

•Stratified by Center Random Sampling
(Block Size 4)
Center ifA

A

B

B

B

A

A

Center 2 B

A

B

A

A

A

B

B

Center 3: B

A

B

A

A

B

A

B

Center 4 A

B

B

A

B

B

A

A

B

Summary Statistics - Outline
Study population parameters and sample
population statistics
Making sense of Data
Distributions

Data Properties of Distributions
• Central Tendency (Representative Value)
• Dispersion (Variation)

Summary Statistics
Types of Data
• Nominal
• Red, Green, Yellow

• Ordinal
• Mild, moderate, severe
• Continuous
• LDL-C

We will focus on Continuous Data
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Proportions
• Sometimes the parameter of interest is the
percentage of patients in a given target
population who have a given condition or
response.

• We estimate by seeing how many patients
have the condition or response in the sample
(Study)

Summary Statistics
Study population parameters and sample
statistics

Central Tendency (RepresentativeValue)^
Dispersion (Variation)
Distribution (Shape)

Population Parameter (Unknown)
• A descriptive measure computed from the
population data that describes a characteristic
of the population
• Example:

Mean LDL-C of all people with

LDL-C levels above 160

Fixed value that is usually unknown to us
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Sample Statistic (Known)
• A descriptive measure computed from the
sample data
• Example:

Mean LDL-C of patient in the study

• Value that depends on the particular sample
chosen and the variability of the measurement
• Each sample taken (Study conducted) will
provided a potentially different sample
statistic
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Thinking about Data
The data in a sample has a distribution
• Characteristics of the distribution are of interest

• Overall picture of the values
• Middle of the values

• Spread of values
• Tails (values near the largest or smallest value), data
in groups, data far from other data
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Thinking about Data
• A Statistician looks at Data as
• Data = Model + Residual

• Think: General + Specific
• Model represents a feature general to all
the data (such as a middle)
• Residual represents how far the data is
from the general feature (middle)

An Example
Total Cholesterol Values (n = 40)
187, 217, 240, 275, 233, 276, 234,
230, 280, 221, 223, 243, 248, 255,

245, 173, 205, 300, 186, 270,226,
265, 209, 230, 222, 199, 271, 216,
216,315,229,270,230,197,
232, 305, 253, 258, 205, 250

Histogram
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Histogram
• The left (vertical) axis is Counts of values
in the intervals on the lower (horizontal)
axis

• This gives a general impression of the
arrangement of the values

Distribution Shape
(another example)

rk^W rV Va vwliMXk um>\
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140

150

160
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180
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Measures of Central Tendency

• Mean
• Median

• Percentiles

• Data = Model + Residual

45
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Mean

• The average of the data
• A summary statistic that measures the center
of a distribution

• Extreme values in the sample have an
influence on the mean and, in some cases,
can distort it so much that it becomes an

undesirable measure of central tendency

Median
The value which divides the data in half; so

{&>

L2J H5

that half the values are less than and half the

values greater than the median
Represents the center of a data set without
regard for the distance of each point from the
center

More stable than the average in the presence of
extreme observations

Median (cont.)
Often used as a description of the center of
a data set when the data have an

asymmetrical distribution
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Percentiles
50

25

75

• The median is the 50th Percentile other

percentiles can be utilized to summarize the
data.

• The 25th, 50th, and 75th percentile are often
used. These are referred to as the 1st, 2nd

and 3rd quartiles, respectively.

«

Percentiles
• Total Cholesterol Data
• maximum

100.0%

315.00

• 3rd quartile

75.0%

263.25

• median

50.0%

232.50

• 1st quartile

25.0%

216.25

•

0.0%

173.00

minimum

50

Box and Whisker Plot

• Maximum

• 3rd Quartile

Median

1st Quartile
Minimum
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Measures of Dispersion
(Variation)

• Sample Range
• Sample Standard Deviation
• Sample Standard Error

• /Sa!n>l£CoefjteTeTin>fV

Sample Range
• The difference between the smallest and the

largest values in the dataset (.r*vr> - fM*A
• More variable than the standard deviation

(i.e., less stable)
• Simple to compute

Sample Standard Deviation and
Sample Variance
Measures of the spread of a group of
individual observations; the variability in data
Summary of residuals from data model
The standard deviation is the square root of
the variance

IS

Sample Standard Error
• The variability of the mean; the variability in
estimators

• Standard error is the standard deviation

divided by the square root of n, where n is the
sample size.
• Tells us how close the sample population mean
is to the patient population mean

• As n gets larger, the standard error gets smaller

What Standard Errors Do for Us
• Every estimate has a standard error
• Measure of spread for an estimator
• Tells us how much the estimator value

could be different and how much to believe
the estimator value

• Form of Standard Error:

• Value / Vn

SEvs.. SD
Standard deviation is a measure of

uncertainty about the DATA
Standard error is a measure of uncertainty
about an ESTIMATOR
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m&m Clinical Trial (Don't Eat)
• Want to develop a treatment that cures at
least 25% of patients
• Each person will conduct a trial to
determine if the treatment is effective

• Bag of m&m's represents the sample of
patients in your trial
• Each candy represents a patient in your trial

First trial
• Open smaller bag of candy
• Brown m&m's correspond to cured patients
• Compute percentage of cured patients

Question
• Were at least 25% of the patients in your
trial cured?

l)Yes

2) No

20

Second Trial
Repeatthe process with the larger bag of
candy

Qi/\jtorr^sR- in bcvhph> Sfci,

Again,brownm&m's correspond to cured
patients

Compute the percentage of cured patients

Question
• Were at least 25% of the patients in your
second trial cured?

l)Yes

2) No

Randomization
The Randomization Distribution

Randomization and Random Sampling
Central Limit Theorem
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Randomization Distribution
Each person has their own LDL-C value.
Those randomized to be on Atorvastatin are

lowered by a Treatment Effect (Placebo
mean - Atorvastatin mean)
• Data = Person Effect + Treatment Effect

Randomization distributes the person
effects fairly to both groups

Randomization and

Random Sampling
Random Sampling is selection of a sample
from the Patient Population in a way that
every patient has an equal chance of being
in the sample (representative)
Randomization sampling is randomly
selecting one arrangement from the
Randomization Distribution

Randomization
Randomly select an
arrangement from
the Randomization
Distribution

Select a random sample
from the Patient

Population
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Lessons from Randomization
• The Randomization Distribution is close to

bell-shaped (normal)
NOTE: Randomization analysis is difficult
• There is another reason to concentrate on a

bell-shaped distribution!

Central Limit Theorem
• For a sample mean calculated from a
randomly gathered sample, the sample
population mean minus the patient
population mean acts like a value randomly
selected from a bell-shaped (Normal) curve.
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Population ConnectedJo Sampl
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Sample Population Mean
Real

Lessons from Randomizaton and
the Central Limit Theorem
• We must have Representativeness and
Randomization in clinical trials to be able to

infer correctly from sample to population
• Means and statistics calculated like means

can be treated as being from a bell-shaped
(Normal) distribution

Lessons from Randomizaton and
the Central Limit Theorem
CLT

Normality
Randomization
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Randomization Example
• Randomness comes from Randomization,

randomly dividing patients into a Drug
Group and a Placebo Group

• Example: In a 12 week study to compare
the effects of Atorvastatin and Placebo on

LDL-C values, the final values were:
• Atorvastatin: 120, 124, 127, 132
• Placebo: 125, 131, 135, 137

Randomization Distribution
All possible arrangements of the eight
values into two groups of 4 are considered.
There are 70 arrangements possible, and we
have one of these 70.

We can summarize the data by calculating
Placebo mean - Atorvastatin mean

Randomization Distribution

s^^WV^

Example
Atorvastatin
120 124

132 127

Placebo
131

125

135

137

120

124

135

127

131

132

125

137

120

124

137

127

131

132

135

125

120

131

125

127

124

132

135

137

120

132

125

127

131

124

135

137

120

135

125

127

131

132

124

137
75
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Randomization Distribution

Example
Mean Atorva

Mean Placebo

Difference

125.75

132

-6.25

126.5

131.25

-4.75

127

130.75

-3.75

125.75

132

-6.25

126

131.75

-5.75

126.75

131

-4.25
76

Randomization Distribution
• All 70 arrangements, means for the two
groups and the difference in means are
summarized below with a Histogram.
- i •,

<
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Hypothesis Testing
• Null and Alternative Hypotheses
• p-value
• Type I and Type II errors
• Power
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Hypothesis Testing
Hypothesis testing deals with asking "Yes
or No" questions. Sometimes the answers it
provides are shades of "Maybe"
In Phase III clinical trials, the Yes or No

question is often: "Does the drug work?" or
more specifically, "Is the drug's effect
different from the placebo's effect?"

Null and Alternative Hypotheses
Null hypothesis (H0) - what we believe
in the absence of further evidence

Similar to legal trials: "Innocent until proven
guilty"

Phase III clinical trials: H0 is usually "The
drug's effect is equal to the placebo's effect"

Alternative Hypothesis
Alternative hypothesis (HA)- what we are
trying to show
In Phase III clinical trials, HA is usually "The
drug's effect is not equal to the placebo's
effect"
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Example
• Null hypothesis (H0): Mean Change in
LDL-C from baseline to follow-up is the
same for Atorvastatin and Placebo

• Alternative hypothesis (HA): Mean Change
in LDL-C from baseline to follow-up is not
the same for Atorvastatin and Placebo

Doing a Hypothesis Test
• Start with a statistic from the clinical trial data

Example: the sample average change in LDLC while on Atorvastatin, minus the sample
average change in LDL-C while on placebo
• This statistic estimates a parameter

Example: the population average change in
LDL-C while on Atorvastatin, minus the

population average change in LDL-C while on
placebo
83

WHAT!
• The statistic has associated with it a

standard error, which measures the

variability of, or the uncertainty in,
the statistic

• The statistic and its standard error are

combined and eventually transformed
into a p-value
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General Idea
• We calculate a test statistic from the data

that is appropriate for the study design and
parameter

• Under the assumption of the null hypothesis
the Test Statistic should behave in a certain

way (i.e. follow a normal distribution)
• If the test statistic is extreme than

something must be wrong: Conclude the
alternative hypothesis.

P-values
• p-value - a probability that measures how
surprising the data are if H0 (the drug effect is
equal to the placebo effect) is true

• A p-value near 0 means that, if H0is true, then
an unexpected result has occurred: the nearer
it is to 0, the bigger the surprise.

••>
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• A p-value near 1 means that we've seen data
that we'd expect to see if H0 were true

What p-values mean
If a p-value < 0.05, we say

"We reject H0at the 0.05 significance level, and
we conclude HA"
Or

• "The difference between drug and placebo is
statistically significant at the 0.05 level"
• In legal terms, the verdict is guilty

dbPtA^ 'A fjjW^lL hem •dfljJoh
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What p-values mean
If a p-value > 0.05, we say

• "We fail to reject H0at the 0.05
significance level"
Or

• "The difference between drug
and placebo failed to achieve
statistical significance"

• In legal terms, the verdict is not guilty

Innocent or Not Guilty
• Failing to reject H0doesn't mean that H0 is
true; it means that there's insufficient evidence

to show HA (a verdict of 'not guilty' versus
'innocent')

• Showing that two treatments are the same is a
different statistical problem (e.g., equivalence
trials)

Type I and Type II errors:
Our decision

Fail toreject Hq
Hois true

Correct

Reject H,,
Type I error

decision

Reality
H4 is true

Type II error

Correct
decision
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Type I and Type II errors:
The probability of committing a Type I
error is called the significance level a
The probability of committing a Type II
error is denoted P

£HX

• The chance of concluding HA when in fact
HA is true is called the Pow5f(l- (3).

Type I and Type II errors:
• The a = 0.05 significance level is set by the
regulatory authorities and journal editors

• The power (1 - (3) of a clinical trial is chosen
by us. Typically, clinical trials are designed to
have between 80% and 95% power

Determinants of power

Power is proportional to:

Effect Size x Sample Size
Variability
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Determinants of power
• #1) Treatment effect: the difference between
drug and placebo - as this difference increases,
the power increases

• #2) Variability in the data: as the variability
increases, the power decreases

• #3) Sample size: as the number of observations
increases, the power increases

When planning clinical trials, we
can't do anything about the treatment effect
can do some things about variability in the data
Example: reduce variability by using a
crossover design

<r
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obtain the power we want by estimating the
sample size appropriately

Statistical significance and clinical
significance are two different things
An observed difference between drug and
placebo may be ...

• clinically significant, but may fail to attain
statistical significance due to inadequate power
• statistically significant, but may not be clinically
significant
M
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How Many Patients

• How many patients = How much money

How many patients = How much information
and certainty

What Determines How Many
Patients
1) Objective^ of the Study
-

Patient Population

Specific Parameter of interest
Hypothesis of interest (=, Not <, >, not =)
Study Design (usually parallel groups)

®

o
Sampled population
(we allow in the study)

Target population
(we want to treat)

2) Significance Level and Power
Decision

No drug effect
«

No drug effect

OK

Drug effect
Type I Error

V

>

Drug effect

Type II Error

h

Power

FDA = Type I
Parke-Davis= Type II
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3) Signal to Noise ratio

Signal is the MAGNITUDE (minimal
effect that has clinical relevance)
Noise is the Variation

4) Dropout Rates

• Determining sample size is a collaborative
effort that requires several key decisions

• Precise parameter definition

J\

]Q

• How Certain (Power)
• How big of difference
• Assumptions of variability
• Previous study or literature
• Watch out for
- Publication bias

-Age of reference
- Similarity of protocols
- Dropout bias

Confidence Intervals
• What do Confidence Intervals Mean?
• How do we use them?
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Confidence Intervals
• An estimate of a population mean is never
correct, only close to its value.
• We may want to indicate how close the
sample mean is to the population mean
• Standard error provides an indication
• Mean ± Standard Error

&
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Confidence Intervals
• For our data in the Randomization Example
• Atorvastatin:

125.75 ±2.53

•Placebo:

132.00 ±2.65

• Displaying the mean and standard error
together helps remind us of the variation in
the mean

Confidence Intervals
• For the Mean ± SE interval, about 68% of

the samples will give an interval that
contains the Patient Population Mean
• We may want to increase the percent of
samples which give an interval that contains
the Patient Population Mean by using a
larger interval
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Confidence Intervals
• We work with Confidence Intervals of the
form

• Mean ± (Normal Curve Factor) * SE

• The Normal Curve Factor is near 2, and is

larger when the sample size is small.
• The Normal Curve Factor is selected so that

95% of the samples give intervals which
contain the Patient Population Mean.

Confidence Intervals
• Recall for our randomization sample
• Atorvastatin mean = 125.75, SE = 2.53

• Placebo mean = 132.00, SE - 2.65
• The Normal Curve Factor is 3.182

(remember, the sample size is only 4!)
• Atorvastatin: 125.75 ± 3.182 * 2.53
• Placebo: 132 ± 3.182 * 2.54

Confidence Intervals
• Atorvastatin: The Interval is (117.7, 133.8)

• Placebo: The Interval is (123.92, 140.08)
• What do these intervals mean?
• Textbook statement: "We're 95% confident the

Patient Population Mean for Atorvastatin is
between 117.7 and 133.8"
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Confidence Intervals
• Statistical Interpretation: If a sample of a
type that occurs 95% of the time was
selected, then the Patient Population Mean
is in the interval.

• The confidence interval gives a set of
reasonable values for the Patient Population
Mean.

Confidence Intervals for
Differences
A confidence Interval can be developed for
a difference in Patient Population Means,
for example:
Atorvastatin Mean - Placebo Mean ± SED
• SED is Standard Error of the Difference

• Atorvastatin mean = 125.75, SE = 2.53
• Placebo mean = 132.00, SE = 2.65

Confidence Intervals for
Differences
• Atorvastatin Mean - Placebo Mean =
Difference =

125.75-132.00 =-6.25

• SED is calculated to be 3.6
• Normal Curve Factor = 2.447

• Confidence Interval for Difference is

Difference ± (Normal Curve Factor)*SED
• -6.25 ±2.447* 3.6
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Confidence Intervals for
Differences
• The 95% Confidence Interval for the

Atorvastatin Patient Population Mean minus
the Placebo Patient Population Mean is
• (-15.06,2.56)
• Note that one limit is negative and one positive.
• Zero is one of the reasonable values

Confidence Intervals for
Differences
• The value zero indicates that the

Atorvastatin Patient Population mean is not
different from the Placebo Patient

Population mean
• If zero is not in the interval, a "real"

difference is indicated (positive or negative)
A is better

Same

Negative

P is better
Positive

Confidence Intervals for

iw

Differences - Randomization
• Using the CI form for differences, the 70
Confidence Intervals were generated and
are displayed on the next page
• Particular values of the Difference in

Patient Population means will fall in the
intervals - we consider values which fall in
95% of the intervals
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Confidence Intervals for
Differences - Randomization
• As we look at a horizontal line we see a

range of values for the Patient Population
Difference in Means will fall in the

Confidence Limits for 66 (about 95% of 70)
of the samples

Reference Ranges and
Predictions
• The Percent Limit for a prediction is
different from a Confidence Limit.

• A prediction is more variable than a mean
• Predicted Value = Mean + Deviation

• Reference ranges are:
• Mean - NCF*Standard Error for Prediction

• Mean +NCF*~Standard Error for Prediction

jS bjffij S[ sltaxLr{
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• NCF = Normal Curve Factor
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Overview ofEvidence-Based
Medicine
Stephen Durst, PkarmD, BCPS
Assistant Dean/Department Head, Pharmacy Practice
Ferris State University

RickDettloffjPtiarmD, BCPS
Clinical Education Consultant, Pfizer

Adjunct Faculty FSU,WMU, MSU

Learning Objectives
• To review the concept of Evidence-Based
Medicine.

-What, Why, Where?
• To provide practical applications of EvidenceBased Medicine in stroke and communityacquired pneumonia.
- Benefits
- Limitations

• To extrapolate clinical science to patient-oriented
evidence.

Evidence-Based Medicine

"Evidence-based medicine (EBM) is the

integration of best research evidence with
clinical expertise and patient values"
Sackett DL, Straus SE, Richardson WS. et al, 2000

Further Explanation
•best research evidence"

-from patient-centered clinical research
-precision of diagnostic tests
-power of prognostic markers
-efficacy and safety of:
-therapeutic, rehabilitative, and

preventative regimens

Further Explanation
"clinical expertise"

-allows for identification of patient's health
state, diagnosis, risks and benefits

Further Explanation
"patient values"
-the patient's preferences, concerns and
expectations

Evidence-Based Medicine

'Evidence-based medicine (EBM) is the

integration of best research evidence with
clinical expertise and patient values"
Sackett DL,Straus SE, Richardson WS, et al, 2000

EBM'sEffect
-a diagnostic and therapeutic alliance is
formed between physician and patient
-clinical outcomes and quality of life are
optimized

1

EBM - Why Now?
EB M is not new

-ancient Chinese medicine

-post-revolutionary Paris
-1992 Gordon Guyatt consolidated several

earlier concepts and called them Evidence
Based Medicine.

EBM - Why Now?
Four primary reasons are identified:
1. There is a tremendous need for valid

information (5 times for each inpatient, 3
times for each outpatient encounter)
2. Traditional sources of information are

outdated, wrong, ineffective or
overwhelming

EBM - Why Now?
3. Up-to-date knowledge and clinical

performance decline as diagnostic skills and
clinical judgement increase
4. Clinicians don't have time! Per patient,

only seconds. Per week, only one-half
hour!
But none of these are new—

EBM - Why Now?
Recent developments have allowed
"medicine" to develop a solution—

1.Evidence is now easier to find and appraise
2. Reviews and concise summaries now exist

3. EB journals are now available

EBM - Why Now?
Recent developments have allowed
"medicine" to develop a solution—
4. Information systems deliver in seconds
5. Strategies for lifelong learning and
constant improvement of clinical skills

EBM - Will I Know It When I See It?

Five steps can be identified in EBM practice:
-The information need must be converted to<«_

an answerable question
-Identification and location of the best

evidence to answer the question

-Evaluate the literature for is Validity, Impact,
and Applicability

a

EBM - Will I Know It When I See It?

-Integration of the information gathered with
clinical expertise and patient's unique
attributes

-Assessment of effectiveness and efficacy
with further improvement for the next time

EBM - Limitations
Non-EBM based limitations

1. Paucity of evidence i<£A*
2. Application of evidence to individuals
3. Barriers to practice of high-quality
medicine

EBM - Limitations
i
EBM-based Limitations
I.

New skills - searching and appraisal are
needed

2.

Limited time to master new techniques
and secure access to resources

3.

EBM's evidence of efficacy is limited

co,sV -Wii jjaa, fdxxuc o.s* L\aaj

EBM's Other Benefits
• Forces a high-level of communication between
practitioner and patient
• Skills of finding, appraising and implementing
evidence from the basic science are fostered

• Develops a framework for lifelong learning
• May identify an agenda for further clinical
research

• Common language for interdisciplinary practice

EBM - Summary,^
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Hierarchy of Evidence
High

Systematic reviewsand meta-analyses
RCTs with definitive, significant results
RCTs with nondefinitive results (i.e., confidence intervals
suggestive of trend)
Cohort studies (follow-up. incidence, longitudinal,
prospective studies)
Case-control studies (case-referent, case-comparison,

retrospective studies)
Cross-sectional surveys (prevalence studies)
Case reports (anecdotal, case history, case study)

Study Types
Primary Research Studies
• Therapy (Treatment)
• Diagnosis (Procedures, Tests)
• Harm (Etiology)
• Prognosis

Each ofthe above studieshas it's own set of
validity requirements

Study Types
Integrative Research Studies
• Systematic Reviews

#^

• Clinical Decision Analysis
• Clinical Practice Guidelines/Consensus Statements

• Economic/Quality of Life Analyses
- CMA, CEA, CUA, CBA

• These studies seek to assemble and summarize a

body ofresearch

Systematic Reviews
• The most clinically useful evidence!!!
• Overviews

- Summary of medical literature
• Meta-analyses

- Utilize statistical/quantitative methods to
summarize results

^^
*

<^c?

Systematic Reviews:
Advantages
Rapid assimilation of largeamounts of
information

Explicitly defined methods limit biases
Methods used produce accurate conclusions
Results of different studies can be compared
Inconsistencies can be evaluated and new

hypotheses generated
Meta-analyses increase precision/generalizability

Clinical Practice Guidelines
Systematically developed statements to
assist practitioner and patient decisions
about appropriate health care for specific
clinical circumstances.

• An attempt to distill a large body of medical
knowledge into a convenient, readily usable
format.

JAMA 1995;274:570-574.

Clinical Practice Guidelines:
The Goal
• Reduce practice variation
- should reduce only harmful variation!

• Increase quality of care
• Educate about medical advances

• Aid in complex decisions

• Increase public participation

Guidelines for How to Use

Articles Describing Clinical
Practice Guidelines
Are the recommendations valid?

- Primary Guides:
• were all important options and outcomes identified?
• was an explicit and sensible process used to identify,
select, and combine evidence?

Secondary Guides:
• was an explicit and sensible process used to consider
the relative value of different outcomes?

• does the guideline account for recent developments?
• has the guideline been subject to peer review?
JAMA 1995;274:570-574.

Guidelines for How to Use

Articles Describing Clinical
Practice Guidelines
• What are the recommendations?

- Arc practical, clinically important
recommendations made?

- How strong are the recommendations?

- What is the impact of uncertainty associated
with the evidence used?

JAMA 1995;274:570-574.

Guidelines for How to Use

Articles Describing Clinical
Practice Guidelines
Will the recommendations help you in
caring for your patients?
- Is the primary objective of the guideline
consistent with your objective?
- Arc the recommendations applicable to your
practice?

JAMA 1995;274:570-574.
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EBM-Let's Get Started!
A 45-year-old male develops right-sided
weakness which is noticed as he awakens in

the morning. His wife immediately
transports him to the local Hospital where
he is examined in the Emergency

Department. Will thrombolytic therapy
reduce the morbidity from this episode?

EBM - Clinical Impetus
Every encounter with a patient highlights our
gaps in knowledge:
-translate into answerable questions
-ferret out the best evidence

-evaluate the evidence (validity and applicability)

-integrate evidence with experience
-evaluate the intervention

"Issues" to Keep in Mind
• The need to ask a specific question
• Recognize urgency of information need
• Must know more about the patient

11

Develop an "Answerable" Question

Will the use of a thrombolytic agent (and what
thrombolytic agent) reduce morbidity in the
setting of an acute ischemic stroke?

Identify/Locate Best Evidence
The National Institute of Neurological Disorders and
Stroke rt-PA Stroke Study Group. Tissue plasminogen
activator for acute ischemic stroke. N Engl J Med
1995;333:1581-7.

Findings: Despite an increased incidence of symptomatic
intracerebral hemorrhage, treatment with intravenous t-PA
within three hours of the onset of ischemic stroke

improved clinical outcome at three months.
-30% more likely to have minimal or no disability with

tPA; mortalityat 3 months was 17% in t-PA group and
21% in the placebo group.

Identify/Locate Best Evidence
Albers GW et al. Antithrombotic and thrombolytic

therapy Tor ischemic stroke. Chest 1998;114?683S*698S
Findings: TV tPA in a doseof 0.9mg/kg (maximum of 90mg
with 10% of the total dose given as an initial bolus and the
remainder infused over 60 minutes is recommended for

eligiblepatients(see inclusion andexclusion criterialisted
below),providedthat treatment is initiated within3 hours
of clearly defined symptoms onset (grade A2).

12

Levels of Evidence/Grades of Recommendation

• Grade A - Methods strong, results
consistent - RCTs with no heterogeneity
- 1 - Effect clear - clear that benefits do (or do

not) outweigh risks
- 2 - Effect equivocal - uncertainty whether
benefits outweigh risks
Chest 1998:114(suppl):441S-444S

Levels of Evidence/Grades of Recommendation

• Grade B - Methods strong, results
inconsistent - RCTs, heterogeneity present
"- 1 - Effect clear - clear that benefits do (or do
not) outweigh risks

- 2 - Effect equivocal - uncertainty whether
beenftis outweigh risks
Chest 1998;114(suppr):441S-444S

Levels of Evidence/Grades of Recommendation

1
Grade C - Methods weak - Observational
studies
- 1 - Effect clear - clear that benefits do (or do

not) outweigh risks

- 2 - Effects equivocal - Uncertainty whether
benefits outweigh risks
Chest 1998;114(suppl):441S-444S
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Identify/Locate Best Evidence
Albers GW et al. Intravenous tissue-type plasminogen
activator for threatment of acute stroke. JAMA

2000;283:1145-50.

Findings: This study, conducted at multiple institutions
throughout the UnitedStates, suggeststhat favorable
clinical outcomes and low rates of symptomatic

intracerebral hemorrhage can be achieved using tPA for
stroke treatment.

Identify/Locate Best Evidence
Katzan IL et al. Use of tissue-type plasminogen activator
for acute ischemic stroke. The Cleveland area

experience. JAMA 2000;283:1151-1158

Findings: A small proportion of patientsadmittedwith acute
ischemic stroke in Cleveland received tPA; they

experienceda high rate of ICH. Clevelandcommunity
experience withtPA foracuteischemic strokemaydiffer
from that reported in clinicaltrials.

IQl- inWr^l Wmrfoju

-15.7% had ICH: 50% had deviations from national

guidelines; fatality was 15.7%in treated group v. 5.1%in
patients not receiving tPA.

Disparate Results - Why?
Validity
- all evidence reviewed is valid

Impact
- significance of reducingmorbidity in stroke

Applicability
- clinical trials v. community application
-the KillerBs

14

Disparate Results - Why?
• Integration of Information
—Clinical Expertise
;;» Cleveland - is more or less like your clinical setting
- Patient Attributes
• detailed inclusion/exclusion criteria

Disparate Results - Why?
• Assessment of Effectiveness/Efficacy
- Data is all studies is carefully reported

- approximately 4% Ofall potential patients met
inclusion/exclusion criteria in NINDS trial

- 1.8% of patients in Cleveland trial received tPA

The Killer B's
1. Is the Burden of illness too low to warrant

implementation?
•^ Ex: malaria in Washtenaw County

- is the outcome we wish to control unlikely in
the patient

15

The Killer B's
2. Are the Beliefs of individual patients or
communities about the value of the

interventions or their consequences
incompatible with the guideline?
-beliefs, values and preferences of patients
may be much different than those assumed
in the guideline. Ex: angina patients may
demonstrate very different treatment desires

The Killer B's
3. Would the opportunity cost of
implementing the guideline constitute a bad
Bargain in the use of our energy or our
community's resources?
-the practice of medicine is based on
local decision-making

The Killer B's
4. Are the Barriers (geographic,
organizational, traditional, authoritarian,

legal or behavioral) so high that it is not
worth trying to overcome them?
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EBM - A Second Case Study
A 68-year old male with a long-history of
smoking is seen in the clinic with
complaints of difficulty in breathing, fatigue
and fever. After a physical examination and
chest X-ray, the diagnosis of Community
Acquired Pneumonia is made and the
patient is admitted to the hospital.
Appropriate antimicrobial therapy is being
discussed...

Grades of Recommendations for

a Specified Level of Baseline
Risk
•t/ fit. f. no ki-terogiiietty. <'fall mtone
xiJcof/hrexhoM XXT

A2

RCT, no heterogeneity, CI overlap
threshold NNT

Bl

RCT, heterogeneity, Q all on one side of
threshold NNT

B2

RCT, heterogeneity, CI overlap threshold

CI

Observational studies, CI all on one side

NNT
of threshold NNT

C2 Observational studies, CI overlap
threshold NNT

JAMA 1995;274:1630-1632.

American Thoracic Society
(ATS) Guidelines, 1993
[Community Acquired Pnaumonia

Outpabant
Aga<60y
No comorbidity

|

Ag*>60y
and/or comorbidity

Inp atari t
Ward

1 -

I

Am Rrv Re*pCr Oi» 1993;)4R;141g.26.
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ATS Treatment

Recommendations, 1999
• Group 1
- Low risk for DRSP(drug resistant S. pneumo)
- new macrolides or doxycyline

• Group 2
- Ix>w risk for DRSP

• new macrolides or doxycycline
- At risk for DRSP

• FQ or amoxicillin plus new macrolide

- Nursing Home
• 3rd generation ceph IV plus macrolide

Risk Factors for DRSP
• Antibiotic therapy within the last 3 months

• Age > 65y

• Nursing home patient
• Immunosuppresive therapy
• Alcohol abuse

Q»« :»«;115 1*« J«

ATS Treatment

Recommendations, 1999
Group 3
- Low DRSP risk

• B-lactam plus macrolide or doxycycline or FQ alone
- DRSP risk

• cefotaxime or ceftriaxone plus macrolide or FQ
alone

19

ATS Treatment

Recommendations, 1999
Group 4
- Without P. aeruginosa risk
» cefotaxime or ceftriaxone

• B-lactam/B-lactamase inhibitor plus macrolide or
FQ alone

- With P. aeruginosa risk
• macrolide plus two antipseudomonal agents

- High-level penicillin-resistant S. pneumo
• vancomycin

Patient Oriented Evidence that

Matters (POEMs)
• 3 criteria

- outcomes are patient-oriented
- practice content
• addresses a decision made by family physicians or a
problem encountered by them at least once every six
months

- practice impact
• changes current practices

JFam Pract 1999;48:350-355

c%\4- ct(- £5 {0

POEMs in the Literature
i

jj^Jourttal

POEMs/Month POEMs/Issue •

JAMA

2.67

0.62

NEJM

2.67

0.62

Arch Int Med

2.50

2.50

Ann Int Med

2

2

BMJ

1.67

0.39

Lancet

1.50

0.35

J Font Prac r 7999,48:350-355
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MEDICAL SECTION OF THE AMERICAN LUNG ASSOCIATION

Guidelines for the Initial Management of Adults with

Community-acquired Pneumonia: Diagnosis, Assessment
of Severity, and Initial Antimicrobial Therapy

This official ATS Statement was adopted by

the ATS Board of Directors, July 1993.

Community-acquired pneumonia (CAP) remains a common and
serious illness despite the availability ofpotent new antimicrobials
and effective vaccines. In the United States, pneumonia is the

sixth leading causeofdeath, andthenumber onecauseof death
from infectious diseases (1,2). Because pneumoniais nota report

able illness, information about its incidence is based on crude

estimates, but it appears that as many as 4 million cases of
community-acquired pneumonia occur annually, and as much as
onefifth ofthese require hospitalization (1). In the outpatient set
ting, the mortality rate of pneumonia remains low, in the range
of1 to 5%, but among patientswith community-acquired pneu
monia who require hospitalization, the mortality rate approaches
25%, particularly if the patient requires admission to the inten
sive care unit (3-9).

In recent years, both the epidemiology andtreatment of pneu
monia have undergone changes. Pneumonia isincreasingly com
mon among older patients and those with comorbidity (coexist

ing illness). Such illnesses include chronic obstructive lung
disease, diabetes mellitus, renal insufficiency, congestive heart
failure, chronic liver disease,andother similar medical conditions.

These patients may become infected with a variety of newly iden
tified, orpreviously unrecognized, pathogens (5). At the same time,
a number of new antimicrobial agents have become available,

some with utility for community-acquired pneumonia. Parallel to
the improvement in our antibiotic armamentarium, bacterial re
sistance mechanisms have evolved. In the 1990s, the prospect

of pneumococcal resistance to penicillin therapy has become a
reality.

This document is a summary of a conference that was con

vened to develop an approach tojhe initial management of
community-acquired pneumonia, taking into account the evolv

ing epidemiology of this infection and current therapeutic ap
proaches. The discussion is limited to the apparently immuno
competent patient with community-acquired pneumonia because
this represents thepopulation encountered most commonly. The
approach to the immunocompromised patient isdifferent because
of the large number of potential etiologic agents for pneumonia
in these patients. Thus, thediscussion does not deal directly with
the problems of pneumonia in theHIV-infected patient orin those
patients immunocompromised because of myelosuppressive che
motherapy, organ transplantation, or"traditional" immunosuppres
sive illnesses such as Hodgkin's disease.

Am Rev Respir Dis Vol 148. pp 1418-1426, 1993

The goal ofthis statement is to provide a framework for the
initial evaluation and therapy of the patient with community-

acquired pneumonia. The most common pathogens have been
defined from published studies, and the determination of which
diagnostic testsshould beobtained routinely hasbeen made on
the basis of published data. The approach emphasizes the im
portance of assessing severity of illness because of its relevance
to decisions about hospitalization and admission to an intensive

care unit. Thepresence ofcoexisting illness, as well as advanced

paiient age, are also important in determining the severity of ill
ness and the patterns of clinical presentation.
Because ofthe nonspecificity ofclinical and radiographic find

ings, and the limitations of diagnostic testing for identifying an
etiologic pathogen, most initial therapy isnecessarily empiric. The
approach to such therapy must be based on an assessment of
the likelihood thata given pathogen iscausingdisease ina given

patient, a determination guided by information from theliterature.
Two major variables that influence thespectrum of etiologic agents
and the initial approach to therapy are: the severity of illness at

initial presentation and the presence ofeither coexisting illness
oradvanced age. Patients with severecommunity-acquired pneu
moniahave a distinctepidemiology and a somewhatdifferent dis
tribution ofetiologic pathogensthan do patients with otherforms

of pneumonia. Similarly, thepresence of comorbidity oradvanced
agecan determine the likely pathogens involved. This approach
incorporates many of the same principles presented in the pro
ceedings of a Canadian consensus conference (10). Once em
piric therapy has been initiated, other questions such as the du
ration oftherapy andthetiming of thediscontinuation of parenteral
therapy become relevant, and these issues have been addressed.
Finally, it isinevitable that empiric therapy will not besuccessful
for all patients, andthusan approach is provided for theclinician
to use if the patient isnotresponding tothe regimen thathas been
selected.

ETIOLOGY OF COMMUNITY-ACQUIRED PNEUMONIA

Although an early etiologic diagnosis isoptimal in the manage
ment ofcommunity-acquired pneumonia, the responsible patho

gen isnot defined in as much as50% of patients, even when ex
tensive diagnostic testing is performed (3-5). No single test is
presently available that can identify all potential pathogens, and
each diagnostic test has limitations. For example, sputum Gram's
stain and culture may be discordant for the presence of Strep

tococcus pneumoniae, andthesetestsarealsonot abletodetect
frequently encountered pathogens such as Mycoplasma pneu
moniae, Chlamydia pneumoniae, and respiratory viruses.
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ease and the patient"s age. The four major categories that resulted
from these determinations relate not only to microbial etiology but

Because of the limitations of diagnostic testing, an empiric ap

proach to initial antimicrobial therapy is usually necessary. In an
attempt to develop arational framework for such therapy, the liter

also to ultimate prognosis and outcome. These categories are:

1 Community-acquired pneumonia occurring in patients 60

ature addressing the incidence of specific pathogens causing

years of age or younger who have no evidence of comorbidity and

mmunity-acquired pneumonia has been reviewed. Although

who can be treated in an outpatient setting liable 1).
2 Community-acquired pneumonia occurring in patients with

..umerous studies detailing the incidence and etiology of pneu
monia have been published, all have limitations. The approach
used in this statement is based on studies that were long enough

evidence of comorbidity and/or-who are 60 yr of age or older who
can be treated in an outpatient setting (table 2).

to avoid seasonal bias, recent enough to include newly recognized
pathogens, and comprehensive enough to include an extensive

3. Community-acquired pneumonia requiring hospitalization
but not admission to an intensive care unit (table 3).
4. Severe community-acquired pneumonia, generally requir

diagnostic approach. Therefore, only prospective studies with a
duration of 1yr or more, reported in the past 10 yr, and involving

ing ICU care (table 4).

adults from either Western Europe orNorth America were con

For each group, results from available studies were averaged
to identify the most common pathogens associated with pneu

sidered (3-9,11,12). All of these studies included an extensive
diagnostic approach to define the etiologic pathogen, not relying
on sputum Gram's stain and culture alone for this determination.

monia An attempt was made to rank the incidence of pathogens

broadly but aprecise numeric incidence or percentage was not

Most of the studies involved hospitalized patients, but awide spec

included. Nursing-home-acquired pneumonias were not catego

trum of patients was included, ranging from outpatients to those
admitted to an intensive care unit. In some of the studies asmall
minority of the patients were receiving antimicrobials at the time

rized separately because of alack of appropriate studies and our
conclusion that the location of residence was less important than

the presence of coexisting disease and age. However, the follow
ing pathogens are recognized more frequently in nursing-home
patients than in patients with the same coexisting illnesses who
are residing in the community: Methicillin-resistant S. aureus, M

of initial diagnostic evaluation.

Four patient categories were defined on the basis of informa

tion collected at the time of initial evaluation: the need for hospi
talization, the severity of illness, the presence of coexisting dis-

tuberculosis, and certain viral agents (i.e., adenovirus, RSV, and
influenza) (13,14). Amiscellaneous group is included in each ta

TABLE 1

OUTPATIENT PNEUMONIA WITHOUT COMORBIDITY AND
60 YEARS OF AGE OR YOUNGER*T

_

ble and represents organisms that were present in about 1% of
patients in these studies, or pathogens that have been otherwise
reported to occur in this setting.

The most common pathogens in outpatients 60 yr of age or

Organisms

younger and without coexisting illness were S. pneumoniae M.
pneumoniae, respiratory viruses, C. pneumoniae, and H. influen
zae (table 1). Miscellaneous pathogens included Legionella sp.,

S. pneumoniae
M. pneumoniae
Respiratory viruses
C. pneumoniae

S aureus, M. tuberculosis, endemic fungi, and gram-negative
bacilli. The mortality of patients in this category has been low (1

H. influenzae
Miscellaneous

Legionella sp., S. aureus, M. tuberculosis,
endemic fungi, aerobic gram-negative bacilli

to 5%)

Pathogens among outpatients with coexisting disease and/or

Therapy

who are 60 yr of age or older include S. pneumoniae, respiratory
viruses H. influenzae, aerobic gram-negative bacilli, and S. aureus

Macrolide*
OR

(table 2) Less common pathogens include Moraxella catarrhalis,

Tetracyclines
• Excludes patients at risk for HIV.

t in roughly one third to one half of the cases no etiology was identified.

*EryThromycin. The newer macrolides. clarithromycin or azithromycin, should be considered

in those intolerant of erythromycin, and in smokers (to treat H. influenzae).

CrwZ of S^hneumoniae are resistant to tetracycline, and it should be used only I

Leoionella sp., Mycobacterium sp., and endemic fungi. Mortality
in this setting is also less than 5%, but about 20% of patients

initially treated as outpatients may require hospitalization. Differ

TABLE 2

ences between the pathogens in this group and those listed in
table 1include the presence of aerobic gram-negative bacilli, M.
catarrhalis, and M. tuberculosis, which were felt to be due to the

OUTPATIENT PNEUMONIA WITH COMORBIDITY AND/OR
60 YEARS OF AGE OR OLDER't

monary disease. Anaerobic infection could also be a concern in

the patient isallergic to or intolerant ofmacrolides.

presence of coexisting illness, including chronic obstructive pul

patients with comorbidity, but generally patients with this type of
infection will require hospitalization (table 3).

Organisms

S pneumoniae, H. influenzae, polymicrobial infection (includ

S. pneumoniae
Respiratory viruses

ing anaerobes), aerobic gram-negative bacilli, Legionella sp., S.

H. influenzae

aureus, C. pneumoniae, and respiratory viruses are common

Aerobic gram-negative bacilli
S. aureus
Miscellaneous

.

.

Moraxella catarrhal, Legionella sp., M. tuberculosis, endemic fungi

Therapy

Second-generation cephalosporin
OR

among patients requiring hospitalization but who are not crit.caly
ill (table 3). Less common in this setting are M. pneumoniae, M.

catarrhalis, M. tuberculosis, and endemic fungi. Most patients who

required hospitalization were either older than 60 yr of age or had
coexisting illness, and thus this group could not be subdivided
in the same fashion aspatients who were treated out of the hos

TMP/SMX
OR

Beta-lactam/beta-lactamase inhibitor
x

Erythromycin or other macrolide*
* Excludes patients at risk for HIV.

t mroughly one third to one half of the cases no etiology was tdent.f.ed.
t If Infectionwith Legionella sp. is a concern.

pital (3). Mortality rates reported for these patients ranged from
(3). As shown in table 3, this group differs from those with less
severe pneumonia by having more patients with polymicrobial
pathogens, which probably reflects coexisting processes leading

5to 25%, and most of the deaths occurred within the first 7days
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TABLE 3

HOSPITALIZED PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA*t
Organisms
S. pneumoniae
H. influenzae

Polymicrobial (including anaerobic bacteria)
Aerobic gram-negative bacilli
Legionella sp.
S. aureus

VOL 148
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the possibility of pneumonia, although this will not be practical
in all situations. This test can be useful in differentiating pneumo
nia from other conditions that may mimic it. In addition, the radio
graphic findings may suggest specific etiologies or conditions such
as lung abscess, pneumonia caused by Pneumocystis carinii, or
tuberculosis. The radiograph can also suggest coexisting condi
tions such as bronchial obstruction or pleural effusions. Radiog
raphy is also useful for evaluating illness severity by identifying
multilobar involvement, which is an indication of severe illness

C. pneumoniae
Respiratory viruses
Miscellaneous

M. pneumoniae, Moraxella catarrhalis, M. tuberculosis, endemic fungi
Therapy

Second- orthird-generation cephalosporin*
OR

Beta-lactam/beta-lactamase inhibitor
±

Macrolide§
* Excludes patients at risk for HIV.

1" In roughly one third to one halfof the cases no etiology was identified.
$ See comments about third generationcephalosporins in text.
§ Use a macrolide if infection with Legionella sp. is a concern; rifampin may be added if
Legionella sp. is documented.

TABLE 4

SEVERE HOSPITALIZED COMMUNITY-ACQUIRED PNEUMONIAE
Organisms
S. pneumoniae
Legionella sp.

(below).
Although its value is debated, some authorities feel that a
properly performed Gram's stain of expectorated sputum, exam
ined according to strict criteria, is useful in the initial evaluation

of patients with pneumonia (15,16). However, instudies ofthe ability
of Gram's stain to predict sputum culture recovery of pneumococcus, in patients with community-acquired pneumonia, sensi
tivity and specificity vary widely depending on the criteria used
to define a "positive"stain (15).Although sputum Gram's stain and
culture are commonly used by practitioners to manage patients
with community-acquired pneumonia, there are no studies cor
relating data from these tests to cultures of alveolar material in
large numbers of patients with community-acquired pneumonia.
Even if the commonly used criterion of examining and culturing
a sputum sample only if it has more than 25 neutrophils and less
than five squamous epithelial cells per low power field is applied,
the usefulness of the data obtained is uncertain. However, direct

staining of sputum may be diagnostic for some pulmonary infec
tions, including those caused by Mycobacterium sp., endemic
fungi, Legionella sp. (direct fluorescent antibody staining is re

Aerobic gram-negative bacilli
M. pneumoniae
Respiratory viruses

quired), and P. carinii.
Routine bacterial cultures of sputum often demonstrate patho

Miscellaneous

H. influenzae, M. tuberculosis
Endemic fungi
Therapy

Macrolide*
PLUS

Third-generation cephalosporin with anti-Pseudomonas activity^
OR

Other antipseudomonal agents such as imipenem/cilastatin, ciprofloxacin
* Excludes patients at risk for HIV.

"•" In roughly one third to one halfof the cases no etiology was identified.
$ Rifampin maybe added if Legionella sp. is documented.
5 Although uncommonbecause of highmortality associatedwith P. aeniginosa pneumonia,
an aminoglycoside should be added, at least forthe first few days of treatment, whether one
is using a third-genration cephalosporin, imipenem, or ciprofloxacin.

to aspiration ofcolonized oropharyngealsecretions, and more pa
tientswith Legionella sp. because this infection may present with
more severe disease.

Severe community-acquired pneumonia (defined below) has
been separated from cases of less severe pneumonia requiring
hospitalization, because of the high mortality rate of the former
illness(as much as 50%) and the need for immediate recognition
of the patients with this degree of illness (7-9). Although severe
pneumonia was defined differently by the various investigators,
a practical definition is included in a subsequent section of this
statement. The pathogens most frequently identified among pa
tients withsevere pneumonia are listed in table 4. These include

S. pneumoniae, Legionella sp., aerobic gram-negative bacilli, M.
pneumoniae, respiratorytract viruses, and a group of miscellane
ous pathogens (H. influenzae, M. tuberculosis, and endemic fungi).
DIAGNOSTIC STUDIES IN PATIENTS WITH

COMMUNITY-ACQUIRED PNEUMONIA

genic organisms, but sensitivity and specificity are poor. However,
the recovery from cultures of organisms that are never part of the
normal respiratory flora may be meaningful. In appropriate clini
cal circumstances, sputum should be cultured for Mycobacterium
sp., Legionella sp., and endemic fungi. When recovery of penicillinresistant pneumococci is anticipated (because of previous ex
perience), sputum culture and sensitivity results can be useful.
In addition, ifthe patient is already receiving antibiotics at the time
of evaluation, sputum culture and sensitivity results may demon
strate a resistant organism. Viralcultures are not useful in the ini
tial evaluation of patients with community-acquired pneumonia
and should not be routinely performed (3).
A number of invasive diagnostic techniques to obtain lowerair
ways specimens, uncontaminated by oropharyngeal flora, have
been described (17). These include transtracheal aspiration, bron
choscopy with a protected brush catheter, bronchoalveolar lavage
with or without balloon protection, and direct needle aspiration
of the lung. These procedures are not indicated in most patients
with community-acquired pneumonia. It may be useful to have
an early accurate diagnosis in occasional patients who are se
verely ill. In such patients, bronchoscopy with a protected brush
catheter or bronchoalveolar lavage have reasonable sensitivity
and specificity when performed correctly.These procedures carry
less risk and are usually more acceptable to patients and physi
cians than are transtracheal aspiration and direct needle aspira
tion of the lung, although some physicians have special exper
tise in using ultrathin needles for direct lung aspiration.
Hospitalized patients should have two sets of blood cultures
collected, and patients with a pleural effusion should have a di
agnostic thoracentesis. Pleural fluid examination should include
white blood cell count and differential; measurement of protein,

A standard PA and lateral chest radiograph should be performed

glucose, LDH, and pH; Gram's stain and acid-faststain; and cul

in patients whose symptoms and physical examination suggest

ture for bacteria, fungi, and mycobacteria.
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Serologic testing and cold agglutinin measurements are not
useful in the initial evaluation of patients with community-acquired
pneumoniaand should not be routinely performed. However, acute

and convalescent serologic testing may occasionally be useful
for a retrospective confirmation of a suspected diagnosis, and it
nay be useful in epidemiologic studies. Serial complement fix
ing antibodytiters may be useful in following patients with exten
sive coccidioidomycosis.

Currently available tests thatdirectly measure specificmicrobial
antigens are notyetuseful inthe initial evaluationof patients with
community-acquired pneumonia. However, there is a great deal
of current research in this area, and in the future, methods utiliz

ing monoclonal antibodies, DNA probes, and polymerase chain
reaction amplificationmay offer accurate diagnostic tests on clin
ical specimens.

Routine laboratory tests (complete blood counts, serum elec

trolytes, hepatic enzymes, and tests of renal function) are of little
value in determining the etiology of pneumonia. However, these
tests mayhave prognostic significance and may influencethe de
cision to hospitalize and the choice and dose of therapy in pa
tients with moderate to severe pneumonia. They should be ob
tained in patients who are hospitalized (see below), or being
considered for hospitalization, and in any patient who is 60 yr of

age or older or who has coexisting illness. In addition, hospital
ized patients should have assessment of arterial oxygen satura
tion, which may also provide useful prognostic information.
The emphasis in the initial diagnostic approach is not to order
extensive tests. Itis quite clear that when patients have had mul
tipleserologic tests, along withcultures of respiratory tract secre
tions, the yieldis limited (3-5,18). Even withextensive diagnostic

testing, most investigators cannot identify the specific etiology for
community-acquired pneumonia inas many as halfof allpatients.

agents have been identified to produce a subacute illness indis
tinguishable from that caused by M. pneumoniae (22,23). Some
of these agents, however, such as Legionella species and influenza
can cause a wide spectrum of illness, ranging from a fulminant
life-threatening pneumonia to a more subacute atypical presen

tation (23). Thus, the term atypical pneumonia, which includes
diverse entities, is often used in an unfocused manner.

The attribution of specific clinical features to an etiologic agent
is a common clinical practice, particularly for patients suspected
of having pneumonia with Legionella species (24). However, re
cent data have cast doubt on the specificity of these observations

(4), concluding thatthe diagnosis ofLegionella sp. infection could
not be made on clinical grounds alone. Other comparative studies

involving both pediatric and adult populations, have concluded
that an etiologicdiagnosis could not be established using clinical
criteria alone (25-28). In addition, roentgenographic evaluation
does not offersignificantadditionaldiagnostic discrimination, and
no pattern is sufficiently distinctive to allow classification of in
dividual cases (29, 30).

The presence of advanced age and coexisting illness are im
portantfactorsthat affectthe clinical presentation of pneumonia.
Persons older than 65 yr of age are particularly at risk for mortal

ityfrom bacteremic pneumococcal disease (31), and among the
elderly, the expression of common clinical features of pneumo
nia is often atypical, obscured, or even absent (32).
Thus, it appears that the use of presenting clinical features,

including history, physical examination, routine laboratory, and
roentgenographic evaluation, does not reliably allow the clinician
to make a specific etiologicdiagnosis in patients withcommunityacquired pneumonia. Although some signs and symptoms ap

pear tooccur morecommonly inMycoplasma and Legionella pneu
monia, excessive overlap with other infectious and noninfectious

There is a role for some of the more advanced diagnostic tests

causes of lung infiltrates, does not permit therapeutic decisions

foridentification of pneumonia pathogens, but this role is primar

to be made on the basis of this information.

ily inepidemiologic evaluations and inthe assessment ofthe pa
tient whose illness is not resolving despite apparently appropri
ate empiric therapy (see below).
CAN CLINICAL SYMPTOMS PREDICT MICROBIAL
ETIOLOGY FOR CAP?

The syndrome approach (i.e., defining the etiologic pathogen on
the basis ofthe patient having a "typical" or "atypical" pneumonia
presentation) would be the simplest, ifit reliably allowed the clini
cian to predict specific etiologic pathogens, and thereby guide
specific therapy. However, the clinical featuresofCAP (symptoms,
signs, and radiographic findings) cannot be reliably used to es
tablish the etiologic diagnosis of pneumonia with adequate sen
sitivity andspecificity. Although, insome circumstances, clinicians
can confidently use clinical features to establish a specific etio

logic diagnosis, in the majority ofcases this is notpossible. This
relatesnotonlytovariations invirulence factorsof particularpatho

gens but also to the presence of coexisting illnesses, resulting

THE DECISION TO HOSPITALIZE PATIENTS WITH
COMMUNITY-ACQUIRED PNEUMONIA

There are no firm guidelines for when patients should be admit
ted to the hospital, and ultimatelythe decision rests with the phy
sician after an appropriate clinical assessment. The decision to
hospitalize a patient is perhaps the single most important deci
sion during the entire course of illness with community-acquired

pneumonia. Thereare a series ofwell-recognized risk factors that
increase either the risk of death or the risk of a complicated course

for community-acquired pneumonia (33). When these risk factors

are present, especiallyifmultiple risk factorscoexist, then hospi
talization should be strongly considered. The decision to hospital
ize is not necessarily a commitment to long-term inpatient care.
Rather, it is a decision that certain patients should be observed
closely until it is clear that their infection is responding to therapy.

Specific risk factors for mortality or a complicated course of
pneumonia include:

in an overlap of clinical symptoms among various etiologic

1. Age over 65 yr.

pathogens.

2. Presence of coexisting illnesses or other findings:
a. Chronic obstructive airway disease, including chronic
structural disease of the lung (bronchiectasis, cystic

Originally, the classification of pneumonia into "atypical" and
"typical" forms arose from the observation that the presentation
and natural historyof some patients with pneumonia were differ
ent compared with those of patients with pneumococcal infection
(19, 20). Some pathogens such as H. influenzae, S. aureus and
gram-negative enteric bacteriacaused clinical syndromesidenti
cal to that produced byS. pneumoniae (21). However, other patho
gens caused an atypical pneumoniasyndromethat was initially
attributed to M. pneumoniae (20), but other bacterial and viral

fibrosis).
b.

Diabetes mellitus.

c. Chronic renal failure.

d. Congestive heart failure.
e. Chronic liver disease of any etiology.

f. Previous hospitalization within 1 yr of the onset of
community-acquired pneumonia.
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g. Suspicion of aspiration (gastric or oropharyngeal secre
tions),
h. Altered mental status,

i. Postsplenectomy state,

j. Chronic alcohol abuse or malnutrition.

3. Certain physical findings also predict either mortality, in
creased morbidity, ora complicated course (34,35). These
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tients withsevere community-acquired pneumoniawill aid ines

tablishing a more focused empiric antibiotic treatment because
theseverity of illness appears tobeara strong relationship tothe

likely etiologic pathogens (table 4). Although there isnot a univer
sally accepted definition ofsevere community-acquired pneumo
nia, the presence of at least one of thefollowing conditions justi
fies defining the pneumonia as severe:

physical findings include:

1. Respiratory frequency > 30 breaths min at admission.

a. Respiratory rate in excess of 30 breaths/min.
b. Diastolic blood pressure< 60mm Hg ora systolic blood

2. Severe respiratory failure defined bya Pao2/Fio2 ratio < 250

pressure < 90 mm Hg.

c. Temperature > 38.3° C (101° F).
d. Evidence ofextrapulmonary sites ofdisease-presence
of septic arthritis, meningitis, etc.
e. Confusion and/or decreased level of consciousness.

4. There are a series of laboratory findings that also predict
increased morbidity or mortality. These are:

a. White blood cell count < 4 x 109/L or > 30 x 109/L or
an absolute neutrophil count below 1 x 109/L.

b. Pao2 <60 mm Hg or Paco2 of >50 mm Hg while breath
ing room air.
c. Need for mechanical ventilation.

d. Evidence of abnormal renal function, as manifested by
serum creatinine of> 1.2 mg/dl or a blood urea nitrogen
determination > 20 mg/dl (> 7 mmol/L) (35).
e. Presence ofcertain unfavorable chest radiographic find

ings, for example, more than 1 lobe involvement, pres
ence of a cavity, rapid radiographic spreading (8) and
the presence of a pleural effusion.
f. Hematocrit of < 30% or hemoglobin < 9 g/dl.

g. Other evidence of sepsis or organ dysfunction as
manifested by a metabolic acidosis, an increased pro
thrombin time, an increased partial thromboplastin time,

decreased platelets, orthepresence of fibrin split prod
ucts > 1:40.

Social considerations may enterinto the decision to hospital
ize. The absenceofa responsible caregiver in a stable home sit

uation isa strong indication for hospitalization, atleast for obser

vation purposes. Because community-acquired pneumonia remains
a significant cause of morbidity and mortality, when the overall
appearance of the patient seems unfavorable, even if the above-

mm Hg.

3. Requirement for mechanical ventilation.

4. Chest radiograph showing bilateral involvement or involve
ment of multiple lobes. In addition, an increase in thesize
ofthe opacity by 50% or greater within 48 h ofadmission
is indicative of severe pneumonia.

5. Shock (systolic blood pressure below 90mm Hg ordiastolic
blood pressure below 60 mm Hg) (35).

6. Requirement for vasopressors for more than 4 h.
7. Urine output lower than 20 ml/h, ortotal urine output lower
than 80 ml in 4 h, unless another explanation is available

(39), or acute renal failure requiring dialysis.
If severe pneumonia is identified, expectant admission tothe
intensive care unit should be considered.

TREATMENT GUIDELINES FOR COMMUNITY-ACQUIRED
PNEUMONIA

The purpose of theseguidelines istoprovide thepracticing phy
sician witha rational and manageable approach to the initial an

timicrobial management ofcommunity-acquired pneumonia. By
their very nature, theseguidelines cannot encompass all eventu
alities. The approach that was chosen is based upon a number
of considerations, including the presence or absence ofcoexist

ing illness (33), severity of illness upon clinical presentation, and
whether treatment is to be givenon an outpatientor inpatient ba

sis (8, 9, 35). Our current antibiotic armamentarium includes an
expanding array of beta-lactams, fluoroquinolones, and macro
lides, as well as the aminoglycosides.lincosamides, tetracyclines,
andmiscellaneous agents suchas trimethoprim-sulfamethoxazole.
As discussed in the section on diagnostic testing, ifa specificor

ganism isidentified, then treatment with oneof theseagents can

DEFINITION OF SEVERE COMMUNITY-ACQUIRED

be specifically directed against this pathogen.
The clinician often does not face such a straightforward deci
sion and must make an educated guess based upon the informa
tion at hand and institute therapyaccordingly. Therefore, itis of
ten the case that initial empiric therapyis bynecessitysomewhat

PNEUMONIA

broader inspectrum than is perhapsnecessary. Obviously, once

mentioned criteria are notfully met, itseems prudent toplace the

patient in the hospital on observation status for 24 to 48 hor until

such time as these concerns are resolved.

In the last several years, several investigators (7-9, 36-38) have

more information becomes availablesuch as culture and sensi

reported data concerning the incidence, etiology, prognostic fac

tivity data appropriate modifications can be made.

pneumonia requiring intensive care. These data are important be
cause etiologies reported in these series differ from those in the
overall population with community-acquired pneumonia.
The majority of series dealing with severe community-acquired

treatment regimens are presented in tables 1 to 4. When appro
priate, names of classes of drugs have been used rather than spe
cific individual agents. However, if only one drug in a given class
ofcompounds is felt to be suitable, then the specific drug name
is used; table 1 deals with outpatients who have no comorbidity
and are 60 yrofage or younger, whereas table 2 deals with out

tors, and outcome of patients with severe community-acquired

pneumonia show a distinct spectrum of etiologic agents: (1) S.

pneumoniae and L. pneumophila areby far themost common or

ganisms responsible for these pneumonias; (2) gram-negative
bacilli cause pneumonia only in those patients with concomitant
coexisting illness, including COPD, diabetes mellitus, and alco
holism; (3) Pseudomonas aeruginosa was rarely present, except
in patients with bronchiectasis.
Theassessment ofseverity ofillness and mortality prediction

was described in the previous section. Early recognition of pa

Given the above-mentioned considerations, the suggested

patients who have comorbidity and/or are 60 yr of ageorolder.
Intable 3 patients whoare to be hospitalized butwhoare not se
verely ill are dealt with, whereas table 4 deals with patients who
are hospitalized with severe community-acquired pneumonia.
Although a beta-lactam antibiotic such as penicillin isthedrug
of choice for infections caused by sensitive strains of S. pneumo

niae, none of the beta-lactams provide coverage for organisms
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such as M. pneumoniae, C. pneumoniae, and L pneumophila. On
the other hand, a macrolide such as erythromycin has excellent

activity againstthe latter three organisms, butitis relatively inac
tive in vitro againstH. influenzae. Thenew macrolides, clarithromy
cinand azithromycin, haveinvitro activity against S. pneumoniae
and H. influenzae, as well as M. pneumoniae, C. pneumoniae, and

L pneumophila, thereby providing theoption of monotherapy when
these pathogens are a consideration (40). This may be particu
larly appropriate for the patient 60yrofage or younger who has
nocomorbidity and will be treated as an outpatient, but inwhom
H. influenzae is being considered in addition to the other usual
pathogens because of a history of smoking.

Trimethoprim-sulfamethoxazole has not been formally studied
in patients with pneumonia, but its in vitro activity and efficacy
ininfections otherthan pneumonia,against the pathogens shown
intable2, suggest that itmight be an effective alternative therapy

for patients who are treated according to the guidelines in this
table. Inaddition, a carbacepham may also be useful for therapy

ofthis type of patient. The third generation cephalosporins are
listed in both tables 3 and 4, and this requires clarification. In

general, theseagents are lessactive against pneumococcus and
anaerobes than are second generation cephalosporins (such as

cefuroxime), butcefotaxime andceftriaxone havebeen used suc
cessfully totreat community-acquired pneumonia among thetypes
of patients listed in table 3.If P. aeruginosa issuspected, as would
be the case for patientswith structural lung disease (e.g., bron
chiectasis), and with those having the clinical picture described
intable 4, then the onlythirdgeneration cephalosporins that can
be used are ceftazidime and cefoperazone. Other alternative

agents that are active against P. aeruginosa include imipe-

Immunocompetent patients with Legionnaire's disease shouldre
ceive 14 days of treatment, whereas, immunocompromised pa
tients may require up to 21 days of therapy.
When Can the Switch be Made from Intravenous

to Oral Therapy?

The remaining question relates to when hospitalized patients
receiving parenteral therapy can be switched tooral therapy. There
are two perspectives from which this issue must be considered:
the host and the drug. In the former case the patient mustbe able
to take drugs by mouth and must have a functioning gastrointes
tinal tract. From the perspectiveof the drug, the key question is
which antimicrobials, when given by mouth, achieve adequate
tissue and serum levels. Some orallyadministered drugs are able
to achieve serum levels comparable to parenteral therapy. These

include: doxycycline, minocycline, chforamephenicol, trimetho
prim-sulfamethoxazole, and most fluoroquinolones (44). For other
agents, theswitch tooral therapy canoccur only when thehigher
drug levels achieved with parenteral therapy are no longer re
quired. Thus, after a few days have elapsed and the patient has
stabilized on parenteral therapy, one maynot need the same de

gree of tissue penetration by antimicrobials, and therapy can be
continued with orally administered antibiotics. Two randomized
controlled studies havespecifically addressed the issue ofswitch

ing from intravenous tooral treatment (45,46). The time of switch
overwas Day 6 and Day 3 inthe two studies respectively and pa
tients switched to oral therapy at an early time point had a good

clinical response. Despite these disparate figures, a reasonable

approach might be to begin oral therapy once the patient's clini
cal condition has stabilized and fever has subsided.

nem/cilastatin and ciprofloxacin.
ASSESSMENT OF RESPONSE TO INITIAL
Duration of Treatment

When discussingtreatment, questions arise not onlyas to what

drugs to give, but how long togive them and when parenteral ther
apy can be switched to oral therapy. Surprisingly, little informa
tionexists that addresses these questions, and standard textbooks

ANTIMICROBIAL THERAPY

Having initiated a course oftherapy based on the above guide
lines, it is essential that the patient'sresponse be carefully evalu
ated. With effective antimicrobial therapy, some improvement in
the clinical manifestations of pneumonia should be seen in 48

provide little, if any, specific referenced information to support

to 72 h, although certain hostand pathogen factors can delay reso

statements regarding duration of treatment.
Shorter treatment courses may be possible with the introduc
tion of a new 15-member macrolide, azithromycin.This agent has

lution. Because of this natural time course of response to treat

an exceedingly long half-life of 11 to 14 h compared with 1.5 to
3 and38 hfor erythromycin andclarithromycin, respectively. Since
azithromycin has such a long half-life, it remains in the tissues

In patients who are otherwise healthy, fever can last for 2 to
4 days, with defervescence occurring most rapidly with S. pneu

longer than most agents, so that the reduced length oftreatment
based on the numberofdays oforalingestion ofthe drug is some

what misleading. At currently approved oral doses, azithromycin
does not achieve high serumlevels, and, consequently, thisagent
should not be used if bacteremic infection is suspected or ifthe

patient is judged to be moderately or severely ill due to pneumo
nia.Controlled trials comparing azithromycin takenfor5 days with

erythromycin and cefaclor taken for 10 days in the treatment of
atypical pneumonias and acute bacterial pneumonias respectively
suggest that shorter courses with this agent may beused(41,42).
However, more data are required to adequately answer this
question.

The presence of coexisting illness and/or bacteremia, the
severity ofillness at the onsetof antibiotic therapy, and the sub
sequent hospital course must be taken into account in determin
ing theduration of antibiotic therapy (43). Generally, bacterial in
fections, such as S. pneumoniae pneumonia, should be treated

for approximately 7 to 10 days. Cases ofM. pneumoniae and C.
pneumoniae may need longer therapy ranging from 10 to14days.

ment, therapy should not be changed within the first 72 h, unless
there is a marked clinical deterioration.

moniae infection, and slower with other etiologies (47). Leukocy

tosis usually resolves by Day4, whereas abnormal physical find

ings(crackles) can persist beyond 7 days in 20to40%ofpatients.
Abnormalfindings on chest radiographs clear much more slowly
than do clinical signs of pneumonia. For those who are younger
than 50 yrofage and otherwisehealthy, S.pneumoniae pneumo
nia will clear radiographicallyby4 wkin only60°/o of patients (48).
If the patient is older, has bacteremic pneumonia, COPD, alco
holism, or underlyingchronic illness, radiographic clearing is even
slower, and only 25% will have a normal radiograph at 4 wk (48).

M. pneumoniae infection can clear radiographically morerapidly
than pneumococcal infection, whereas pneumonia caused by
Legionella sp. will clear more slowly (29).
It is quite common for the radiograph to worsen initially after
therapy is started, with progression of the infiltrate and/or devel
opment of a pleuraleffusion. If the patient has a mild pneumonia
or is showing an otherwise good clinical response to treatment,

this radiographic progression may have no significance. However,
radiographic deterioration in the setting of severe communityacquired pneumonia has been noted to be a particularly poor prog-
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of broad antimicrobial therapy are necessary if there is accom

These includepulmonary embolus,congestiveheart failure, ob
structing bronchogenic carcinoma, and certain inflammatory lung
diseases (bronchiolitis obliterans and organizing pneumonia,
Wegener's granulomatosis, eosinophilic pneumonia).

panying clinical deterioration.

Evaluation and Testing

nostic feature, highly predictive ofmortality (8). In the setting of
severepneumonia, radiographic deterioration may signify inade
quately treatedinfection, and aggressive evaluation and initiation
In general, with increasing patient age, multiple coexisting ill
nesses, and increasingseverity ofdisease, the resolution ofclin
ical signs and symptoms will be delayed. Thus, as patients are
encountered who fitthe descriptions in tables 1 to 4, those catego

rized intoprogressively higher numbered tables will have a more
prolonged rate of pneumonia resolution.
MANAGEMENT OF PATIENTS WHO DO NOT

RESPOND ADEQUATELY TO INITIAL THERAPY

If the patient's clinical findings are not improving or are deteri
orating after initial empiric therapy, consideration must be given
to several possible causes.

Although there are data that indicate patients with bacteremic
pneumococcal pneumonia can have a slower re'sponse to ther
apy than patients with nonbacteremic infection (48), there are no
other clearly demonstrated relationships between the expected
response to therapy and the severity of illness. However, in the
settingofan inadequate response to therapy, itis appropriate to
modify the extent and aggressiveness ofthe evaluation in direct
proportion to the severity of a patient's illness.
When a patient is not adequately improving after initial em
piric therapy, itis first necessary to considerthe factthat the pa
tient is already receiving antibiotics. This not only enhances the
possibility thata resistant, orsuperinfecting, pathogen ispresent
but it interferes withthe utility of invasivediagnostic methods. Ex

Inadequate Antimicrobial Selection

otictherapy). Forexample, the therapies outlined above are not
necessarily optimal fora pathogen such as S. aureus, and an ag

perience with bronchoscopic methods usedtodiagnose bacterial
pneumonia has shown that when sampling is done in patients
receiving antibiotics, a high false negative rate will be observed
(50). However, bronchoscopy may be useful for identifying unusual
organisms anddrug-resistant pathogens, andtheclinician should

gressive search for this pathogen should be undertaken in the
patient who worsens onthe above regimens. Alternatively, the in

considercollecting lower respiratory tract secretionsfor quantita
tive cultures in the patient who is not responding adequately to

fection could be caused by an agent that is not responsive to an

antibiotics used, but it has now become resistant, and thus or

therapy. One study has examined the utility of bronchoscopy in
patients who failed empiric therapy for community-acquired pneu
monia (51). Therapeutic failures were defined as early (no clinical
response within 72 h) or late(initial improvement, butthen after

ganism sensitivities on both theinitial (if obtained) and repeat spu

72 hours a deterioration).The incidence of such failures was rel

tum cultures should be checked.

atively low, 6.5% of277 patients having early failure and7%hav
ing late failure. Diagnostic bronchoscopy was done when failure

Unusual Pathogens

occurred, and itprovided diagnostically useful information in41%
of cases. Bronchoscopy, even in the presence of antibiotics, led
to such diagnoses as Legionella sp. infection, anaerobic pneu
monia, infection with resistant or unusual pathogens, and tuber

The etiologic organism may be resistant to the drug(s) used in
the initial empiric regimen (i.e., not covered by the initial antibi

timicrobials of any type (i.e., a virus). Another possible explana
tion isthat the responsible pathogen was initially sensitiveto the

An additional consideration is that while the patient may appear

to have community-acquired pneumonia, the etiology is an un

usual organism. Such infections should beconsidered when clin
ical and radiographic findings persist, and the differential diag
nosis includes tuberculosis, endemic fungal pneumonia, and P.

carinii pneumonia. Although a discussion of the immunocom

promised and/or HIV-infected patient isnot included in this state
ment, it is possible that a patient will have one of these condi
tions, even though this was not initially suspected. Patients who
receive corticosteroids have been reported to developcommunityacquired fungal pneumonia (49).

Acareful repeat of the history is essential in the patient who
is not improving with therapy, and certain epidemiologic clues
related toanimal exposures and travel mayindicate the presence

of specific pathogens that can be detected with special serolo
gies orcultures. Qfever (C. burnetii) may follow exposure to par
turient cats, cattle, sheep, or goats, fularemia can occur with ex
posure to infected rabbits and ticks. Psittacosis may occur after
exposure toavian sources of infection; and plague orleptospirosis can follow exposure to rats. Travel to South EastAsia can be

complicated by infection with Pseudomonas pseudomallei, and
paragonomiasis can beacquired in Asia, Africa, orCentral and
SouthAmerica. Ahistory oftuberculosisexposureand prior tuber
culin skin test status should also be elicited. If the skin test for
tuberculosis has not been done and the patientis in an epidemi

ologic risk group, it should be applied.
Noninfectious Illness

Afinal consideration is the group of noninfectious diseases that

canmimic pneumonia and initially be misdiagnosed as infection.
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culosis. In addition, bronchoscopy can diagnose other infections,

including those caused byfungi and P. carinii, and it may be use
ful in detecting mechanical factors that are delaying resolution
such as an aspirated, obstructingforeign body, or an obstructing
endobronchial lesion.

Inaddition to sampling lower respiratory tractsecretions,other
tests should be considered. Computed tomography may reveal

the presence ofunsuspected collections ofpleural fluid, multiple
lung nodules, orcavitation within a lung infiltrate. Lung scanning
and/or pulmonary angiography should be considered if the pa
tient is at risk for pulmonary embolus with infarction. Although
the routine use of serologic testing is probably not useful in the
initial evaluation of patients with community-acquired pneumo
nia, collection ofserum for serologic testing may be useful inthe

nonresponding patient. Serologic tests for Legionella sp., Mycoplasma pneumoniae (including cold agglutinins), viral agents, en
demic fungi, andotherunusual pathogens should be considered
atthis point. If all ofthe diagnostic evaluation has not beenuseful
andif the patient isseriously ill, openlung biopsy should becon
sidered, and should be done in an involved area oflung.Thisin

vasive approach is best for defining noninfectious processes in
the immunocompetent patient, but it mayalso detect tuberculo
sis, fungal infections, and other infectious causes.

As already mentioned, itmay take many weeks to months for
the chest radiograph to return to normal ortostop improving. It

may be useful to obtain a chest radiograph prior to discharge in

all hospitalized patients and after 10 to 14 days in outpatients to

••»**
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establish information on the course of resolution. Patients should

be followedover the ensuing months until a new radiographic base
line is reached, and evaluation may be needed if the chest radio
graph fails to return to normal, especially if the patient remains
inically ill. One series has evaluated the utility of bronchoscopy
m patients with persistent radiographic and clinical abnormalities
(52). In that study, bronchoscopy did yield specific diagnoses, but
primarily this occurred in nonsmoking patients younger than 55
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improve our ability to define the etiologic pathogens of communityacquired pneumonia? (5) What pathogens are responsible for
pneumonia when no organism is identified, even with extensive
diagnostic testing?
This Statement was prepared by an ad hoc Committee of the Sci
entific Assembly on Microbiology, Tuberculosis, and Pulmonary
Infections. Members of the Committee were:

Michael S. Niederman, M.D. (Chairman)
John B. Bass Jr., M.D.
G. Douglas Campbell, M.D.
Alan M. Fein, M.D.
Ronald F. Grossman, M.D.
Lionel A. Mandell, M.D
"THomas J. Marrie, M.D.
George A. Sarosi, M.D.
Antonio Torres, M.D.
Victor L Yu, M.D.

yr of age who had multilobar infiltrates of long duration. Those
who were older, those who have smoked, and those with focal

infiltrates had a much lower yield of a specific diagnosis (other
than slowly resolving pneumonia) with fiberoptic bronchoscopy.
In general, however, bronchoscopy is usually not needed, and pa
tience is necessary to observe the full course of radiographic clear
ing of community-acquired pneumonia.
Complications of Pneumonia

In addition to the diagnoses considered above, the patient who
remains ill despite empiric therapy may have extrapulmonary com
plications of pneumonia. These include metastatic infection, which
can occur in as many as 10% of patients with bacteremic pneu
mococcal pneumonia (53). Metastatic infections include menin
gitis, arthritis, endocarditis, pericarditis, peritonitis, and empyema,
and these complications should be considered. Particularly be
cause of concern about empyema, any patient with an inadequate
clinical response to therapy should have a repeat chest radiograph
and any pleural fluid should be sampled, cultured, and analyzed
for cell count and chemistry. In addition to metastatic infection,
other extrapulmonary complications of pneumonia can delay ra
diographic clearing. These include renal failure, heart failure, pul
monary embolus with infarction, and acute myocardial infarction.
Rnally, ifthe patient has developed sepsis syndrome from pneujnia, the chest radiograph and clinical course may deteriorate
because of the presence of the adult respiratory distress syndrome
and multiple system organ failure.
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Critical Appraisal Worksheet for Clinical Practice Guidelines

|| Guide
1, Are the recommendations valid?

Were all important options and
outcomes clearly identified?
Was an explicit process used to
identify, select, and combine
evidence?

Is the guideline likely to account for
important recent developments?
Has the guideline been subject to
peer review?
2. What are the recommendations?

Are clear, practical, and important
recommendations made?

How strong are the
recommendations?

What is the impact of uncertainty
associated with the evidence?

3. Will the results help me in caring
for my patients?
Is the primary objective of the

guideline consistent with your
objective?
Are the recommendations applicable
to your patients?
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